



US 20100190652A1

(19) **United States**

(12) **Patent Application Publication**  
**Nagalla et al.**

(10) **Pub. No.: US 2010/0190652 A1**

(43) **Pub. Date: Jul. 29, 2010**

(54) **BIOMARKERS FOR DETECTION OF NEONATAL SEPSIS IN BIOLOGICAL FLUID**

(76) Inventors: **Srinivasa Nagalla**, Hillsboro, OR (US); **Michael Gravett**, Seattle, WA (US)

Correspondence Address:  
**ARNOLD & PORTER LLP**  
**ATTN: IP DOCKETING DEPT.**  
**555 TWELFTH STREET, N.W.**  
**WASHINGTON, DC 20004-1206 (US)**

(21) Appl. No.: **12/693,387**

(22) Filed: **Jan. 25, 2010**

**Related U.S. Application Data**

(60) Provisional application No. 61/147,635, filed on Jan. 27, 2009.

**Publication Classification**

(51) **Int. Cl.**  
**C40B 30/00** (2006.01)  
**G01N 33/53** (2006.01)  
**G01N 33/573** (2006.01)

(52) **U.S. Cl.** ..... **506/7; 435/7.1; 435/7.4**

(57) **ABSTRACT**

The present invention concerns the identification and detection of biological fluid biomarkers of neonatal sepsis using global proteomic approaches.






Figure 1



# Figure 2A




Figure 2B





Figure 2C



## BIOMARKERS FOR DETECTION OF NEONATAL SEPSIS IN BIOLOGICAL FLUID

### RELATED APPLICATION

**[0001]** This application claims priority under 35 U.S.C. §119(e) to U.S. provisional application No. 61/147,635, filed Jan. 27, 2009, the entire contents of which are incorporated herein by reference.

### BACKGROUND OF THE INVENTION

**[0002]** 1. Field of the Invention

**[0003]** The present invention concerns the identification and detection of biomarkers of neonatal sepsis and neonatal sepsis associated complications in biological fluids using global proteomic approaches.

**[0004]** 2. Sequence Listing

**[0005]** The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 9, 2009, is named PTX-0013PR.txt, and is 412,016 bytes in size.

**[0006]** 3. Description of the Related Art

**[0007]** Sepsis is a serious problem for neonates who are admitted for neonatal intensive care. It is associated with an increase in mortality, morbidity, and prolonged length of hospital stay. Thus, both the human and fiscal costs of these infections are high. Possible (“rule-out” or “suspected”) early onset septicemia remains the most common admitting diagnosis to the neonatal intensive care unit (NICU). Although the rate of early-onset sepsis increases with the degree of both prematurity and low birth weight, no specific laboratory test has been shown to be sufficiently precise to allow the identification of patients who have a “real” blood-stream infection and, therefore, who need to be treated with a full course of antibiotics. As a result, antibiotic use is many times the rate of “proven” sepsis and overuse of these agents facilitates the growth of resistant organisms in the neonatal intensive care unit. (Clarke 2004). In addition, the prolongation of hospital stay adds immeasurably to the cost of care in the NICU and enhances the risk of nosocomial septicemia from subsequent hospital acquired micro-organisms.

**[0008]** The U.S. Department of Health and Human Services Centers for Disease Control and Prevention defines early-onset infection as an infection during hospitalization that occurs during the first 72 hours of life, whereas late-onset infection occurs after that period of time. (Lopez 2002). Nosocomial infection is equivalent to late-onset, or infection after the first 72 hours of life. (Craft 2001). Infection rates may be stated as a percent of admissions, percent of liveborn infants, or by the number of infections per 1000 patient days. Early onset infection rates consistently run at approximately 2 per thousand live births. As 20% to 30% of preterm neonates may have two or more nosocomial infection episodes, infection rates per patient days probably gives a more accurate idea of magnitude in late-onset infection, whereas rates per patient group (admissions, liveborn infants, birth-weight range, gestational age range) give a good idea of attack or incidence rates.

**[0009]** The neonatal intensive care unit (NICU) nosocomial or late onset infection rate has increased over the past decade. (Craft 2001, Zafar 2001). The total number of neonates who develop nosocomial infection per admission varies from 6.2% (Ferguson 1996) to 33% (Hentschel 1999) or,

when reported as total infections per 1000 patient days, the rate varies from 4.8 (Ferguson 1996) to 22 (Drews 1995). Blood-stream infections (nosocomial sepsis) vary from 3% to 28% of admissions. (Ferguson 1996, Hentschel 1999, Berger 1998, Horbar 2001, Nagata 2002). The variability of infection rates depends on the gestational age, the distribution of the infants surveyed for the report, and on the specific environment and care practices. (Gaynes 1996).

**[0010]** The gold standard for the diagnosis of true early-onset sepsis remains the finding of a positive blood culture for a known pathogen. Commonly, early onset sepsis will be considered present when a neonate has at least two of the following features in the clinical course, and a positive blood culture of 1 mL or greater volume:

**[0011]** 1) Maternal history of fever >100.4° F., prolonged premature rupture of membranes during labor (>12 hours duration), or presumed chorioamnionitis

**[0012]** 2) Malodorous or purulent appearing amniotic fluid at delivery

**[0013]** 3) Clinical findings consistent with sepsis that may include any of the following signs: low 5 minute Apgar score (<6), pallor, cyanosis, hypotension, tachypnea, tachycardia, apnea, abdominal distension, poor feeding, or lethargy

**[0014]** 4) Supporting laboratory data that includes a WBC count on CBC <8000/mm<sup>3</sup> or >35,000/mm<sup>3</sup>; I:T neutrophil count >2; CRP >8; or pneumonia on chest radiograph.

**[0015]** This points to the need for the identification of sepsis-associated biomarkers within biological fluid obtained at delivery able to identify subjects with early-onset neonatal sepsis and neonatal sepsis associated complications to facilitate early treatment. Reductions in the risk of neonatal sepsis and its associated morbidities may well depend upon earlier identification of patients at risk.

### SUMMARY OF THE INVENTION

**[0016]** In one aspect, the invention provides a method for diagnosis of neonatal sepsis in a mammalian subject comprising: (a) testing in a sample of biological fluid obtained from said subject the level of one or more proteins selected from the group consisting of C-reactive protein precursor (SEQ ID NO:1), Interleukin-1 receptor accessory protein precursor (SEQ ID NO:2), Interleukin-6 precursor (SEQ ID NO:3), Interleukin-1 receptor-like 1 precursor (SEQ ID NO:4), Serum amyloid A protein precursor (SEQ ID NO:5), CD5 antigen-like precursor (SEQ ID NO:6), Beta-2-microglobulin precursor (SEQ ID NO:7), Bone-marrow proteoglycan precursor (SEQ ID NO:8), Selenium-binding protein 1 (SEQ ID NO:9), Lipopolysaccharide-binding protein precursor (SEQ ID NO:10), Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO:11), Osteopontin precursor (SEQ ID NO:12), Rho GDP-dissociation inhibitor 2 (SEQ ID NO:13), Carbonic anhydrase 2 (SEQ ID NO:14), Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO:15), Collagen alpha-5(IV) chain precursor (SEQ ID NO:16), Connective tissue growth factor precursor (SEQ ID NO:17), Macrophage colony-stimulating factor 1 precursor (SEQ ID NO:18), Protein kinase C-binding protein NELL2 precursor (SEQ ID NO:19), Neudesin precursor (SEQ ID NO:20), Protein disulfide-isomerase precursor (SEQ ID NO:21), Ribonuclease pancreatic precursor (SEQ ID NO:22), Delta-like protein precursor (SEQ ID NO:23), Chromogranin-A precursor (SEQ ID NO:24), Osteomodulin precursor (SEQ ID NO:25), Collagen alpha-2(I) chain precursor (SEQ ID NO:26), Pro-low-density lipoprotein receptor-related protein 1 precursor

(SEQ ID NO:27), Laminin subunit gamma-1 precursor (SEQ ID NO:28), Laminin subunit beta-1 precursor (SEQ ID NO:29), Collagen alpha-1(II) chain precursor (SEQ ID NO:30), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), Protein FAM3C precursor (SEQ ID NO:32), Alpha-actinin-1 (SEQ ID NO:33), F-actin-capping protein subunit alpha-1 (SEQ ID NO:34), Aminopeptidase N (SEQ ID NO:35), Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Cell adhesion molecule 1 precursor (SEQ ID NO:37), Cathepsin B precursor (SEQ ID NO:38), Exostosin-2 (SEQ ID NO:39), Cathepsin D precursor (SEQ ID NO:40), Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO:41), Cystatin-M precursor (SEQ ID NO:42), Noelin precursor (SEQ ID NO:43), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Endoplasmic precursor (SEQ ID NO:45), Proprotein convertase subtilisin/kexin type 9 precursor (SEQ ID NO:46), Insulin-like growth factor-binding protein complex acid labile chain precursor (SEQ ID NO:47), Ezrin (SEQ ID NO:48), Fatty acid-binding protein, liver (SEQ ID NO:49), Probable G-protein coupled receptor 116 precursor (SEQ ID NO:50), Sepsin (SEQ ID NO:51), Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO:52), Hypoxia up-regulated protein 1 precursor (SEQ ID NO:53), Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO:54), Transketolase (SEQ ID NO:55), Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO:56), Intercellular adhesion molecule 1 precursor (SEQ ID NO:57), Low-density lipoprotein receptor precursor (SEQ ID NO:58), 78 kDa glucose-regulated protein precursor (SEQ ID NO:59), Neighbor of p115 precursor (SEQ ID NO:60), Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ ID NO:61), Pyruvate kinase isozymes M1/M2 (SEQ ID NO:62), Matrix metalloproteinase-9 (SEQ ID NO:64), Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and Stress-induced-phosphoprotein 1 (SEQ ID NO:63), relative to the level in normal biological fluid or biological fluid known to be indicative of neonatal sepsis; and (b)

**[0017]** diagnosing said subject with neonatal sepsis if said level shows a statistically significant difference relative to the level in said normal biological fluid, or does not show a statistically significant difference relative to the level in said biological fluid known to be indicative of neonatal sepsis.

**[0018]** In certain embodiments, the method includes testing the level of at least two, at least three, at least four, at least five, at least six, at least seven, and so on, of the listed proteins, in any combination.

**[0019]** In a specific embodiment, the subject is a human patient.

**[0020]** In certain embodiments, the biological fluid is selected from the group consisting of cord blood, cerebrospinal fluid, and neonatal serum. In a specific embodiment, the biological fluid is cord blood.

**[0021]** In another embodiment, the diagnosis is determined within 24 hours of birth.

**[0022]** In one embodiment, the testing is implemented using an apparatus adapted to determine the level of said proteins. In another embodiment, the testing is performed by using a software program executed by a suitable processor. In certain embodiments, the program is embodied in software stored on a tangible medium. In certain other embodiments, the tangible medium is selected from the group consisting of a CD-ROM, a floppy disk, a hard drive, a DVD, and a memory associated with the processor.

**[0023]** In certain embodiments, the methods of the invention further include a step of preparing a report recording the results of the testing or the diagnosis. In one embodiment, the report is recorded or stored on a tangible medium. In a specific embodiment, the tangible medium is paper. In another embodiment, the tangible medium is selected from the group consisting of a CD-ROM, a floppy disk, a hard drive, a DVD, and a memory associated with the processor.

**[0024]** In certain other embodiments, the methods of the invention further include a step of communicating the results of said diagnosis to an interested party. In one embodiment, the interested party is the patient or the attending physician. In another embodiment, the communication is in writing, by email, or by telephone.

**[0025]** In one embodiment, the method includes testing the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Interleukin-6 precursor (SEQ ID NO:3), C-reactive protein precursor (SEQ ID NO:1), Beta-2-microglobulin precursor (SEQ ID NO:7), Cathepsin B precursor (SEQ ID NO:38), Cystatin-M precursor (SEQ ID NO:42), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Matrix metalloproteinase-9 (SEQ ID NO:64), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), and Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and diagnosing said subject with neonatal sepsis, if one or more of said tested proteins shows a significant difference in the cord blood sample relative to normal cord blood. In a certain embodiment, the method includes diagnosing said subject with neonatal sepsis, if all of said tested proteins show a significant difference in the cord blood sample relative to normal cord blood.

**[0026]** In one embodiment, the method includes testing the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36) and Interleukin-6 precursor (SEQ ID NO:3), and diagnosing said subject with neonatal sepsis, if one or more of said tested proteins shows a significant difference in the cord blood sample relative to normal cord blood. In other embodiments, the method includes testing the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36) and C-reactive protein precursor (SEQ ID NO:1). In yet other embodiments, the method includes testing the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36) and Beta-2-microglobulin precursor (SEQ ID NO:7). In still other embodiments, the method includes testing the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36) and Cathepsin B precursor (SEQ ID NO:38). In still other embodiments, the method includes testing the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36) and Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44). In still other embodiments, the method includes testing the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36) and Matrix metalloproteinase-9 (SEQ ID NO:64). In still other embodiments, the method includes testing the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36) and Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31). In still other embodiments, the method includes

testing the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36) and Alpha-1-acid glycoprotein 1 (SEQ ID NO:65).

**[0027]** In certain embodiments, the level of the listed proteins is determined by an immunoassay, by mass spectrometry, or by using a protein array.

**[0028]** In another aspect, the invention provides the use of any one or more proteins selected from the group consisting of C-reactive protein precursor (SEQ ID NO:1), Interleukin-1 receptor accessory protein precursor (SEQ ID NO:2), Interleukin-6 precursor (SEQ ID NO:3), Interleukin-1 receptor-like 1 precursor (SEQ ID NO:4), Serum amyloid A protein precursor (SEQ ID NO:5), CD5 antigen-like precursor (SEQ ID NO:6), Beta-2-microglobulin precursor (SEQ ID NO:7), Bone-marrow proteoglycan precursor (SEQ ID NO:8), Selenium-binding protein 1 (SEQ ID NO:9), Lipopolysaccharide-binding protein precursor (SEQ ID NO:10), Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO:11), Osteopontin precursor (SEQ ID NO:12), Rho GDP-dissociation inhibitor 2 (SEQ ID NO:13), Carbonic anhydrase 2 (SEQ ID NO:14), Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO:15), Collagen alpha-5(IV) chain precursor (SEQ ID NO:16), Connective tissue growth factor precursor (SEQ ID NO:17), Macrophage colony-stimulating factor 1 precursor (SEQ ID NO:18), Protein kinase C-binding protein NELL2 precursor (SEQ ID NO:19), Neudesin precursor (SEQ ID NO:20), Protein disulfide-isomerase precursor (SEQ ID NO:21), Ribonuclease pancreatic precursor (SEQ ID NO:22), Delta-like protein precursor (SEQ ID NO:23), Chromogranin-A precursor (SEQ ID NO:24), Osteomodulin precursor (SEQ ID NO:25), Collagen alpha-2(I) chain precursor (SEQ ID NO:26), Prolow-density lipoprotein receptor-related protein 1 precursor (SEQ ID NO:27), Laminin subunit gamma-1 precursor (SEQ ID NO:28), Laminin subunit beta-1 precursor (SEQ ID NO:29), Collagen alpha-1(II) chain precursor (SEQ ID NO:30), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), Protein FAM3C precursor (SEQ ID NO:32), Alpha-actinin-1 (SEQ ID NO:33), F-actin-capping protein subunit alpha-1 (SEQ ID NO:34), Aminopeptidase N (SEQ ID NO:35), Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Cell adhesion molecule 1 precursor (SEQ ID NO:37), Cathepsin B precursor (SEQ ID NO:38), Exostosin-2 (SEQ ID NO:39), Cathepsin D precursor (SEQ ID NO:40), Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO:41), Cystatin-M precursor (SEQ ID NO:42), Noelin precursor (SEQ ID NO:43), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Endoplasmic precursor (SEQ ID NO:45), Proprotein convertase subtilisin/kexin type 9 precursor (SEQ ID NO:46), Insulin-like growth factor-binding protein complex acid labile chain precursor (SEQ ID NO:47), Ezrin (SEQ ID NO:48), Fatty acid-binding protein, liver (SEQ ID NO:49), Probable G-protein coupled receptor 116 precursor (SEQ ID NO:50), Seprase (SEQ ID NO:51), Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO:52), Hypoxia up-regulated protein 1 precursor (SEQ ID NO:53), Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO:54), Transketolase (SEQ ID NO:55), Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO:56), Intercellular adhesion molecule 1 precursor (SEQ ID NO:57), Low-density lipoprotein receptor precursor (SEQ ID NO:58), 78 kDa glucose-regulated protein precursor (SEQ ID NO:59), Neighbor of punc e11 precursor (SEQ ID NO:60), Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ

ID NO:61), Pyruvate kinase isozymes M1/M2 (SEQ ID NO:62), Matrix metalloproteinase-9 (SEQ ID NO:64), Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and Stress-induced-phosphoprotein 1 (SEQ ID NO:63), in the manufacture of a proteomic profile of a biological fluid for the early diagnosis of neonatal sepsis in a subject.

**[0029]** In certain embodiments, the proteomic profile comprises information of the level of at least two of said proteins, at least three, at least four, at least five, at least six, at least seven, and so on, of the listed proteins, in any combination.

**[0030]** In a specific embodiment, the subject is a human patient.

**[0031]** In certain embodiments, the biological fluid is selected from the group consisting of cord blood, neonatal serum and cerebrospinal fluid. In a specific embodiment, the biological fluid is cord blood.

**[0032]** In one embodiment, the proteomic profile comprises information of the level of said proteins and wherein the diagnosis of said subject with neonatal sepsis is made if one or more of said tested proteins shows a significant difference in the biological fluid sample relative to normal biological fluid.

**[0033]** In another embodiment, the diagnosis is determined within 24 hours of birth.

**[0034]** In one embodiment, the proteomic profile comprises information of the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Interleukin-6 precursor (SEQ ID NO:3), C-reactive protein precursor (SEQ ID NO:1), Beta-2-microglobulin precursor (SEQ ID NO:7), Cathepsin B precursor (SEQ ID NO:38), Cystatin-M precursor (SEQ ID NO:42), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Matrix metalloproteinase-9 (SEQ ID NO:64), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), and Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and wherein the diagnosis of said subject with neonatal sepsis is made if one or more of said tested proteins shows a significant difference in the biological fluid sample relative to normal biological fluid. In a specific embodiment, the diagnosis of said subject with neonatal sepsis is made if all of said tested proteins show a significant difference in the biological fluid sample relative to normal biological fluid.

**[0035]** In certain embodiments, the level of the listed proteins is determined by an immunoassay, by mass spectrometry, or by using a protein array.

**[0036]** In yet another aspect, the invention provides an immunoassay kit comprising antibodies and reagents for the detection of one or more proteins selected from the group consisting of C-reactive protein precursor (SEQ ID NO:1), Interleukin-1 receptor accessory protein precursor (SEQ ID NO:2), Interleukin-6 precursor (SEQ ID NO:3), Interleukin-1 receptor-like 1 precursor (SEQ ID NO:4), Serum amyloid A protein precursor (SEQ ID NO:5), CD5 antigen-like precursor (SEQ ID NO:6), Beta-2-microglobulin precursor (SEQ ID NO:7), Bone-marrow proteoglycan precursor (SEQ ID NO:8), Selenium-binding protein 1 (SEQ ID NO:9), Lipopolysaccharide-binding protein precursor (SEQ ID NO:10), Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO:11), Osteopontin precursor (SEQ ID NO:12), Rho GDP-dissociation inhibitor 2 (SEQ ID NO:13), Carbonic anhydrase 2 (SEQ ID NO:14), Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO:15), Collagen alpha-5 (IV) chain precursor (SEQ ID NO:16), Connective tissue growth factor precursor (SEQ ID NO:17), Macrophage

colony-stimulating factor 1 precursor (SEQ ID NO:18), Protein kinase C-binding protein NELL2 precursor (SEQ ID NO:19), Neudesin precursor (SEQ ID NO:20), Protein disulfide-isomerase precursor (SEQ ID NO:21), Ribonuclease pancreatic precursor (SEQ ID NO:22), Delta-like protein precursor (SEQ ID NO:23), Chromogranin-A precursor (SEQ ID NO:24), Osteomodulin precursor (SEQ ID NO:25), Collagen alpha-2(I) chain precursor (SEQ ID NO:26), Pro-low-density lipoprotein receptor-related protein 1 precursor (SEQ ID NO:27), Laminin subunit gamma-1 precursor (SEQ ID NO:28), Laminin subunit beta-1 precursor (SEQ ID NO:29), Collagen alpha-1(II) chain precursor (SEQ ID NO:30), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), Protein FAM3C precursor (SEQ ID NO:32), Alpha-actinin-1 (SEQ ID NO:33), F-actin-capping protein subunit alpha-1 (SEQ ID NO:34), Aminopeptidase N (SEQ ID NO:35), Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Cell adhesion molecule 1 precursor (SEQ ID NO:37), Cathepsin B precursor (SEQ ID NO:38), Exostosin-2 (SEQ ID NO:39), Cathepsin D precursor (SEQ ID NO:40), Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO:41), Cystatin-M precursor (SEQ ID NO:42), Noelin precursor (SEQ ID NO:43), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Endoplasmic precursor (SEQ ID NO:45), Proprotein convertase subtilisin/kexin type 9 precursor (SEQ ID NO:46), Insulin-like growth factor-binding protein complex acid labile chain precursor (SEQ ID NO:47), Ezrin (SEQ ID NO:48), Fatty acid-binding protein, liver (SEQ ID NO:49), Probable G-protein coupled receptor 116 precursor (SEQ ID NO:50), Seprase (SEQ ID NO:51), Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO:52), Hypoxia up-regulated protein 1 precursor (SEQ ID NO:53), Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO:54), Transketolase (SEQ ID NO:55), Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO:56), Intercellular adhesion molecule 1 precursor (SEQ ID NO:57), Low-density lipoprotein receptor precursor (SEQ ID NO:58), 78 kDa glucose-regulated protein precursor (SEQ ID NO:59), Neighbor of punc e11 precursor (SEQ ID NO:60), Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ ID NO:61), Pyruvate kinase isozymes M1/M2 (SEQ ID NO:62), Matrix metalloproteinase-9 (SEQ ID NO:64), Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and Stress-induced-phosphoprotein 1 (SEQ ID NO:63).

**[0037]** In another aspect, the invention provides an immunoassay kit comprising antibodies and reagents for the detection of one or more proteins selected from the group consisting of Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Interleukin-6 precursor (SEQ ID NO:3), C-reactive protein precursor (SEQ ID NO:1), Beta-2-microglobulin precursor (SEQ ID NO:7), Cathepsin B precursor (SEQ ID NO:38), Cystatin-M precursor (SEQ ID NO:42), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Matrix metalloproteinase-9 (SEQ ID NO:64), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), and Alpha-1-acid glycoprotein 1 (SEQ ID NO:65).

**[0038]** In one embodiment, the immunoassay kit includes antibodies and reagents for the detection of all of listed proteins.

**[0039]** In yet another aspect, the invention provides a report comprising the results of and/or diagnosis based on a test comprising (a) testing in a sample of biological fluid obtained from said subject the level of one or more proteins selected from the group consisting of C-reactive protein precursor

(SEQ ID NO:1), Interleukin-1 receptor accessory protein precursor (SEQ ID NO:2), Interleukin-6 precursor (SEQ ID NO:3), Interleukin-1 receptor-like 1 precursor (SEQ ID NO:4), Serum amyloid A protein precursor (SEQ ID NO:5), CD5 antigen-like precursor (SEQ ID NO:6), Beta-2-microglobulin precursor (SEQ ID NO:7), Bone-marrow proteoglycan precursor (SEQ ID NO:8), Selenium-binding protein 1 (SEQ ID NO:9), Lipopolysaccharide-binding protein precursor (SEQ ID NO:10), Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO:11), Osteopontin precursor (SEQ ID NO:12), Rho GDP-dissociation inhibitor 2 (SEQ ID NO:13), Carbonic anhydrase 2 (SEQ ID NO:14), Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO:15), Collagen alpha-5(IV) chain precursor (SEQ ID NO:16), Connective tissue growth factor precursor (SEQ ID NO:17), Macrophage colony-stimulating factor 1 precursor (SEQ ID NO:18), Protein kinase C-binding protein NELL2 precursor (SEQ ID NO:19), Neudesin precursor (SEQ ID NO:20), Protein disulfide-isomerase precursor (SEQ ID NO:21), Ribonuclease pancreatic precursor (SEQ ID NO:22), Delta-like protein precursor (SEQ ID NO:23), Chromogranin-A precursor (SEQ ID NO:24), Osteomodulin precursor (SEQ ID NO:25), Collagen alpha-2(I) chain precursor (SEQ ID NO:26), Pro-low-density lipoprotein receptor-related protein 1 precursor (SEQ ID NO:27), Laminin subunit gamma-1 precursor (SEQ ID NO:28), Laminin subunit beta-1 precursor (SEQ ID NO:29), Collagen alpha-1(II) chain precursor (SEQ ID NO:30), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), Protein FAM3C precursor (SEQ ID NO:32), Alpha-actinin-1 (SEQ ID NO:33), F-actin-capping protein subunit alpha-1 (SEQ ID NO:34), Aminopeptidase N (SEQ ID NO:35), Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Cell adhesion molecule 1 precursor (SEQ ID NO:37), Cathepsin B precursor (SEQ ID NO:38), Exostosin-2 (SEQ ID NO:39), Cathepsin D precursor (SEQ ID NO:40), Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO:41), Cystatin-M precursor (SEQ ID NO:42), Noelin precursor (SEQ ID NO:43), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Endoplasmic precursor (SEQ ID NO:45), Proprotein convertase subtilisin/kexin type 9 precursor (SEQ ID NO:46), Insulin-like growth factor-binding protein complex acid labile chain precursor (SEQ ID NO:47), Ezrin (SEQ ID NO:48), Fatty acid-binding protein, liver (SEQ ID NO:49), Probable G-protein coupled receptor 116 precursor (SEQ ID NO:50), Seprase (SEQ ID NO:51), Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO:52), Hypoxia up-regulated protein 1 precursor (SEQ ID NO:53), Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO:54), Transketolase (SEQ ID NO:55), Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO:56), Intercellular adhesion molecule 1 precursor (SEQ ID NO:57), Low-density lipoprotein receptor precursor (SEQ ID NO:58), 78 kDa glucose-regulated protein precursor (SEQ ID NO:59), Neighbor of punc e11 precursor (SEQ ID NO:60), Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ ID NO:61), Pyruvate kinase isozymes M1/M2 (SEQ ID NO:62), Matrix metalloproteinase-9 (SEQ ID NO:64), Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and Stress-induced-phosphoprotein 1 (SEQ ID NO:63), relative to the level in normal biological fluid or biological fluid known to be indicative of neonatal sepsis; and (b) diagnosing said subject with neonatal sepsis if said level shows a statistically significant difference relative to the level in said normal biological fluid, or does not

show a statistically significant difference relative to the level in said biological fluid known to be indicative of neonatal sepsis.

**[0040]** In still another aspect, the invention provides a tangible medium storing the results of and/or diagnosis based on a test comprising (a) testing in a sample of biological fluid obtained from said subject the level of one or more proteins selected from the group consisting of C-reactive protein precursor (SEQ ID NO:1), Interleukin-1 receptor accessory protein precursor (SEQ ID NO:2), Interleukin-6 precursor (SEQ ID NO:3), Interleukin-1 receptor-like 1 precursor (SEQ ID NO:4), Serum amyloid A protein precursor (SEQ ID NO:5), CD5 antigen-like precursor (SEQ ID NO:6), Beta-2-microglobulin precursor (SEQ ID NO:7), Bone-marrow proteoglycan precursor (SEQ ID NO:8), Selenium-binding protein 1 (SEQ ID NO:9), Lipopolysaccharide-binding protein precursor (SEQ ID NO:10), Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO:11), Osteopontin precursor (SEQ ID NO:12), Rho GDP-dissociation inhibitor 2 (SEQ ID NO:13), Carbonic anhydrase 2 (SEQ ID NO:14), Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO:15), Collagen alpha-5(IV) chain precursor (SEQ ID NO:16), Connective tissue growth factor precursor (SEQ ID NO:17), Macrophage colony-stimulating factor 1 precursor (SEQ ID NO:18), Protein kinase C-binding protein NELL2 precursor (SEQ ID NO:19), Neudesin precursor (SEQ ID NO:20), Protein disulfide-isomerase precursor (SEQ ID NO:21), Ribonuclease pancreatic precursor (SEQ ID NO:22), Delta-like protein precursor (SEQ ID NO:23), Chromogranin-A precursor (SEQ ID NO:24), Osteomodulin precursor (SEQ ID NO:25), Collagen alpha-2(I) chain precursor (SEQ ID NO:26), Pro-low-density lipoprotein receptor-related protein 1 precursor (SEQ ID NO:27), Laminin subunit gamma-1 precursor (SEQ ID NO:28), Laminin subunit beta-1 precursor (SEQ ID NO:29), Collagen alpha-1(II) chain precursor (SEQ ID NO:30), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), Protein FAM3C precursor (SEQ ID NO:32), Alpha-actinin-1 (SEQ ID NO:33), F-actin-capping protein subunit alpha-1 (SEQ ID NO:34), Aminopeptidase N (SEQ ID NO:35), Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Cell adhesion molecule 1 precursor (SEQ ID NO:37), Cathepsin B precursor (SEQ ID NO:38), Exostosin-2 (SEQ ID NO:39), Cathepsin D precursor (SEQ ID NO:40), Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO:41), Cystatin-M precursor (SEQ ID NO:42), Noelin precursor (SEQ ID NO:43), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Endoplasmic precursor (SEQ ID NO:45), Proprotein convertase subtilisin/kexin type 9 precursor (SEQ ID NO:46), Insulin-like growth factor-binding protein complex acid labile chain precursor (SEQ ID NO:47), Ezrin (SEQ ID NO:48), Fatty acid-binding protein, liver (SEQ ID NO:49), Probable G-protein coupled receptor 116 precursor (SEQ ID NO:50), Seprase (SEQ ID NO:51), Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO:52), Hypoxia up-regulated protein 1 precursor (SEQ ID NO:53), Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO:54), Transketolase (SEQ ID NO:55), Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO:56), Intercellular adhesion molecule 1 precursor (SEQ ID NO:57), Low-density lipoprotein receptor precursor (SEQ ID NO:58), 78 kDa glucose-regulated protein precursor (SEQ ID NO:59), Neighbor of punc e11 precursor (SEQ ID NO:60), Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ ID NO:61),

Pyruvate kinase isozymes M1/M2 (SEQ ID NO:62), Matrix metalloproteinase-9 (SEQ ID NO:64), Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and Stress-induced-phosphoprotein 1 (SEQ ID NO:63), relative to the level in normal biological fluid or biological fluid known to be indicative of neonatal sepsis; and (b) diagnosing said subject with neonatal sepsis if said level shows a statistically significant difference relative to the level in said normal biological fluid, or does not show a statistically significant difference relative to the level in said biological fluid known to be indicative of neonatal sepsis.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0041]** FIG. 1 depicts Cord Blood DIGE Analysis: (A) control (red) vs. suspected sepsis (SS) (green) DIGE gel. (B) control (red) vs. confirmed sepsis (CS) (green) DIGE gel. Spots that are not differentially expressed appear yellow. (C) Differentially expressed spots between suspected sepsis (SS) vs. control. (D) Differentially expressed spots between confirmed sepsis (CS) vs. control. Spots highlighted in red were determined to be  $\geq 2$  fold down regulated and spots highlighted in green were determined to be  $\geq 2$  fold up regulated.

**[0042]** FIG. 2 depicts spectral counts of cord blood proteins from control, suspected sepsis (SS), and confirmed sepsis (CS) neonatal subjects are loaded into GeneMaths software for differential expression visualization. Proteins are hierarchically clustered using Euclidean distance learning in 200 iterations and shown in FIG. 2A. Selected sub clusters of up regulated (FIG. 2B) and down regulated proteins (FIG. 2C) are also shown. Positions of the selected sub clusters in FIG. 2A are marked accordingly.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

##### I. Definitions

**[0043]** Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, N.Y. 1994) provides one skilled in the art with a general guide to many of the terms used in the present application.

**[0044]** The term "neonatal sepsis" is used herein to describe infection of the blood of a newborn and includes all complications associated with such infection. Neonatal sepsis associated complications include but are not limited to respiratory distress syndrome (RDS), central nervous system (CNS) complications, e.g., periventricular hemorrhage and periventricular leukomalacia, mental retardation, cerebral palsy (CP), disability and death.

**[0045]** The term "proteome" is used herein to describe a significant portion of proteins in a biological sample at a given time. The concept of proteome is fundamentally different from the genome. While the genome is virtually static, the proteome continually changes in response to internal and external events.

**[0046]** The term "proteomic profile" is used to refer to a representation of the expression pattern of a plurality of proteins in a biological sample, e.g. a biological fluid at a given time. The proteomic profile can, for example, be represented as a mass spectrum, but other representations based on any physicochemical or biochemical properties of the proteins are also included. Thus the proteomic profile may, for example,

be based on differences in the electrophoretic properties of proteins, as determined by two-dimensional gel electrophoresis, e.g. by 2-D PAGE, and can be represented, e.g. as a plurality of spots in a two-dimensional electrophoresis gel.

**[0047]** Differential expression profiles may have important diagnostic value, even in the absence of specifically identified proteins. Single protein spots can then be detected, for example, by immunoblotting, multiple spots or proteins using protein microarrays. The proteomic profile typically represents or contains information that could range from a few peaks to a complex profile representing 50 or more peaks. Thus, for example, the proteomic profile may contain or represent at least 2, or at least 5 or at least 10 or at least 15, or at least 20, or at least 25, or at least 30, or at least 35, or at least 40, or at least 45, or at least 50, or at least 60, or at least 65, or at least 70, or at least 75, or at least 80, or at least 85, or at least 85, or at least 90, or at least 95, or at least 100, or at least 125, or at least 150, or at least 175, or at least 200 proteins.

**[0048]** The term "biological fluid" as used herein refers to refers to liquid material derived from a human or other animal. Biological fluids include, but are not limited to, cord blood, neonatal serum, cerebrospinal fluid (CSF), cervical-vaginal fluid (CVF), amniotic fluid, serum, plasma, urine, cerebrospinal fluid, breast milk, mucus, saliva, and sweat.

**[0049]** "Patient response" can be assessed using any endpoint indicating a benefit to the patient, including, without limitation, (1) inhibition, at least to some extent, of the progression of a pathologic condition, (2) prevention of the pathologic condition, (3) relief, at least to some extent, of one or more symptoms associated with the pathologic condition; (4) increase in the length of survival following treatment; and/or (5) decreased mortality at a given point of time following treatment.

**[0050]** The term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.

**[0051]** The designation of any particular protein, as used herein, includes all fragments, precursors, and naturally occurring variants, such as alternatively spliced and allelic variants and isoforms, as well as soluble forms of the protein named, along with native sequence homologs (including all naturally occurring variants) in other species. Thus, for example, when it is stated that the level of haptoglobin precursor (Swiss-Prot Acc. No. P00738) is tested, the statement specifically includes testing any fragments, precursors, or naturally occurring variant of the protein listed under Swiss-Prot Acc. No. P00738, as well as its non-human homologs and naturally occurring variants thereof, if subject is non-human.

## II. Detailed Description

**[0052]** The present invention concerns methods and means for an early, reliable and non-invasive testing of neonatal sepsis and/or neonatal sepsis associated complications by proteomic analysis of biological fluid, such as cord blood. The invention further concerns identification of biomarkers of neonatal sepsis. In another aspect, the invention concerns the use of proteins in the preparation or manufacture of proteomic profiles as a means for the early determination of neonatal sepsis. The invention utilizes proteomics techniques

well known in the art, as described, for example, in the following textbooks, the contents of which are hereby expressly incorporated by reference: *Proteome Research: New Frontiers in Functional Genomics (Principles and Practice)*, M. R. Wilkins et al., eds., Springer Verlag, 1007; *2-D Proteome Analysis Protocols*, Andrew L Link, editor, Humana Press, 1999; *Proteome Research: Two-Dimensional Gel Electrophoresis and Identification Methods (Principles and Practice)*, T. Rabilloud editor, Springer Verlag, 2000; *Proteome Research: Mass Spectrometry (Principles and Practice)*, P. James editor, Springer Verlag, 2001; *Introduction to Proteomics*, D. C. Liebler editor, Humana Press, 2002; *Proteomics in Practice: A Laboratory Manual of Proteome Analysis*, R. Westermeier et al., eds., John Wiley & Sons, 2002.

**[0053]** One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described.

**[0054]** 1. Identification of Proteins and Polypeptides Expressed in Biological Fluids

**[0055]** According to the present invention, proteomics analysis of biological fluids can be performed using a variety of methods known in the art. Biological fluids include, for example, cord blood, neonatal serum, cerebrospinal fluid (CSF), cervical-vaginal fluid (CVF), amniotic fluid, serum, plasma, urine, cerebrospinal fluid, breast milk, mucus, saliva, and sweat.

**[0056]** Typically, protein patterns (proteome maps) of samples from different sources, such as normal biological fluid (normal sample) and a test biological fluid (test sample), are compared to detect proteins that are up- or down-regulated in a disease. These proteins can then be excised for identification and full characterization, e.g. using peptide-mass fingerprinting and/or mass spectrometry and sequencing methods, or the normal and/or disease-specific proteome map can be used directly for the diagnosis of the disease of interest, or to confirm the presence or absence of the disease.

**[0057]** In comparative analysis, it is important to treat the normal and test samples exactly the same way, in order to correctly represent the relative level or abundance of proteins, and obtain accurate results. The required amount of total proteins will depend on the analytical technique used, and can be readily determined by one skilled in the art. The proteins present in the biological samples are typically separated by two-dimensional gel electrophoresis (2-DE) according to their pI and molecular weight. The proteins are first separated by their charge using isoelectric focusing (one-dimensional gel electrophoresis). This step can, for example, be carried out using immobilized pH-gradient (IPG) strips, which are commercially available. The second dimension is a normal SDS-PAGE analysis, where the focused IPG strip is used as the sample. After 2-DE separation, proteins can be visualized with conventional dyes, like Coomassie Blue or silver staining, and imaged using known techniques and equipment, such as, e.g. Bio-Rad GS800 densitometer and PDQUEST software, both of which are commercially available. Individual spots are then cut from the gel, destained, and subjected to tryptic digestion. The peptide mixtures can be analyzed by mass spectrometry (MS). Alternatively, the peptides can be separated, for example by capillary high pressure liquid chromatography (HPLC) and can be analyzed by MS either individually, or in pools.

**[0058]** Mass spectrometers consist of an ion source, mass analyzer, ion detector, and data acquisition unit. First, the peptides are ionized in the ion source. Then the ionized peptides are separated according to their mass-to-charge ratio in the mass analyzer and the separate ions are detected. Mass spectrometry has been widely used in protein analysis, especially since the invention of matrix-assisted laser-desorption ionisation/time-of-flight (MALDI-TOF) and electrospray ionisation (ESI) methods. There are several versions of mass analyzer, including, for example, MALDI-TOF and triple or quadrupole-TOF, or ion trap mass analyzer coupled to ESI. Thus, for example, a Q-ToF-2 mass spectrometer utilizes an orthogonal time-of-flight analyzer that allows the simultaneous detection of ions across the full mass spectrum range. For further details see, e.g. Chemusevich et al., *J. Mass Spectrom.* 36:849-865 (2001). If desired, the amino acid sequences of the peptide fragments and eventually the proteins from which they derived can be determined by techniques known in the art, such as certain variations of mass spectrometry, or Edman degradation.

**[0059]** 2. Early Detection of Neonatal Sepsis

**[0060]** Neonatal sepsis, defined as infection of the blood of a newborn, is difficult to diagnose clinically. Despite advances in neonatal care, the mortality and morbidity from neonatal sepsis remains high (Stoll 2002). Neonatal sepsis is an important contributor to neonatal morbidity including poor neurodevelopmental outcomes and neonatal death. Neonatal sepsis associated complications include, for example, respiratory distress syndrome (RDS), central nervous system (CNS) complications, cerebral palsy (CP), disability and death.

**[0061]** The highest rates of neonatal sepsis occur in low-birth-weight (LBW) infants, those with depressed respiratory function at birth, and those with maternal perinatal risk factors. Risk factors for early-onset neonatal sepsis include obstetric complications, including preterm delivery, premature rupture of membranes, maternal bleeding, e.g., as caused by placenta previa, abruptio placentae, infection of the amniotic fluid, placenta, urinary tract or endometrium, toxemia, precipitous delivery, and frequent vaginal examinations during delivery. Extended hospital stays and contaminated hospital equipment are common causes of late-onset neonatal sepsis. Organisms which can cause neonatal sepsis include the following non-limiting examples: Coagulase-negative staphylococci, including *S. epidermidis*, *S. haemolyticus*, *S. hominis*, *S. warneri*, *S. saprophyticus*, *S. cohnii*, and *S. capitis*, Group B *Streptococcus*, *Staphylococcus aureus*, *Enterococcus faecalis* and *E. faecium*, *Listeria monocytogenes*, *Escherichia coli*, *P. aeruginosa*, *Haemophilus influenzae*, *Streptococcus bovis*,  $\alpha$ -hemolytic streptococci, *Streptococcus pneumoniae*, *Neisseria meningitidis* and *N. gonorrhoeae*. Typically, the organisms which give rise to early-onset neonatal sepsis are acquired intrapartum as an ascending infection from the cervix, transplacentally from the mother or as the fetus passes through the birth canal.

**[0062]** Unfortunately, due to nonspecific and subtle early signs, the diagnosis of neonatal sepsis is difficult. Signs and symptoms of neonatal sepsis include, for example, body temperature changes breathing problems, diarrhea, low blood sugar, reduced movements, reduced sucking, seizures, slow heart rate, swollen belly area, vomiting, and jaundice. The gold standard for diagnosing neonatal sepsis is blood culture; however, negative blood cultures occur even when strong clinical indicators of septicemia are present and even in cases

where bacterial infection is later proven by autopsy (Kaufman D, Fairchild K D, *Clin Microbiol Rev.* 2004 July; 17(3):638-80). Furthermore, it is often difficult to obtain a sufficient blood sample in neonates, particularly preterm neonates. Given its rapid progression and high mortality rate, rapid empiric antibiotic therapy is typically administered, pending blood culture results. Initial therapy can include ampicillin or penicillin G and an aminoglycoside, e.g., gentamicin, or cefotaxime. Given negative outcomes associated with neonatal sepsis and the lack of confidence in currently available means for detecting neonatal sepsis, use of antibiotic treatment is not only common but prolonged, which contributes to drug resistance among neonatal pathogens. Therefore, development of early, reliable and non-invasive markers for neonatal sepsis and neonatal sepsis associated complications is imperative to allow for therapy and intervention to optimize the outcome for the neonate and to minimize the use or prolonged use of potentially unnecessary antibiotics.

**[0063]** 3. Early Detection and Diagnosis of Neonatal Sepsis Using Biomarkers in Biological Fluids

**[0064]** In one aspect, the present invention provides reliable, non-invasive methods for the diagnosis of the neonatal sepsis and neonatal sepsis associated complications using biomarkers identified in biological fluid, such as cord blood, using a proteomics approach. In certain embodiment, the biomarkers associated with neonatal sepsis are predictors for early and late onset central nervous system (CNS) complications. In one embodiment, the biomarkers are predictors for periventricular hemorrhage and/or periventricular leukomalacia. In another embodiment, the biomarkers are predictors for mental retardation.

**[0065]** In one embodiment, the instant invention allows detection of neonatal sepsis and neonatal sepsis associated complications biomarkers within about 30 minutes and 24 hours of sample collection. In certain embodiments, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 30 minutes and 48 hours of sample collection. In another embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 48 hours of sample collection. In yet another embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 24 hours of sample collection. In still another embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 12 hours of sample collection. In another embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 4 hours of sample collection. In other embodiments, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 2 hours of sample collection. In one embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 1 hours of sample collection. In another embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 30 minutes of sample collection.

**[0066]** In certain other embodiments, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 30 minutes and 48 hours of birth. In another embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 48 hours of birth. In yet another embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 24 hours of birth. In still another embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 12 hours of birth. In another embodiment, early-onset

neonatal sepsis and/or an associated complication is diagnosed within about 4 hours of birth. In other embodiments, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 2 hours of birth. In one embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 1 hours of birth. In another embodiment, early-onset neonatal sepsis and/or an associated complication is diagnosed within about 30 minutes of birth.

**[0067]** As noted before, in the context of the present invention the term "proteomic profile" is used to refer to a representation of the expression pattern of a plurality of proteins in a biological sample, e.g. a biological fluid at a given time. The proteomic profile can, for example, be represented as a mass spectrum, but other representations based on any physicochemical or biochemical properties of the proteins are also included. Although it is possible to identify and sequence all or some of the proteins present in the proteome of a biological fluid, this is not necessary for the diagnostic use of the proteomic profiles generated in accordance with the present invention. Diagnosis of a particular disease can be based on characteristic differences (unique expression signatures) between a normal proteomic profile, and proteomic profile of the same biological fluid obtained under the same circumstances, when the disease or pathologic condition to be diagnosed is present. The unique expression signature can be any unique feature or motif within the proteomic profile of a test or reference biological sample that differs from the proteomic profile of a corresponding normal biological sample obtained from the same type of source, in a statistically significant manner. For example, if the proteomic profile is presented in the form of a mass spectrum, the unique expression signature is typically a peak or a combination of peaks that differ, qualitatively or quantitatively, from the mass spectrum of a corresponding normal sample. Thus, the appearance of a new peak or a combination of new peaks in the mass spectrum, or any statistically significant change in the amplitude or shape of an existing peak or combination of existing peaks, or the disappearance of an existing peak, in the mass spectrum can be considered a unique expression signature. When the proteomic profile of the test sample obtained from a mammalian subject is compared with the proteomic profile of a reference sample comprising a unique expression signature characteristic of a pathologic maternal or fetal condition, the mammalian subject is diagnosed with such pathologic condition if it shares the unique expression signature with the reference sample.

**[0068]** A particular pathologic maternal/fetal condition can be diagnosed by comparing the proteomic profile of a biological fluid obtained from the subject to be diagnosed with the proteomic profile of a normal biological fluid of the same kind, obtained and treated in the same manner. If the proteomic profile of the test sample is essentially the same as the proteomic profile of the normal sample, the subject is considered to be free of the subject pathologic maternal/fetal condition. If the proteomic profile of the test sample shows a unique expression signature relative to the proteomic profile of the normal sample, the subject is diagnosed with the maternal/fetal condition in question.

**[0069]** Alternatively or in addition, the proteomic profile of the test sample may be compared with the proteomic profile of a reference sample, obtained from a biological fluid of a subject independently diagnosed with the pathologic maternal/fetal condition in question. In this case, the subject is

diagnosed with the pathologic condition if the proteomic profile of the test sample shares at least one feature, or a combination of features representing a unique expression signature, with the proteomic profile of the reference sample.

**[0070]** Statistical methods for comparing proteomic profiles are well known in the art. For example, in the case of a mass spectrum, the proteomic profile is defined by the peak amplitude values at key mass/charge ( $M/Z$ ) positions along the horizontal axis of the spectrum. Accordingly, a characteristic proteomic profile can, for example, be characterized by the pattern formed by the combination of spectral amplitudes at given  $M/Z$  values. The presence or absence of a characteristic expression signature, or the substantial identity of two profiles can be determined by matching the proteomic profile (pattern) of a test sample with the proteomic profile (pattern) of a reference or normal sample, with an appropriate algorithm. A statistical method for analyzing proteomic patterns is disclosed, for example, in Petricoin III, et al., *The Lancet* 359:572-77 (2002); Issaq et al., *Biochem Biophys Commun* 292:587-92 (2002); Ball et al., *Bioinformatics* 18:395-404 (2002); and Li et al., *Clinical Chemistry Journal*, 48:1296-1304 (2002).

**[0071]** In a particular embodiment, the diagnostic tests of the present invention are performed in the form of protein arrays or immunoassays.

**[0072]** 4. Protein Arrays

**[0073]** In recent years, protein arrays have gained wide recognition as a powerful means to detect proteins, monitor their expression levels, and investigate protein interactions and functions. They enable high-throughput protein analysis, when large numbers of determinations can be performed simultaneously, using automated means. In the microarray or chip format, that was originally developed for DNA arrays, such determinations can be carried out with minimum use of materials while generating large amounts of data.

**[0074]** Although proteome analysis by 2D gel electrophoresis and mass spectrometry, as described above, is very effective, it does not always provide the needed high sensitivity and this might miss many proteins that are expressed at low abundance. Protein microarrays, in addition to their high efficiency, provide improved sensitivity. Protein arrays are formed by immobilizing proteins on a solid surface, such as glass, silicon, micro-wells, nitrocellulose, PVDF membranes, and microbeads, using a variety of covalent and non-covalent attachment chemistries well known in the art. The solid support should be chemically stable before and after the coupling procedure, allow good spot morphology, display minimal nonspecific binding, should not contribute a background in detection systems, and should be compatible with different detection systems.

**[0075]** In general, protein microarrays use the same detection methods commonly used for the reading of DNA arrays. Similarly, the same instrumentation as used for reading DNA microarrays is applicable to protein arrays.

**[0076]** Thus, capture arrays (e.g. antibody arrays) can be probed with fluorescently labeled proteins from two different sources, such as normal and diseased biological fluids. In this case, the readout is based on the change in the fluorescent signal as a reflection of changes in the expression level of a target protein. Alternative readouts include, without limitation, fluorescence resonance energy transfer, surface plasmon resonance, rolling circle DNA amplification, mass spectrometry, resonance light scattering, and atomic force microscopy.

[0077] For further details, see, for example, Zhou H, et al., *Trends Biotechnol.* 19:S34-9 (2001); Zhu et al., *Current Opin. Chem. Biol.* 5:40-45-(2001); Wilson and Nock, *Angew Chem Int Ed Engl* 42:494-500 (2003); and Schweitzer and Kingsmore, *Curr Opin Biotechnol* 13:14-9 (2002). Biomolecule arrays are also disclosed in U.S. Pat. No. 6,406,921, issued Jun. 18, 2002, the entire disclosure of which is hereby expressly incorporated by reference.

[0078] 5. Immunoassays

[0079] The diagnostic assays of the present invention can also be performed in the form of various immunoassay formats, which are well known in the art. There are two main types of immunoassays, homogenous and heterogeneous. In homogenous immunoassays, both the immunological reaction between an antigen and an antibody and the detection are carried out in a homogenous reaction. Heterogeneous immunoassays include at least one separation step, which allows the differentiation of reaction products from unreacted reagents.

[0080] ELISA is a heterogeneous immunoassay, which has been widely used in laboratory practice since the early 1970's. The assay can be used to detect antigens in various formats.

[0081] In the "sandwich" format the antigen being assayed is held between two different antibodies. In this method, a solid surface is first coated with a solid phase antibody. The test sample, containing the antigen (i.e. a diagnostic protein), or a composition containing the antigen, being measured, is then added and the antigen is allowed to react with the bound antibody. Any unbound antigen is washed away. A known amount of enzyme-labeled antibody is then allowed to react with the bound antigen. Any excess unbound enzyme-linked antibody is washed away after the reaction. The substrate for the enzyme used in the assay is then added and the reaction between the substrate and the enzyme produces a color change. The amount of visual color change is a direct measurement of specific enzyme-conjugated bound antibody, and consequently the antigen present in the sample tested.

[0082] ELISA can also be used as a competitive assay. In the competitive assay format, the test specimen containing the antigen to be determined is mixed with a precise amount of enzyme-labeled antigen and both compete for binding to an anti-antigen antibody attached to a solid surface. Excess free enzyme-labeled antigen is washed off before the substrate for the enzyme is added. The amount of color intensity resulting from the enzyme-substrate interaction is a measure of the amount of antigen in the sample tested. Homogenous immunoassays include, for example, the Enzyme Multiplied Immunoassay Technique (EMIT), which typically includes a biological sample comprising the compound or compounds to be measured, enzyme-labeled molecules of the compound (s) to be measured, specific antibody or antibodies binding the compound(s) to be measured, and a specific enzyme chromogenic substrate. In a typical EMIT excess of specific antibodies is added to a biological sample. If the biological sample contains the proteins to be detected, such proteins bind to the antibodies. A measured amount of the corresponding enzyme-labeled proteins is then added to the mixture. Antibody binding sites not occupied by molecules of the protein in the sample are occupied by molecules of the added enzyme-labeled protein. As a result, enzyme activity is reduced because only free enzyme-labeled protein can act on the substrate. The amount of substrate converted from a colorless to a colored form determines the amount of free

enzyme left in the mixture. A high concentration of the protein to be detected in the sample causes higher absorbance readings. Less protein in the sample results in less enzyme activity and consequently lower absorbance readings. Inactivation of the enzyme label when the Ag-enzyme complex is Ab-bound makes the EMIT a unique system, enabling the test to be performed without a separation of bound from unbound compounds as is necessary with other immunoassay methods.

[0083] Part of this invention is also an immunoassay kit. In one aspect, the invention includes a sandwich immunoassay kit comprising a capture antibody and a detector antibody. The capture antibody and detector antibody can be monoclonal or polyclonal. In another aspect, the invention includes a diagnostic kit comprising lateral flow devices, such as immunochromatographic strip (ICS) tests, using immunoflow chromatography. The lateral flow devices employ lateral flow assay techniques as generally described in U.S. Pat. Nos. 4,943,522; 4,861,711; 4,857,453; 4,855,240; 4,775,636; 4,703,017; 4,361,537; 4,235,601; 4,168,146; 4,094,647, the entire contents of each of which is incorporated by reference. In yet another aspect, the immunoassay kit may comprise, for example, in separate containers (a) monoclonal antibodies having binding specificity for the polypeptides used in the diagnosis of a particular maternal/fetal condition, such as neonatal sepsis; (b) and anti-antibody immunoglobulins. This immunoassay kit may be utilized for the practice of the various methods provided herein. The monoclonal antibodies and the anti-antibody immunoglobulins may be provided in an amount of about 0.001 mg to about 100 grams, and more preferably about 0.01 mg to about 1 gram. The anti-antibody immunoglobulin may be a polyclonal immunoglobulin, protein A or protein G or functional fragments thereof, which may be labeled prior to use by methods known in the art. The diagnostic kit may further include where necessary agents for reducing background interference in a test, agents for increasing signal, software and algorithms for combining and interpolating marker values to produce a prediction of clinical outcome of interest, apparatus for conducting a test, calibration curves and charts, standardization curves and charts, and the like. The test kit may be packaged in any suitable manner, typically with all elements in a single container along with a sheet of printed instructions for carrying out the test.

[0084] 6. Diagnostic and Treatment Methods

[0085] The diagnostic methods of the present invention are valuable tools for practicing physicians to make quick treatment decisions, which are often critical for the survival of the neonate. Thus, for example, if a neonate shows symptoms of neonatal sepsis, or is otherwise at risk for neonatal sepsis, it is important to take immediate steps to treat the condition and improve the chances of the survival of the neonate.

[0086] Following the measurement or obtainment of the expression levels of the proteins identified herein, the assay results, findings, diagnoses, predictions and/or treatment recommendations are typically recorded and communicated to technicians, physicians and/or patients, for example. In certain embodiments, computers will be used to communicate such information to interested parties, such as, patients and/or the attending physicians. In some embodiments, the assays will be performed or the assay results analyzed in a country or jurisdiction which differs from the country or jurisdiction to which the results or diagnoses are communicated.

[0087] In a preferred embodiment, a diagnosis, prediction and/or treatment recommendation based on the expression

level in a test subject of one or more of the biomarkers presented herein is communicated to the subject as soon as possible after the assay is completed and the diagnosis and/or prediction is generated. The one or more biomarkers identified and quantified in the methods described herein can be contained in one or more panels. The number of biomarkers comprising a panel can include 1 biomarker, 2 biomarkers, 3 biomarkers, 4 biomarkers, 5 biomarkers, 6 biomarkers, 7 biomarkers, 8 biomarkers, 9 biomarkers, 10 biomarkers, 11 biomarkers, 12 biomarkers, 13 biomarkers, 14 biomarkers, 15 biomarkers, 16 biomarkers, 17 biomarkers, 18 biomarkers, 19 biomarkers, 20 biomarkers, etc. The results and/or related information may be communicated to the subject by the subject's treating physician. Alternatively, the results may be communicated directly to a test subject by any means of communication, including writing, such as by providing a written report, electronic forms of communication, such as email, or telephone. Communication may be facilitated by use of a computer, such as in case of email communications. In certain embodiments, the communication containing results of a diagnostic test and/or conclusions drawn from and/or treatment recommendations based on the test, may be generated and delivered automatically to the subject using a combination of computer hardware and software which will be familiar to artisans skilled in telecommunications. One example of a healthcare-oriented communications system is described in U.S. Pat. No. 6,283,761, the entire contents of which are incorporated by reference herein; however, the present invention is not limited to methods which utilize this particular communications system. In certain embodiments of the methods of the invention, all or some of the method steps, including the assaying of samples, diagnosing of diseases, and communicating of assay results or diagnoses, may be carried out in diverse (e.g., foreign) jurisdictions.

**[0088]** To facilitate diagnosis, the reference and/or subject biomarker profiles or expression level of one or more of the biomarkers presented herein of the present invention can be displayed on a display device, contained electronically, or in a machine-readable medium, such as but not limited to, analog tapes like those readable by a VCR, CD-ROM, DVD-ROM, USB flash media, among others. Such machine-readable media can also contain additional test results, such as, without limitation, measurements of clinical parameters and traditional laboratory risk factors. Alternatively or additionally, the machine-readable media can also comprise subject information such as medical history and any relevant family history.

**[0089]** Further details of the invention will be apparent from the following non-limiting examples. All references cited throughout the disclosure, and the references cited therein, are expressly incorporated by reference herein.

#### Example 1

##### Identification of Cord Blood Biomarkers of Neonatal Sepsis Using Global Proteomic Approaches

##### Experimental Methods

**[0090]** **Sample Collection:** Umbilical cord blood samples from a prospective observational cohort of 82 women in spontaneous preterm labor at 20-34 weeks' gestation were analyzed. Early-onset neonatal sepsis was defined as a positive neonatal blood culture within 72 hours of delivery. Of 82 subjects, 71 delivered at <34 weeks and 5 of neonates had confirmed neonatal sepsis (neonatal blood culture positive)

and 8 of the neonates had diagnosis of suspected sepsis (blood culture negative, clinical symptoms suggestive of infection).

**[0091]** **Immunodepletion of cord serum:** Serum samples used for 2-DLC experiments were depleted of 12 most abundant proteins (albumin, IgG, IgA, IgM,  $\alpha$ -1-anti-trypsin, transferrin, haptoglobin,  $\alpha$ -1-acid glycoprotein,  $\alpha$ -2-macroglobulin, fibrinogen, apolipoproteins A-I and A-II) using IgY-12 LC2 proteome partitioning system (Beckman Coulter, Fullerton, Calif.). Appropriate fractions were collected, concentrated, and buffer exchanged with 10 mM Tris (pH 8.4). Protein concentration was determined using a DC protein assay kit (Bio-Rad, Hercules, Calif.).

**[0092]** **Differential Gel Electrophoresis (DIGE):** Following protein assay, 50  $\mu$ g of protein was labeled with CyDye DIGE Fluor minimal dye (GE Lifesciences) at a concentration of 400 pm of dye. Different dyes (Cy5, Cy3, Cy2) were used to label control, suspected sepsis (SS), or confirmed sepsis (CS) cord blood serum (CBS) samples, respectively. Labeled proteins were dissolved in IEF buffer containing 0.5% ampholytes and rehydrated on to a 24 cm IPG strip (pH 4-7) for 12 h at room temperature. After rehydration, the IPG strip was subjected to isoelectric focusing for ~10 h to attain a total of 64000 volt\*hours. Focused proteins in the IPG strip were first reduced by equilibrating with buffer containing 1% DTT for 15 min and then alkylated with buffer containing 2.5% IAA. After reduction and alkylation steps, the IPG strip was loaded on to a gradient (8-16%) polyacrylamide gel (24x20 cm) and the SDS-PAGE was conducted at 85 V for 18 h to resolve proteins in the second dimension. After electrophoresis, the gel was scanned in a Typhoon 9400 scanner (GE Lifesciences) using appropriate lasers and filters with PMT voltage set at 600. Images in different channels were overlaid using selected colors and differences were visualized using ImageQuant TL software (v7.0, GE Lifesciences). Raw scanned image files were loaded into Phoretix 2D Evolution (Nonlinear Dynamics), and difference maps were generated for confirmed and suspected sepsis versus control.

**[0093]** **2-DLC Sample Processing:** Following protein assay, 1 mg portions of samples were digested with trypsin, and resulting peptides were separated with strong cation exchange (SCX) chromatography. Samples were dried and dissolved in 105  $\mu$ l of digestion buffer containing 0.2 M  $\text{NH}_4\text{HCO}_3$  and 0.3% Rapigest (Waters, Milford, Mass.) (pH 8.5). Cysteine residues were reduced and alkylated by incubating in 12.5  $\mu$ l of 0.1 M DTT at 50° C. for 45 min followed by dark room incubation in 7  $\mu$ l of 0.5 M iodoacetamide for another 30 min. Proteins were digested for 2 h at 37° C. by adding 4  $\mu$ l of 0.1 M  $\text{CaCl}_2$  and sequencing grade trypsin (Trypsin Gold, Promega) at an enzyme to substrate ratio of 33:1. Digestion was stopped by adding 60  $\mu$ l of 0.2 M HCl and resulting peptides were purified using C18 SepPak Plus cartridges (Waters, Milford, Mass.).

**[0094]** **SCX chromatography** was performed using a 100x 2.1 mm polysulfoethyl A column (The Nest Group, Southborough, Mass.). Mobile phase A contained 10 mM potassium phosphate (pH 3) and 25% acetonitrile (ACN). Mobile phase B was identical except that it contained 350 mM KCl. Following loading and washing in mobile phase A, peptides were eluted using a linear gradient of 0-50% B over 45 min, followed by a linear gradient of 50-100% B over 15 min, followed by a 20 min wash at 100% A. A total of 95 one-minute fractions were collected, dried by vacuum centrifugation, and re-dissolved by shaking in 100  $\mu$ l of 0.1% TFA. Peptide fractions were desalted using a 96-well spin column,

Vydac C18 silica (The Nest Group, Southborough, Mass.). The desalted fractions were consolidated into 35 fractions, evaporated, and dissolved in 20  $\mu$ L of 5% formic acid (FA) for LC-MS/MS analysis.

**[0095]** LC-MS/MS Analysis: Portions of each fraction were analyzed by LC/MS using an Agilent 1100 series capillary LC system and an LTQ ion trap mass spectrometer (Thermo Electron, San Jose, Calif., USA) with an Ion Max electrospray source fitted with a 34-gauge metal needle kit (ThermoFinnigan, San Jose, Calif.). Samples were applied at 20  $\mu$ L/min to a trap cartridge, and then switched onto a 0.5 $\times$ 250 mm Zorbax SB-C18 column (Agilent Technologies, Palo Alto, Calif., USA) using mobile phase A containing 0.1% FA. Mass spectra files were generated from raw data using Bioworks Browser software (version 3.1, ThermoFinnigan, San Jose, Calif.). A total of 1,195,238 tandem mass spectra were generated from all LC-MS/MS analyses.

**[0096]** Peptide and Protein Identification: Tandem mass spectra were searched against a composite protein database containing forward and reversed entries (decoy proteins) of Swiss-Prot (version 54.2) database selected for human subspecies. All searches were performed using X! Tandem (Fenyó 2003) search engine configured to use a mass tolerance of 1.8 Da and 0.4 Da for parent and fragment ions, trypsin enzyme specificity, fixed carbamidomethyl modification on cysteine residues, and several potential *in vivo* and *in vitro* modifications. Peptide and protein identifications in all samples were compiled together to generate a comprehensive cord blood proteome, using probabilistic protein identification algorithms (Nesvizhskii 2003) implemented in Scaffold software (version 1.6, Proteome Software, Portland, Oreg.). Peptide identifications with probability  $\geq 0.8$  are considered as likely to be present in the sample. Protein identifications with at least two unique peptide identifications are considered to be present in cord blood.

**[0097]** Label-Free Quantification: The total number of tandem mass spectra matched to a protein (spectral counting) is a label-free, sensitive, and semi-quantitative measure for estimating its abundance in complex mixtures. (Liu 2004). The difference of a protein's spectral counts between two complex samples was used to quantify its relative expression. (Old 2005). In this study, cord blood proteins with at least two unique peptide identifications in one sample were considered for label-free quantification. Homologous proteins (sequence homology >50%) with shared spectral counts were combined into single entry. Shared spectral counts of non-homologous were assigned to the protein with highest number of spectral matches (Occam's razor). Spectral counts of curated proteins were subjected to independent pair-wise comparisons between control and CS neonatal subjects were used to quantify the relative expression of a protein. (Gravett 2007, Nagalla 2007, Pereira 2007, Zybailov 2006). Proteins with a p-value of  $\leq 0.05$  in the pair-wise comparison were considered as significantly differentially expressed between the samples. The fold expression change (FC) of differentially expressed proteins was quantified using the equation described in Old et al. 2005).

**[0098]** Enzyme Linked Immunosorbent Assay (ELISA): 10 candidate biomarkers for detection of sepsis were measured with solid phase sandwich immunoassays. Available commercial antibodies and antigens were purchased from various vendors to prepare immunoassays. Standard curves were developed using known quantities of recombinant proteins or standards provided by manufacturer, to reference

sample concentrations. All assays were performed in triplicate and interassay and intrassay coefficient of variations ranged from 3-7%.

**[0099]** One-way analyses of variance (ANOVA) were conducted to compare log-transformed ELISA values of samples from subjects without sepsis and subjects with confirmed sepsis. For presentation, we transformed the average log value back to original units (harmonic mean), and applied the Bonferroni correction to account for multiple comparisons. Based on results from individual protein comparisons, we evaluated the classification performance of several different combinations of 2, 3 or 4 proteins using logistic regression models. Receiver operating characteristic (ROC) curves were computed based on the risk scores from each of the multi-protein models. Descriptive and inferential statistics were computed using SAS software (v9.1); ROC curves were produced and compared using customized STATA modules. (Pepe 2003).

**[0100]** Statistical Analysis of ELISA Data: Candidate protein biomarker concentrations in cord blood measured by ELISA experiments in control subjects without sepsis (n=77), and subjects with confirmed sepsis (n=5) were log transformed before subjecting them to statistical analysis. Independent pair-wise comparisons of log-transformed protein concentrations between control vs. sepsis were performed using one-way analysis of variance (ANOVA) test. For presentation, we transformed the average log value back to original units (harmonic mean), and applied the Bonferroni correction to account for multiple comparisons. Based on results from individual protein comparisons, we evaluated the classification performance of several different combinations of 2, 3 or 4 proteins using logistic regression models. Receiver operating characteristic (ROC) curves were computed based on the risk scores from each of the multi-protein models.

**[0101]** Descriptive and inferential statistics were computed using SAS software (v9.1); ROC curves were produced and compared using customized STATA modules. (Pepe 2003).

## Results

**[0102]** Proteomic changes in cord blood proteome in neonatal sepsis: 2-dimensional gel electrophoresis analysis: Cord blood (CB) from control, suspected sepsis (SS), and confirmed sepsis (CS) subjects was subjected to affinity purification to remove high abundance serum proteins. Depleted CBS from control, SS, and CS subjects were labeled with Cy5, Cy3, and Cy2 dyes, respectively. Labeled samples were resolved on a 2D gel. FIGS. 1A and 1B show DIGE gel images of CBS from control (red) vs. SS (green) and control (red) vs. CS (green), respectively. Spots that are differentially expressed between SS vs. control (FIG. 1C) and CS vs. control (FIG. 1D) were determined using Phoretix 2D evolution software. Spot intensities in difference maps (FIGS. 1C and 1D) were normalized based on total spot volume. Spots in difference maps that are  $\geq 2$  fold down regulated were highlighted in red and  $\geq 2$  fold up regulated were highlighted in green.

**[0103]** Conclusion: 2-D gel analysis identified differential expression of multiple proteins in the cord blood of neonatal sepsis subjects.

**[0104]** Cord Blood Proteome: A total of 670 proteins with at least two unique peptide (p $\geq 0.8$ ) matches were identified from all 2-DLC mass spectrometry experiments. Cord blood proteins are ranked according to the decreasing order of spectral counts and shown in Supplemental Table 1 (column No.

5). Functional annotation of cord blood proteome was performed using Gene Ontology (GO) annotations from DAVID bioinformatics resource (Dennis 2003). Proteins with metabolic (21%), immune response (10%), transport (10%), and developmental (7%) functions constituted a majority of the cord blood proteome.

**[0105]** Clustering of differentially expressed proteins in cord blood proteome in neonatal sepsis: Total number of MS/MS spectra matched to a protein is directly related to its abundance in complex mixtures. (Liu 2004). Global protein expression changes in CB between control, SS, and CS subjects are visualized using GeneMaths software (version 1.5, Applied Maths, Austin, Tex.). Spectral counts of proteins with at least two peptide identifications ( $p \geq 0.8$ ) in one of the samples were individually mean normalized and analyzed by GeneMaths software. Proteins with similar expression changes between samples were hierarchically clustered using Euclidean distance learning method with 200 simulations (FIG. 2A). Representative protein clusters with proteins that are up regulated in CS and control samples are shown in FIG. 2B and FIG. 2C, respectively.

**[0106]** Conclusion: Visualization of cord blood proteome using hierarchical clustering demonstrated specific clusters of proteins over expressed in neonatal sepsis subjects.

**[0107]** Cord blood biomarkers for neonatal sepsis identified by 2-dimensional liquid chromatography and tandem mass spectrometry (2D LC-MS-MS): CB samples from control and confirmed sepsis (CS) samples were subjected to 2-DLC based tandem mass spectrometry followed by label-free quantification. CB proteins that passed label-free quantification with a p value of  $\leq 0.05$  and a fold change of  $\geq +2.0$  were considered as significantly differentially expressed between control and neonatal sepsis subjects (Table 1). Biological function annotation for differentially expressed proteins in Table 1 was performed using Bioinformatics Harvester. Table 1 below lists differentially expressed cord blood proteins between control and neonatal sepsis samples with their Swiss-Prot accession number, description, fold change, and p-value. Proteins were grouped according to their biological function.

TABLE 1

Cord Blood Biomarkers of Neonatal Sepsis					
Biological Function	Swiss-		CS vs. Control		
	Prot Acc. No	Description	Fold Change	P Value	
Inflammation and Immune response modulators	P02741	C-reactive protein precursor (SEQ ID NO: 1)	6.6	<0.0001	
	Q9NPH3	Interleukin-1 receptor accessory protein precursor (SEQ ID NO: 2)	6.4	0.0117	
	P05231	Interleukin-6 precursor (SEQ ID NO: 3)	5.5	0.0246	
	Q01638	Interleukin-1 receptor-like 1 precursor (SEQ ID NO: 4)	5.5	0.0246	
	P02735	Serum amyloid A protein precursor (SEQ ID NO: 5)	3.8	0.0179	
	O43866	CD5 antigen-like precursor (SEQ ID NO: 6)	3.4	0.0095	
	P61769	Beta-2-microglobulin precursor (SEQ ID NO: 7)	2.5	0.0001	
	P13727	Bone-marrow proteoglycan precursor (SEQ ID NO: 8)	2.5	0.0039	
	Q13228	Selenium-binding protein 1 (SEQ ID NO: 9)	2.4	0.0231	
	P18428	Lipopolysaccharide-binding protein precursor (SEQ ID NO: 10)	2.4	<0.0001	
	Q6UVK1	Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO: 11)	2.3	0.0104	
	P10451	Osteopontin precursor (SEQ ID NO: 12)	2.2	0.0022	
	P52566	Rho GDP-dissociation inhibitor 2 (SEQ ID NO: 13)	-2.2	0.0189	
	P00918	Carbonic anhydrase 2 (SEQ ID NO: 14)	-3.1	0.0234	
	P80188	Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO: 15)	-3.5	0.0087	
	Extracellular Matrix, Matricellular, and Cytoskeletal	P29400	Collagen alpha-5(IV) chain precursor (SEQ ID NO: 16)	7.2	0.0056
		P29279	Connective tissue growth factor precursor (SEQ ID NO: 17)	7.2	0.0056
P09603		Macrophage colony-stimulating factor 1 precursor (SEQ ID NO: 18)	5.5	0.0246	
Q99435		Protein kinase C-binding protein NELL2 precursor (SEQ ID NO: 19)	4.5	0.0019	
Q9UMX5		Neudesin precursor (SEQ ID NO: 20)	4.5	0.0168	
P07237		Protein disulfide-isomerase precursor (SEQ ID NO: 21)	4	0.0317	
P07998		Ribonuclease pancreatic precursor (SEQ ID NO: 22)	3.9	0.0007	
P80370		Delta-like protein precursor (SEQ ID NO: 23)	3.8	0.0034	
P10645		Chromogranin-A precursor (SEQ ID NO: 24)	3.6	0.0002	
Q99983		Osteomodulin precursor (SEQ ID NO: 25)	3.5	0.0318	
P08123	Collagen alpha-2(I) chain precursor (SEQ ID NO: 26)	3.2	0.0004		
Q07954	Prolow-density lipoprotein receptor-related protein 1 precursor (SEQ ID NO: 27)	3.1	0.0005		

TABLE 1-continued

Cord Blood Biomarkers of Neonatal Sepsis				
Biological Function	Swiss- Prot Acc. No	Description	CS vs. Control	
			Fold Change	P Value
	P11047	Laminin subunit gamma-1 precursor (SEQ ID NO: 28)	2.8	0.0422
	P07942	Laminin subunit beta-1 precursor (SEQ ID NO: 29)	2.4	0.001
	P02458	Collagen alpha-1(II) chain precursor (SEQ ID NO: 30)	2.4	0.0231
	P01033	Metalloproteinase inhibitor 1 precursor (SEQ ID NO: 31)	2.3	0.0169
	Q92520	Protein FAM3C precursor (SEQ ID NO: 32)	2.2	0.0418
	P12814	Alpha-actinin-1 (SEQ ID NO: 33)	-3.3	0.0143
	P52907	F-actin-capping protein subunit alpha-1 (SEQ ID NO: 34)	-6.7	0.0083
	P15144	Aminopeptidase N (SEQ ID NO: 35)	13.4	<0.0001
	P08833	Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO: 36)	10.1	<0.0001
	Q9BY67	Cell adhesion molecule 1 precursor (SEQ ID NO: 37)	8.1	0.0027
	P07858	Cathepsin B precursor (SEQ ID NO: 38)	5.5	0.0046
	Q93063	Exostosin-2 (SEQ ID NO: 39)	5.5	0.0246
	P07339	Cathepsin D precursor (SEQ ID NO: 40)	3.8	<0.0001
Development and Apoptosis	Q9UM47	Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO: 41)	3.4	0.0095
	Q15828	Cystatin-M precursor (SEQ ID NO: 42)	2.9	0.0031
	Q99784	Noelin precursor (SEQ ID NO: 43)	2.9	0.0491
	P18065	Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO: 44)	2.6	<0.0001
	P14625	Endoplasmin precursor (SEQ ID NO: 45)	2.3	0.0169
	Q8NBP7	Proprotein convertase subtilisin/kexin type 9 precursor (SEQ ID NO: 46)	2.2	0.0046
	P35858	Insulin-like growth factor-binding protein complex acid labile chain precursor (SEQ ID NO: 47)	-2.3	0.0016
ERM	P15311	Ezrin (SEQ ID NO: 48)	5.5	0.0046
	P07148	Fatty acid-binding protein, liver (SEQ ID NO: 49)	8.1	0.0027
	Q8IZF2	Probable G-protein coupled receptor 116 precursor (SEQ ID NO: 50)	6.5	0.0012
	Q12884	Seprase (SEQ ID NO: 51)	6.4	0.0117
	Q8WWZ8	Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO: 52)	4.5	0.0168
	Q9Y4L1	Hypoxia up-regulated protein 1 precursor (SEQ ID NO: 53)	3.5	0.0318
	O43493	Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO: 54)	3.5	0.0318
Proteins of miscellaneous class or unknown	P29401	Transketolase (SEQ ID NO: 55)	3.4	0.0173
	P10586	Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO: 56)	2.9	0.0491
	P05362	Intercellular adhesion molecule 1 precursor (SEQ ID NO: 57)	2.8	0.006
	P01130	Low-density lipoprotein receptor precursor (SEQ ID NO: 58)	2.8	0.006
	P11021	78 kDa glucose-regulated protein precursor (SEQ ID NO: 59)	2.6	0.0049
	Q8TDY8	Neighbor of punc e11 precursor (SEQ ID NO: 60)	2.3	0.0455
	P33908	Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ ID NO: 61)	2.2	0.0418
	P14618	Pyruvate kinase isozymes M1/M2 (SEQ ID NO: 62)	-5	0.007
	P31948	Stress-induced-phosphoprotein 1 (SEQ ID NO: 63)	-5.3	0.0323

**[0108]** Conclusion: 2D-LC MS-MS analysis identified differential abundance of 60 potential biomarkers of neonatal sepsis in cord blood that are statistically significant.

**[0109]** Validation of potential neonatal sepsis biomarkers using enzyme linked immunosorbent assays: A total of 10 significantly differentially expressed proteins from the 2-DLC study were cross validated on a cohort of 77 control and 5 neonatal sepsis subjects, using ELISA. Measured protein concentrations were log-transformed and compared in a pair-wise between control and sepsis groups, using an ANOVA test. Proteins that passed the comparison with a p-value  $\leq 0.05$  are shown in Table 2 below. The mean concentration of each protein in respective sample groups was determined by computing the harmonic mean of protein concentrations (ng/ml) measured by ELISA (shown in Table 2).

demiological study from the "Grupo de Hospitales Castillo". *J Perinat Med* 2002; 30(2):149-57.

**[0113]** Craft A, Finer N. Nosocomial coagulase negative staphylococcal (CoNS) catheter-related sepsis in preterm infants: definition, diagnosis, prophylaxis, and prevention. *J Perinatol* 2001; 21(3):186-92.

**[0114]** Zafar N, Wallace C M, Kieffer P, Schroeder P, Schootman M, Hamvas A. Improving survival of vulnerable infants increases neonatal intensive care unit nosocomial infection rate. *Arch Pediatr Adolesc Med* 2001; 155(10):1098-104.

**[0115]** Ferguson J K, Gill A. Risk-stratified nosocomial infection surveillance in a neonatal intensive care unit: report on 24 months of surveillance. *J Paediatr Child Health* 1996; 32(6):525-31.

TABLE 2

Validation of potential neonatal sepsis biomarkers with ELISA						
Accession (SEQ ID NO)	ID	Protein	Control, No Sepsis (n = 77) Geometric Mean ng/ml	Confirmed Sepsis (n = 5) Geometric Mean ng/ml	Confirmed Sepsis vs. Control, No Sepsis p value	AUROC
P08833 (SEQ ID NO: 36)	IBP1	Insulin-like growth factor-binding protein 1	74.3	1671.2	0.0061	0.918
P05231 (SEQ ID NO: 3)	IL6	Interleukin-6	0.7	401.1	0.0009	0.790
P02741 (SEQ ID NO: 1)	CRP	C-reactive protein	248.2	4910.4	0.0030	0.862
P61769 (SEQ ID NO: 7)	B2MG	Beta-2-microglobulin	2434.2	4410.2	0.0082	0.835
P07858 (SEQ ID NO: 38)	CATB	Cathepsin B	162.2	487.8	0.0012	0.805
Q15828 (SEQ ID NO: 42)	CYTM	Cystatin-M	154.5	211.3	0.2295	0.600
P18065 (SEQ ID NO: 44)	IBP2	Insulin-like growth factor-binding protein 2	142.5	212.7	0.0910	0.719
P14780 (SEQ ID NO: 64)	MMP9	Matrix metalloproteinase-9	178.3	54.7	0.0052	0.881
P01033 (SEQ ID NO: 31)	TIMP1	Metalloproteinase inhibitor 1	278.0	473.0	0.0131	0.761
P02763 (SEQ ID NO: 65)	A1AG1	Alpha-1-acid glycoprotein 1	32225.8	285987.5	0.0291	0.783

**[0110]** Conclusion: ELISA analysis of potential biomarkers on individual samples confirmed the differential expression of candidate proteins observed by 2D-LC-MS-MS analysis.

## REFERENCES

**[0111]** Clark R, Powers R, White R, Bloom B, Sanchez P, Benjamin D K, Jr. Nosocomial infection in the NICU: a medical complication or unavoidable problem? *J Perinatol* 2004; 24(6):382-8.

**[0112]** Lopez Sastre J B, Coto Cotallo D, Fernandez Colomer B. Neonatal sepsis of nosocomial origin: an epi-

**[0116]** Hentschel J, de Veer I, Gastmeier P, Ruden H, Obladen M. Neonatal nosocomial infection surveillance: incidences by site and a cluster of necrotizing enterocolitis. *Infection* 1999; 27(4-5):234-8.

**[0117]** Drews M B, Ludwig A C, Leititis J U, Daschner F D. Low birth weight and nosocomial infection of neonates in a neonatal intensive care unit. *J Hosp Infect* 1995; 30(1): 65-72.

**[0118]** Berger A, Salzer H R, Weninger M, Sageder B, Aspöck C. Septicaemia in an Austrian neonatal intensive care unit: a 7-year analysis. *Acta Paediatr* 1998; 87(10): 1066-9.

**[0119]** Horbar J D, Rogowski J, Plsek P E, et al. Collaborative quality improvement for neonatal intensive care.

- NIC/Q Project Investigators of the Vermont Oxford Network. *Pediatrics* 2001; 107(1):14-22.
- [0120] Nagata E, Brito A S, Matsuo T. Nosocomial infections in a neonatal intensive care unit: incidence and risk factors. *Am J Infect Control* 2002; 30(1):26-31.
- [0121] Gaynes R P, Edwards J R, Jarvis W R, Culver D H, Tolson J S, Martone W J. Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System. *Pediatrics* 1996; 98(3 Pt 1):357-61.
- [0122] Fenyo D, Beavis R C. A method for assessing the statistical significance of mass spectrometry-based protein identifications using general scoring schemes. *Anal Chem* 2003; 75(4):768-74.
- [0123] Nesvizhskii A I, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. *Anal Chem* 2003; 75(17):4646-58.
- [0124] Liu H, Sadygov R G, Yates J R, 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. *Anal Chem* 2004; 76(14):4193-201.
- [0125] Old W M, Meyer-Arendt K, Aveline-Wolf L, et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. *Mol Cell Proteomics* 2005; 4(10):1487-502. Epub 2005 Jun. 23.
- [0126] Gravett M G, Thomas A, Schneider K A, et al. Proteomic analysis of cervical-vaginal fluid: identification of novel biomarkers for detection of intra-amniotic infection. *J Proteome Res* 2007; 6(1):89-96.
- [0127] Nagalla S R, Canick J A, Jacob T, et al. Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers. *J Proteome Res* 2007; 6(4):1245-57.
- [0128] Pereira L, Reddy A P, Jacob T, et al. Identification of novel protein biomarkers of preterm birth in human cervical-vaginal fluid. *J Proteome Res* 2007; 6(4):1269-76.
- [0129] Zybailov B, Mosley A L, Sardi M E, Coleman M K, Florens L, Washburn M P. Statistical analysis of membrane proteome expression changes in *Saccharomyces cerevisiae*. *J Proteome Res* 2006; 5(9):2339-47.
- [0130] Pepe M S. The statistical evaluation of medical tests for classification and prediction. Oxford: Oxford University Press; 2003.
- [0131] Dennis G, Jr., Sherman B T, Hosack D A, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. *Genome Biol* 2003; 4(5):P3.
- [0132] Stoll B J, Hansen N, Fanaroff A A, et al. Late onset sepsis in very low birth weight neonates; the experience of National Institute of Child Health and Human Development Neonatal Research Network. *J Pediatr* 1996; 110:285-91.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 65

<210> SEQ ID NO 1

<211> LENGTH: 224

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

Met Glu Lys Leu Leu Cys Phe Leu Val Leu Thr Ser Leu Ser His Ala
1          5          10          15

Phe Gly Gln Thr Asp Met Ser Arg Lys Ala Phe Val Phe Pro Lys Glu
20          25          30

Ser Asp Thr Ser Tyr Val Ser Leu Lys Ala Pro Leu Thr Lys Pro Leu
35          40          45

Lys Ala Phe Thr Val Cys Leu His Phe Tyr Thr Glu Leu Ser Ser Thr
50          55          60

Arg Gly Tyr Ser Ile Phe Ser Tyr Ala Thr Lys Arg Gln Asp Asn Glu
65          70          75          80

Ile Leu Ile Phe Trp Ser Lys Asp Ile Gly Tyr Ser Phe Thr Val Gly
85          90          95

Gly Ser Glu Ile Leu Phe Glu Val Pro Glu Val Thr Val Ala Pro Val
100         105         110

His Ile Cys Thr Ser Trp Glu Ser Ala Ser Gly Ile Val Glu Phe Trp
115        120        125

Val Asp Gly Lys Pro Arg Val Arg Lys Ser Leu Lys Lys Gly Tyr Thr
130        135        140

Val Gly Ala Glu Ala Ser Ile Ile Leu Gly Gln Glu Gln Asp Ser Phe
145        150        155        160

Gly Gly Asn Phe Glu Gly Ser Gln Ser Leu Val Gly Asp Ile Gly Asn

```

-continued

	165							170						175	
Val	Asn	Met	Trp	Asp	Phe	Val	Leu	Ser	Pro	Asp	Glu	Ile	Asn	Thr	Ile
	180							185						190	
Tyr	Leu	Gly	Gly	Pro	Phe	Ser	Pro	Asn	Val	Leu	Asn	Trp	Arg	Ala	Leu
	195						200					205			
Lys	Tyr	Glu	Val	Gln	Gly	Glu	Val	Phe	Thr	Lys	Pro	Gln	Leu	Trp	Pro
	210					215					220				

&lt;210&gt; SEQ ID NO 2

&lt;211&gt; LENGTH: 570

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 2

Met	Thr	Leu	Leu	Trp	Cys	Val	Val	Ser	Leu	Tyr	Phe	Tyr	Gly	Ile	Leu
1			5					10						15	
Gln	Ser	Asp	Ala	Ser	Glu	Arg	Cys	Asp	Asp	Trp	Gly	Leu	Asp	Thr	Met
		20						25					30		
Arg	Gln	Ile	Gln	Val	Phe	Glu	Asp	Glu	Pro	Ala	Arg	Ile	Lys	Cys	Pro
	35						40					45			
Leu	Phe	Glu	His	Phe	Leu	Lys	Phe	Asn	Tyr	Ser	Thr	Ala	His	Ser	Ala
	50					55					60				
Gly	Leu	Thr	Leu	Ile	Trp	Tyr	Trp	Thr	Arg	Gln	Asp	Arg	Asp	Leu	Glu
65				70					75					80	
Glu	Pro	Ile	Asn	Phe	Arg	Leu	Pro	Glu	Asn	Arg	Ile	Ser	Lys	Glu	Lys
			85						90					95	
Asp	Val	Leu	Trp	Phe	Arg	Pro	Thr	Leu	Leu	Asn	Asp	Thr	Gly	Asn	Tyr
			100					105					110		
Thr	Cys	Met	Leu	Arg	Asn	Thr	Thr	Tyr	Cys	Ser	Lys	Val	Ala	Phe	Pro
		115					120						125		
Leu	Glu	Val	Val	Gln	Lys	Asp	Ser	Cys	Phe	Asn	Ser	Pro	Met	Lys	Leu
	130					135						140			
Pro	Val	His	Lys	Leu	Tyr	Ile	Glu	Tyr	Gly	Ile	Gln	Arg	Ile	Thr	Cys
	145				150					155					160
Pro	Asn	Val	Asp	Gly	Tyr	Phe	Pro	Ser	Ser	Val	Lys	Pro	Thr	Ile	Thr
			165						170					175	
Trp	Tyr	Met	Gly	Cys	Tyr	Lys	Ile	Gln	Asn	Phe	Asn	Asn	Val	Ile	Pro
		180						185						190	
Glu	Gly	Met	Asn	Leu	Ser	Phe	Leu	Ile	Ala	Leu	Ile	Ser	Asn	Asn	Gly
		195					200					205			
Asn	Tyr	Thr	Cys	Val	Val	Thr	Tyr	Pro	Glu	Asn	Gly	Arg	Thr	Phe	His
	210					215					220				
Leu	Thr	Arg	Thr	Leu	Thr	Val	Lys	Val	Val	Gly	Ser	Pro	Lys	Asn	Ala
	225				230					235					240
Val	Pro	Pro	Val	Ile	His	Ser	Pro	Asn	Asp	His	Val	Val	Tyr	Glu	Lys
			245						250					255	
Glu	Pro	Gly	Glu	Glu	Leu	Leu	Ile	Pro	Cys	Thr	Val	Tyr	Phe	Ser	Phe
		260						265					270		
Leu	Met	Asp	Ser	Arg	Asn	Glu	Val	Trp	Trp	Thr	Ile	Asp	Gly	Lys	Lys
	275						280					285			
Pro	Asp	Asp	Ile	Thr	Ile	Asp	Val	Thr	Ile	Asn	Glu	Ser	Ile	Ser	His
	290					295					300				



-continued

---

Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe Asn Glu Glu Thr Cys Leu  
                   100                                  105                                  110  
 Val Lys Ile Ile Thr Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu Tyr  
                   115                                  120                                  125  
 Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu Gln Ala Arg Ala Val Gln  
                   130                                  135                                  140  
 Met Ser Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys Asn  
                   145                                  150                                  155                                  160  
 Leu Asp Ala Ile Thr Thr Pro Asp Pro Thr Thr Asn Ala Ser Leu Leu  
                   165                                  170                                  175  
 Thr Lys Leu Gln Ala Gln Asn Gln Trp Leu Gln Asp Met Thr Thr His  
                   180                                  185                                  190  
 Leu Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser Leu Arg Ala  
                   195                                  200                                  205  
 Leu Arg Gln Met  
                   210

<210> SEQ ID NO 4  
 <211> LENGTH: 556  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Met Gly Phe Trp Ile Leu Ala Ile Leu Thr Ile Leu Met Tyr Ser Thr  
 1                  5                                  10                                  15  
 Ala Ala Lys Phe Ser Lys Gln Ser Trp Gly Leu Glu Asn Glu Ala Leu  
                   20                                  25                                  30  
 Ile Val Arg Cys Pro Arg Gln Gly Lys Pro Ser Tyr Thr Val Asp Trp  
                   35                                  40                                  45  
 Tyr Tyr Ser Gln Thr Asn Lys Ser Ile Pro Thr Gln Glu Arg Asn Arg  
                   50                                  55                                  60  
 Val Phe Ala Ser Gly Gln Leu Leu Lys Phe Leu Pro Ala Ala Val Ala  
                   65                                  70                                  75                                  80  
 Asp Ser Gly Ile Tyr Thr Cys Ile Val Arg Ser Pro Thr Phe Asn Arg  
                   85                                  90                                  95  
 Thr Gly Tyr Ala Asn Val Thr Ile Tyr Lys Lys Gln Ser Asp Cys Asn  
                   100                                  105                                  110  
 Val Pro Asp Tyr Leu Met Tyr Ser Thr Val Ser Gly Ser Glu Lys Asn  
                   115                                  120                                  125  
 Ser Lys Ile Tyr Cys Pro Thr Ile Asp Leu Tyr Asn Trp Thr Ala Pro  
                   130                                  135                                  140  
 Leu Glu Trp Phe Lys Asn Cys Gln Ala Leu Gln Gly Ser Arg Tyr Arg  
                   145                                  150                                  155                                  160  
 Ala His Lys Ser Phe Leu Val Ile Asp Asn Val Met Thr Glu Asp Ala  
                   165                                  170                                  175  
 Gly Asp Tyr Thr Cys Lys Phe Ile His Asn Glu Asn Gly Ala Asn Tyr  
                   180                                  185                                  190  
 Ser Val Thr Ala Thr Arg Ser Phe Thr Val Lys Asp Glu Gln Gly Phe  
                   195                                  200                                  205  
 Ser Leu Phe Pro Val Ile Gly Ala Pro Ala Gln Asn Glu Ile Lys Glu  
                   210                                  215                                  220  
 Val Glu Ile Gly Lys Asn Ala Asn Leu Thr Cys Ser Ala Cys Phe Gly

-continued

---

```

225                230                235                240
Lys Gly Thr Gln Phe Leu Ala Ala Val Leu Trp Gln Leu Asn Gly Thr
      245                250                255

Lys Ile Thr Asp Phe Gly Glu Pro Arg Ile Gln Gln Glu Glu Gly Gln
      260                265                270

Asn Gln Ser Phe Ser Asn Gly Leu Ala Cys Leu Asp Met Val Leu Arg
      275                280                285

Ile Ala Asp Val Lys Glu Glu Asp Leu Leu Leu Gln Tyr Asp Cys Leu
      290                295

Ala Leu Asn Leu His Gly Leu Arg Arg His Thr Val Arg Leu Ser Arg
      305                310                315

Lys Asn Pro Ile Asp His His Ser Ile Tyr Cys Ile Ile Ala Val Cys
      325                330                335

Ser Val Phe Leu Met Leu Ile Asn Val Leu Val Ile Ile Leu Lys Met
      340                345                350

Phe Trp Ile Glu Ala Thr Leu Leu Trp Arg Asp Ile Ala Lys Pro Tyr
      355                360                365

Lys Thr Arg Asn Asp Gly Lys Leu Tyr Asp Ala Tyr Val Val Tyr Pro
      370                375                380

Arg Asn Tyr Lys Ser Ser Thr Asp Gly Ala Ser Arg Val Glu His Phe
      385                390                395

Val His Gln Ile Leu Pro Asp Val Leu Glu Asn Lys Cys Gly Tyr Thr
      405                410                415

Leu Cys Ile Tyr Gly Arg Asp Met Leu Pro Gly Glu Asp Val Val Thr
      420                425                430

Ala Val Glu Thr Asn Ile Arg Lys Ser Arg Arg His Ile Phe Ile Leu
      435                440                445

Thr Pro Gln Ile Thr His Asn Lys Glu Phe Ala Tyr Glu Gln Glu Val
      450                455                460

Ala Leu His Cys Ala Leu Ile Gln Asn Asp Ala Lys Val Ile Leu Ile
      465                470                475

Glu Met Glu Ala Leu Ser Glu Leu Asp Met Leu Gln Ala Glu Ala Leu
      485                490                495

Gln Asp Ser Leu Gln His Leu Met Lys Val Gln Gly Thr Ile Lys Trp
      500                505                510

Arg Glu Asp His Ile Ala Asn Lys Arg Ser Leu Asn Ser Lys Phe Trp
      515                520                525

Lys His Val Arg Tyr Gln Met Pro Val Pro Ser Lys Ile Pro Arg Lys
      530                535                540

Ala Ser Ser Leu Thr Pro Leu Ala Ala Gln Lys Gln
      545                550                555

```

```

<210> SEQ ID NO 5
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 5

```

```

Met Lys Leu Leu Thr Gly Leu Val Phe Cys Ser Leu Val Leu Gly Val
 1                5                10                15

Ser Ser Arg Ser Phe Phe Ser Phe Leu Gly Glu Ala Phe Asp Gly Ala
 20                25                30

```

-continued

---

```

Arg Asp Met Trp Arg Ala Tyr Ser Asp Met Arg Glu Ala Asn Tyr Ile
 35          40          45
Gly Ser Asp Lys Tyr Phe His Ala Arg Gly Asn Tyr Asp Ala Ala Lys
 50          55
Arg Gly Pro Gly Gly Val Trp Ala Ala Glu Ala Ile Ser Asp Ala Arg
 65          70          75          80
Glu Asn Ile Gln Arg Phe Phe Gly His Gly Ala Glu Asp Ser Leu Ala
 85          90          95
Asp Gln Ala Ala Asn Glu Trp Gly Arg Ser Gly Lys Asp Pro Asn His
 100         105         110
Phe Arg Pro Ala Gly Leu Pro Glu Lys Tyr
 115          120

```

```

<210> SEQ ID NO 6
<211> LENGTH: 347
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 6

```

```

Met Ala Leu Leu Phe Ser Leu Ile Leu Ala Ile Cys Thr Arg Pro Gly
 1          5          10          15
Phe Leu Ala Ser Pro Ser Gly Val Arg Leu Val Gly Gly Leu His Arg
 20          25          30
Cys Glu Gly Arg Val Glu Val Glu Gln Lys Gly Gln Trp Gly Thr Val
 35          40          45
Cys Asp Asp Gly Trp Asp Ile Lys Asp Val Ala Val Leu Cys Arg Glu
 50          55          60
Leu Gly Cys Gly Ala Ala Ser Gly Thr Pro Ser Gly Ile Leu Tyr Glu
 65          70          75          80
Pro Pro Ala Glu Lys Glu Gln Lys Val Leu Ile Gln Ser Val Ser Cys
 85          90          95
Thr Gly Thr Glu Asp Thr Leu Ala Gln Cys Glu Gln Glu Glu Val Tyr
 100         105         110
Asp Cys Ser His Asp Glu Asp Ala Gly Ala Ser Cys Glu Asn Pro Glu
 115         120         125
Ser Ser Phe Ser Pro Val Pro Glu Gly Val Arg Leu Ala Asp Gly Pro
 130         135         140
Gly His Cys Lys Gly Arg Val Glu Val Lys His Gln Asn Gln Trp Tyr
 145         150         155         160
Thr Val Cys Gln Thr Gly Trp Ser Leu Arg Ala Ala Lys Val Val Cys
 165         170         175
Arg Gln Leu Gly Cys Gly Arg Ala Val Leu Thr Gln Lys Arg Cys Asn
 180         185         190
Lys His Ala Tyr Gly Arg Lys Pro Ile Trp Leu Ser Gln Met Ser Cys
 195         200         205
Ser Gly Arg Glu Ala Thr Leu Gln Asp Cys Pro Ser Gly Pro Trp Gly
 210         215         220
Lys Asn Thr Cys Asn His Asp Glu Asp Thr Trp Val Glu Cys Glu Asp
 225         230         235         240
Pro Phe Asp Leu Arg Leu Val Gly Gly Asp Asn Leu Cys Ser Gly Arg
 245         250         255
Leu Glu Val Leu His Lys Gly Val Trp Gly Ser Val Cys Asp Asp Asn
 260         265         270

```

-continued

Trp Gly Glu Lys Glu Asp Gln Val Val Cys Lys Gln Leu Gly Cys Gly  
 275 280 285

Lys Ser Leu Ser Pro Ser Phe Arg Asp Arg Lys Cys Tyr Gly Pro Gly  
 290 295 300

Val Gly Arg Ile Trp Leu Asp Asn Val Arg Cys Ser Gly Glu Glu Gln  
 305 310 315 320

Ser Leu Glu Gln Cys Gln His Arg Phe Trp Gly Phe His Asp Cys Thr  
 325 330 335

His Gln Glu Asp Val Ala Val Ile Cys Ser Gly  
 340 345

<210> SEQ ID NO 7  
 <211> LENGTH: 119  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

Met Ser Arg Ser Val Ala Leu Ala Val Leu Ala Leu Leu Ser Leu Ser  
 1 5 10 15

Gly Leu Glu Ala Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg  
 20 25 30

His Pro Ala Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser  
 35 40 45

Gly Phe His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu  
 50 55 60

Arg Ile Glu Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp  
 65 70 75 80

Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp  
 85 90 95

Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile  
 100 105 110

Val Lys Trp Asp Arg Asp Met  
 115

<210> SEQ ID NO 8  
 <211> LENGTH: 222  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

Met Lys Leu Pro Leu Leu Leu Ala Leu Leu Phe Gly Ala Val Ser Ala  
 1 5 10 15

Leu His Leu Arg Ser Glu Thr Ser Thr Phe Glu Thr Pro Leu Gly Ala  
 20 25 30

Lys Thr Leu Pro Glu Asp Glu Glu Thr Pro Glu Gln Glu Met Glu Glu  
 35 40 45

Thr Pro Cys Arg Glu Leu Glu Glu Glu Glu Trp Gly Ser Gly Ser  
 50 55 60

Glu Asp Ala Ser Lys Lys Asp Gly Ala Val Glu Ser Ile Ser Val Pro  
 65 70 75 80

Asp Met Val Asp Lys Asn Leu Thr Cys Pro Glu Glu Glu Asp Thr Val  
 85 90 95

Lys Val Val Gly Ile Pro Gly Cys Gln Thr Cys Arg Tyr Leu Leu Val  
 100 105 110

-continued

---

```

Arg Ser Leu Gln Thr Phe Ser Gln Ala Trp Phe Thr Cys Arg Arg Cys
    115                                120                125

Tyr Arg Gly Asn Leu Val Ser Ile His Asn Phe Asn Ile Asn Tyr Arg
    130                                135                140

Ile Gln Cys Ser Val Ser Ala Leu Asn Gln Gly Gln Val Trp Ile Gly
    145                                150                155                160

Gly Arg Ile Thr Gly Ser Gly Arg Cys Arg Arg Phe Gln Trp Val Asp
    165                                170                175

Gly Ser Arg Trp Asn Phe Ala Tyr Trp Ala Ala His Gln Pro Trp Ser
    180                                185                190

Arg Gly Gly His Cys Val Ala Leu Cys Thr Arg Gly Gly Tyr Trp Arg
    195                                200                205

Arg Ala His Cys Leu Arg Arg Leu Pro Phe Ile Cys Ser Tyr
    210                                215                220

```

```

<210> SEQ ID NO 9
<211> LENGTH: 472
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 9

```

```

Met Ala Thr Lys Cys Gly Asn Cys Gly Pro Gly Tyr Ser Thr Pro Leu
  1      5      10      15

Glu Ala Met Lys Gly Pro Arg Glu Glu Ile Val Tyr Leu Pro Cys Ile
  20      25      30

Tyr Arg Asn Thr Gly Thr Glu Ala Pro Asp Tyr Leu Ala Thr Val Asp
  35      40      45

Val Asp Pro Lys Ser Pro Gln Tyr Cys Gln Val Ile His Arg Leu Pro
  50      55      60

Met Pro Asn Leu Lys Asp Glu Leu His His Ser Gly Trp Asn Thr Cys
  65      70      75      80

Ser Ser Cys Phe Gly Asp Ser Thr Lys Ser Arg Thr Lys Leu Val Leu
  85      90      95

Pro Ser Leu Ile Ser Ser Arg Ile Tyr Val Val Asp Val Gly Ser Glu
  100     105     110

Pro Arg Ala Pro Lys Leu His Lys Val Ile Glu Pro Lys Asp Ile His
  115     120     125

Ala Lys Cys Glu Leu Ala Phe Leu His Thr Ser His Cys Leu Ala Ser
  130     135     140

Gly Glu Val Met Ile Ser Ser Leu Gly Asp Val Lys Gly Asn Gly Lys
  145     150     155     160

Gly Gly Phe Val Leu Leu Asp Gly Glu Thr Phe Glu Val Lys Gly Thr
  165     170     175

Trp Glu Arg Pro Gly Gly Ala Ala Pro Leu Gly Tyr Asp Phe Trp Tyr
  180     185     190

Gln Pro Arg His Asn Val Met Ile Ser Thr Glu Trp Ala Ala Pro Asn
  195     200     205

Val Leu Arg Asp Gly Phe Asn Pro Ala Asp Val Glu Ala Gly Leu Tyr
  210     215     220

Gly Ser His Leu Tyr Val Trp Asp Trp Gln Arg His Glu Ile Val Gln
  225     230     235     240

Thr Leu Ser Leu Lys Asp Gly Leu Ile Pro Leu Glu Ile Arg Phe Leu

```

-continued

245										250					255				
His	Asn	Pro	Asp	Ala	Ala	Gln	Gly	Phe	Val	Gly	Cys	Ala	Leu	Ser	Ser				
			260					265						270					
Thr	Ile	Gln	Arg	Phe	Tyr	Lys	Asn	Glu	Gly	Gly	Thr	Trp	Ser	Val	Glu				
		275					280					285							
Lys	Val	Ile	Gln	Val	Pro	Pro	Lys	Lys	Val	Lys	Gly	Trp	Leu	Leu	Pro				
	290					295					300								
Glu	Met	Pro	Gly	Leu	Ile	Thr	Asp	Ile	Leu	Leu	Ser	Leu	Asp	Asp	Arg				
305					310						315				320				
Phe	Leu	Tyr	Phe	Ser	Asn	Trp	Leu	His	Gly	Asp	Leu	Arg	Gln	Tyr	Asp				
				325					330					335					
Ile	Ser	Asp	Pro	Gln	Arg	Pro	Arg	Leu	Thr	Gly	Gln	Leu	Phe	Leu	Gly				
			340					345						350					
Gly	Ser	Ile	Val	Lys	Gly	Gly	Pro	Val	Gln	Val	Leu	Glu	Asp	Glu	Glu				
		355					360						365						
Leu	Lys	Ser	Gln	Pro	Glu	Pro	Leu	Val	Val	Lys	Gly	Lys	Arg	Val	Ala				
	370					375					380								
Gly	Gly	Pro	Gln	Met	Ile	Gln	Leu	Ser	Leu	Asp	Gly	Lys	Arg	Leu	Tyr				
385					390					395					400				
Ile	Thr	Thr	Ser	Leu	Tyr	Ser	Ala	Trp	Asp	Lys	Gln	Phe	Tyr	Pro	Asp				
			405						410					415					
Leu	Ile	Arg	Glu	Gly	Ser	Val	Met	Leu	Gln	Val	Asp	Val	Asp	Thr	Val				
			420					425						430					
Lys	Gly	Gly	Leu	Lys	Leu	Asn	Pro	Asn	Phe	Leu	Val	Asp	Phe	Gly	Lys				
		435					440						445						
Glu	Pro	Leu	Gly	Pro	Ala	Leu	Ala	His	Glu	Leu	Arg	Tyr	Pro	Gly	Gly				
	450					455						460							
Asp	Cys	Ser	Ser	Asp	Ile	Trp	Ile												
465					470														
<210> SEQ ID NO 10																			
<211> LENGTH: 481																			
<212> TYPE: PRT																			
<213> ORGANISM: Homo sapiens																			
<400> SEQUENCE: 10																			
Met	Gly	Ala	Leu	Ala	Arg	Ala	Leu	Pro	Ser	Ile	Leu	Leu	Ala	Leu	Leu				
1				5					10					15					
Leu	Thr	Ser	Thr	Pro	Glu	Ala	Leu	Gly	Ala	Asn	Pro	Gly	Leu	Val	Ala				
			20					25					30						
Arg	Ile	Thr	Asp	Lys	Gly	Leu	Gln	Tyr	Ala	Ala	Gln	Glu	Gly	Leu	Leu				
		35					40					45							
Ala	Leu	Gln	Ser	Glu	Leu	Leu	Arg	Ile	Thr	Leu	Pro	Asp	Phe	Thr	Gly				
	50					55					60								
Asp	Leu	Arg	Ile	Pro	His	Val	Gly	Arg	Gly	Arg	Tyr	Glu	Phe	His	Ser				
65					70					75				80					
Leu	Asn	Ile	His	Ser	Cys	Glu	Leu	Leu	His	Ser	Ala	Leu	Arg	Pro	Val				
				85					90					95					
Pro	Gly	Gln	Gly	Leu	Ser	Leu	Ser	Ile	Ser	Asp	Ser	Ser	Ile	Arg	Val				
		100						105					110						
Gln	Gly	Arg	Trp	Lys	Val	Arg	Lys	Ser	Phe	Phe	Lys	Leu	Gln	Gly	Ser				
		115					120						125						

-continued

---

```

Phe Asp Val Ser Val Lys Gly Ile Ser Ile Ser Val Asn Leu Leu Leu
130                               135                               140

Gly Ser Glu Ser Ser Gly Arg Pro Thr Val Thr Ala Ser Ser Cys Ser
145                               150                               155                               160

Ser Asp Ile Ala Asp Val Glu Val Asp Met Ser Gly Asp Leu Gly Trp
165                               170                               175

Leu Leu Asn Leu Phe His Asn Gln Ile Glu Ser Lys Phe Gln Lys Val
180                               185                               190

Leu Glu Ser Arg Ile Cys Glu Met Ile Gln Lys Ser Val Ser Ser Asp
195                               200                               205

Leu Gln Pro Tyr Leu Gln Thr Leu Pro Val Thr Thr Glu Ile Asp Ser
210                               215                               220

Phe Ala Asp Ile Asp Tyr Ser Leu Val Glu Ala Pro Arg Ala Thr Ala
225                               230                               235                               240

Gln Met Leu Glu Val Met Phe Lys Gly Glu Ile Phe His Arg Asn His
245                               250                               255

Arg Ser Pro Val Thr Leu Leu Ala Ala Val Met Ser Leu Pro Glu Glu
260                               265                               270

His Asn Lys Met Val Tyr Phe Ala Ile Ser Asp Tyr Val Phe Asn Thr
275                               280                               285

Ala Ser Leu Val Tyr His Glu Glu Gly Tyr Leu Asn Phe Ser Ile Thr
290                               295                               300

Asp Asp Met Ile Pro Pro Asp Ser Asn Ile Arg Leu Thr Thr Lys Ser
305                               310                               315                               320

Phe Arg Pro Phe Val Pro Arg Leu Ala Arg Leu Tyr Pro Asn Met Asn
325                               330                               335

Leu Glu Leu Gln Gly Ser Val Pro Ser Ala Pro Leu Leu Asn Phe Ser
340                               345                               350

Pro Gly Asn Leu Ser Val Asp Pro Tyr Met Glu Ile Asp Ala Phe Val
355                               360                               365

Leu Leu Pro Ser Ser Ser Lys Glu Pro Val Phe Arg Leu Ser Val Ala
370                               375                               380

Thr Asn Val Ser Ala Thr Leu Thr Phe Asn Thr Ser Lys Ile Thr Gly
385                               390                               395                               400

Phe Leu Lys Pro Gly Lys Val Lys Val Glu Leu Lys Glu Ser Lys Val
405                               410                               415

Gly Leu Phe Asn Ala Glu Leu Leu Glu Ala Leu Leu Asn Tyr Tyr Ile
420                               425                               430

Leu Asn Thr Phe Tyr Pro Lys Phe Asn Asp Lys Leu Ala Glu Gly Phe
435                               440                               445

Pro Leu Pro Leu Leu Lys Arg Val Gln Leu Tyr Asp Leu Gly Leu Gln
450                               455                               460

Ile His Lys Asp Phe Leu Phe Leu Gly Ala Asn Val Gln Tyr Met Arg
465                               470                               475                               480

Val

```

```

<210> SEQ ID NO 11
<211> LENGTH: 2322
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

```

-continued

---

Met	Gln	Ser	Gly	Arg	Gly	Pro	Pro	Leu	Pro	Ala	Pro	Gly	Leu	Ala	Leu
1				5					10					15	
Ala	Leu	Thr	Leu	Thr	Met	Leu	Ala	Arg	Leu	Ala	Ser	Ala	Ala	Ser	Phe
			20					25					30		
Phe	Gly	Glu	Asn	His	Leu	Glu	Val	Pro	Val	Ala	Thr	Ala	Leu	Thr	Asp
		35					40					45			
Ile	Asp	Leu	Gln	Leu	Gln	Phe	Ser	Thr	Ser	Gln	Pro	Glu	Ala	Leu	Leu
	50					55					60				
Leu	Leu	Ala	Ala	Gly	Pro	Ala	Asp	His	Leu	Leu	Leu	Gln	Leu	Tyr	Ser
65					70					75					80
Gly	Arg	Leu	Gln	Val	Arg	Leu	Val	Leu	Gly	Gln	Glu	Glu	Leu	Arg	Leu
				85					90					95	
Gln	Thr	Pro	Ala	Glu	Thr	Leu	Leu	Ser	Asp	Ser	Ile	Pro	His	Thr	Val
			100					105					110		
Val	Leu	Thr	Val	Val	Glu	Gly	Trp	Ala	Thr	Leu	Ser	Val	Asp	Gly	Phe
		115					120					125			
Leu	Asn	Ala	Ser	Ser	Ala	Val	Pro	Gly	Ala	Pro	Leu	Glu	Val	Pro	Tyr
	130					135					140				
Gly	Leu	Phe	Val	Gly	Gly	Thr	Gly	Thr	Leu	Gly	Leu	Pro	Tyr	Leu	Arg
145					150					155					160
Gly	Thr	Ser	Arg	Pro	Leu	Arg	Gly	Cys	Leu	His	Ala	Ala	Thr	Leu	Asn
			165					170						175	
Gly	Arg	Ser	Leu	Leu	Arg	Pro	Leu	Thr	Pro	Asp	Val	His	Glu	Gly	Cys
		180						185					190		
Ala	Glu	Glu	Phe	Ser	Ala	Ser	Asp	Asp	Val	Ala	Leu	Gly	Phe	Ser	Gly
		195					200					205			
Pro	His	Ser	Leu	Ala	Ala	Phe	Pro	Ala	Trp	Gly	Thr	Gln	Asp	Glu	Gly
	210					215					220				
Thr	Leu	Glu	Phe	Thr	Leu	Thr	Thr	Gln	Ser	Arg	Gln	Ala	Pro	Leu	Ala
225					230					235					240
Phe	Gln	Ala	Gly	Gly	Arg	Arg	Gly	Asp	Phe	Ile	Tyr	Val	Asp	Ile	Phe
			245						250					255	
Glu	Gly	His	Leu	Arg	Ala	Val	Val	Glu	Lys	Gly	Gln	Gly	Thr	Val	Leu
			260					265					270		
Leu	His	Asn	Ser	Val	Pro	Val	Ala	Asp	Gly	Gln	Pro	His	Glu	Val	Ser
		275					280					285			
Val	His	Ile	Asn	Ala	His	Arg	Leu	Glu	Ile	Ser	Val	Asp	Gln	Tyr	Pro
	290					295					300				
Thr	His	Thr	Ser	Asn	Arg	Gly	Val	Leu	Ser	Tyr	Leu	Glu	Pro	Arg	Gly
305					310					315					320
Ser	Leu	Leu	Leu	Gly	Gly	Leu	Asp	Ala	Glu	Ala	Ser	Arg	His	Leu	Gln
				325					330					335	
Glu	His	Arg	Leu	Gly	Leu	Thr	Pro	Glu	Ala	Thr	Asn	Ala	Ser	Leu	Leu
			340					345					350		
Gly	Cys	Met	Glu	Asp	Leu	Ser	Val	Asn	Gly	Gln	Arg	Arg	Gly	Leu	Arg
		355					360					365			
Glu	Ala	Leu	Leu	Thr	Arg	Asn	Met	Ala	Ala	Gly	Cys	Arg	Leu	Glu	Glu
	370					375					380				
Glu	Glu	Tyr	Glu	Asp	Asp	Ala	Tyr	Gly	His	Tyr	Glu	Ala	Phe	Ser	Thr
385					390					395					400
Leu	Ala	Pro	Glu	Ala	Trp	Pro	Ala	Met	Glu	Leu	Pro	Glu	Pro	Cys	Val

-continued

405				410				415							
Pro	Glu	Pro	Gly	Leu	Pro	Pro	Val	Phe	Ala	Asn	Phe	Thr	Gln	Leu	Leu
			420												430
Thr	Ile	Ser	Pro	Leu	Val	Val	Ala	Glu	Gly	Gly	Thr	Ala	Trp	Leu	Glu
			435												445
Trp	Arg	His	Val	Gln	Pro	Thr	Leu	Asp	Leu	Met	Glu	Ala	Glu	Leu	Arg
			450												460
Lys	Ser	Gln	Val	Leu	Phe	Ser	Val	Thr	Arg	Gly	Ala	Arg	His	Gly	Glu
			465												480
Leu	Glu	Leu	Asp	Ile	Pro	Gly	Ala	Gln	Ala	Arg	Lys	Met	Phe	Thr	Leu
			485												495
Leu	Asp	Val	Val	Asn	Arg	Lys	Ala	Arg	Phe	Ile	His	Asp	Gly	Ser	Glu
			500												510
Asp	Thr	Ser	Asp	Gln	Leu	Val	Leu	Glu	Val	Ser	Val	Thr	Ala	Arg	Val
			515												525
Pro	Met	Pro	Ser	Cys	Leu	Arg	Arg	Gly	Gln	Thr	Tyr	Leu	Leu	Pro	Ile
			530												540
Gln	Val	Asn	Pro	Val	Asn	Asp	Pro	Pro	His	Ile	Ile	Phe	Pro	His	Gly
			545												560
Ser	Leu	Met	Val	Ile	Leu	Glu	His	Thr	Gln	Lys	Pro	Leu	Gly	Pro	Glu
			565												575
Val	Phe	Gln	Ala	Tyr	Asp	Pro	Asp	Ser	Ala	Cys	Glu	Gly	Leu	Thr	Phe
			580												590
Gln	Val	Leu	Gly	Thr	Ser	Ser	Gly	Leu	Pro	Val	Glu	Arg	Arg	Asp	Gln
			595												605
Pro	Gly	Glu	Pro	Ala	Thr	Glu	Phe	Ser	Cys	Arg	Glu	Leu	Glu	Ala	Gly
			610												620
Ser	Leu	Val	Tyr	Val	His	Arg	Gly	Gly	Pro	Ala	Gln	Asp	Leu	Thr	Phe
			625												640
Arg	Val	Ser	Asp	Gly	Leu	Gln	Ala	Ser	Pro	Pro	Ala	Thr	Leu	Lys	Val
			645												655
Val	Ala	Ile	Arg	Pro	Ala	Ile	Gln	Ile	His	Arg	Ser	Thr	Gly	Leu	Arg
			660												670
Leu	Ala	Gln	Gly	Ser	Ala	Met	Pro	Ile	Leu	Pro	Ala	Asn	Leu	Ser	Val
			675												685
Glu	Thr	Asn	Ala	Val	Gly	Gln	Asp	Val	Ser	Val	Leu	Phe	Arg	Val	Thr
			690												700
Gly	Ala	Leu	Gln	Phe	Gly	Glu	Leu	Gln	Lys	Gln	Gly	Ala	Gly	Gly	Val
			705												720
Glu	Gly	Ala	Glu	Trp	Trp	Ala	Thr	Gln	Ala	Phe	His	Gln	Arg	Asp	Val
			725												735
Glu	Gln	Gly	Arg	Val	Arg	Tyr	Leu	Ser	Thr	Asp	Pro	Gln	His	His	Ala
			740												750
Tyr	Asp	Thr	Val	Glu	Asn	Leu	Ala	Leu	Glu	Val	Gln	Val	Gly	Gln	Glu
			755												765
Ile	Leu	Ser	Asn	Leu	Ser	Phe	Pro	Val	Thr	Ile	Gln	Arg	Ala	Thr	Val
			770												780
Trp	Met	Leu	Arg	Leu	Glu	Pro	Leu	His	Thr	Gln	Asn	Thr	Gln	Gln	Glu
			785												800
Thr	Leu	Thr	Thr	Ala	His	Leu	Glu	Ala	Thr	Leu	Glu	Glu	Ala	Gly	Pro
			805												815

-continued

---

Ser Pro Pro Thr Phe His Tyr Glu Val Val Gln Ala Pro Arg Lys Gly  
 820 825 830

Asn Leu Gln Leu Gln Gly Thr Arg Leu Ser Asp Gly Gln Gly Phe Thr  
 835 840 845

Gln Asp Asp Ile Gln Ala Gly Arg Val Thr Tyr Gly Ala Thr Ala Arg  
 850 855 860

Ala Ser Glu Ala Val Glu Asp Thr Phe Arg Phe Arg Val Thr Ala Pro  
 865 870 875 880

Pro Tyr Phe Ser Pro Leu Tyr Thr Phe Pro Ile His Ile Gly Gly Asp  
 885 890 895

Pro Asp Ala Pro Val Leu Thr Asn Val Leu Leu Val Val Pro Glu Gly  
 900 905 910

Gly Glu Gly Val Leu Ser Ala Asp His Leu Phe Val Lys Ser Leu Asn  
 915 920 925

Ser Ala Ser Tyr Leu Tyr Glu Val Met Glu Arg Pro Arg His Gly Arg  
 930 935 940

Leu Ala Trp Arg Gly Thr Gln Asp Lys Thr Thr Met Val Thr Ser Phe  
 945 950 955 960

Thr Asn Glu Asp Leu Leu Arg Gly Arg Leu Val Tyr Gln His Asp Asp  
 965 970 975

Ser Glu Thr Thr Glu Asp Asp Ile Pro Phe Val Ala Thr Arg Gln Gly  
 980 985 990

Glu Ser Ser Gly Asp Met Ala Trp Glu Glu Val Arg Gly Val Phe Arg  
 995 1000 1005

Val Ala Ile Gln Pro Val Asn Asp His Ala Pro Val Gln Thr Ile  
 1010 1015 1020

Ser Arg Ile Phe His Val Ala Arg Gly Gly Arg Arg Leu Leu Thr  
 1025 1030 1035

Thr Asp Asp Val Ala Phe Ser Asp Ala Asp Ser Gly Phe Ala Asp  
 1040 1045 1050

Ala Gln Leu Val Leu Thr Arg Lys Asp Leu Leu Phe Gly Ser Ile  
 1055 1060 1065

Val Ala Val Asp Glu Pro Thr Arg Pro Ile Tyr Arg Phe Thr Gln  
 1070 1075 1080

Glu Asp Leu Arg Lys Arg Arg Val Leu Phe Val His Ser Gly Ala  
 1085 1090 1095

Asp Arg Gly Trp Ile Gln Leu Gln Val Ser Asp Gly Gln His Gln  
 1100 1105 1110

Ala Thr Ala Leu Leu Glu Val Gln Ala Ser Glu Pro Tyr Leu Arg  
 1115 1120 1125

Val Ala Asn Gly Ser Ser Leu Val Val Pro Gln Gly Gly Gln Gly  
 1130 1135 1140

Thr Ile Asp Thr Ala Val Leu His Leu Asp Thr Asn Leu Asp Ile  
 1145 1150 1155

Arg Ser Gly Asp Glu Val His Tyr His Val Thr Ala Gly Pro Arg  
 1160 1165 1170

Trp Gly Gln Leu Val Arg Ala Gly Gln Pro Ala Thr Ala Phe Ser  
 1175 1180 1185

Gln Gln Asp Leu Leu Asp Gly Ala Val Leu Tyr Ser His Asn Gly  
 1190 1195 1200

-continued

---

Ser 1205	Leu	Ser	Pro	Arg	Asp	Thr 1210	Met	Ala	Phe	Ser	Val 1215	Glu	Ala	Gly
Pro 1220	Val	His	Thr	Asp	Ala	Thr 1225	Leu	Gln	Val	Thr	Ile 1230	Ala	Leu	Glu
Gly 1235	Pro	Leu	Ala	Pro	Leu	Lys 1240	Leu	Val	Arg	His	Lys 1245	Lys	Ile	Tyr
Val 1250	Phe	Gln	Gly	Glu	Ala	Ala 1255	Glu	Ile	Arg	Arg	Asp 1260	Gln	Leu	Glu
Ala 1265	Ala	Gln	Glu	Ala	Val	Pro 1270	Pro	Ala	Asp	Ile	Val 1275	Phe	Ser	Val
Lys 1280	Ser	Pro	Pro	Ser	Ala	Gly 1285	Tyr	Leu	Val	Met	Val 1290	Ser	Arg	Gly
Ala 1295	Leu	Ala	Asp	Glu	Pro	Pro 1300	Ser	Leu	Asp	Pro	Val 1305	Gln	Ser	Phe
Ser 1310	Gln	Glu	Ala	Val	Asp	Thr 1315	Gly	Arg	Val	Leu	Tyr 1320	Leu	His	Ser
Arg 1325	Pro	Glu	Ala	Trp	Ser	Asp 1330	Ala	Phe	Ser	Leu	Asp 1335	Val	Ala	Ser
Gly 1340	Leu	Gly	Ala	Pro	Leu	Glu 1345	Gly	Val	Leu	Val	Glu 1350	Leu	Glu	Val
Leu 1355	Pro	Ala	Ala	Ile	Pro	Leu 1360	Glu	Ala	Gln	Asn	Phe 1365	Ser	Val	Pro
Glu 1370	Gly	Gly	Ser	Leu	Thr	Leu 1375	Ala	Pro	Pro	Leu	Leu 1380	Arg	Val	Ser
Gly 1385	Pro	Tyr	Phe	Pro	Thr	Leu 1390	Leu	Gly	Leu	Ser	Leu 1395	Gln	Val	Leu
Glu 1400	Pro	Pro	Gln	His	Gly	Ala 1405	Leu	Gln	Lys	Glu	Asp 1410	Gly	Pro	Gln
Ala 1415	Arg	Thr	Leu	Ser	Ala	Phe 1420	Ser	Trp	Arg	Met	Val 1425	Glu	Glu	Gln
Leu 1430	Ile	Arg	Tyr	Val	His	Asp 1435	Gly	Ser	Glu	Thr	Leu 1440	Thr	Asp	Ser
Phe 1445	Val	Leu	Met	Ala	Asn	Ala 1450	Ser	Glu	Met	Asp	Arg 1455	Gln	Ser	His
Pro 1460	Val	Ala	Phe	Thr	Val	Thr 1465	Val	Leu	Pro	Val	Asn 1470	Asp	Gln	Pro
Pro 1475	Ile	Leu	Thr	Thr	Asn	Thr 1480	Gly	Leu	Gln	Met	Trp 1485	Glu	Gly	Ala
Thr 1490	Ala	Pro	Ile	Pro	Ala	Glu 1495	Ala	Leu	Arg	Ser	Thr 1500	Asp	Gly	Asp
Ser 1505	Gly	Ser	Glu	Asp	Leu	Val 1510	Tyr	Thr	Ile	Glu	Gln 1515	Pro	Ser	Asn
Gly 1520	Arg	Val	Val	Leu	Arg	Gly 1525	Ala	Pro	Gly	Thr	Glu 1530	Val	Arg	Ser
Phe 1535	Thr	Gln	Ala	Gln	Leu	Asp 1540	Gly	Gly	Leu	Val	Leu 1545	Phe	Ser	His
Arg 1550	Gly	Thr	Leu	Asp	Gly	Gly 1555	Phe	Arg	Phe	Arg	Leu 1560	Ser	Asp	Gly
Glu 1565	His	Thr	Ser	Pro	Gly	His 1570	Phe	Phe	Arg	Val	Thr 1575	Ala	Gln	Lys
Gln 1580	Val	Leu	Leu	Ser	Leu	Lys 1585	Gly	Ser	Gln	Thr	Leu 1590	Thr	Val	Cys

-continued

---

1580	1585	1590
Pro Gly Ser Val Gln Pro	Leu Ser Ser Gln Thr	Leu Arg Ala Ser
1595	1600	1605
Ser Ser Ala Gly Thr Asp	Pro Gln Leu Leu Leu Tyr	Arg Val Val
1610	1615	1620
Arg Gly Pro Gln Leu Gly	Arg Leu Phe His Ala Gln	Gln Asp Ser
1625	1630	1635
Thr Gly Glu Ala Leu Val	Asn Phe Thr Gln Ala Glu	Val Tyr Ala
1640	1645	1650
Gly Asn Ile Leu Tyr Glu	His Glu Met Pro Pro Glu	Pro Phe Trp
1655	1660	1665
Glu Ala His Asp Thr Leu	Glu Leu Gln Leu Ser Ser	Pro Pro Ala
1670	1675	1680
Arg Asp Val Ala Ala Thr	Leu Ala Val Ala Val Ser	Phe Glu Ala
1685	1690	1695
Ala Cys Pro Gln Arg Pro	Ser His Leu Trp Lys Asn	Lys Gly Leu
1700	1705	1710
Trp Val Pro Glu Gly Gln	Arg Ala Arg Ile Thr Val	Ala Ala Leu
1715	1720	1725
Asp Ala Ser Asn Leu Leu	Ala Ser Val Pro Ser Pro	Gln Arg Ser
1730	1735	1740
Glu His Asp Val Leu Phe	Gln Val Thr Gln Phe Pro	Ser Arg Gly
1745	1750	1755
Gln Leu Leu Val Ser Glu	Glu Pro Leu His Ala Gly	Gln Pro His
1760	1765	1770
Phe Leu Gln Ser Gln Leu	Ala Ala Gly Gln Leu Val	Tyr Ala His
1775	1780	1785
Gly Gly Gly Gly Thr Gln	Gln Asp Gly Phe His Phe	Arg Ala His
1790	1795	1800
Leu Gln Gly Pro Ala Gly	Ala Ser Val Ala Gly Pro	Gln Thr Ser
1805	1810	1815
Glu Ala Phe Ala Ile Thr	Val Arg Asp Val Asn Glu	Arg Pro Pro
1820	1825	1830
Gln Pro Gln Ala Ser Val	Pro Leu Arg Leu Thr Arg	Gly Ser Arg
1835	1840	1845
Ala Pro Ile Ser Arg Ala	Gln Leu Ser Val Val Asp	Pro Asp Ser
1850	1855	1860
Ala Pro Gly Glu Ile Glu	Tyr Glu Val Gln Arg Ala	Pro His Asn
1865	1870	1875
Gly Phe Leu Ser Leu Val	Gly Gly Gly Leu Gly Pro	Val Thr Arg
1880	1885	1890
Phe Thr Gln Ala Asp Val	Asp Ser Gly Arg Leu Ala	Phe Val Ala
1895	1900	1905
Asn Gly Ser Ser Val Ala	Gly Ile Phe Gln Leu Ser	Met Ser Asp
1910	1915	1920
Gly Ala Ser Pro Pro Leu	Pro Met Ser Leu Ala Val	Asp Ile Leu
1925	1930	1935
Pro Ser Ala Ile Glu Val	Gln Leu Arg Ala Pro Leu	Glu Val Pro
1940	1945	1950
Gln Ala Leu Gly Arg Ser	Ser Leu Ser Gln Gln Gln	Leu Arg Val
1955	1960	1965

-continued

---

Val	Ser	Asp	Arg	Glu	Glu	Pro	Glu	Ala	Ala	Tyr	Arg	Leu	Ile	Gln
1970						1975						1980		
Gly	Pro	Gln	Tyr	Gly	His	Leu	Leu	Val	Gly	Gly	Arg	Pro	Thr	Ser
1985						1990						1995		
Ala	Phe	Ser	Gln	Phe	Gln	Ile	Asp	Gln	Gly	Glu	Val	Val	Phe	Ala
2000						2005						2010		
Phe	Thr	Asn	Phe	Ser	Ser	Ser	His	Asp	His	Phe	Arg	Val	Leu	Ala
2015						2020						2025		
Leu	Ala	Arg	Gly	Val	Asn	Ala	Ser	Ala	Val	Val	Asn	Val	Thr	Val
2030						2035						2040		
Arg	Ala	Leu	Leu	His	Val	Trp	Ala	Gly	Gly	Pro	Trp	Pro	Gln	Gly
2045						2050						2055		
Ala	Thr	Leu	Arg	Leu	Asp	Pro	Thr	Val	Leu	Asp	Ala	Gly	Glu	Leu
2060						2065						2070		
Ala	Asn	Arg	Thr	Gly	Ser	Val	Pro	Arg	Phe	Arg	Leu	Leu	Glu	Gly
2075						2080						2085		
Pro	Arg	His	Gly	Arg	Val	Val	Arg	Val	Pro	Arg	Ala	Arg	Thr	Glu
2090						2095						2100		
Pro	Gly	Gly	Ser	Gln	Leu	Val	Glu	Gln	Phe	Thr	Gln	Gln	Asp	Leu
2105						2110						2115		
Glu	Asp	Gly	Arg	Leu	Gly	Leu	Glu	Val	Gly	Arg	Pro	Glu	Gly	Arg
2120						2125						2130		
Ala	Pro	Gly	Pro	Ala	Gly	Asp	Ser	Leu	Thr	Leu	Glu	Leu	Trp	Ala
2135						2140						2145		
Gln	Gly	Val	Pro	Pro	Ala	Val	Ala	Ser	Leu	Asp	Phe	Ala	Thr	Glu
2150						2155						2160		
Pro	Tyr	Asn	Ala	Ala	Arg	Pro	Tyr	Ser	Val	Ala	Leu	Leu	Ser	Val
2165						2170						2175		
Pro	Glu	Ala	Ala	Arg	Thr	Glu	Ala	Gly	Lys	Pro	Glu	Ser	Ser	Thr
2180						2185						2190		
Pro	Thr	Gly	Glu	Pro	Gly	Pro	Met	Ala	Ser	Ser	Pro	Glu	Pro	Ala
2195						2200						2205		
Val	Ala	Lys	Gly	Gly	Phe	Leu	Ser	Phe	Leu	Glu	Ala	Asn	Met	Phe
2210						2215						2220		
Ser	Val	Ile	Ile	Pro	Met	Cys	Leu	Val	Leu	Leu	Leu	Leu	Ala	Leu
2225						2230						2235		
Ile	Leu	Pro	Leu	Leu	Phe	Tyr	Leu	Arg	Lys	Arg	Asn	Lys	Thr	Gly
2240						2245						2250		
Lys	His	Asp	Val	Gln	Val	Leu	Thr	Ala	Lys	Pro	Arg	Asn	Gly	Leu
2255						2260						2265		
Ala	Gly	Asp	Thr	Glu	Thr	Phe	Arg	Lys	Val	Glu	Pro	Gly	Gln	Ala
2270						2275						2280		
Ile	Pro	Leu	Thr	Ala	Val	Pro	Gly	Gln	Gly	Pro	Pro	Pro	Gly	Gly
2285						2290						2295		
Gln	Pro	Asp	Pro	Glu	Leu	Leu	Gln	Phe	Cys	Arg	Thr	Pro	Asn	Pro
2300						2305						2310		
Ala	Leu	Lys	Asn	Gly	Gln	Tyr	Trp	Val						
2315						2320								

&lt;210&gt; SEQ ID NO 12

&lt;211&gt; LENGTH: 314

-continued

---

```

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

Met Arg Ile Ala Val Ile Cys Phe Cys Leu Leu Gly Ile Thr Cys Ala
1           5           10           15
Ile Pro Val Lys Gln Ala Asp Ser Gly Ser Ser Glu Glu Lys Gln Leu
20           25           30
Tyr Asn Lys Tyr Pro Asp Ala Val Ala Thr Trp Leu Asn Pro Asp Pro
35           40           45
Ser Gln Lys Gln Asn Leu Leu Ala Pro Gln Asn Ala Val Ser Ser Glu
50           55           60
Glu Thr Asn Asp Phe Lys Gln Glu Thr Leu Pro Ser Lys Ser Asn Glu
65           70           75           80
Ser His Asp His Met Asp Asp Met Asp Asp Glu Asp Asp Asp Asp His
85           90           95
Val Asp Ser Gln Asp Ser Ile Asp Ser Asn Asp Ser Asp Asp Val Asp
100          105          110
Asp Thr Asp Asp Ser His Gln Ser Asp Glu Ser His His Ser Asp Glu
115          120          125
Ser Asp Glu Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala Thr Glu
130          135          140
Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly
145          150          155          160
Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg
165          170          175
Pro Asp Ile Gln Tyr Pro Asp Ala Thr Asp Glu Asp Ile Thr Ser His
180          185          190
Met Glu Ser Glu Glu Leu Asn Gly Ala Tyr Lys Ala Ile Pro Val Ala
195          200          205
Gln Asp Leu Asn Ala Pro Ser Asp Trp Asp Ser Arg Gly Lys Asp Ser
210          215          220
Tyr Glu Thr Ser Gln Leu Asp Asp Gln Ser Ala Glu Thr His Ser His
225          230          235          240
Lys Gln Ser Arg Leu Tyr Lys Arg Lys Ala Asn Asp Glu Ser Asn Glu
245          250          255
His Ser Asp Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser Arg Glu
260          265          270
Phe His Ser His Glu Phe His Ser His Glu Asp Met Leu Val Val Asp
275          280          285
Pro Lys Ser Lys Glu Glu Asp Lys His Leu Lys Phe Arg Ile Ser His
290          295          300
Glu Leu Asp Ser Ala Ser Ser Glu Val Asn
305          310

```

```

<210> SEQ ID NO 13
<211> LENGTH: 201
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13

```

```

Met Thr Glu Lys Ala Pro Glu Pro His Val Glu Glu Asp Asp Asp Asp
1           5           10           15

```

-continued

---

Glu Leu Asp Ser Lys Leu Asn Tyr Lys Pro Pro Pro Gln Lys Ser Leu  
 20 25 30  
 Lys Glu Leu Gln Glu Met Asp Lys Asp Asp Glu Ser Leu Ile Lys Tyr  
 35 40 45  
 Lys Lys Thr Leu Leu Gly Asp Gly Pro Val Val Thr Asp Pro Lys Ala  
 50 55 60  
 Pro Asn Val Val Val Thr Arg Leu Thr Leu Val Cys Glu Ser Ala Pro  
 65 70 75 80  
 Gly Pro Ile Thr Met Asp Leu Thr Gly Asp Leu Glu Ala Leu Lys Lys  
 85 90 95  
 Glu Thr Ile Val Leu Lys Glu Gly Ser Glu Tyr Arg Val Lys Ile His  
 100 105 110  
 Phe Lys Val Asn Arg Asp Ile Val Ser Gly Leu Lys Tyr Val Gln His  
 115 120 125  
 Thr Tyr Arg Thr Gly Val Lys Val Asp Lys Ala Thr Phe Met Val Gly  
 130 135 140  
 Ser Tyr Gly Pro Arg Pro Glu Glu Tyr Glu Phe Leu Thr Pro Val Glu  
 145 150 155 160  
 Glu Ala Pro Lys Gly Met Leu Ala Arg Gly Thr Tyr His Asn Lys Ser  
 165 170 175  
 Phe Phe Thr Asp Asp Asp Lys Gln Asp His Leu Ser Trp Glu Trp Asn  
 180 185 190  
 Leu Ser Ile Lys Lys Glu Trp Thr Glu  
 195 200

<210> SEQ ID NO 14  
 <211> LENGTH: 260  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

Met Ser His His Trp Gly Tyr Gly Lys His Asn Gly Pro Glu His Trp  
 1 5 10 15  
 His Lys Asp Phe Pro Ile Ala Lys Gly Glu Arg Gln Ser Pro Val Asp  
 20 25 30  
 Ile Asp Thr His Thr Ala Lys Tyr Asp Pro Ser Leu Lys Pro Leu Ser  
 35 40 45  
 Val Ser Tyr Asp Gln Ala Thr Ser Leu Arg Ile Leu Asn Asn Gly His  
 50 55 60  
 Ala Phe Asn Val Glu Phe Asp Asp Ser Gln Asp Lys Ala Val Leu Lys  
 65 70 75 80  
 Gly Gly Pro Leu Asp Gly Thr Tyr Arg Leu Ile Gln Phe His Phe His  
 85 90 95  
 Trp Gly Ser Leu Asp Gly Gln Gly Ser Glu His Thr Val Asp Lys Lys  
 100 105 110  
 Lys Tyr Ala Ala Glu Leu His Leu Val His Trp Asn Thr Lys Tyr Gly  
 115 120 125  
 Asp Phe Gly Lys Ala Val Gln Gln Pro Asp Gly Leu Ala Val Leu Gly  
 130 135 140  
 Ile Phe Leu Lys Val Gly Ser Ala Lys Pro Gly Leu Gln Lys Val Val  
 145 150 155 160  
 Asp Val Leu Asp Ser Ile Lys Thr Lys Gly Lys Ser Ala Asp Phe Thr  
 165 170 175

-continued

---

```

Asn Phe Asp Pro Arg Gly Leu Leu Pro Glu Ser Leu Asp Tyr Trp Thr
    180                      185                      190
Tyr Pro Gly Ser Leu Thr Thr Pro Pro Leu Leu Glu Cys Val Thr Trp
    195                      200                      205
Ile Val Leu Lys Glu Pro Ile Ser Val Ser Ser Glu Gln Val Leu Lys
    210                      215                      220
Phe Arg Lys Leu Asn Phe Asn Gly Glu Gly Glu Pro Glu Glu Leu Met
    225                      230                      235                      240
Val Asp Asn Trp Arg Pro Ala Gln Pro Leu Lys Asn Arg Gln Ile Lys
    245                      250                      255
Ala Ser Phe Lys
    260

```

```

<210> SEQ ID NO 15
<211> LENGTH: 198
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 15

```

```

Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala Leu
 1      5      10      15
His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro
 20     25     30
Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln
 35     40     45
Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu
 50     55     60
Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu
 65     70     75     80
Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys
 85     90     95
Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe
100    105    110
Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val
115    120    125
Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys
130    135    140
Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg
145    150    155    160
Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser
165    170    175
Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile
180    185    190
Asp Gln Cys Ile Asp Gly
195

```

```

<210> SEQ ID NO 16
<211> LENGTH: 1685
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 16

```

```

Met Lys Leu Arg Gly Val Ser Leu Ala Ala Gly Leu Phe Leu Leu Ala
 1      5      10      15

```

-continued

---

Leu Ser Leu Trp Gly Gln Pro Ala Glu Ala Ala Ala Cys Tyr Gly Cys  
 20 25 30  
 Ser Pro Gly Ser Lys Cys Asp Cys Ser Gly Ile Lys Gly Glu Lys Gly  
 35 40 45  
 Glu Arg Gly Phe Pro Gly Leu Glu Gly His Pro Gly Leu Pro Gly Phe  
 50 55 60  
 Pro Gly Pro Glu Gly Pro Pro Gly Pro Arg Gly Gln Lys Gly Asp Asp  
 65 70 75 80  
 Gly Ile Pro Gly Pro Pro Gly Pro Lys Gly Ile Arg Gly Pro Pro Gly  
 85 90 95  
 Leu Pro Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Met Pro Gly His  
 100 105 110  
 Asp Gly Ala Pro Gly Pro Gln Gly Ile Pro Gly Cys Asn Gly Thr Lys  
 115 120 125  
 Gly Glu Arg Gly Phe Pro Gly Ser Pro Gly Phe Pro Gly Leu Gln Gly  
 130 135 140  
 Pro Pro Gly Pro Pro Gly Ile Pro Gly Met Lys Gly Glu Pro Gly Ser  
 145 150 155 160  
 Ile Ile Met Ser Ser Leu Pro Gly Pro Lys Gly Asn Pro Gly Tyr Pro  
 165 170 175  
 Gly Pro Pro Gly Ile Gln Gly Leu Pro Gly Pro Thr Gly Ile Pro Gly  
 180 185 190  
 Pro Ile Gly Pro Pro Gly Pro Pro Gly Leu Met Gly Pro Pro Gly Pro  
 195 200 205  
 Pro Gly Leu Pro Gly Pro Lys Gly Asn Met Gly Leu Asn Phe Gln Gly  
 210 215 220  
 Pro Lys Gly Glu Lys Gly Glu Gln Gly Leu Gln Gly Pro Pro Gly Pro  
 225 230 235 240  
 Pro Gly Gln Ile Ser Glu Gln Lys Arg Pro Ile Asp Val Glu Phe Gln  
 245 250 255  
 Lys Gly Asp Gln Gly Leu Pro Gly Asp Arg Gly Pro Pro Gly Pro Pro  
 260 265 270  
 Gly Ile Arg Gly Pro Pro Gly Pro Pro Gly Gly Glu Lys Gly Glu Lys  
 275 280 285  
 Gly Glu Gln Gly Glu Pro Gly Lys Arg Gly Lys Pro Gly Lys Asp Gly  
 290 295 300  
 Glu Asn Gly Gln Pro Gly Ile Pro Gly Leu Pro Gly Asp Pro Gly Tyr  
 305 310 315 320  
 Pro Gly Glu Pro Gly Arg Asp Gly Glu Lys Gly Gln Lys Gly Asp Thr  
 325 330 335  
 Gly Pro Pro Gly Pro Pro Gly Leu Val Ile Pro Arg Pro Gly Thr Gly  
 340 345 350  
 Ile Thr Ile Gly Glu Lys Gly Asn Ile Gly Leu Pro Gly Leu Pro Gly  
 355 360 365  
 Glu Lys Gly Glu Arg Gly Phe Pro Gly Ile Gln Gly Pro Pro Gly Leu  
 370 375 380  
 Pro Gly Pro Pro Gly Ala Ala Val Met Gly Pro Pro Gly Pro Pro Gly  
 385 390 395 400  
 Phe Pro Gly Glu Arg Gly Gln Lys Gly Asp Glu Gly Pro Pro Gly Ile  
 405 410 415

-continued

---

Ser Ile Pro Gly Pro Pro Gly Leu Asp Gly Gln Pro Gly Ala Pro Gly  
 420 425 430

Leu Pro Gly Pro Pro Gly Pro Ala Gly Pro His Ile Pro Pro Ser Asp  
 435 440 445

Glu Ile Cys Glu Pro Gly Pro Pro Gly Pro Pro Gly Ser Pro Gly Asp  
 450 455 460

Lys Gly Leu Gln Gly Glu Gln Gly Val Lys Gly Asp Lys Gly Asp Thr  
 465 470 475 480

Cys Phe Asn Cys Ile Gly Thr Gly Ile Ser Gly Pro Pro Gly Gln Pro  
 485 490 495

Gly Leu Pro Gly Leu Pro Gly Pro Pro Gly Ser Leu Gly Phe Pro Gly  
 500 505 510

Gln Lys Gly Glu Lys Gly Gln Ala Gly Ala Thr Gly Pro Lys Gly Leu  
 515 520 525

Pro Gly Ile Pro Gly Ala Pro Gly Ala Pro Gly Phe Pro Gly Ser Lys  
 530 535 540

Gly Glu Pro Gly Asp Ile Leu Thr Phe Pro Gly Met Lys Gly Asp Lys  
 545 550 555 560

Gly Glu Leu Gly Ser Pro Gly Ala Pro Gly Leu Pro Gly Leu Pro Gly  
 565 570 575

Thr Pro Gly Gln Asp Gly Leu Pro Gly Leu Pro Gly Pro Lys Gly Glu  
 580 585 590

Pro Gly Gly Ile Thr Phe Lys Gly Glu Arg Gly Pro Pro Gly Asn Pro  
 595 600 605

Gly Leu Pro Gly Leu Pro Gly Asn Ile Gly Pro Met Gly Pro Pro Gly  
 610 615 620

Phe Gly Pro Pro Gly Pro Val Gly Glu Lys Gly Ile Gln Gly Val Ala  
 625 630 635 640

Gly Asn Pro Gly Gln Pro Gly Ile Pro Gly Pro Lys Gly Asp Pro Gly  
 645 650 655

Gln Thr Ile Thr Gln Pro Gly Lys Pro Gly Leu Pro Gly Asn Pro Gly  
 660 665 670

Arg Asp Gly Asp Val Gly Leu Pro Gly Asp Pro Gly Leu Pro Gly Gln  
 675 680 685

Pro Gly Leu Pro Gly Ile Pro Gly Ser Lys Gly Glu Pro Gly Ile Pro  
 690 695 700

Gly Ile Gly Leu Pro Gly Pro Pro Gly Pro Lys Gly Phe Pro Gly Ile  
 705 710 715 720

Pro Gly Pro Pro Gly Ala Pro Gly Thr Pro Gly Arg Ile Gly Leu Glu  
 725 730 735

Gly Pro Pro Gly Pro Pro Gly Phe Pro Gly Pro Lys Gly Glu Pro Gly  
 740 745 750

Phe Ala Leu Pro Gly Pro Pro Gly Pro Pro Gly Leu Pro Gly Phe Lys  
 755 760 765

Gly Ala Leu Gly Pro Lys Gly Asp Arg Gly Phe Pro Gly Pro Pro Gly  
 770 775 780

Pro Pro Gly Arg Thr Gly Leu Asp Gly Leu Pro Gly Pro Lys Gly Asp  
 785 790 795 800

Val Gly Pro Asn Gly Gln Pro Gly Pro Met Gly Pro Pro Gly Leu Pro  
 805 810 815

Gly Ile Gly Val Gln Gly Pro Pro Gly Pro Pro Gly Ile Pro Gly Pro

-continued

820				825				830							
Ile	Gly	Gln	Pro	Gly	Leu	His	Gly	Ile	Pro	Gly	Glu	Lys	Gly	Asp	Pro
	835						840					845			
Gly	Pro	Pro	Gly	Leu	Asp	Val	Pro	Gly	Pro	Pro	Gly	Glu	Arg	Gly	Ser
	850					855					860				
Pro	Gly	Ile	Pro	Gly	Ala	Pro	Gly	Pro	Ile	Gly	Pro	Pro	Gly	Ser	Pro
865					870					875					880
Gly	Leu	Pro	Gly	Lys	Ala	Gly	Ala	Ser	Gly	Phe	Pro	Gly	Thr	Lys	Gly
			885						890					895	
Glu	Met	Gly	Met	Gly	Pro	Pro	Gly	Pro	Pro	Pro	Gly	Pro	Leu	Gly	Ile
		900					905						910		
Pro	Gly	Arg	Ser	Gly	Val	Pro	Gly	Leu	Lys	Gly	Asp	Asp	Gly	Leu	Gln
		915					920					925			
Gly	Gln	Pro	Gly	Leu	Pro	Gly	Pro	Thr	Gly	Glu	Lys	Gly	Ser	Lys	Gly
	930					935					940				
Glu	Pro	Gly	Leu	Pro	Gly	Pro	Pro	Gly	Pro	Met	Asp	Pro	Asn	Leu	Leu
945					950					955					960
Gly	Ser	Lys	Gly	Glu	Lys	Gly	Glu	Pro	Gly	Leu	Pro	Gly	Ile	Pro	Gly
			965						970					975	
Val	Ser	Gly	Pro	Lys	Gly	Tyr	Gln	Gly	Leu	Pro	Gly	Asp	Pro	Gly	Gln
			980						985					990	
Pro	Gly	Leu	Ser	Gly	Gln	Pro	Gly	Leu	Pro	Gly	Pro	Pro	Gly	Pro	Lys
		995					1000						1005		
Gly	Asn	Pro	Gly	Leu	Pro	Gly	Gln	Pro	Gly	Leu	Ile	Gly	Pro	Pro	
	1010					1015					1020				
Gly	Leu	Lys	Gly	Thr	Ile	Gly	Asp	Met	Gly	Phe	Pro	Gly	Pro	Gln	
	1025					1030					1035				
Gly	Val	Glu	Gly	Pro	Pro	Gly	Pro	Ser	Gly	Val	Pro	Gly	Gln	Pro	
	1040					1045					1050				
Gly	Ser	Pro	Gly	Leu	Pro	Gly	Gln	Lys	Gly	Asp	Lys	Gly	Asp	Pro	
	1055					1060					1065				
Gly	Ile	Ser	Ser	Ile	Gly	Leu	Pro	Gly	Leu	Pro	Gly	Pro	Lys	Gly	
	1070					1075					1080				
Glu	Pro	Gly	Leu	Pro	Gly	Tyr	Pro	Gly	Asn	Pro	Gly	Ile	Lys	Gly	
	1085					1090					1095				
Ser	Val	Gly	Asp	Pro	Gly	Leu	Pro	Gly	Leu	Pro	Gly	Thr	Pro	Gly	
	1100					1105					1110				
Ala	Lys	Gly	Gln	Pro	Gly	Leu	Pro	Gly	Phe	Pro	Gly	Thr	Pro	Gly	
	1115					1120					1125				
Pro	Pro	Gly	Pro	Lys	Gly	Ile	Ser	Gly	Pro	Pro	Gly	Asn	Pro	Gly	
	1130					1135					1140				
Leu	Pro	Gly	Glu	Pro	Gly	Pro	Val	Gly	Gly	Gly	Gly	His	Pro	Gly	
	1145					1150					1155				
Gln	Pro	Gly	Pro	Pro	Gly	Glu	Lys	Gly	Lys	Pro	Gly	Gln	Asp	Gly	
	1160					1165					1170				
Ile	Pro	Gly	Pro	Ala	Gly	Gln	Lys	Gly	Glu	Pro	Gly	Gln	Pro	Gly	
	1175					1180					1185				
Phe	Gly	Asn	Pro	Gly	Pro	Pro	Gly	Leu	Pro	Gly	Leu	Ser	Gly	Gln	
	1190					1195					1200				
Lys	Gly	Asp	Gly	Gly	Leu	Pro	Gly	Ile	Pro	Gly	Asn	Pro	Gly	Leu	
	1205					1210					1215				

-continued

---

Pro Gly 1220	Pro Lys Gly Glu 1225	Pro Gly Phe His Gly Phe 1230	Pro Gly Val
Gln Gly 1235	Pro Pro Gly Pro 1240	Pro Gly Ser Pro Gly Pro 1245	Ala Leu Glu
Gly Pro 1250	Lys Gly Asn Pro 1255	Pro Gln Gly Pro 1260	Gly Arg Pro
Gly Leu 1265	Pro Gly Pro Glu 1270	Gly Pro Pro Gly Leu 1275	Gly Asn Gly
Gly Ile 1280	Lys Gly Glu Lys 1285	Gly Asn Pro Gly Gln 1290	Gly Leu Pro
Gly Leu 1295	Pro Gly Leu Lys 1300	Gly Asp Gln Gly Pro 1305	Gly Leu Gln
Gly Asn 1310	Pro Gly Arg Pro 1315	Gly Leu Asn Gly Met 1320	Lys Gly Asp Pro
Gly Leu 1325	Pro Gly Val Pro 1330	Gly Phe Pro Gly Met 1335	Lys Gly Pro Ser
Gly Val 1340	Pro Gly Ser Ala 1345	Gly Pro Glu Gly Glu 1350	Pro Gly Leu Ile
Gly Pro 1355	Pro Gly Pro Pro 1360	Gly Leu Pro Gly Pro 1365	Ser Gly Gln Ser
Ile Ile 1370	Ile Lys Gly Asp 1375	Ala Gly Pro Pro Gly 1380	Pro Gly Gln
Pro Gly 1385	Leu Lys Gly Leu 1390	Gly Pro Gln Gly 1395	Gln Gly Leu
Pro Gly 1400	Pro Thr Gly Pro 1405	Gly Asp Pro Gly Arg 1410	Asn Gly Leu
Pro Gly 1415	Phe Asp Gly Ala 1420	Gly Gly Arg Lys Gly 1425	Asp Pro Gly Leu
Pro Gly 1430	Gln Pro Gly Thr 1435	Arg Gly Leu Asp Gly 1440	Pro Gly Pro
Asp Gly 1445	Leu Gln Gly Pro 1450	Pro Gly Pro Pro Gly 1455	Thr Ser Ser Val
Ala His 1460	Gly Phe Leu Ile 1465	Thr Arg His Ser Gln 1470	Thr Thr Asp Ala
Pro Gln 1475	Cys Pro Gln Gly 1480	Thr Leu Gln Val Tyr 1485	Glu Gly Phe Ser
Leu Leu 1490	Tyr Val Gln Gly 1495	Asn Lys Arg Ala His 1500	Gly Gln Asp Leu
Gly Thr 1505	Ala Gly Ser Cys 1510	Leu Arg Arg Phe Ser 1515	Thr Met Pro Phe
Met Phe 1520	Cys Asn Ile Asn 1525	Asn Val Cys Asn Phe 1530	Ala Ser Arg Asn
Asp Tyr 1535	Ser Tyr Trp Leu 1540	Ser Thr Pro Glu Pro 1545	Met Pro Met Ser
Met Gln 1550	Pro Leu Lys Gly 1555	Gln Ser Ile Gln Pro 1560	Phe Ile Ser Arg
Cys Ala 1565	Val Cys Glu Ala 1570	Pro Ala Val Val Ile 1575	Ala Val His Ser
Gln Thr 1580	Ile Gln Ile Pro 1585	His Cys Pro Gln Gly 1590	Trp Asp Ser Leu

-continued

---

Trp Ile Gly Tyr Ser Phe Met Met His Thr Ser Ala Gly Ala Glu  
 1595 1600 1605

Gly Ser Gly Gln Ala Leu Ala Ser Pro Gly Ser Cys Leu Glu Glu  
 1610 1615 1620

Phe Arg Ser Ala Pro Phe Ile Glu Cys His Gly Arg Gly Thr Cys  
 1625 1630 1635

Asn Tyr Tyr Ala Asn Ser Tyr Ser Phe Trp Leu Ala Thr Val Asp  
 1640 1645 1650

Val Ser Asp Met Phe Ser Lys Pro Gln Ser Glu Thr Leu Lys Ala  
 1655 1660 1665

Gly Asp Leu Arg Thr Arg Ile Ser Arg Cys Gln Val Cys Met Lys  
 1670 1675 1680

Arg Thr  
 1685

<210> SEQ ID NO 17  
 <211> LENGTH: 349  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

Met Thr Ala Ala Ser Met Gly Pro Val Arg Val Ala Phe Val Val Leu  
 1 5 10 15

Leu Ala Leu Cys Ser Arg Pro Ala Val Gly Gln Asn Cys Ser Gly Pro  
 20 25 30

Cys Arg Cys Pro Asp Glu Pro Ala Pro Arg Cys Pro Ala Gly Val Ser  
 35 40 45

Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Lys Gln Leu  
 50 55 60

Gly Glu Leu Cys Thr Glu Arg Asp Pro Cys Asp Pro His Lys Gly Leu  
 65 70 75 80

Phe Cys His Phe Gly Ser Pro Ala Asn Arg Lys Ile Gly Val Cys Thr  
 85 90 95

Ala Lys Asp Gly Ala Pro Cys Ile Phe Gly Gly Thr Val Tyr Arg Ser  
 100 105 110

Gly Glu Ser Phe Gln Ser Ser Cys Lys Tyr Gln Cys Thr Cys Leu Asp  
 115 120 125

Gly Ala Val Gly Cys Met Pro Leu Cys Ser Met Asp Val Arg Leu Pro  
 130 135 140

Ser Pro Asp Cys Pro Phe Pro Arg Arg Val Lys Leu Pro Gly Lys Cys  
 145 150 155 160

Cys Glu Glu Trp Val Cys Asp Glu Pro Lys Asp Gln Thr Val Val Gly  
 165 170 175

Pro Ala Leu Ala Ala Tyr Arg Leu Glu Asp Thr Phe Gly Pro Asp Pro  
 180 185 190

Thr Met Ile Arg Ala Asn Cys Leu Val Gln Thr Thr Glu Trp Ser Ala  
 195 200 205

Cys Ser Lys Thr Cys Gly Met Gly Ile Ser Thr Arg Val Thr Asn Asp  
 210 215 220

Asn Ala Ser Cys Arg Leu Glu Lys Gln Ser Arg Leu Cys Met Val Arg  
 225 230 235 240

Pro Cys Glu Ala Asp Leu Glu Glu Asn Ile Lys Lys Gly Lys Lys Cys  
 245 250 255

-continued

---

```

Ile Arg Thr Pro Lys Ile Ser Lys Pro Ile Lys Phe Glu Leu Ser Gly
      260                               265                               270
Cys Thr Ser Met Lys Thr Tyr Arg Ala Lys Phe Cys Gly Val Cys Thr
      275                               280                               285
Asp Gly Arg Cys Cys Thr Pro His Arg Thr Thr Thr Leu Pro Val Glu
      290                               295                               300
Phe Lys Cys Pro Asp Gly Glu Val Met Lys Lys Asn Met Met Phe Ile
      305                               310                               315                               320
Lys Thr Cys Ala Cys His Tyr Asn Cys Pro Gly Asp Asn Asp Ile Phe
      325                               330                               335
Glu Ser Leu Tyr Tyr Arg Lys Met Tyr Gly Asp Met Ala
      340                               345

```

&lt;210&gt; SEQ ID NO 18

&lt;211&gt; LENGTH: 554

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 18

```

Met Thr Ala Pro Gly Ala Ala Gly Arg Cys Pro Pro Thr Thr Trp Leu
 1      5      10      15
Gly Ser Leu Leu Leu Leu Val Cys Leu Leu Ala Ser Arg Ser Ile Thr
 20      25      30
Glu Glu Val Ser Glu Tyr Cys Ser His Met Ile Gly Ser Gly His Leu
 35      40      45
Gln Ser Leu Gln Arg Leu Ile Asp Ser Gln Met Glu Thr Ser Cys Gln
 50      55      60
Ile Thr Phe Glu Phe Val Asp Gln Glu Gln Leu Lys Asp Pro Val Cys
 65      70      75      80
Tyr Leu Lys Lys Ala Phe Leu Leu Val Gln Asp Ile Met Glu Asp Thr
 85      90      95
Met Arg Phe Arg Asp Asn Thr Pro Asn Ala Ile Ala Ile Val Gln Leu
100     105     110
Gln Glu Leu Ser Leu Arg Leu Lys Ser Cys Phe Thr Lys Asp Tyr Glu
115     120     125
Glu His Asp Lys Ala Cys Val Arg Thr Phe Tyr Glu Thr Pro Leu Gln
130     135     140
Leu Leu Glu Lys Val Lys Asn Val Phe Asn Glu Thr Lys Asn Leu Leu
145     150     155     160
Asp Lys Asp Trp Asn Ile Phe Ser Lys Asn Cys Asn Asn Ser Phe Ala
165     170     175
Glu Cys Ser Ser Gln Asp Val Val Thr Lys Pro Asp Cys Asn Cys Leu
180     185     190
Tyr Pro Lys Ala Ile Pro Ser Ser Asp Pro Ala Ser Val Ser Pro His
195     200     205
Gln Pro Leu Ala Pro Ser Met Ala Pro Val Ala Gly Leu Thr Trp Glu
210     215     220
Asp Ser Glu Gly Thr Glu Gly Ser Ser Leu Leu Pro Gly Glu Gln Pro
225     230     235     240
Leu His Thr Val Asp Pro Gly Ser Ala Lys Gln Arg Pro Pro Arg Ser
245     250     255
Thr Cys Gln Ser Phe Glu Pro Pro Glu Thr Pro Val Val Lys Asp Ser

```

-continued

---

```

                260                265                270
Thr Ile Gly Gly Ser Pro Gln Pro Arg Pro Ser Val Gly Ala Phe Asn
      275                280                285

Pro Gly Met Glu Asp Ile Leu Asp Ser Ala Met Gly Thr Asn Trp Val
      290                295                300

Pro Glu Glu Ala Ser Gly Glu Ala Ser Glu Ile Pro Val Pro Gln Gly
      305                310                315                320

Thr Glu Leu Ser Pro Ser Arg Pro Gly Gly Gly Ser Met Gln Thr Glu
      325                330                335

Pro Ala Arg Pro Ser Asn Phe Leu Ser Ala Ser Ser Pro Leu Pro Ala
      340                345                350

Ser Ala Lys Gly Gln Gln Pro Ala Asp Val Thr Gly Thr Ala Leu Pro
      355                360                365

Arg Val Gly Pro Val Arg Pro Thr Gly Gln Asp Trp Asn His Thr Pro
      370                375                380

Gln Lys Thr Asp His Pro Ser Ala Leu Leu Arg Asp Pro Pro Glu Pro
      385                390                395                400

Gly Ser Pro Arg Ile Ser Ser Leu Arg Pro Gln Gly Leu Ser Asn Pro
      405                410                415

Ser Thr Leu Ser Ala Gln Pro Gln Leu Ser Arg Ser His Ser Ser Gly
      420                425                430

Ser Val Leu Pro Leu Gly Glu Leu Glu Gly Arg Arg Ser Thr Arg Asp
      435                440                445

Arg Arg Ser Pro Ala Glu Pro Glu Gly Gly Pro Ala Ser Glu Gly Ala
      450                455                460

Ala Arg Pro Leu Pro Arg Phe Asn Ser Val Pro Leu Thr Asp Thr Gly
      465                470                475                480

His Glu Arg Gln Ser Glu Gly Ser Ser Ser Pro Gln Leu Gln Glu Ser
      485                490                495

Val Phe His Leu Leu Val Pro Ser Val Ile Leu Val Leu Leu Ala Val
      500                505                510

Gly Gly Leu Leu Phe Tyr Arg Trp Arg Arg Arg Ser His Gln Glu Pro
      515                520                525

Gln Arg Ala Asp Ser Pro Leu Glu Gln Pro Glu Gly Ser Pro Leu Thr
      530                535                540

Gln Asp Asp Arg Gln Val Glu Leu Pro Val
      545                550

```

```

<210> SEQ ID NO 19
<211> LENGTH: 816
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 19

```

```

Met Glu Ser Arg Val Leu Leu Arg Thr Phe Cys Leu Ile Phe Gly Leu
 1      5      10      15

Gly Ala Val Trp Gly Leu Gly Val Asp Pro Ser Leu Gln Ile Asp Val
 20     25     30

Leu Thr Glu Leu Glu Leu Gly Glu Ser Thr Thr Gly Val Arg Gln Val
 35     40     45

Pro Gly Leu His Asn Gly Thr Lys Ala Phe Leu Phe Gln Asp Thr Pro
 50     55     60

```

-continued

---

Arg	Ser	Ile	Lys	Ala	Ser	Thr	Ala	Thr	Ala	Glu	Gln	Phe	Phe	Gln	Lys
65					70					75					80
Leu	Arg	Asn	Lys	His	Glu	Phe	Thr	Ile	Leu	Val	Thr	Leu	Lys	Gln	Thr
				85					90					95	
His	Leu	Asn	Ser	Gly	Val	Ile	Leu	Ser	Ile	His	His	Leu	Asp	His	Arg
			100					105					110		
Tyr	Leu	Glu	Leu	Glu	Ser	Ser	Gly	His	Arg	Asn	Glu	Val	Arg	Leu	His
		115					120					125			
Tyr	Arg	Ser	Gly	Ser	His	Arg	Pro	His	Thr	Glu	Val	Phe	Pro	Tyr	Ile
	130					135					140				
Leu	Ala	Asp	Asp	Lys	Trp	His	Lys	Leu	Ser	Leu	Ala	Ile	Ser	Ala	Ser
145					150					155					160
His	Leu	Ile	Leu	His	Ile	Asp	Cys	Asn	Lys	Ile	Tyr	Glu	Arg	Val	Val
				165				170						175	
Glu	Lys	Pro	Ser	Thr	Asp	Leu	Pro	Leu	Gly	Thr	Thr	Phe	Trp	Leu	Gly
			180					185					190		
Gln	Arg	Asn	Asn	Ala	His	Gly	Tyr	Phe	Lys	Gly	Ile	Met	Gln	Asp	Val
		195					200					205			
Gln	Leu	Leu	Val	Met	Pro	Gln	Gly	Phe	Ile	Ala	Gln	Cys	Pro	Asp	Leu
	210					215					220				
Asn	Arg	Thr	Cys	Pro	Thr	Cys	Asn	Asp	Phe	His	Gly	Leu	Val	Gln	Lys
225					230				235						240
Ile	Met	Glu	Leu	Gln	Asp	Ile	Leu	Ala	Lys	Thr	Ser	Ala	Lys	Leu	Ser
			245					250						255	
Arg	Ala	Glu	Gln	Arg	Met	Asn	Arg	Leu	Asp	Gln	Cys	Tyr	Cys	Glu	Arg
		260						265					270		
Thr	Cys	Thr	Met	Lys	Gly	Thr	Thr	Tyr	Arg	Glu	Phe	Glu	Ser	Trp	Ile
	275						280					285			
Asp	Gly	Cys	Lys	Asn	Cys	Thr	Cys	Leu	Asn	Gly	Thr	Ile	Gln	Cys	Glu
290						295					300				
Thr	Leu	Ile	Cys	Pro	Asn	Pro	Asp	Cys	Pro	Leu	Lys	Ser	Ala	Leu	Ala
305					310					315					320
Tyr	Val	Asp	Gly	Lys	Cys	Cys	Lys	Glu	Cys	Lys	Ser	Ile	Cys	Gln	Phe
			325					330						335	
Gln	Gly	Arg	Thr	Tyr	Phe	Glu	Gly	Glu	Arg	Asn	Thr	Val	Tyr	Ser	Ser
			340					345						350	
Ser	Gly	Val	Cys	Val	Leu	Tyr	Glu	Cys	Lys	Asp	Gln	Thr	Met	Lys	Leu
		355					360					365			
Val	Glu	Ser	Ser	Gly	Cys	Pro	Ala	Leu	Asp	Cys	Pro	Glu	Ser	His	Gln
	370					375						380			
Ile	Thr	Leu	Ser	His	Ser	Cys	Cys	Lys	Val	Cys	Lys	Gly	Tyr	Asp	Phe
385					390					395					400
Cys	Ser	Glu	Arg	His	Asn	Cys	Met	Glu	Asn	Ser	Ile	Cys	Arg	Asn	Leu
			405					410						415	
Asn	Asp	Arg	Ala	Val	Cys	Ser	Cys	Arg	Asp	Gly	Phe	Arg	Ala	Leu	Arg
			420					425					430		
Glu	Asp	Asn	Ala	Tyr	Cys	Glu	Asp	Ile	Asp	Glu	Cys	Ala	Glu	Gly	Arg
		435					440					445			
His	Tyr	Cys	Arg	Glu	Asn	Thr	Met	Cys	Val	Asn	Thr	Pro	Gly	Ser	Phe
	450					455						460			
Met	Cys	Ile	Cys	Lys	Thr	Gly	Tyr	Ile	Arg	Ile	Asp	Asp	Tyr	Ser	Cys



-continued

---

Ala Leu Val Leu Ala Leu Ala Pro Gly Leu Pro Thr Ala Arg Ala Gly  
 20 25 30

Gln Thr Pro Arg Pro Ala Glu Arg Gly Pro Pro Val Arg Leu Phe Thr  
 35 40 45

Glu Glu Glu Leu Ala Arg Tyr Gly Gly Glu Glu Glu Asp Gln Pro Ile  
 50 55 60

Tyr Leu Ala Val Lys Gly Val Val Phe Asp Val Thr Ser Gly Lys Glu  
 65 70 75 80

Phe Tyr Gly Arg Gly Ala Pro Tyr Asn Ala Leu Thr Gly Lys Asp Ser  
 85 90 95

Thr Arg Gly Val Ala Lys Met Ser Leu Asp Pro Ala Asp Leu Thr His  
 100 105 110

Asp Thr Thr Gly Leu Thr Ala Lys Glu Leu Glu Ala Leu Asp Glu Val  
 115 120 125

Phe Thr Lys Val Tyr Lys Ala Lys Tyr Pro Ile Val Gly Tyr Thr Ala  
 130 135 140

Arg Arg Ile Leu Asn Glu Asp Gly Ser Pro Asn Leu Asp Phe Lys Pro  
 145 150 155 160

Glu Asp Gln Pro His Phe Asp Ile Lys Asp Glu Phe  
 165 170

&lt;210&gt; SEQ ID NO 21

&lt;211&gt; LENGTH: 508

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 21

Met Leu Arg Arg Ala Leu Leu Cys Leu Ala Val Ala Ala Leu Val Arg  
 1 5 10 15

Ala Asp Ala Pro Glu Glu Glu Asp His Val Leu Val Leu Arg Lys Ser  
 20 25 30

Asn Phe Ala Glu Ala Leu Ala Ala His Lys Tyr Leu Leu Val Glu Phe  
 35 40 45

Tyr Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala Pro Glu Tyr Ala  
 50 55 60

Lys Ala Ala Gly Lys Leu Lys Ala Glu Gly Ser Glu Ile Arg Leu Ala  
 65 70 75 80

Lys Val Asp Ala Thr Glu Glu Ser Asp Leu Ala Gln Gln Tyr Gly Val  
 85 90 95

Arg Gly Tyr Pro Thr Ile Lys Phe Phe Arg Asn Gly Asp Thr Ala Ser  
 100 105 110

Pro Lys Glu Tyr Thr Ala Gly Arg Glu Ala Asp Asp Ile Val Asn Trp  
 115 120 125

Leu Lys Lys Arg Thr Gly Pro Ala Ala Thr Thr Leu Pro Asp Gly Ala  
 130 135 140

Ala Ala Glu Ser Leu Val Glu Ser Ser Glu Val Ala Val Ile Gly Phe  
 145 150 155 160

Phe Lys Asp Val Glu Ser Asp Ser Ala Lys Gln Phe Leu Gln Ala Ala  
 165 170 175

Glu Ala Ile Asp Asp Ile Pro Phe Gly Ile Thr Ser Asn Ser Asp Val  
 180 185 190

Phe Ser Lys Tyr Gln Leu Asp Lys Asp Gly Val Val Leu Phe Lys Lys  
 195 200 205

-continued

---

Phe Asp Glu Gly Arg Asn Asn Phe Glu Gly Glu Val Thr Lys Glu Asn  
 210 215 220  
 Leu Leu Asp Phe Ile Lys His Asn Gln Leu Pro Leu Val Ile Glu Phe  
 225 230 235 240  
 Thr Glu Gln Thr Ala Pro Lys Ile Phe Gly Gly Glu Ile Lys Thr His  
 245 250 255  
 Ile Leu Leu Phe Leu Pro Lys Ser Val Ser Asp Tyr Asp Gly Lys Leu  
 260 265 270  
 Ser Asn Phe Lys Thr Ala Ala Glu Ser Phe Lys Gly Lys Ile Leu Phe  
 275 280 285  
 Ile Phe Ile Asp Ser Asp His Thr Asp Asn Gln Arg Ile Leu Glu Phe  
 290 295 300  
 Phe Gly Leu Lys Lys Glu Glu Cys Pro Ala Val Arg Leu Ile Thr Leu  
 305 310 315 320  
 Glu Glu Glu Met Thr Lys Tyr Lys Pro Glu Ser Glu Glu Leu Thr Ala  
 325 330 335  
 Glu Arg Ile Thr Glu Phe Cys His Arg Phe Leu Glu Gly Lys Ile Lys  
 340 345 350  
 Pro His Leu Met Ser Gln Glu Leu Pro Glu Asp Trp Asp Lys Gln Pro  
 355 360 365  
 Val Lys Val Leu Val Gly Lys Asn Phe Glu Asp Val Ala Phe Asp Glu  
 370 375 380  
 Lys Lys Asn Val Phe Val Glu Phe Tyr Ala Pro Trp Cys Gly His Cys  
 385 390 395 400  
 Lys Gln Leu Ala Pro Ile Trp Asp Lys Leu Gly Glu Thr Tyr Lys Asp  
 405 410 415  
 His Glu Asn Ile Val Ile Ala Lys Met Asp Ser Thr Ala Asn Glu Val  
 420 425 430  
 Glu Ala Val Lys Val His Ser Phe Pro Thr Leu Lys Phe Phe Pro Ala  
 435 440 445  
 Ser Ala Asp Arg Thr Val Ile Asp Tyr Asn Gly Glu Arg Thr Leu Asp  
 450 455 460  
 Gly Phe Lys Lys Phe Leu Glu Ser Gly Gly Gln Asp Gly Ala Gly Asp  
 465 470 475 480  
 Asp Asp Asp Leu Glu Asp Leu Glu Glu Ala Glu Glu Pro Asp Met Glu  
 485 490 495  
 Glu Asp Asp Asp Gln Lys Ala Val Lys Asp Glu Leu  
 500 505

&lt;210&gt; SEQ ID NO 22

&lt;211&gt; LENGTH: 156

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 22

Met Ala Leu Glu Lys Ser Leu Val Arg Leu Leu Leu Val Leu Ile  
 1 5 10 15  
 Leu Leu Val Leu Gly Trp Val Gln Pro Ser Leu Gly Lys Glu Ser Arg  
 20 25 30  
 Ala Lys Lys Phe Gln Arg Gln His Met Asp Ser Asp Ser Ser Pro Ser  
 35 40 45  
 Ser Ser Ser Thr Tyr Cys Asn Gln Met Met Arg Arg Arg Asn Met Thr







-continued

130				135				140							
Gln	Leu	His	Leu	Glu	His	Asn	Asn	Leu	Glu	Glu	Phe	Pro	Phe	Pro	Leu
145				150					155						160
Pro	Lys	Ser	Leu	Glu	Arg	Leu	Leu	Leu	Gly	Tyr	Asn	Glu	Ile	Ser	Lys
			165						170					175	
Leu	Gln	Thr	Asn	Ala	Met	Asp	Gly	Leu	Val	Asn	Leu	Thr	Met	Leu	Asp
			180						185					190	
Leu	Cys	Tyr	Asn	Tyr	Leu	His	Asp	Ser	Leu	Leu	Lys	Asp	Lys	Ile	Phe
	195						200					205			
Ala	Lys	Met	Glu	Lys	Leu	Met	Gln	Leu	Asn	Leu	Cys	Ser	Asn	Arg	Leu
	210					215					220				
Glu	Ser	Met	Pro	Pro	Gly	Leu	Pro	Ser	Ser	Leu	Met	Tyr	Leu	Ser	Leu
	225				230						235				240
Glu	Asn	Asn	Ser	Ile	Ser	Ser	Ile	Pro	Glu	Lys	Tyr	Phe	Asp	Lys	Leu
			245						250					255	
Pro	Lys	Leu	His	Thr	Leu	Arg	Met	Ser	His	Asn	Lys	Leu	Gln	Asp	Ile
			260						265					270	
Pro	Tyr	Asn	Ile	Phe	Asn	Leu	Pro	Asn	Ile	Val	Glu	Leu	Ser	Val	Gly
		275					280					285			
His	Asn	Lys	Leu	Lys	Gln	Ala	Phe	Tyr	Ile	Pro	Arg	Asn	Leu	Glu	His
	290					295					300				
Leu	Tyr	Leu	Gln	Asn	Asn	Glu	Ile	Glu	Lys	Met	Asn	Leu	Thr	Val	Met
	305				310					315					320
Cys	Pro	Ser	Ile	Asp	Pro	Leu	His	Tyr	His	His	Leu	Thr	Tyr	Ile	Arg
			325						330					335	
Val	Asp	Gln	Asn	Lys	Leu	Lys	Glu	Pro	Ile	Ser	Ser	Tyr	Ile	Phe	Phe
			340						345					350	
Cys	Phe	Pro	His	Ile	His	Thr	Ile	Tyr	Tyr	Gly	Glu	Gln	Arg	Ser	Thr
		355					360					365			
Asn	Gly	Gln	Thr	Ile	Gln	Leu	Lys	Thr	Gln	Val	Phe	Arg	Arg	Phe	Pro
	370					375					380				
Asp	Asp	Asp	Asp	Glu	Ser	Glu	Asp	His	Asp	Asp	Pro	Asp	Asn	Ala	His
	385				390					395					400
Glu	Ser	Pro	Glu	Gln	Glu	Gly	Ala	Glu	Gly	His	Phe	Asp	Leu	His	Tyr
			405						410					415	
Tyr	Glu	Asn	Gln	Glu											
			420												

&lt;210&gt; SEQ ID NO 26

&lt;211&gt; LENGTH: 1366

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 26

Met	Leu	Ser	Phe	Val	Asp	Thr	Arg	Thr	Leu	Leu	Leu	Leu	Ala	Val	Thr
1				5					10					15	
Leu	Cys	Leu	Ala	Thr	Cys	Gln	Ser	Leu	Gln	Glu	Glu	Thr	Val	Arg	Lys
			20					25					30		
Gly	Pro	Ala	Gly	Asp	Arg	Gly	Pro	Arg	Gly	Glu	Arg	Gly	Pro	Pro	Gly
		35					40					45			
Pro	Pro	Gly	Arg	Asp	Gly	Glu	Asp	Gly	Pro	Thr	Gly	Pro	Pro	Gly	Pro
		50				55					60				

-continued

---

Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala Ala Gln  
 65 70 75 80  
 Tyr Asp Gly Lys Gly Val Gly Leu Gly Pro Gly Pro Met Gly Leu Met  
 85 90 95  
 Gly Pro Arg Gly Pro Pro Gly Ala Ala Gly Ala Pro Gly Pro Gln Gly  
 100 105 110  
 Phe Gln Gly Pro Ala Gly Glu Pro Gly Glu Pro Gly Gln Thr Gly Pro  
 115 120 125  
 Ala Gly Ala Arg Gly Pro Ala Gly Pro Pro Gly Lys Ala Gly Glu Asp  
 130 135 140  
 Gly His Pro Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Val Val Gly  
 145 150 155 160  
 Pro Gln Gly Ala Arg Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Phe  
 165 170 175  
 Lys Gly Ile Arg Gly His Asn Gly Leu Asp Gly Leu Lys Gly Gln Pro  
 180 185 190  
 Gly Ala Pro Gly Val Lys Gly Glu Pro Gly Ala Pro Gly Glu Asn Gly  
 195 200 205  
 Thr Pro Gly Gln Thr Gly Ala Arg Gly Leu Pro Gly Glu Arg Gly Arg  
 210 215 220  
 Val Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Ser Asp Gly Ser Val  
 225 230 235 240  
 Gly Pro Val Gly Pro Ala Gly Pro Ile Gly Ser Ala Gly Pro Pro Gly  
 245 250 255  
 Phe Pro Gly Ala Pro Gly Pro Lys Gly Glu Ile Gly Ala Val Gly Asn  
 260 265 270  
 Ala Gly Pro Ala Gly Pro Ala Gly Pro Arg Gly Glu Val Gly Leu Pro  
 275 280 285  
 Gly Leu Ser Gly Pro Val Gly Pro Pro Gly Asn Pro Gly Ala Asn Gly  
 290 295 300  
 Leu Thr Gly Ala Lys Gly Ala Ala Gly Leu Pro Gly Val Ala Gly Ala  
 305 310 315 320  
 Pro Gly Leu Pro Gly Pro Arg Gly Ile Pro Gly Pro Val Gly Ala Ala  
 325 330 335  
 Gly Ala Thr Gly Ala Arg Gly Leu Val Gly Glu Pro Gly Pro Ala Gly  
 340 345 350  
 Ser Lys Gly Glu Ser Gly Asn Lys Gly Glu Pro Gly Ser Ala Gly Pro  
 355 360 365  
 Gln Gly Pro Pro Gly Pro Ser Gly Glu Glu Gly Lys Arg Gly Pro Asn  
 370 375 380  
 Gly Glu Ala Gly Ser Ala Gly Pro Pro Gly Pro Pro Gly Leu Arg Gly  
 385 390 395 400  
 Ser Pro Gly Ser Arg Gly Leu Pro Gly Ala Asp Gly Arg Ala Gly Val  
 405 410 415  
 Met Gly Pro Pro Gly Ser Arg Gly Ala Ser Gly Pro Ala Gly Val Arg  
 420 425 430  
 Gly Pro Asn Gly Asp Ala Gly Arg Pro Gly Glu Pro Gly Leu Met Gly  
 435 440 445  
 Pro Arg Gly Leu Pro Gly Ser Pro Gly Asn Ile Gly Pro Ala Gly Lys  
 450 455 460  
 Glu Gly Pro Val Gly Leu Pro Gly Ile Asp Gly Arg Pro Gly Pro Ile

-continued

465	470	475	480
Gly Pro Ala Gly	Ala Arg Gly Glu Pro Gly	Asn Ile Gly Phe Pro Gly	485 490 495
Pro Lys Gly Pro	Thr Gly Asp Pro Gly	Lys Asn Gly Asp Lys Gly	500 505 510
Ala Gly Leu Ala Gly	Ala Arg Gly Ala Pro Gly	Pro Asp Gly Asn Asn	515 520 525
Gly Ala Gln Gly Pro	Pro Gly Pro Gln Gly Val Gln Gly	Gly Lys Gly	530 535 540
Glu Gln Gly Pro Ala	Gly Pro Pro Gly Phe Gln Gly	Leu Pro Gly Pro	545 550 555 560
Ser Gly Pro Ala Gly	Glu Val Gly Lys Pro Gly	Glu Arg Gly Leu His	565 570 575
Gly Glu Phe Gly Leu	Pro Gly Pro Ala Gly Pro	Arg Gly Glu Arg Gly	580 585 590
Pro Pro Gly Glu Ser	Gly Ala Ala Gly Pro Thr Gly	Pro Ile Gly Ser	595 600 605
Arg Gly Pro Ser Gly	Pro Pro Gly Pro Asp Gly	Asn Lys Gly Glu Pro	610 615 620
Gly Val Val Gly Ala	Val Gly Thr Ala Gly Pro	Ser Gly Pro Ser Gly	625 630 635 640
Leu Pro Gly Glu Arg	Gly Ala Ala Gly Ile Pro Gly	Gly Lys Gly Glu	645 650 655
Lys Gly Glu Pro Gly	Leu Arg Gly Glu Ile Gly	Asn Pro Gly Arg Asp	660 665 670
Gly Ala Arg Gly Ala	Pro Gly Ala Val Gly Ala Pro	Gly Pro Ala Gly	675 680 685
Ala Thr Gly Asp Arg	Gly Glu Ala Gly Ala Ala Gly	Pro Ala Gly Pro	690 695 700
Ala Gly Pro Arg Gly	Ser Pro Gly Glu Arg Gly	Glu Val Gly Pro Ala	705 710 715 720
Gly Pro Asn Gly Phe	Ala Gly Pro Ala Gly Ala Ala Gly	Gln Pro Gly	725 730 735
Ala Lys Gly Glu Arg	Gly Ala Lys Gly Pro Lys Gly	Glu Asn Gly Val	740 745 750
Val Gly Pro Thr Gly	Pro Val Gly Ala Ala Gly Pro	Ala Gly Pro Asn	755 760 765
Gly Pro Pro Gly Pro	Ala Gly Ser Arg Gly Asp Gly	Pro Pro Gly	770 775 780
Met Thr Gly Phe Pro	Gly Ala Ala Gly Arg Thr Gly	Pro Pro Gly Pro	785 790 795 800
Ser Gly Ile Ser Gly	Pro Pro Gly Pro Pro Gly	Pro Ala Gly Lys Glu	805 810 815
Gly Leu Arg Gly Pro	Arg Gly Asp Gln Gly Pro Val Gly	Arg Thr Gly	820 825 830
Glu Val Gly Ala Val	Gly Pro Pro Gly Phe Ala Gly	Glu Lys Gly Pro	835 840 845
Ser Gly Glu Ala Gly	Thr Ala Gly Pro Pro Gly Thr	Pro Gly Pro Gln	850 855 860
Gly Leu Leu Gly Ala	Pro Gly Ile Leu Gly Leu Pro Gly	Ser Arg Gly	865 870 875 880

-continued

---

Glu Arg Gly Leu Pro Gly Val Ala Gly Ala Val Gly Glu Pro Gly Pro  
                   885  890  895

Leu Gly Ile Ala Gly Pro Pro Gly Ala Arg Gly Pro Pro Gly Ala Val  
                   900  905  910

Gly Ser Pro Gly Val Asn Gly Ala Pro Gly Glu Ala Gly Arg Asp Gly  
                   915  920  925

Asn Pro Gly Asn Asp Gly Pro Pro Gly Arg Asp Gly Gln Pro Gly His  
                   930  935  940

Lys Gly Glu Arg Gly Tyr Pro Gly Asn Ile Gly Pro Val Gly Ala Ala  
                   945  950  955  960

Gly Ala Pro Gly Pro His Gly Pro Val Gly Pro Ala Gly Lys His Gly  
                   965  970  975

Asn Arg Gly Glu Thr Gly Pro Ser Gly Pro Val Gly Pro Ala Gly Ala  
                   980  985  990

Val Gly Pro Arg Gly Pro Ser Gly Pro Gln Gly Ile Arg Gly Asp Lys  
                   995  1000  1005

Gly Glu Pro Gly Glu Lys Gly Pro Arg Gly Leu Pro Gly Leu Lys  
                   1010  1015  1020

Gly His Asn Gly Leu Gln Gly Leu Pro Gly Ile Ala Gly His His  
                   1025  1030  1035

Gly Asp Gln Gly Ala Pro Gly Ser Val Gly Pro Ala Gly Pro Arg  
                   1040  1045  1050

Gly Pro Ala Gly Pro Ser Gly Pro Ala Gly Lys Asp Gly Arg Thr  
                   1055  1060  1065

Gly His Pro Gly Thr Val Gly Pro Ala Gly Ile Arg Gly Pro Gln  
                   1070  1075  1080

Gly His Gln Gly Pro Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro  
                   1085  1090  1095

Gly Pro Pro Gly Val Ser Gly Gly Gly Tyr Asp Phe Gly Tyr Asp  
                   1100  1105  1110

Gly Asp Phe Tyr Arg Ala Asp Gln Pro Arg Ser Ala Pro Ser Leu  
                   1115  1120  1125

Arg Pro Lys Asp Tyr Glu Val Asp Ala Thr Leu Lys Ser Leu Asn  
                   1130  1135  1140

Asn Gln Ile Glu Thr Leu Leu Thr Pro Glu Gly Ser Arg Lys Asn  
                   1145  1150  1155

Pro Ala Arg Thr Cys Arg Asp Leu Arg Leu Ser His Pro Glu Trp  
                   1160  1165  1170

Ser Ser Gly Tyr Tyr Trp Ile Asp Pro Asn Gln Gly Cys Thr Met  
                   1175  1180  1185

Asp Ala Ile Lys Val Tyr Cys Asp Phe Ser Thr Gly Glu Thr Cys  
                   1190  1195  1200

Ile Arg Ala Gln Pro Glu Asn Ile Pro Ala Lys Asn Trp Tyr Arg  
                   1205  1210  1215

Ser Ser Lys Asp Lys Lys His Val Trp Leu Gly Glu Thr Ile Asn  
                   1220  1225  1230

Ala Gly Ser Gln Phe Glu Tyr Asn Val Glu Gly Val Thr Ser Lys  
                   1235  1240  1245

Glu Met Ala Thr Gln Leu Ala Phe Met Arg Leu Leu Ala Asn Tyr  
                   1250  1255  1260

-continued

---

Ala Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile Ala Tyr  
1265 1270 1275

Met Asp Glu Glu Thr Gly Asn Leu Lys Lys Ala Val Ile Leu Gln  
1280 1285 1290

Gly Ser Asn Asp Val Glu Leu Val Ala Glu Gly Asn Ser Arg Phe  
1295 1300 1305

Thr Tyr Thr Val Leu Val Asp Gly Cys Ser Lys Lys Thr Asn Glu  
1310 1315 1320

Trp Gly Lys Thr Ile Ile Glu Tyr Lys Thr Asn Lys Pro Ser Arg  
1325 1330 1335

Leu Pro Phe Leu Asp Ile Ala Pro Leu Asp Ile Gly Gly Ala Asp  
1340 1345 1350

Gln Glu Phe Phe Val Asp Ile Gly Pro Val Cys Phe Lys  
1355 1360 1365

&lt;210&gt; SEQ ID NO 27

&lt;211&gt; LENGTH: 4544

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 27

Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu  
1 5 10 15

Val Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe  
20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp  
35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys  
50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu  
65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln  
85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln  
100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu  
115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp  
130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys  
145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val  
165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn  
180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn  
195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro  
210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu  
225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu  
245 250 255

-continued

---

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr  
 260 265 270  
 Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp  
 275 280 285  
 Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile  
 290 295 300  
 Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu  
 305 310 315 320  
 Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys  
 325 330 335  
 Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp  
 340 345 350  
 Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe  
 355 360 365  
 Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala  
 370 375 380  
 Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly  
 385 390 395 400  
 Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu  
 405 410 415  
 Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn  
 420 425 430  
 Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr  
 435 440 445  
 Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile  
 450 455 460  
 Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn  
 465 470 475 480  
 Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala  
 485 490 495  
 Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu  
 500 505 510  
 Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu  
 515 520 525  
 Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly  
 530 535 540  
 Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn  
 545 550 555 560  
 Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala  
 565 570 575  
 Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu  
 580 585 590  
 Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala  
 595 600 605  
 Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys  
 610 615  
 Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys  
 625 630 635 640  
 Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp  
 645 650 655

-continued

---

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys  
 660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His  
 675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu  
 690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr  
 705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val  
 725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly  
 740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu  
 755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser  
 770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln  
 785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser  
 805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp  
 820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr  
 835 840 845

Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser  
 850 855 860

Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu  
 865 870 875 880

Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro  
 885 890 895

Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp  
 900 905 910

Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn  
 915 920 925

Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala  
 930 935 940

Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp  
 945 950 955 960

Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys  
 965 970 975

Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn Gly Arg Cys Ile Asn Ile  
 980 985 990

Asn Trp Arg Cys Asp Asn Asp Asn Asp Cys Gly Asp Asn Ser Asp Glu  
 995 1000 1005

Ala Gly Cys Ser His Ser Cys Ser Ser Thr Gln Phe Lys Cys Asn  
 1010 1015 1020

Ser Gly Arg Cys Ile Pro Glu His Trp Thr Cys Asp Gly Asp Asn  
 1025 1030 1035

Asp Cys Gly Asp Tyr Ser Asp Glu Thr His Ala Asn Cys Thr Asn  
 1040 1045 1050

Gln Ala Thr Arg Pro Pro Gly Gly Cys His Thr Asp Glu Phe Gln

-continued

---

1055	1060	1065
Cys Arg Leu Asp Gly Leu	Cys Ile Pro Leu Arg Trp	Arg Cys Asp
1070	1075	1080
Gly Asp Thr Asp Cys Met	Asp Ser Ser Asp Glu Lys	Ser Cys Glu
1085	1090	1095
Gly Val Thr His Val Cys	Asp Pro Ser Val Lys Phe	Gly Cys Lys
1100	1105	1110
Asp Ser Ala Arg Cys Ile	Ser Lys Ala Trp Val Cys	Asp Gly Asp
1115	1120	1125
Asn Asp Cys Glu Asp Asn	Ser Asp Glu Glu Asn Cys	Glu Ser Leu
1130	1135	1140
Ala Cys Arg Pro Pro Ser	His Pro Cys Ala Asn Asn	Thr Ser Val
1145	1150	1155
Cys Leu Pro Pro Asp Lys	Leu Cys Asp Gly Asn Asp	Asp Cys Gly
1160	1165	1170
Asp Gly Ser Asp Glu Gly	Glu Leu Cys Asp Gln Cys	Ser Leu Asn
1175	1180	1185
Asn Gly Gly Cys Ser His	Asn Cys Ser Val Ala Pro	Gly Glu Gly
1190	1195	1200
Ile Val Cys Ser Cys Pro	Leu Gly Met Glu Leu Gly	Pro Asp Asn
1205	1210	1215
His Thr Cys Gln Ile Gln	Ser Tyr Cys Ala Lys His	Leu Lys Cys
1220	1225	1230
Ser Gln Lys Cys Asp Gln	Asn Lys Phe Ser Val Lys	Cys Ser Cys
1235	1240	1245
Tyr Glu Gly Trp Val Leu	Glu Pro Asp Gly Glu Ser	Cys Arg Ser
1250	1255	1260
Leu Asp Pro Phe Lys Pro	Phe Ile Ile Phe Ser Asn	Arg His Glu
1265	1270	1275
Ile Arg Arg Ile Asp Leu	His Lys Gly Asp Tyr Ser	Val Leu Val
1280	1285	1290
Pro Gly Leu Arg Asn Thr	Ile Ala Leu Asp Phe His	Leu Ser Gln
1295	1300	1305
Ser Ala Leu Tyr Trp Thr	Asp Val Val Glu Asp Lys	Ile Tyr Arg
1310	1315	1320
Gly Lys Leu Leu Asp Asn	Gly Ala Leu Thr Ser Phe	Glu Val Val
1325	1330	1335
Ile Gln Tyr Gly Leu Ala	Thr Pro Glu Gly Leu Ala	Val Asp Trp
1340	1345	1350
Ile Ala Gly Asn Ile Tyr	Trp Val Glu Ser Asn Leu	Asp Gln Ile
1355	1360	1365
Glu Val Ala Lys Leu Asp	Gly Thr Leu Arg Thr Thr	Leu Leu Ala
1370	1375	1380
Gly Asp Ile Glu His Pro	Arg Ala Ile Ala Leu Asp	Pro Arg Asp
1385	1390	1395
Gly Ile Leu Phe Trp Thr	Asp Trp Asp Ala Ser Leu	Pro Arg Ile
1400	1405	1410
Glu Ala Ala Ser Met Ser	Gly Ala Gly Arg Arg Thr	Val His Arg
1415	1420	1425
Glu Thr Gly Ser Gly Gly	Trp Pro Asn Gly Leu Thr	Val Asp Tyr
1430	1435	1440

-continued

---

Leu	Glu	Lys	Arg	Ile	Leu	Trp	Ile	Asp	Ala	Arg	Ser	Asp	Ala	Ile
1445						1450					1455			
Tyr	Ser	Ala	Arg	Tyr	Asp	Gly	Ser	Gly	His	Met	Glu	Val	Leu	Arg
1460						1465					1470			
Gly	His	Glu	Phe	Leu	Ser	His	Pro	Phe	Ala	Val	Thr	Leu	Tyr	Gly
1475						1480					1485			
Gly	Glu	Val	Tyr	Trp	Thr	Asp	Trp	Arg	Thr	Asn	Thr	Leu	Ala	Lys
1490						1495					1500			
Ala	Asn	Lys	Trp	Thr	Gly	His	Asn	Val	Thr	Val	Val	Gln	Arg	Thr
1505						1510					1515			
Asn	Thr	Gln	Pro	Phe	Asp	Leu	Gln	Val	Tyr	His	Pro	Ser	Arg	Gln
1520						1525					1530			
Pro	Met	Ala	Pro	Asn	Pro	Cys	Glu	Ala	Asn	Gly	Gly	Gln	Gly	Pro
1535						1540					1545			
Cys	Ser	His	Leu	Cys	Leu	Ile	Asn	Tyr	Asn	Arg	Thr	Val	Ser	Cys
1550						1555					1560			
Ala	Cys	Pro	His	Leu	Met	Lys	Leu	His	Lys	Asp	Asn	Thr	Thr	Cys
1565						1570					1575			
Tyr	Glu	Phe	Lys	Lys	Phe	Leu	Leu	Tyr	Ala	Arg	Gln	Met	Glu	Ile
1580						1585					1590			
Arg	Gly	Val	Asp	Leu	Asp	Ala	Pro	Tyr	Tyr	Asn	Tyr	Ile	Ile	Ser
1595						1600					1605			
Phe	Thr	Val	Pro	Asp	Ile	Asp	Asn	Val	Thr	Val	Leu	Asp	Tyr	Asp
1610						1615					1620			
Ala	Arg	Glu	Gln	Arg	Val	Tyr	Trp	Ser	Asp	Val	Arg	Thr	Gln	Ala
1625						1630					1635			
Ile	Lys	Arg	Ala	Phe	Ile	Asn	Gly	Thr	Gly	Val	Glu	Thr	Val	Val
1640						1645					1650			
Ser	Ala	Asp	Leu	Pro	Asn	Ala	His	Gly	Leu	Ala	Val	Asp	Trp	Val
1655						1660					1665			
Ser	Arg	Asn	Leu	Phe	Trp	Thr	Ser	Tyr	Asp	Thr	Asn	Lys	Lys	Gln
1670						1675					1680			
Ile	Asn	Val	Ala	Arg	Leu	Asp	Gly	Ser	Phe	Lys	Asn	Ala	Val	Val
1685						1690					1695			
Gln	Gly	Leu	Glu	Gln	Pro	His	Gly	Leu	Val	Val	His	Pro	Leu	Arg
1700						1705					1710			
Gly	Lys	Leu	Tyr	Trp	Thr	Asp	Gly	Asp	Asn	Ile	Ser	Met	Ala	Asn
1715						1720					1725			
Met	Asp	Gly	Ser	Asn	Arg	Thr	Leu	Leu	Phe	Ser	Gly	Gln	Lys	Gly
1730						1735					1740			
Pro	Val	Gly	Leu	Ala	Ile	Asp	Phe	Pro	Glu	Ser	Lys	Leu	Tyr	Trp
1745						1750					1755			
Ile	Ser	Ser	Gly	Asn	His	Thr	Ile	Asn	Arg	Cys	Asn	Leu	Asp	Gly
1760						1765					1770			
Ser	Gly	Leu	Glu	Val	Ile	Asp	Ala	Met	Arg	Ser	Gln	Leu	Gly	Lys
1775						1780					1785			
Ala	Thr	Ala	Leu	Ala	Ile	Met	Gly	Asp	Lys	Leu	Trp	Trp	Ala	Asp
1790						1795					1800			
Gln	Val	Ser	Glu	Lys	Met	Gly	Thr	Cys	Ser	Lys	Ala	Asp	Gly	Ser
1805						1810					1815			

-continued

Gly	Ser	Val	Val	Leu	Arg	Asn	Ser	Thr	Thr	Leu	Val	Met	His	Met
1820						1825						1830		
Lys	Val	Tyr	Asp	Glu	Ser	Ile	Gln	Leu	Asp	His	Lys	Gly	Thr	Asn
1835						1840					1845			
Pro	Cys	Ser	Val	Asn	Asn	Gly	Asp	Cys	Ser	Gln	Leu	Cys	Leu	Pro
1850						1855					1860			
Thr	Ser	Glu	Thr	Thr	Arg	Ser	Cys	Met	Cys	Thr	Ala	Gly	Tyr	Ser
1865						1870					1875			
Leu	Arg	Ser	Gly	Gln	Gln	Ala	Cys	Glu	Gly	Val	Gly	Ser	Phe	Leu
1880						1885					1890			
Leu	Tyr	Ser	Val	His	Glu	Gly	Ile	Arg	Gly	Ile	Pro	Leu	Asp	Pro
1895						1900					1905			
Asn	Asp	Lys	Ser	Asp	Ala	Leu	Val	Pro	Val	Ser	Gly	Thr	Ser	Leu
1910						1915					1920			
Ala	Val	Gly	Ile	Asp	Phe	His	Ala	Glu	Asn	Asp	Thr	Ile	Tyr	Trp
1925						1930					1935			
Val	Asp	Met	Gly	Leu	Ser	Thr	Ile	Ser	Arg	Ala	Lys	Arg	Asp	Gln
1940						1945					1950			
Thr	Trp	Arg	Glu	Asp	Val	Val	Thr	Asn	Gly	Ile	Gly	Arg	Val	Glu
1955						1960					1965			
Gly	Ile	Ala	Val	Asp	Trp	Ile	Ala	Gly	Asn	Ile	Tyr	Trp	Thr	Asp
1970						1975					1980			
Gln	Gly	Phe	Asp	Val	Ile	Glu	Val	Ala	Arg	Leu	Asn	Gly	Ser	Phe
1985						1990					1995			
Arg	Tyr	Val	Val	Ile	Ser	Gln	Gly	Leu	Asp	Lys	Pro	Arg	Ala	Ile
2000						2005					2010			
Thr	Val	His	Pro	Glu	Lys	Gly	Tyr	Leu	Phe	Trp	Thr	Glu	Trp	Gly
2015						2020					2025			
Gln	Tyr	Pro	Arg	Ile	Glu	Arg	Ser	Arg	Leu	Asp	Gly	Thr	Glu	Arg
2030						2035					2040			
Val	Val	Leu	Val	Asn	Val	Ser	Ile	Ser	Trp	Pro	Asn	Gly	Ile	Ser
2045						2050					2055			
Val	Asp	Tyr	Gln	Asp	Gly	Lys	Leu	Tyr	Trp	Cys	Asp	Ala	Arg	Thr
2060						2065					2070			
Asp	Lys	Ile	Glu	Arg	Ile	Asp	Leu	Glu	Thr	Gly	Glu	Asn	Arg	Glu
2075						2080					2085			
Val	Val	Leu	Ser	Ser	Asn	Asn	Met	Asp	Met	Phe	Ser	Val	Ser	Val
2090						2095					2100			
Phe	Glu	Asp	Phe	Ile	Tyr	Trp	Ser	Asp	Arg	Thr	His	Ala	Asn	Gly
2105						2110					2115			
Ser	Ile	Lys	Arg	Gly	Ser	Lys	Asp	Asn	Ala	Thr	Asp	Ser	Val	Pro
2120						2125					2130			
Leu	Arg	Thr	Gly	Ile	Gly	Val	Gln	Leu	Lys	Asp	Ile	Lys	Val	Phe
2135						2140					2145			
Asn	Arg	Asp	Arg	Gln	Lys	Gly	Thr	Asn	Val	Cys	Ala	Val	Ala	Asn
2150						2155					2160			
Gly	Gly	Cys	Gln	Gln	Leu	Cys	Leu	Tyr	Arg	Gly	Arg	Gly	Gln	Arg
2165						2170					2175			
Ala	Cys	Ala	Cys	Ala	His	Gly	Met	Leu	Ala	Glu	Asp	Gly	Ala	Ser
2180						2185					2190			
Cys	Arg	Glu	Tyr	Ala	Gly	Tyr	Leu	Leu	Tyr	Ser	Glu	Arg	Thr	Ile

-continued

2195	2200	2205
Leu Lys Ser Ile His Leu	Ser Asp Glu Arg Asn	Leu Asn Ala Pro
2210	2215	2220
Val Gln Pro Phe Glu Asp	Pro Glu His Met Lys	Asn Val Ile Ala
2225	2230	2235
Leu Ala Phe Asp Tyr Arg	Ala Gly Thr Ser Pro	Gly Thr Pro Asn
2240	2245	2250
Arg Ile Phe Phe Ser Asp	Ile His Phe Gly Asn	Ile Gln Gln Ile
2255	2260	2265
Asn Asp Asp Gly Ser Arg	Arg Ile Thr Ile Val	Glu Asn Val Gly
2270	2275	2280
Ser Val Glu Gly Leu Ala	Tyr His Arg Gly Trp	Asp Thr Leu Tyr
2285	2290	2295
Trp Thr Ser Tyr Thr Thr	Ser Thr Ile Thr Arg	His Thr Val Asp
2300	2305	2310
Gln Thr Arg Pro Gly Ala	Phe Glu Arg Glu Thr	Val Ile Thr Met
2315	2320	2325
Ser Gly Asp Asp His Pro	Arg Ala Phe Val Leu	Asp Glu Cys Gln
2330	2335	2340
Asn Leu Met Phe Trp Thr	Asn Trp Asn Glu Gln	His Pro Ser Ile
2345	2350	2355
Met Arg Ala Ala Leu Ser	Gly Ala Asn Val Leu	Thr Leu Ile Glu
2360	2365	2370
Lys Asp Ile Arg Thr Pro	Asn Gly Leu Ala Ile	Asp His Arg Ala
2375	2380	2385
Glu Lys Leu Tyr Phe Ser	Asp Ala Thr Leu Asp	Lys Ile Glu Arg
2390	2395	2400
Cys Glu Tyr Asp Gly Ser	His Arg Tyr Val Ile	Leu Lys Ser Glu
2405	2410	2415
Pro Val His Pro Phe Gly	Leu Ala Val Tyr Gly	Glu His Ile Phe
2420	2425	2430
Trp Thr Asp Trp Val Arg	Arg Ala Val Gln Arg	Ala Asn Lys His
2435	2440	2445
Val Gly Ser Asn Met Lys	Leu Leu Arg Val Asp	Ile Pro Gln Gln
2450	2455	2460
Pro Met Gly Ile Ile Ala	Val Ala Asn Asp Thr	Asn Ser Cys Glu
2465	2470	2475
Leu Ser Pro Cys Arg Ile	Asn Asn Gly Gly Cys	Gln Asp Leu Cys
2480	2485	2490
Leu Leu Thr His Gln Gly	His Val Asn Cys Ser	Cys Arg Gly Gly
2495	2500	2505
Arg Ile Leu Gln Asp Asp	Leu Thr Cys Arg Ala	Val Asn Ser Ser
2510	2515	2520
Cys Arg Ala Gln Asp Glu	Phe Glu Cys Ala Asn	Gly Glu Cys Ile
2525	2530	2535
Asn Phe Ser Leu Thr Cys	Asp Gly Val Pro His	Cys Lys Asp Lys
2540	2545	2550
Ser Asp Glu Lys Pro Ser	Tyr Cys Asn Ser Arg	Arg Cys Lys Lys
2555	2560	2565
Thr Phe Arg Gln Cys Ser	Asn Gly Arg Cys Val	Ser Asn Met Leu
2570	2575	2580

-continued

---

Trp	Cys	Asn	Gly	Ala	Asp	Asp	Cys	Gly	Asp	Gly	Ser	Asp	Glu	Ile
2585						2590					2595			
Pro	Cys	Asn	Lys	Thr	Ala	Cys	Gly	Val	Gly	Glu	Phe	Arg	Cys	Arg
2600						2605					2610			
Asp	Gly	Thr	Cys	Ile	Gly	Asn	Ser	Ser	Arg	Cys	Asn	Gln	Phe	Val
2615						2620					2625			
Asp	Cys	Glu	Asp	Ala	Ser	Asp	Glu	Met	Asn	Cys	Ser	Ala	Thr	Asp
2630						2635					2640			
Cys	Ser	Ser	Tyr	Phe	Arg	Leu	Gly	Val	Lys	Gly	Val	Leu	Phe	Gln
2645						2650					2655			
Pro	Cys	Glu	Arg	Thr	Ser	Leu	Cys	Tyr	Ala	Pro	Ser	Trp	Val	Cys
2660						2665					2670			
Asp	Gly	Ala	Asn	Asp	Cys	Gly	Asp	Tyr	Ser	Asp	Glu	Arg	Asp	Cys
2675						2680					2685			
Pro	Gly	Val	Lys	Arg	Pro	Arg	Cys	Pro	Leu	Asn	Tyr	Phe	Ala	Cys
2690						2695					2700			
Pro	Ser	Gly	Arg	Cys	Ile	Pro	Met	Ser	Trp	Thr	Cys	Asp	Lys	Glu
2705						2710					2715			
Asp	Asp	Cys	Glu	His	Gly	Glu	Asp	Glu	Thr	His	Cys	Asn	Lys	Phe
2720						2725					2730			
Cys	Ser	Glu	Ala	Gln	Phe	Glu	Cys	Gln	Asn	His	Arg	Cys	Ile	Ser
2735						2740					2745			
Lys	Gln	Trp	Leu	Cys	Asp	Gly	Ser	Asp	Asp	Cys	Gly	Asp	Gly	Ser
2750						2755					2760			
Asp	Glu	Ala	Ala	His	Cys	Glu	Gly	Lys	Thr	Cys	Gly	Pro	Ser	Ser
2765						2770					2775			
Phe	Ser	Cys	Pro	Gly	Thr	His	Val	Cys	Val	Pro	Glu	Arg	Trp	Leu
2780						2785					2790			
Cys	Asp	Gly	Asp	Lys	Asp	Cys	Ala	Asp	Gly	Ala	Asp	Glu	Ser	Ile
2795						2800					2805			
Ala	Ala	Gly	Cys	Leu	Tyr	Asn	Ser	Thr	Cys	Asp	Asp	Arg	Glu	Phe
2810						2815					2820			
Met	Cys	Gln	Asn	Arg	Gln	Cys	Ile	Pro	Lys	His	Phe	Val	Cys	Asp
2825						2830					2835			
His	Asp	Arg	Asp	Cys	Ala	Asp	Gly	Ser	Asp	Glu	Ser	Pro	Glu	Cys
2840						2845					2850			
Glu	Tyr	Pro	Thr	Cys	Gly	Pro	Ser	Glu	Phe	Arg	Cys	Ala	Asn	Gly
2855						2860					2865			
Arg	Cys	Leu	Ser	Ser	Arg	Gln	Trp	Glu	Cys	Asp	Gly	Glu	Asn	Asp
2870						2875					2880			
Cys	His	Asp	Gln	Ser	Asp	Glu	Ala	Pro	Lys	Asn	Pro	His	Cys	Thr
2885						2890					2895			
Ser	Pro	Glu	His	Lys	Cys	Asn	Ala	Ser	Ser	Gln	Phe	Leu	Cys	Ser
2900						2905					2910			
Ser	Gly	Arg	Cys	Val	Ala	Glu	Ala	Leu	Leu	Cys	Asn	Gly	Gln	Asp
2915						2920					2925			
Asp	Cys	Gly	Asp	Ser	Ser	Asp	Glu	Arg	Gly	Cys	His	Ile	Asn	Glu
2930						2935					2940			
Cys	Leu	Ser	Arg	Lys	Leu	Ser	Gly	Cys	Ser	Gln	Asp	Cys	Glu	Asp
2945						2950					2955			

-continued

Leu 2960	Lys	Ile	Gly	Phe	Lys	Cys 2965	Arg	Cys	Arg	Pro	Gly 2970	Phe	Arg	Leu
Lys 2975	Asp	Asp	Gly	Arg	Thr	Cys 2980	Ala	Asp	Val	Asp	Glu 2985	Cys	Ser	Thr
Thr 2990	Phe	Pro	Cys	Ser	Gln	Arg 2995	Cys	Ile	Asn	Thr	His 3000	Gly	Ser	Tyr
Lys 3005	Cys	Leu	Cys	Val	Glu	Gly 3010	Tyr	Ala	Pro	Arg	Gly 3015	Gly	Asp	Pro
His 3020	Ser	Cys	Lys	Ala	Val	Thr 3025	Asp	Glu	Glu	Pro	Phe 3030	Leu	Ile	Phe
Ala 3035	Asn	Arg	Tyr	Tyr	Leu	Arg 3040	Lys	Leu	Asn	Leu	Asp 3045	Gly	Ser	Asn
Tyr 3050	Thr	Leu	Leu	Lys	Gln	Gly 3055	Leu	Asn	Asn	Ala	Val 3060	Ala	Leu	Asp
Phe 3065	Asp	Tyr	Arg	Glu	Gln	Met 3070	Ile	Tyr	Trp	Thr	Asp 3075	Val	Thr	Thr
Gln 3080	Gly	Ser	Met	Ile	Arg	Arg 3085	Met	His	Leu	Asn	Gly 3090	Ser	Asn	Val
Gln 3095	Val	Leu	His	Arg	Thr	Gly 3100	Leu	Ser	Asn	Pro	Asp 3105	Gly	Leu	Ala
Val 3110	Asp	Trp	Val	Gly	Gly	Asn 3115	Leu	Tyr	Trp	Cys	Asp 3120	Lys	Gly	Arg
Asp 3125	Thr	Ile	Glu	Val	Ser	Lys 3130	Leu	Asn	Gly	Ala	Tyr 3135	Arg	Thr	Val
Leu 3140	Val	Ser	Ser	Gly	Leu	Arg 3145	Glu	Pro	Arg	Ala	Leu 3150	Val	Val	Asp
Val 3155	Gln	Asn	Gly	Tyr	Leu	Tyr 3160	Trp	Thr	Asp	Trp	Gly 3165	Asp	His	Ser
Leu 3170	Ile	Gly	Arg	Ile	Gly	Met 3175	Asp	Gly	Ser	Ser	Arg 3180	Ser	Val	Ile
Val 3185	Asp	Thr	Lys	Ile	Thr	Trp 3190	Pro	Asn	Gly	Leu	Thr 3195	Leu	Asp	Tyr
Val 3200	Thr	Glu	Arg	Ile	Tyr	Trp 3205	Ala	Asp	Ala	Arg	Glu 3210	Asp	Tyr	Ile
Glu 3215	Phe	Ala	Ser	Leu	Asp	Gly 3220	Ser	Asn	Arg	His	Val 3225	Val	Leu	Ser
Gln 3230	Asp	Ile	Pro	His	Ile	Phe 3235	Ala	Leu	Thr	Leu	Phe 3240	Glu	Asp	Tyr
Val 3245	Tyr	Trp	Thr	Asp	Trp	Glu 3250	Thr	Lys	Ser	Ile	Asn 3255	Arg	Ala	His
Lys 3260	Thr	Thr	Gly	Thr	Asn	Lys 3265	Thr	Leu	Leu	Ile	Ser 3270	Thr	Leu	His
Arg 3275	Pro	Met	Asp	Leu	His	Val 3280	Phe	His	Ala	Leu	Arg 3285	Gln	Pro	Asp
Val 3290	Pro	Asn	His	Pro	Cys	Lys 3295	Val	Asn	Asn	Gly	Gly 3300	Cys	Ser	Asn
Leu 3305	Cys	Leu	Leu	Ser	Pro	Gly 3310	Gly	Gly	His	Lys	Cys 3315	Ala	Cys	Pro
Thr 3320	Asn	Phe	Tyr	Leu	Gly	Ser 3325	Asp	Gly	Arg	Thr	Cys 3330	Val	Ser	Asn
Cys 3335	Thr	Ala	Ser	Gln	Phe	Val	Cys	Lys	Asn	Asp	Lys	Cys	Ile	Pro

-continued

3335						3340						3345			
Phe Trp	Trp Lys Cys Asp	Thr Glu Asp Asp Cys Gly	Asp His Ser			Thr Glu Asp Asp Cys Gly						Asp His Ser			
3350						3355						3360			
Asp Glu	Pro Pro Asp Cys	Pro Glu Phe Lys Cys Arg	Pro Gly Gln			Pro Glu Phe Lys Cys Arg						Pro Gly Gln			
3365						3370						3375			
Phe Gln	Cys Ser Thr Gly	Ile Cys Thr Asn Pro Ala	Phe Ile Cys			Ile Cys Thr Asn Pro Ala						Phe Ile Cys			
3380						3385						3390			
Asp Gly	Asp Asn Asp Cys	Gln Asp Asn Ser Asp Glu	Ala Asn Cys			Gln Asp Asn Ser Asp Glu						Ala Asn Cys			
3395						3400						3405			
Asp Ile	His Val Cys Leu	Pro Ser Gln Phe Lys Cys	Thr Asn Thr			Pro Ser Gln Phe Lys Cys						Thr Asn Thr			
3410						3415						3420			
Asn Arg	Cys Ile Pro Gly	Ile Phe Arg Cys Asn Gly	Gln Asp Asn			Ile Phe Arg Cys Asn Gly						Gln Asp Asn			
3425						3430						3435			
Cys Gly	Asp Gly Glu Asp	Glu Arg Asp Cys Pro Glu	Val Thr Cys			Glu Arg Asp Cys Pro Glu						Val Thr Cys			
3440						3445						3450			
Ala Pro	Asn Gln Phe Gln	Cys Ser Ile Thr Lys Arg	Cys Ile Pro			Cys Ser Ile Thr Lys Arg						Cys Ile Pro			
3455						3460						3465			
Arg Val	Trp Val Cys Asp	Arg Asp Asn Asp Cys Val	Asp Gly Ser			Arg Asp Asn Asp Cys Val						Asp Gly Ser			
3470						3475						3480			
Asp Glu	Pro Ala Asn Cys	Thr Gln Met Thr Cys Gly	Val Asp Glu			Thr Gln Met Thr Cys Gly						Val Asp Glu			
3485						3490						3495			
Phe Arg	Cys Lys Asp Ser	Gly Arg Cys Ile Pro Ala	Arg Trp Lys			Gly Arg Cys Ile Pro Ala						Arg Trp Lys			
3500						3505						3510			
Cys Asp	Gly Glu Asp Asp	Cys Gly Asp Gly Ser Asp	Glu Pro Lys			Cys Gly Asp Gly Ser Asp						Glu Pro Lys			
3515						3520						3525			
Glu Glu	Cys Asp Glu Arg	Thr Cys Glu Pro Tyr Gln	Phe Arg Cys			Thr Cys Glu Pro Tyr Gln						Phe Arg Cys			
3530						3535						3540			
Lys Asn	Asn Arg Cys Val	Pro Gly Arg Trp Gln Cys	Asp Tyr Asp			Pro Gly Arg Trp Gln Cys						Asp Tyr Asp			
3545						3550						3555			
Asn Asp	Cys Gly Asp Asn	Ser Asp Glu Glu Ser Cys	Thr Pro Arg			Ser Asp Glu Glu Ser Cys						Thr Pro Arg			
3560						3565						3570			
Pro Cys	Ser Glu Ser Glu	Phe Ser Cys Ala Asn Gly	Arg Cys Ile			Phe Ser Cys Ala Asn Gly						Arg Cys Ile			
3575						3580						3585			
Ala Gly	Arg Trp Lys Cys	Asp Gly Asp His Asp Cys	Ala Asp Gly			Asp Gly Asp His Asp Cys						Ala Asp Gly			
3590						3595						3600			
Ser Asp	Glu Lys Asp Cys	Thr Pro Arg Cys Asp Met	Asp Gln Phe			Thr Pro Arg Cys Asp Met						Asp Gln Phe			
3605						3610						3615			
Gln Cys	Lys Ser Gly His	Cys Ile Pro Leu Arg Trp	Arg Cys Asp			Cys Ile Pro Leu Arg Trp						Arg Cys Asp			
3620						3625						3630			
Ala Asp	Ala Asp Cys Met	Asp Gly Ser Asp Glu Glu	Ala Cys Gly			Asp Gly Ser Asp Glu Glu						Ala Cys Gly			
3635						3640						3645			
Thr Gly	Val Arg Thr Cys	Pro Leu Asp Glu Phe Gln	Cys Asn Asn			Pro Leu Asp Glu Phe Gln						Cys Asn Asn			
3650						3655						3660			
Thr Leu	Cys Lys Pro Leu	Ala Trp Lys Cys Asp Gly	Glu Asp Asp			Ala Trp Lys Cys Asp Gly						Glu Asp Asp			
3665						3670						3675			
Cys Gly	Asp Asn Ser Asp	Glu Asn Pro Glu Glu Cys	Ala Arg Phe			Glu Asn Pro Glu Glu Cys						Ala Arg Phe			
3680						3685						3690			
Val Cys	Pro Pro Asn Arg	Pro Phe Arg Cys Lys Asn	Asp Arg Val			Pro Phe Arg Cys Lys Asn						Asp Arg Val			
3695						3700						3705			
Cys Leu	Trp Ile Gly Arg	Gln Cys Asp Gly Thr Asp	Asn Cys Gly			Gln Cys Asp Gly Thr Asp						Asn Cys Gly			
3710						3715						3720			

-continued

---

Asp Gly Thr Asp Glu Glu Asp Cys Glu Pro Pro Thr Ala His Thr 3725 3730 3735
Thr His Cys Lys Asp Lys Lys Glu Phe Leu Cys Arg Asn Gln Arg 3740 3745 3750
Cys Leu Ser Ser Ser Leu Arg Cys Asn Met Phe Asp Asp Cys Gly 3755 3760 3765
Asp Gly Ser Asp Glu Glu Asp Cys Ser Ile Asp Pro Lys Leu Thr 3770 3775 3780
Ser Cys Ala Thr Asn Ala Ser Ile Cys Gly Asp Glu Ala Arg Cys 3785 3790 3795
Val Arg Thr Glu Lys Ala Ala Tyr Cys Ala Cys Arg Ser Gly Phe 3800 3805 3810
His Thr Val Pro Gly Gln Pro Gly Cys Gln Asp Ile Asn Glu Cys 3815 3820 3825
Leu Arg Phe Gly Thr Cys Ser Gln Leu Cys Asn Asn Thr Lys Gly 3830 3835 3840
Gly His Leu Cys Ser Cys Ala Arg Asn Phe Met Lys Thr His Asn 3845 3850 3855
Thr Cys Lys Ala Glu Gly Ser Glu Tyr Gln Val Leu Tyr Ile Ala 3860 3865 3870
Asp Asp Asn Glu Ile Arg Ser Leu Phe Pro Gly His Pro His Ser 3875 3880 3885
Ala Tyr Glu Gln Ala Phe Gln Gly Asp Glu Ser Val Arg Ile Asp 3890 3895 3900
Ala Met Asp Val His Val Lys Ala Gly Arg Val Tyr Trp Thr Asn 3905 3910 3915
Trp His Thr Gly Thr Ile Ser Tyr Arg Ser Leu Pro Pro Ala Ala 3920 3925 3930
Pro Pro Thr Thr Ser Asn Arg His Arg Arg Gln Ile Asp Arg Gly 3935 3940 3945
Val Thr His Leu Asn Ile Ser Gly Leu Lys Met Pro Arg Gly Ile 3950 3955 3960
Ala Ile Asp Trp Val Ala Gly Asn Val Tyr Trp Thr Asp Ser Gly 3965 3970 3975
Arg Asp Val Ile Glu Val Ala Gln Met Lys Gly Glu Asn Arg Lys 3980 3985 3990
Thr Leu Ile Ser Gly Met Ile Asp Glu Pro His Ala Ile Val Val 3995 4000 4005
Asp Pro Leu Arg Gly Thr Met Tyr Trp Ser Asp Trp Gly Asn His 4010 4015 4020
Pro Lys Ile Glu Thr Ala Ala Met Asp Gly Thr Leu Arg Glu Thr 4025 4030 4035
Leu Val Gln Asp Asn Ile Gln Trp Pro Thr Gly Leu Ala Val Asp 4040 4045 4050
Tyr His Asn Glu Arg Leu Tyr Trp Ala Asp Ala Lys Leu Ser Val 4055 4060 4065
Ile Gly Ser Ile Arg Leu Asn Gly Thr Asp Pro Ile Val Ala Ala 4070 4075 4080
Asp Ser Lys Arg Gly Leu Ser His Pro Phe Ser Ile Asp Val Phe 4085 4090 4095

-continued

Glu 4100	Asp	Tyr	Ile	Tyr	Gly	Val 4105	Thr	Tyr	Ile	Asn	Asn 4110	Arg	Val	Phe
Lys 4115	Ile	His	Lys	Phe	Gly	His 4120	Ser	Pro	Leu	Val	Asn 4125	Leu	Thr	Gly
Gly 4130	Leu	Ser	His	Ala	Ser	Asp 4135	Val	Val	Leu	Tyr	His 4140	Gln	His	Lys
Gln 4145	Pro	Glu	Val	Thr	Asn	Pro 4150	Cys	Asp	Arg	Lys	Lys 4155	Cys	Glu	Trp
Leu 4160	Cys	Leu	Leu	Ser	Pro	Ser 4165	Gly	Pro	Val	Cys	Thr 4170	Cys	Pro	Asn
Gly 4175	Lys	Arg	Leu	Asp	Asn	Gly 4180	Thr	Cys	Val	Pro	Val 4185	Pro	Ser	Pro
Thr 4190	Pro	Pro	Pro	Asp	Ala	Pro 4195	Arg	Pro	Gly	Thr	Cys 4200	Asn	Leu	Gln
Cys 4205	Phe	Asn	Gly	Gly	Ser	Cys 4210	Phe	Leu	Asn	Ala	Arg 4215	Arg	Gln	Pro
Lys 4220	Cys	Arg	Cys	Gln	Pro	Arg 4225	Tyr	Thr	Gly	Asp	Lys 4230	Cys	Glu	Leu
Asp 4235	Gln	Cys	Trp	Glu	His	Cys 4240	Arg	Asn	Gly	Gly	Thr 4245	Cys	Ala	Ala
Ser 4250	Pro	Ser	Gly	Met	Pro	Thr 4255	Cys	Arg	Cys	Pro	Thr 4260	Gly	Phe	Thr
Gly 4265	Pro	Lys	Cys	Thr	Gln	Gln 4270	Val	Cys	Ala	Gly	Tyr 4275	Cys	Ala	Asn
Asn 4280	Ser	Thr	Cys	Thr	Val	Asn 4285	Gln	Gly	Asn	Gln	Pro 4290	Gln	Cys	Arg
Cys 4295	Leu	Pro	Gly	Phe	Leu	Gly 4300	Asp	Arg	Cys	Gln	Tyr 4305	Arg	Gln	Cys
Ser 4310	Gly	Tyr	Cys	Glu	Asn	Phe 4315	Gly	Thr	Cys	Gln	Met 4320	Ala	Ala	Asp
Gly 4325	Ser	Arg	Gln	Cys	Arg	Cys 4330	Thr	Ala	Tyr	Phe	Glu 4335	Gly	Ser	Arg
Cys 4340	Glu	Val	Asn	Lys	Cys	Ser 4345	Arg	Cys	Leu	Glu	Gly 4350	Ala	Cys	Val
Val 4355	Asn	Lys	Gln	Ser	Gly	Asp 4360	Val	Thr	Cys	Asn	Cys 4365	Thr	Asp	Gly
Arg 4370	Val	Ala	Pro	Ser	Cys	Leu 4375	Thr	Cys	Val	Gly	His 4380	Cys	Ser	Asn
Gly 4385	Gly	Ser	Cys	Thr	Met	Asn 4390	Ser	Lys	Met	Met	Pro 4395	Glu	Cys	Gln
Cys 4400	Pro	Pro	His	Met	Thr	Gly 4405	Pro	Arg	Cys	Glu	Glu 4410	His	Val	Phe
Ser 4415	Gln	Gln	Gln	Pro	Gly	His 4420	Ile	Ala	Ser	Ile	Leu 4425	Ile	Pro	Leu
Leu 4430	Leu	Leu	Leu	Leu	Leu	Val 4435	Leu	Val	Ala	Gly	Val 4440	Val	Phe	Trp
Tyr 4445	Lys	Arg	Arg	Val	Gln	Gly 4450	Ala	Lys	Gly	Phe	Gln 4455	His	Gln	Arg
Met 4460	Thr	Asn	Gly	Ala	Met	Asn 4465	Val	Glu	Ile	Gly	Asn 4470	Pro	Thr	Tyr
Lys	Met	Tyr	Glu	Gly	Gly	Glu	Pro	Asp	Asp	Val	Gly	Gly	Leu	Leu

-continued

---

4475	4480	4485
Asp Ala Asp Phe Ala Leu	Asp Pro Asp Lys Pro Thr	Asn Phe Thr
4490	4495	4500
Asn Pro Val Tyr Ala Thr	Leu Tyr Met Gly Gly His	Gly Ser Arg
4505	4510	4515
His Ser Leu Ala Ser Thr	Asp Glu Lys Arg Glu Leu	Leu Gly Arg
4520	4525	4530
Gly Pro Glu Asp Glu Ile	Gly Asp Pro Leu Ala	
4535	4540	

&lt;210&gt; SEQ ID NO 28

&lt;211&gt; LENGTH: 1609

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 28

Met Arg Gly Ser His Arg Ala Ala	Pro Ala Leu Arg Pro Arg Gly Arg
1	5 10 15
Leu Trp Pro Val Leu Ala Val Leu	Ala Ala Ala Ala Ala Gly Cys
	20 25 30
Ala Gln Ala Ala Met Asp Glu Cys	Thr Asp Glu Gly Gly Arg Pro Gln
	35 40 45
Arg Cys Met Pro Glu Phe Val Asn	Ala Ala Phe Asn Val Thr Val Val
	50 55 60
Ala Thr Asn Thr Cys Gly Thr Pro	Pro Glu Glu Tyr Cys Val Gln Thr
	65 70 75 80
Gly Val Thr Gly Val Thr Lys Ser	Cys His Leu Cys Asp Ala Gly Gln
	85 90 95
Pro His Leu Gln His Gly Ala Ala	Phe Leu Thr Asp Tyr Asn Asn Gln
	100 105 110
Ala Asp Thr Thr Trp Trp Gln Ser	Gln Thr Met Leu Ala Gly Val Gln
	115 120 125
Tyr Pro Ser Ser Ile Asn Leu Thr	Leu His Leu Gly Lys Ala Phe Asp
	130 135 140
Ile Thr Tyr Val Arg Leu Lys Phe	His Thr Ser Arg Pro Glu Ser Phe
	145 150 155 160
Ala Ile Tyr Lys Arg Thr Arg Glu	Asp Gly Pro Trp Ile Pro Tyr Gln
	165 170 175
Tyr Tyr Ser Gly Ser Cys Glu Asn	Thr Tyr Ser Lys Ala Asn Arg Gly
	180 185 190
Phe Ile Arg Thr Gly Gly Asp Glu	Gln Gln Ala Leu Cys Thr Asp Glu
	195 200 205
Phe Ser Asp Phe Ser Pro Leu Thr	Gly Gly Asn Val Ala Phe Ser Thr
	210 215 220
Leu Glu Gly Arg Pro Ser Ala Tyr	Asn Phe Asp Asn Ser Pro Val Leu
	225 230 235 240
Gln Glu Trp Val Thr Ala Thr Asp	Ile Arg Val Thr Leu Asn Arg Leu
	245 250 255
Asn Thr Phe Gly Asp Glu Val Phe	Asn Asp Pro Lys Val Leu Lys Ser
	260 265 270
Tyr Tyr Tyr Ala Ile Ser Asp Phe	Ala Val Gly Gly Arg Cys Lys Cys
	275 280 285

-continued

---

Asn Gly His Ala Ser Glu Cys Met Lys Asn Glu Phe Asp Lys Leu Val  
 290 295 300  
 Cys Asn Cys Lys His Asn Thr Tyr Gly Val Asp Cys Glu Lys Cys Leu  
 305 310 315 320  
 Pro Phe Phe Asn Asp Arg Pro Trp Arg Arg Ala Thr Ala Glu Ser Ala  
 325 330 335  
 Ser Glu Cys Leu Pro Cys Asp Cys Asn Gly Arg Ser Gln Glu Cys Tyr  
 340 345 350  
 Phe Asp Pro Glu Leu Tyr Arg Ser Thr Gly His Gly Gly His Cys Thr  
 355 360 365  
 Asn Cys Gln Asp Asn Thr Asp Gly Ala His Cys Glu Arg Cys Arg Glu  
 370 375 380  
 Asn Phe Phe Arg Leu Gly Asn Asn Glu Ala Cys Ser Ser Cys His Cys  
 385 390 395 400  
 Ser Pro Val Gly Ser Leu Ser Thr Gln Cys Asp Ser Tyr Gly Arg Cys  
 405 410 415  
 Ser Cys Lys Pro Gly Val Met Gly Asp Lys Cys Asp Arg Cys Gln Pro  
 420 425 430  
 Gly Phe His Ser Leu Thr Glu Ala Gly Cys Arg Pro Cys Ser Cys Asp  
 435 440 445  
 Pro Ser Gly Ser Ile Asp Glu Cys Asn Val Glu Thr Gly Arg Cys Val  
 450 455 460  
 Cys Lys Asp Asn Val Glu Gly Phe Asn Cys Glu Arg Cys Lys Pro Gly  
 465 470 475 480  
 Phe Phe Asn Leu Glu Ser Ser Asn Pro Arg Gly Cys Thr Pro Cys Phe  
 485 490 495  
 Cys Phe Gly His Ser Ser Val Cys Thr Asn Ala Val Gly Tyr Ser Val  
 500 505 510  
 Tyr Ser Ile Ser Ser Thr Phe Gln Ile Asp Glu Asp Gly Trp Arg Ala  
 515 520 525  
 Glu Gln Arg Asp Gly Ser Glu Ala Ser Leu Glu Trp Ser Ser Glu Arg  
 530 535 540  
 Gln Asp Ile Ala Val Ile Ser Asp Ser Tyr Phe Pro Arg Tyr Phe Ile  
 545 550 555 560  
 Ala Pro Ala Lys Phe Leu Gly Lys Gln Val Leu Ser Tyr Gly Gln Asn  
 565 570 575  
 Leu Ser Phe Ser Phe Arg Val Asp Arg Arg Asp Thr Arg Leu Ser Ala  
 580 585 590  
 Glu Asp Leu Val Leu Glu Gly Ala Gly Leu Arg Val Ser Val Pro Leu  
 595 600 605  
 Ile Ala Gln Gly Asn Ser Tyr Pro Ser Glu Thr Thr Val Lys Tyr Val  
 610 615 620  
 Phe Arg Leu His Glu Ala Thr Asp Tyr Pro Trp Arg Pro Ala Leu Thr  
 625 630 635 640  
 Pro Phe Glu Phe Gln Lys Leu Leu Asn Asn Leu Thr Ser Ile Lys Ile  
 645 650 655  
 Arg Gly Thr Tyr Ser Glu Arg Ser Ala Gly Tyr Leu Asp Asp Val Thr  
 660 665 670  
 Leu Ala Ser Ala Arg Pro Gly Pro Gly Val Pro Ala Thr Trp Val Glu  
 675 680 685  
 Ser Cys Thr Cys Pro Val Gly Tyr Gly Gly Gln Phe Cys Glu Met Cys

-continued

690			695			700									
Leu	Ser	Gly	Tyr	Arg	Arg	Glu	Thr	Pro	Asn	Leu	Gly	Pro	Tyr	Ser	Pro
705					710					715					720
Cys	Val	Leu	Cys	Ala	Cys	Asn	Gly	His	Ser	Glu	Thr	Cys	Asp	Pro	Glu
			725						730					735	
Thr	Gly	Val	Cys	Asn	Cys	Arg	Asp	Asn	Thr	Ala	Gly	Pro	His	Cys	Glu
			740					745					750		
Lys	Cys	Ser	Asp	Gly	Tyr	Tyr	Gly	Asp	Ser	Thr	Ala	Gly	Thr	Ser	Ser
		755						760				765			
Asp	Cys	Gln	Pro	Cys	Pro	Cys	Pro	Gly	Gly	Ser	Ser	Cys	Ala	Val	Val
		770					775					780			
Pro	Lys	Thr	Lys	Glu	Val	Val	Cys	Thr	Asn	Cys	Pro	Thr	Gly	Thr	Thr
785					790					795					800
Gly	Lys	Arg	Cys	Glu	Leu	Cys	Asp	Asp	Gly	Tyr	Phe	Gly	Asp	Pro	Leu
			805						810					815	
Gly	Arg	Asn	Gly	Pro	Val	Arg	Leu	Cys	Arg	Leu	Cys	Gln	Cys	Ser	Asp
			820						825				830		
Asn	Ile	Asp	Pro	Asn	Ala	Val	Gly	Asn	Cys	Asn	Arg	Leu	Thr	Gly	Glu
		835						840					845		
Cys	Leu	Lys	Cys	Ile	Tyr	Asn	Thr	Ala	Gly	Phe	Tyr	Cys	Asp	Arg	Cys
	850						855					860			
Lys	Asp	Gly	Phe	Phe	Gly	Asn	Pro	Leu	Ala	Pro	Asn	Pro	Ala	Asp	Lys
865					870					875					880
Cys	Lys	Ala	Cys	Asn	Cys	Asn	Pro	Tyr	Gly	Thr	Met	Lys	Gln	Gln	Ser
				885					890					895	
Ser	Cys	Asn	Pro	Val	Thr	Gly	Gln	Cys	Glu	Cys	Leu	Pro	His	Val	Thr
			900					905					910		
Gly	Gln	Asp	Cys	Gly	Ala	Cys	Asp	Pro	Gly	Phe	Tyr	Asn	Leu	Gln	Ser
		915					920						925		
Gly	Gln	Gly	Cys	Glu	Arg	Cys	Asp	Cys	His	Ala	Leu	Gly	Ser	Thr	Asn
		930					935				940				
Gly	Gln	Cys	Asp	Ile	Arg	Thr	Gly	Gln	Cys	Glu	Cys	Gln	Pro	Gly	Ile
945					950					955					960
Thr	Gly	Gln	His	Cys	Glu	Arg	Cys	Glu	Val	Asn	His	Phe	Gly	Phe	Gly
				965					970					975	
Pro	Glu	Gly	Cys	Lys	Pro	Cys	Asp	Cys	His	Pro	Glu	Gly	Ser	Leu	Ser
			980					985						990	
Leu	Gln	Cys	Lys	Asp	Asp	Gly	Arg	Cys	Glu	Cys	Arg	Glu	Gly	Phe	Val
			995				1000						1005		
Gly	Asn	Arg	Cys	Asp	Gln	Cys	Glu	Glu	Asn	Tyr	Phe	Tyr	Asn	Arg	
	1010						1015						1020		
Ser	Trp	Pro	Gly	Cys	Gln	Glu	Cys	Pro	Ala	Cys	Tyr	Arg	Leu	Val	
	1025						1030						1035		
Lys	Asp	Lys	Val	Ala	Asp	His	Arg	Val	Lys	Leu	Gln	Glu	Leu	Glu	
	1040						1045						1050		
Ser	Leu	Ile	Ala	Asn	Leu	Gly	Thr	Gly	Asp	Glu	Met	Val	Thr	Asp	
	1055						1060						1065		
Gln	Ala	Phe	Glu	Asp	Arg	Leu	Lys	Glu	Ala	Glu	Arg	Glu	Val	Met	
	1070						1075						1080		
Asp	Leu	Leu	Arg	Glu	Ala	Gln	Asp	Val	Lys	Asp	Val	Asp	Gln	Asn	
	1085						1090						1095		

-continued

---

Leu Met	Asp Arg Leu Gln Arg	Val Asn Asn Thr Leu	Ser Ser Gln
1100	1105	1110	
Ile Ser	Arg Leu Gln Asn Ile	Arg Asn Thr Ile Glu	Glu Thr Gly
1115	1120	1125	
Asn Leu	Ala Glu Gln Ala Arg	Ala His Val Glu Asn	Thr Glu Arg
1130	1135	1140	
Leu Ile	Glu Ile Ala Ser Arg	Glu Leu Glu Lys Ala	Lys Val Ala
1145	1150	1155	
Ala Ala	Asn Val Ser Val Thr	Gln Pro Glu Ser Thr	Gly Asp Pro
1160	1165	1170	
Asn Asn	Met Thr Leu Leu Ala	Glu Glu Ala Arg Lys	Leu Ala Glu
1175	1180	1185	
Arg His	Lys Gln Glu Ala Asp	Asp Ile Val Arg Val	Ala Lys Thr
1190	1195	1200	
Ala Asn	Asp Thr Ser Thr Glu	Ala Tyr Asn Leu Leu	Leu Arg Thr
1205	1210	1215	
Leu Ala	Gly Glu Asn Gln Thr	Ala Phe Glu Ile Glu	Glu Leu Asn
1220	1225	1230	
Arg Lys	Tyr Glu Gln Ala Lys	Asn Ile Ser Gln Asp	Leu Glu Lys
1235	1240	1245	
Gln Ala	Ala Arg Val His Glu	Glu Ala Lys Arg Ala	Gly Asp Lys
1250	1255	1260	
Ala Val	Glu Ile Tyr Ala Ser	Val Ala Gln Leu Ser	Pro Leu Asp
1265	1270	1275	
Ser Glu	Thr Leu Glu Asn Glu	Ala Asn Asn Ile Lys	Met Glu Ala
1280	1285	1290	
Glu Asn	Leu Glu Gln Leu Ile	Asp Gln Lys Leu Lys	Asp Tyr Glu
1295	1300	1305	
Asp Leu	Arg Glu Asp Met Arg	Gly Lys Glu Leu Glu	Val Lys Asn
1310	1315	1320	
Leu Leu	Glu Lys Gly Lys Thr	Glu Gln Gln Thr Ala	Asp Gln Leu
1325	1330	1335	
Leu Ala	Arg Ala Asp Ala Ala	Lys Ala Leu Ala Glu	Glu Ala Ala
1340	1345	1350	
Lys Lys	Gly Arg Asp Thr Leu	Gln Glu Ala Asn Asp	Ile Leu Asn
1355	1360	1365	
Asn Leu	Lys Asp Phe Asp Arg	Arg Val Asn Asp Asn	Lys Thr Ala
1370	1375	1380	
Ala Glu	Glu Ala Leu Arg Lys	Ile Pro Ala Ile Asn	Gln Thr Ile
1385	1390	1395	
Thr Glu	Ala Asn Glu Lys Thr	Arg Glu Ala Gln Gln	Ala Leu Gly
1400	1405	1410	
Ser Ala	Ala Ala Asp Ala Thr	Glu Ala Lys Asn Lys	Ala His Glu
1415	1420	1425	
Ala Glu	Arg Ile Ala Ser Ala	Val Gln Lys Asn Ala	Thr Ser Thr
1430	1435	1440	
Lys Ala	Glu Ala Glu Arg Thr	Phe Ala Glu Val Thr	Asp Leu Asp
1445	1450	1455	
Asn Glu	Val Asn Asn Met Leu	Lys Gln Leu Gln Glu	Ala Glu Lys
1460	1465	1470	

-continued

---

Glu Leu Lys Arg Lys Gln Asp Asp Ala Asp Gln Asp Met Met Met  
 1475 1480 1485  
 Ala Gly Met Ala Ser Gln Ala Ala Gln Glu Ala Glu Ile Asn Ala  
 1490 1495 1500  
 Arg Lys Ala Lys Asn Ser Val Thr Ser Leu Leu Ser Ile Ile Asn  
 1505 1510 1515  
 Asp Leu Leu Glu Gln Leu Gly Gln Leu Asp Thr Val Asp Leu Asn  
 1520 1525 1530  
 Lys Leu Asn Glu Ile Glu Gly Thr Leu Asn Lys Ala Lys Asp Glu  
 1535 1540 1545  
 Met Lys Val Ser Asp Leu Asp Arg Lys Val Ser Asp Leu Glu Asn  
 1550 1555 1560  
 Glu Ala Lys Lys Gln Glu Ala Ala Ile Met Asp Tyr Asn Arg Asp  
 1565 1570 1575  
 Ile Glu Glu Ile Met Lys Asp Ile Arg Asn Leu Glu Asp Ile Arg  
 1580 1585 1590  
 Lys Thr Leu Pro Ser Gly Cys Phe Asn Thr Pro Ser Ile Glu Lys  
 1595 1600 1605

Pro

<210> SEQ ID NO 29  
 <211> LENGTH: 1786  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 29

Met Gly Leu Leu Gln Leu Leu Ala Phe Ser Phe Leu Ala Leu Cys Arg  
 1 5 10 15  
 Ala Arg Val Arg Ala Gln Glu Pro Glu Phe Ser Tyr Gly Cys Ala Glu  
 20 25 30  
 Gly Ser Cys Tyr Pro Ala Thr Gly Asp Leu Leu Ile Gly Arg Ala Gln  
 35 40 45  
 Lys Leu Ser Val Thr Ser Thr Cys Gly Leu His Lys Pro Glu Pro Tyr  
 50 55 60  
 Cys Ile Val Ser His Leu Gln Glu Asp Lys Lys Cys Phe Ile Cys Asn  
 65 70 75 80  
 Ser Gln Asp Pro Tyr His Glu Thr Leu Asn Pro Asp Ser His Leu Ile  
 85 90 95  
 Glu Asn Val Val Thr Thr Phe Ala Pro Asn Arg Leu Lys Ile Trp Trp  
 100 105 110  
 Gln Ser Glu Asn Gly Val Glu Asn Val Thr Ile Gln Leu Asp Leu Glu  
 115 120 125  
 Ala Glu Phe His Phe Thr His Leu Ile Met Thr Phe Lys Thr Phe Arg  
 130 135 140  
 Pro Ala Ala Met Leu Ile Glu Arg Ser Ser Asp Phe Gly Lys Thr Trp  
 145 150 155 160  
 Gly Val Tyr Arg Tyr Phe Ala Tyr Asp Cys Glu Ala Ser Phe Pro Gly  
 165 170 175  
 Ile Ser Thr Gly Pro Met Lys Lys Val Asp Asp Ile Ile Cys Asp Ser  
 180 185 190  
 Arg Tyr Ser Asp Ile Glu Pro Ser Thr Glu Gly Glu Val Ile Phe Arg  
 195 200 205

-continued

---

Ala Leu Asp Pro Ala Phe Lys Ile Glu Asp Pro Tyr Ser Pro Arg Ile  
210 215 220

Gln Asn Leu Leu Lys Ile Thr Asn Leu Arg Ile Lys Phe Val Lys Leu  
225 230 235 240

His Thr Leu Gly Asp Asn Leu Leu Asp Ser Arg Met Glu Ile Arg Glu  
245 250 255

Lys Tyr Tyr Tyr Ala Val Tyr Asp Met Val Val Arg Gly Asn Cys Phe  
260 265 270

Cys Tyr Gly His Ala Ser Glu Cys Ala Pro Val Asp Gly Phe Asn Glu  
275 280 285

Glu Val Glu Gly Met Val His Gly His Cys Met Cys Arg His Asn Thr  
290 295 300

Lys Gly Leu Asn Cys Glu Leu Cys Met Asp Phe Tyr His Asp Leu Pro  
305 310 315 320

Trp Arg Pro Ala Glu Gly Arg Asn Ser Asn Ala Cys Lys Lys Cys Asn  
325 330 335

Cys Asn Glu His Ser Ile Ser Cys His Phe Asp Met Ala Val Tyr Leu  
340 345 350

Ala Thr Gly Asn Val Ser Gly Gly Val Cys Asp Asp Cys Gln His Asn  
355 360 365

Thr Met Gly Arg Asn Cys Glu Gln Cys Lys Pro Phe Tyr Tyr Gln His  
370 375 380

Pro Glu Arg Asp Ile Arg Asp Pro Asn Phe Cys Glu Arg Cys Thr Cys  
385 390 395 400

Asp Pro Ala Gly Ser Gln Asn Glu Gly Ile Cys Asp Ser Tyr Thr Asp  
405 410 415

Phe Ser Thr Gly Leu Ile Ala Gly Gln Cys Arg Cys Lys Leu Asn Val  
420 425 430

Glu Gly Glu His Cys Asp Val Cys Lys Glu Gly Phe Tyr Asp Leu Ser  
435 440 445

Ser Glu Asp Pro Phe Gly Cys Lys Ser Cys Ala Cys Asn Pro Leu Gly  
450 455 460

Thr Ile Pro Gly Gly Asn Pro Cys Asp Ser Glu Thr Gly His Cys Tyr  
465 470 475 480

Cys Lys Arg Leu Val Thr Gly Gln His Cys Asp Gln Cys Leu Pro Glu  
485 490 495

His Trp Gly Leu Ser Asn Asp Leu Asp Gly Cys Arg Pro Cys Asp Cys  
500 505 510

Asp Leu Gly Gly Ala Leu Asn Asn Ser Cys Phe Ala Glu Ser Gly Gln  
515 520 525

Cys Ser Cys Arg Pro His Met Ile Gly Arg Gln Cys Asn Glu Val Glu  
530 535 540

Pro Gly Tyr Tyr Phe Ala Thr Leu Asp His Tyr Leu Tyr Glu Ala Glu  
545 550 555 560

Glu Ala Asn Leu Gly Pro Gly Val Ser Ile Val Glu Arg Gln Tyr Ile  
565 570 575

Gln Asp Arg Ile Pro Ser Trp Thr Gly Ala Gly Phe Val Arg Val Pro  
580 585 590

Glu Gly Ala Tyr Leu Glu Phe Phe Ile Asp Asn Ile Pro Tyr Ser Met  
595 600 605

Glu Tyr Asp Ile Leu Ile Arg Tyr Glu Pro Gln Leu Pro Asp His Trp

-continued

610			615			620									
Glu	Lys	Ala	Val	Ile	Thr	Val	Gln	Arg	Pro	Gly	Arg	Ile	Pro	Thr	Ser
625					630					635					640
Ser	Arg	Cys	Gly	Asn	Thr	Ile	Pro	Asp	Asp	Asp	Asn	Gln	Val	Val	Ser
				645					650						655
Leu	Ser	Pro	Gly	Ser	Arg	Tyr	Val	Val	Leu	Pro	Arg	Pro	Val	Cys	Phe
			660						665						670
Glu	Lys	Gly	Thr	Asn	Tyr	Thr	Val	Arg	Leu	Glu	Leu	Pro	Gln	Tyr	Thr
		675					680						685		
Ser	Ser	Asp	Ser	Asp	Val	Glu	Ser	Pro	Tyr	Thr	Leu	Ile	Asp	Ser	Leu
		690					695					700			
Val	Leu	Met	Pro	Tyr	Cys	Lys	Ser	Leu	Asp	Ile	Phe	Thr	Val	Gly	Gly
705					710					715					720
Ser	Gly	Asp	Gly	Val	Val	Thr	Asn	Ser	Ala	Trp	Glu	Thr	Phe	Gln	Arg
				725					730						735
Tyr	Arg	Cys	Leu	Glu	Asn	Ser	Arg	Ser	Val	Val	Lys	Thr	Pro	Met	Thr
			740						745					750	
Asp	Val	Cys	Arg	Asn	Ile	Ile	Phe	Ser	Ile	Ser	Ala	Leu	Leu	His	Gln
			755				760						765		
Thr	Gly	Leu	Ala	Cys	Glu	Cys	Asp	Pro	Gln	Gly	Ser	Leu	Ser	Ser	Val
			770				775					780			
Cys	Asp	Pro	Asn	Gly	Gly	Gln	Cys	Gln	Cys	Arg	Pro	Asn	Val	Val	Gly
785					790					795					800
Arg	Thr	Cys	Asn	Arg	Cys	Ala	Pro	Gly	Thr	Phe	Gly	Phe	Gly	Pro	Ser
				805					810						815
Gly	Cys	Lys	Pro	Cys	Glu	Cys	His	Leu	Gln	Gly	Ser	Val	Asn	Ala	Phe
				820					825					830	
Cys	Asn	Pro	Val	Thr	Gly	Gln	Cys	His	Cys	Phe	Gln	Gly	Val	Tyr	Ala
			835				840						845		
Arg	Gln	Cys	Asp	Arg	Cys	Leu	Pro	Gly	His	Trp	Gly	Phe	Pro	Ser	Cys
						855						860			
Gln	Pro	Cys	Gln	Cys	Asn	Gly	His	Ala	Asp	Asp	Cys	Asp	Pro	Val	Thr
865					870					875					880
Gly	Glu	Cys	Leu	Asn	Cys	Gln	Asp	Tyr	Thr	Met	Gly	His	Asn	Cys	Glu
				885					890					895	
Arg	Cys	Leu	Ala	Gly	Tyr	Tyr	Gly	Asp	Pro	Ile	Ile	Gly	Ser	Gly	Asp
				900					905					910	
His	Cys	Arg	Pro	Cys	Pro	Cys	Pro	Asp	Gly	Pro	Asp	Ser	Gly	Arg	Gln
				915					920					925	
Phe	Ala	Arg	Ser	Cys	Tyr	Gln	Asp	Pro	Val	Thr	Leu	Gln	Leu	Ala	Cys
				930			935					940			
Val	Cys	Asp	Pro	Gly	Tyr	Ile	Gly	Ser	Arg	Cys	Asp	Asp	Cys	Ala	Ser
945					950					955					960
Gly	Tyr	Phe	Gly	Asn	Pro	Ser	Glu	Val	Gly	Gly	Ser	Cys	Gln	Pro	Cys
				965					970						975
Gln	Cys	His	Asn	Asn	Ile	Asp	Thr	Thr	Asp	Pro	Glu	Ala	Cys	Asp	Lys
				980					985					990	
Glu	Thr	Gly	Arg	Cys	Leu	Lys	Cys	Leu	Tyr	His	Thr	Glu	Gly	Glu	His
				995					1000					1005	
Cys	Gln	Phe	Cys	Arg	Phe	Gly	Tyr	Tyr	Gly	Asp	Ala	Leu	Arg	Gln	
						1015							1020		

-continued

---

Asp Cys	Arg Lys Cys Val	Cys	Asn Tyr Leu Gly Thr	Val Gln Glu
1025		1030		1035
His Cys	Asn Gly Ser Asp	Cys	Gln Cys Asp Lys Ala	Thr Gly Gln
1040		1045		1050
Cys Leu	Cys Leu Pro Asn	Val	Ile Gly Gln Asn Cys	Asp Arg Cys
1055		1060		1065
Ala Pro	Asn Thr Trp Gln	Leu	Ala Ser Gly Thr Gly	Cys Asp Pro
1070		1075		1080
Cys Asn	Cys Asn Ala Ala	His	Ser Phe Gly Pro Ser	Cys Asn Glu
1085		1090		1095
Phe Thr	Gly Gln Cys Gln	Cys	Met Pro Gly Phe Gly	Gly Arg Thr
1100		1105		1110
Cys Ser	Glu Cys Gln Glu	Leu	Phe Trp Gly Asp Pro	Asp Val Glu
1115		1120		1125
Cys Arg	Ala Cys Asp Cys	Asp	Pro Arg Gly Ile Glu	Thr Pro Gln
1130		1135		1140
Cys Asp	Gln Ser Thr Gly	Gln	Cys Val Cys Val Glu	Gly Val Glu
1145		1150		1155
Gly Pro	Arg Cys Asp Lys	Cys	Thr Arg Gly Tyr Ser	Gly Val Phe
1160		1165		1170
Pro Asp	Cys Thr Pro Cys	His	Gln Cys Phe Ala Leu	Trp Asp Val
1175		1180		1185
Ile Ile	Ala Glu Leu Thr	Asn	Arg Thr His Arg Phe	Leu Glu Lys
1190		1195		1200
Ala Lys	Ala Leu Lys Ile	Ser	Gly Val Ile Gly Pro	Tyr Arg Glu
1205		1210		1215
Thr Val	Asp Ser Val Glu	Arg	Lys Val Ser Glu Ile	Lys Asp Ile
1220		1225		1230
Leu Ala	Gln Ser Pro Ala	Ala	Glu Pro Leu Lys Asn	Ile Gly Asn
1235		1240		1245
Leu Phe	Glu Glu Ala Glu	Lys	Leu Ile Lys Asp Val	Thr Glu Met
1250		1255		1260
Met Ala	Gln Val Glu Val	Lys	Leu Ser Asp Thr Thr	Ser Gln Ser
1265		1270		1275
Asn Ser	Thr Ala Lys Glu	Leu	Asp Ser Leu Gln Thr	Glu Ala Glu
1280		1285		1290
Ser Leu	Asp Asn Thr Val	Lys	Glu Leu Ala Glu Gln	Leu Glu Phe
1295		1300		1305
Ile Lys	Asn Ser Asp Ile	Arg	Gly Ala Leu Asp Ser	Ile Thr Lys
1310		1315		1320
Tyr Phe	Gln Met Ser Leu	Glu	Ala Glu Glu Arg Val	Asn Ala Ser
1325		1330		1335
Thr Thr	Glu Pro Asn Ser	Thr	Val Glu Gln Ser Ala	Leu Met Arg
1340		1345		1350
Asp Arg	Val Glu Asp Val	Met	Met Glu Arg Glu Ser	Gln Phe Lys
1355		1360		1365
Glu Lys	Gln Glu Glu Gln	Ala	Arg Leu Leu Asp Glu	Leu Ala Gly
1370		1375		1380
Lys Leu	Gln Ser Leu Asp	Leu	Ser Ala Ala Ala Glu	Met Thr Cys
1385		1390		1395

-continued

Gly	Thr	Pro	Pro	Gly	Ala	Ser	Cys	Ser	Glu	Thr	Glu	Cys	Gly	Gly
1400						1405					1410			
Pro	Asn	Cys	Arg	Thr	Asp	Glu	Gly	Glu	Arg	Lys	Cys	Gly	Gly	Pro
1415						1420					1425			
Gly	Cys	Gly	Gly	Leu	Val	Thr	Val	Ala	His	Asn	Ala	Trp	Gln	Lys
1430						1435					1440			
Ala	Met	Asp	Leu	Asp	Gln	Asp	Val	Leu	Ser	Ala	Leu	Ala	Glu	Val
1445						1450					1455			
Glu	Gln	Leu	Ser	Lys	Met	Val	Ser	Glu	Ala	Lys	Leu	Arg	Ala	Asp
1460						1465					1470			
Glu	Ala	Lys	Gln	Ser	Ala	Glu	Asp	Ile	Leu	Leu	Lys	Thr	Asn	Ala
1475						1480					1485			
Thr	Lys	Glu	Lys	Met	Asp	Lys	Ser	Asn	Glu	Glu	Leu	Arg	Asn	Leu
1490						1495					1500			
Ile	Lys	Gln	Ile	Arg	Asn	Phe	Leu	Thr	Gln	Asp	Ser	Ala	Asp	Leu
1505						1510					1515			
Asp	Ser	Ile	Glu	Ala	Val	Ala	Asn	Glu	Val	Leu	Lys	Met	Glu	Met
1520						1525					1530			
Pro	Ser	Thr	Pro	Gln	Gln	Leu	Gln	Asn	Leu	Thr	Glu	Asp	Ile	Arg
1535						1540					1545			
Glu	Arg	Val	Glu	Ser	Leu	Ser	Gln	Val	Glu	Val	Ile	Leu	Gln	His
1550						1555					1560			
Ser	Ala	Ala	Asp	Ile	Ala	Arg	Ala	Glu	Met	Leu	Leu	Glu	Glu	Ala
1565						1570					1575			
Lys	Arg	Ala	Ser	Lys	Ser	Ala	Thr	Asp	Val	Lys	Val	Thr	Ala	Asp
1580						1585					1590			
Met	Val	Lys	Glu	Ala	Leu	Glu	Glu	Ala	Glu	Lys	Ala	Gln	Val	Ala
1595						1600					1605			
Ala	Glu	Lys	Ala	Ile	Lys	Gln	Ala	Asp	Glu	Asp	Ile	Gln	Gly	Thr
1610						1615					1620			
Gln	Asn	Leu	Leu	Thr	Ser	Ile	Glu	Ser	Glu	Thr	Ala	Ala	Ser	Glu
1625						1630					1635			
Glu	Thr	Leu	Phe	Asn	Ala	Ser	Gln	Arg	Ile	Ser	Glu	Leu	Glu	Arg
1640						1645					1650			
Asn	Val	Glu	Glu	Leu	Lys	Arg	Lys	Ala	Ala	Gln	Asn	Ser	Gly	Glu
1655						1660					1665			
Ala	Glu	Tyr	Ile	Glu	Lys	Val	Val	Tyr	Thr	Val	Lys	Gln	Ser	Ala
1670						1675					1680			
Glu	Asp	Val	Lys	Lys	Thr	Leu	Asp	Gly	Glu	Leu	Asp	Glu	Lys	Tyr
1685						1690					1695			
Lys	Lys	Val	Glu	Asn	Leu	Ile	Ala	Lys	Lys	Thr	Glu	Glu	Ser	Ala
1700						1705					1710			
Asp	Ala	Arg	Arg	Lys	Ala	Glu	Met	Leu	Gln	Asn	Glu	Ala	Lys	Thr
1715						1720					1725			
Leu	Leu	Ala	Gln	Ala	Asn	Ser	Lys	Leu	Gln	Leu	Leu	Lys	Asp	Leu
1730						1735					1740			
Glu	Arg	Lys	Tyr	Glu	Asp	Asn	Gln	Arg	Tyr	Leu	Glu	Asp	Lys	Ala
1745						1750					1755			
Gln	Glu	Leu	Ala	Arg	Leu	Glu	Gly	Glu	Val	Arg	Ser	Leu	Leu	Lys
1760						1765					1770			
Asp	Ile	Ser	Gln	Lys	Val	Ala	Val	Tyr	Ser	Thr	Cys	Leu		

-continued

---

1775                      1780                      1785

<210> SEQ ID NO 30  
 <211> LENGTH: 1487  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 30

Met Ile Arg Leu Gly Ala Pro Gln Thr Leu Val Leu Leu Thr Leu Leu  
 1                      5                      10                      15

Val Ala Ala Val Leu Arg Cys Gln Gly Gln Asp Val Gln Glu Ala Gly  
                     20                      25                      30

Ser Cys Val Gln Asp Gly Gln Arg Tyr Asn Asp Lys Asp Val Trp Lys  
                     35                      40                      45

Pro Glu Pro Cys Arg Ile Cys Val Cys Asp Thr Gly Thr Val Leu Cys  
                     50                      55                      60

Asp Asp Ile Ile Cys Glu Asp Val Lys Asp Cys Leu Ser Pro Glu Ile  
 65                      70                      75                      80

Pro Phe Gly Glu Cys Cys Pro Ile Cys Pro Thr Asp Leu Ala Thr Ala  
                     85                      90                      95

Ser Gly Gln Pro Gly Pro Lys Gly Gln Lys Gly Glu Pro Gly Asp Ile  
                     100                      105                      110

Lys Asp Ile Val Gly Pro Lys Gly Pro Pro Gly Pro Gln Gly Pro Ala  
                     115                      120                      125

Gly Glu Gln Gly Pro Arg Gly Asp Arg Gly Asp Lys Gly Glu Lys Gly  
                     130                      135                      140

Ala Pro Gly Pro Arg Gly Arg Asp Gly Glu Pro Gly Thr Pro Gly Asn  
 145                      150                      155                      160

Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly  
                     165                      170                      175

Gly Asn Phe Ala Ala Gln Met Ala Gly Gly Phe Asp Glu Lys Ala Gly  
                     180                      185                      190

Gly Ala Gln Leu Gly Val Met Gln Gly Pro Met Gly Pro Met Gly Pro  
                     195                      200                      205

Arg Gly Pro Pro Gly Pro Ala Gly Ala Pro Gly Pro Gln Gly Phe Gln  
                     210                      215                      220

Gly Asn Pro Gly Glu Pro Gly Glu Pro Gly Val Ser Gly Pro Met Gly  
 225                      230                      235                      240

Pro Arg Gly Pro Pro Gly Pro Pro Gly Lys Pro Gly Asp Asp Gly Glu  
                     245                      250                      255

Ala Gly Lys Pro Gly Lys Ala Gly Glu Arg Gly Pro Pro Gly Pro Gln  
                     260                      265                      270

Gly Ala Arg Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Val Lys Gly  
                     275                      280                      285

His Arg Gly Tyr Pro Gly Leu Asp Gly Ala Lys Gly Glu Ala Gly Ala  
 290                      295                      300

Pro Gly Val Lys Gly Glu Ser Gly Ser Pro Gly Glu Asn Gly Ser Pro  
 305                      310                      315

Gly Pro Met Gly Pro Arg Gly Leu Pro Gly Glu Arg Gly Arg Thr Gly  
                     325                      330                      335

Pro Ala Gly Ala Ala Gly Ala Arg Gly Asn Asp Gly Gln Pro Gly Pro  
                     340                      345                      350

-continued

---

Ala Gly Pro Pro Gly Pro Val Gly Pro Ala Gly Gly Pro Gly Phe Pro  
355 360 365

Gly Ala Pro Gly Ala Lys Gly Glu Ala Gly Pro Thr Gly Ala Arg Gly  
370 375 380

Pro Glu Gly Ala Gln Gly Pro Arg Gly Glu Pro Gly Thr Pro Gly Ser  
385 390 395 400

Pro Gly Pro Ala Gly Ala Ser Gly Asn Pro Gly Thr Asp Gly Ile Pro  
405 410 415

Gly Ala Lys Gly Ser Ala Gly Ala Pro Gly Ile Ala Gly Ala Pro Gly  
420 425 430

Phe Pro Gly Pro Arg Gly Pro Pro Gly Pro Gln Gly Ala Thr Gly Pro  
435 440 445

Leu Gly Pro Lys Gly Gln Thr Gly Glu Pro Gly Ile Ala Gly Phe Lys  
450 455 460

Gly Glu Gln Gly Pro Lys Gly Glu Pro Gly Pro Ala Gly Pro Gln Gly  
465 470 475 480

Ala Pro Gly Pro Ala Gly Glu Glu Gly Lys Arg Gly Ala Arg Gly Glu  
485 490 495

Pro Gly Gly Val Gly Pro Ile Gly Pro Pro Gly Glu Arg Gly Ala Pro  
500 505 510

Gly Asn Arg Gly Phe Pro Gly Gln Asp Gly Leu Ala Gly Pro Lys Gly  
515 520 525

Ala Pro Gly Glu Arg Gly Pro Ser Gly Leu Ala Gly Pro Lys Gly Ala  
530 535 540

Asn Gly Asp Pro Gly Arg Pro Gly Glu Pro Gly Leu Pro Gly Ala Arg  
545 550 555 560

Gly Leu Thr Gly Arg Pro Gly Asp Ala Gly Pro Gln Gly Lys Val Gly  
565 570 575

Pro Ser Gly Ala Pro Gly Glu Asp Gly Arg Pro Gly Pro Pro Gly Pro  
580 585 590

Gln Gly Ala Arg Gly Gln Pro Gly Val Met Gly Phe Pro Gly Pro Lys  
595 600 605

Gly Ala Asn Gly Glu Pro Gly Lys Ala Gly Glu Lys Gly Leu Pro Gly  
610 615 620

Ala Pro Gly Leu Arg Gly Leu Pro Gly Lys Asp Gly Glu Thr Gly Ala  
625 630 635 640

Ala Gly Pro Pro Gly Pro Ala Gly Pro Ala Gly Glu Arg Gly Glu Gln  
645 650 655

Gly Ala Pro Gly Pro Ser Gly Phe Gln Gly Leu Pro Gly Pro Pro Gly  
660 665 670

Pro Pro Gly Glu Gly Gly Lys Pro Gly Asp Gln Gly Val Pro Gly Glu  
675 680 685

Ala Gly Ala Pro Gly Leu Val Gly Pro Arg Gly Glu Arg Gly Phe Pro  
690 695 700

Gly Glu Arg Gly Ser Pro Gly Ala Gln Gly Leu Gln Gly Pro Arg Gly  
705 710 715 720

Leu Pro Gly Thr Pro Gly Thr Asp Gly Pro Lys Gly Ala Ser Gly Pro  
725 730 735

Ala Gly Pro Pro Gly Ala Gln Gly Pro Pro Gly Leu Gln Gly Met Pro  
740 745 750

Gly Glu Arg Gly Ala Ala Gly Ile Ala Gly Pro Lys Gly Asp Arg Gly

-continued

755			760			765									
Asp	Val	Gly	Glu	Lys	Gly	Pro	Glu	Gly	Ala	Pro	Gly	Lys	Asp	Gly	Gly
770						775					780				
Arg	Gly	Leu	Thr	Gly	Pro	Ile	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Ala	Asn
785					790					795					800
Gly	Glu	Lys	Gly	Glu	Val	Gly	Pro	Pro	Gly	Pro	Ala	Gly	Ser	Ala	Gly
			805						810					815	
Ala	Arg	Gly	Ala	Pro	Gly	Glu	Arg	Gly	Glu	Thr	Gly	Pro	Pro	Gly	Pro
			820					825						830	
Ala	Gly	Phe	Ala	Gly	Pro	Pro	Gly	Ala	Asp	Gly	Gln	Pro	Gly	Ala	Lys
		835						840					845		
Gly	Glu	Gln	Gly	Glu	Ala	Gly	Gln	Lys	Gly	Asp	Ala	Gly	Ala	Pro	Gly
		850					855				860				
Pro	Gln	Gly	Pro	Ser	Gly	Ala	Pro	Gly	Pro	Gln	Gly	Pro	Thr	Gly	Val
865					870					875					880
Thr	Gly	Pro	Lys	Gly	Ala	Arg	Gly	Ala	Gln	Gly	Pro	Pro	Gly	Ala	Thr
				885					890					895	
Gly	Phe	Pro	Gly	Ala	Ala	Gly	Arg	Val	Gly	Pro	Pro	Gly	Ser	Asn	Gly
			900					905					910		
Asn	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Ser	Gly	Lys	Asp	Gly	Pro
		915						920					925		
Lys	Gly	Ala	Arg	Gly	Asp	Ser	Gly	Pro	Pro	Gly	Arg	Ala	Gly	Glu	Pro
		930					935				940				
Gly	Leu	Gln	Gly	Pro	Ala	Gly	Pro	Pro	Gly	Glu	Lys	Gly	Glu	Pro	Gly
945					950					955				960	
Asp	Asp	Gly	Pro	Ser	Gly	Ala	Glu	Gly	Pro	Pro	Gly	Pro	Gln	Gly	Leu
				965					970					975	
Ala	Gly	Gln	Arg	Gly	Ile	Val	Gly	Leu	Pro	Gly	Gln	Arg	Gly	Glu	Arg
			980					985					990		
Gly	Phe	Pro	Gly	Leu	Pro	Gly	Pro	Ser	Gly	Glu	Pro	Gly	Lys	Gln	Gly
			995				1000						1005		
Ala	Pro	Gly	Ala	Ser	Gly	Asp	Arg	Gly	Pro	Pro	Gly	Pro	Val	Gly	
	1010					1015					1020				
Pro	Pro	Gly	Leu	Thr	Gly	Pro	Ala	Gly	Glu	Pro	Gly	Arg	Glu	Gly	
	1025					1030					1035				
Ser	Pro	Gly	Ala	Asp	Gly	Pro	Pro	Gly	Arg	Asp	Gly	Ala	Ala	Gly	
	1040					1045					1050				
Val	Lys	Gly	Asp	Arg	Gly	Glu	Thr	Gly	Ala	Val	Gly	Ala	Pro	Gly	
	1055					1060					1065				
Ala	Pro	Gly	Pro	Pro	Gly	Ser	Pro	Gly	Pro	Ala	Gly	Pro	Thr	Gly	
	1070					1075					1080				
Lys	Gln	Gly	Asp	Arg	Gly	Glu	Ala	Gly	Ala	Gln	Gly	Pro	Met	Gly	
	1085					1090					1095				
Pro	Ser	Gly	Pro	Ala	Gly	Ala	Arg	Gly	Ile	Gln	Gly	Pro	Gln	Gly	
	1100					1105					1110				
Pro	Arg	Gly	Asp	Lys	Gly	Glu	Ala	Gly	Glu	Pro	Gly	Glu	Arg	Gly	
	1115					1120					1125				
Leu	Lys	Gly	His	Arg	Gly	Phe	Thr	Gly	Leu	Gln	Gly	Leu	Pro	Gly	
	1130					1135					1140				
Pro	Pro	Gly	Pro	Ser	Gly	Asp	Gln	Gly	Ala	Ser	Gly	Pro	Ala	Gly	
	1145					1150					1155				

-continued

---

Pro	Ser	Gly	Pro	Arg	Gly	Pro	Pro	Gly	Pro	Val	Gly	Pro	Ser	Gly
1160						1165					1170			
Lys	Asp	Gly	Ala	Asn	Gly	Ile	Pro	Gly	Pro	Ile	Gly	Pro	Pro	Gly
1175						1180					1185			
Pro	Arg	Gly	Arg	Ser	Gly	Glu	Thr	Gly	Pro	Ala	Gly	Pro	Pro	Gly
1190						1195					1200			
Asn	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Gly	Ile
1205						1210					1215			
Asp	Met	Ser	Ala	Phe	Ala	Gly	Leu	Gly	Pro	Arg	Glu	Lys	Gly	Pro
1220						1225					1230			
Asp	Pro	Leu	Gln	Tyr	Met	Arg	Ala	Asp	Gln	Ala	Ala	Gly	Gly	Leu
1235						1240					1245			
Arg	Gln	His	Asp	Ala	Glu	Val	Asp	Ala	Thr	Leu	Lys	Ser	Leu	Asn
1250						1255					1260			
Asn	Gln	Ile	Glu	Ser	Ile	Arg	Ser	Pro	Glu	Gly	Ser	Arg	Lys	Asn
1265						1270					1275			
Pro	Ala	Arg	Thr	Cys	Arg	Asp	Leu	Lys	Leu	Cys	His	Pro	Glu	Trp
1280						1285					1290			
Lys	Ser	Gly	Asp	Tyr	Trp	Ile	Asp	Pro	Asn	Gln	Gly	Cys	Thr	Leu
1295						1300					1305			
Asp	Ala	Met	Lys	Val	Phe	Cys	Asn	Met	Glu	Thr	Gly	Glu	Thr	Cys
1310						1315					1320			
Val	Tyr	Pro	Asn	Pro	Ala	Asn	Val	Pro	Lys	Lys	Asn	Trp	Trp	Ser
1325						1330					1335			
Ser	Lys	Ser	Lys	Glu	Lys	Lys	His	Ile	Trp	Phe	Gly	Glu	Thr	Ile
1340						1345					1350			
Asn	Gly	Gly	Phe	His	Phe	Ser	Tyr	Gly	Asp	Asp	Asn	Leu	Ala	Pro
1355						1360					1365			
Asn	Thr	Ala	Asn	Val	Gln	Met	Thr	Phe	Leu	Arg	Leu	Leu	Ser	Thr
1370						1375					1380			
Glu	Gly	Ser	Gln	Asn	Ile	Thr	Tyr	His	Cys	Lys	Asn	Ser	Ile	Ala
1385						1390					1395			
Tyr	Leu	Asp	Glu	Ala	Ala	Gly	Asn	Leu	Lys	Lys	Ala	Leu	Leu	Ile
1400						1405					1410			
Gln	Gly	Ser	Asn	Asp	Val	Glu	Ile	Arg	Ala	Glu	Gly	Asn	Ser	Arg
1415						1420					1425			
Phe	Thr	Tyr	Thr	Ala	Leu	Lys	Asp	Gly	Cys	Thr	Lys	His	Thr	Gly
1430						1435					1440			
Lys	Trp	Gly	Lys	Thr	Val	Ile	Glu	Tyr	Arg	Ser	Gln	Lys	Thr	Ser
1445						1450					1455			
Arg	Leu	Pro	Ile	Ile	Asp	Ile	Ala	Pro	Met	Asp	Ile	Gly	Gly	Pro
1460						1465					1470			
Glu	Gln	Glu	Phe	Gly	Val	Asp	Ile	Gly	Pro	Val	Cys	Phe	Leu	
1475						1480					1485			

&lt;210&gt; SEQ ID NO 31

&lt;211&gt; LENGTH: 207

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 31

Met Ala Pro Phe Glu Pro Leu Ala Ser Gly Ile Leu Leu Leu Leu Trp

-continued

1	5	10	15
Leu Ile Ala Pro Ser Arg Ala Cys Thr Cys Val Pro Pro His Pro Gln	20	25	30
Thr Ala Phe Cys Asn Ser Asp Leu Val Ile Arg Ala Lys Phe Val Gly	35	40	45
Thr Pro Glu Val Asn Gln Thr Thr Leu Tyr Gln Arg Tyr Glu Ile Lys	50	55	60
Met Thr Lys Met Tyr Lys Gly Phe Gln Ala Leu Gly Asp Ala Ala Asp	65	70	75
Ile Arg Phe Val Tyr Thr Pro Ala Met Glu Ser Val Cys Gly Tyr Phe	85	90	95
His Arg Ser His Asn Arg Ser Glu Glu Phe Leu Ile Ala Gly Lys Leu	100	105	110
Gln Asp Gly Leu Leu His Ile Thr Thr Cys Ser Phe Val Ala Pro Trp	115	120	125
Asn Ser Leu Ser Leu Ala Gln Arg Arg Gly Phe Thr Lys Thr Tyr Thr	130	135	140
Val Gly Cys Glu Glu Cys Thr Val Phe Pro Cys Leu Ser Ile Pro Cys	145	150	155
Lys Leu Gln Ser Gly Thr His Cys Leu Trp Thr Asp Gln Leu Leu Gln	165	170	175
Gly Ser Glu Lys Gly Phe Gln Ser Arg His Leu Ala Cys Leu Pro Arg	180	185	190
Glu Pro Gly Leu Cys Thr Trp Gln Ser Leu Arg Ser Gln Ile Ala	195	200	205

&lt;210&gt; SEQ ID NO 32

&lt;211&gt; LENGTH: 227

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 32

Met Arg Val Ala Gly Ala Ala Lys Leu Val Val Ala Val Ala Val Phe	1	5	10	15
Leu Leu Thr Phe Tyr Val Ile Ser Gln Val Phe Glu Ile Lys Met Asp	20	25	30	
Ala Ser Leu Gly Asn Leu Phe Ala Arg Ser Ala Leu Asp Thr Ala Ala	35	40	45	
Arg Ser Thr Lys Pro Pro Arg Tyr Lys Cys Gly Ile Ser Lys Ala Cys	50	55	60	
Pro Glu Lys His Phe Ala Phe Lys Met Ala Ser Gly Ala Ala Asn Val	65	70	75	80
Val Gly Pro Lys Ile Cys Leu Glu Asp Asn Val Leu Met Ser Gly Val	85	90	95	
Lys Asn Asn Val Gly Arg Gly Ile Asn Val Ala Leu Ala Asn Gly Lys	100	105	110	
Thr Gly Glu Val Leu Asp Thr Lys Tyr Phe Asp Met Trp Gly Gly Asp	115	120	125	
Val Ala Pro Phe Ile Glu Phe Leu Lys Ala Ile Gln Asp Gly Thr Ile	130	135	140	
Val Leu Met Gly Thr Tyr Asp Asp Gly Ala Thr Lys Leu Asn Asp Glu	145	150	155	160

-continued

---

Ala Arg Arg Leu Ile Ala Asp Leu Gly Ser Thr Ser Ile Thr Asn Leu  
165 170

Gly Phe Arg Asp Asn Trp Val Phe Cys Gly Gly Lys Gly Ile Lys Thr  
180 185 190

Lys Ser Pro Phe Glu Gln His Ile Lys Asn Asn Lys Asp Thr Asn Lys  
195 200 205

Tyr Glu Gly Trp Pro Glu Val Val Glu Met Glu Gly Cys Ile Pro Gln  
210 215 220

Lys Gln Asp  
225

<210> SEQ ID NO 33  
 <211> LENGTH: 892  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 33

Met Asp His Tyr Asp Ser Gln Gln Thr Asn Asp Tyr Met Gln Pro Glu  
1 5 10 15

Glu Asp Trp Asp Arg Asp Leu Leu Leu Asp Pro Ala Trp Glu Lys Gln  
20 25 30

Gln Arg Lys Thr Phe Thr Ala Trp Cys Asn Ser His Leu Arg Lys Ala  
35 40 45

Gly Thr Gln Ile Glu Asn Ile Glu Glu Asp Phe Arg Asp Gly Leu Lys  
50 55 60

Leu Met Leu Leu Leu Glu Val Ile Ser Gly Glu Arg Leu Ala Lys Pro  
65 70 75 80

Glu Arg Gly Lys Met Arg Val His Lys Ile Ser Asn Val Asn Lys Ala  
85 90 95

Leu Asp Phe Ile Ala Ser Lys Gly Val Lys Leu Val Ser Ile Gly Ala  
100 105 110

Glu Glu Ile Val Asp Gly Asn Val Lys Met Thr Leu Gly Met Ile Trp  
115 120 125

Thr Ile Ile Leu Arg Phe Ala Ile Gln Asp Ile Ser Val Glu Glu Thr  
130 135 140

Ser Ala Lys Glu Gly Leu Leu Leu Trp Cys Gln Arg Lys Thr Ala Pro  
145 150 155 160

Tyr Lys Asn Val Asn Ile Gln Asn Phe His Ile Ser Trp Lys Asp Gly  
165 170 175

Leu Gly Phe Cys Ala Leu Ile His Arg His Arg Pro Glu Leu Ile Asp  
180 185 190

Tyr Gly Lys Leu Arg Lys Asp Asp Pro Leu Thr Asn Leu Asn Thr Ala  
195 200 205

Phe Asp Val Ala Glu Lys Tyr Leu Asp Ile Pro Lys Met Leu Asp Ala  
210 215 220

Glu Asp Ile Val Gly Thr Ala Arg Pro Asp Glu Lys Ala Ile Met Thr  
225 230 235 240

Tyr Val Ser Ser Phe Tyr His Ala Phe Ser Gly Ala Gln Lys Ala Glu  
245 250 255

Thr Ala Ala Asn Arg Ile Cys Lys Val Leu Ala Val Asn Gln Glu Asn  
260 265 270

Glu Gln Leu Met Glu Asp Tyr Glu Lys Leu Ala Ser Asp Leu Leu Glu  
275 280 285

-continued

---

Trp Ile Arg Arg Thr Ile Pro Trp Leu Glu Asn Arg Val Pro Glu Asn  
 290 295 300

Thr Met His Ala Met Gln Gln Lys Leu Glu Asp Phe Arg Asp Tyr Arg  
 305 310 315 320

Arg Leu His Lys Pro Pro Lys Val Gln Glu Lys Cys Gln Leu Glu Ile  
 325 330 335

Asn Phe Asn Thr Leu Gln Thr Lys Leu Arg Leu Ser Asn Arg Pro Ala  
 340 345 350

Phe Met Pro Ser Glu Gly Arg Met Val Ser Asp Ile Asn Asn Ala Trp  
 355 360 365

Gly Cys Leu Glu Gln Val Glu Lys Gly Tyr Glu Glu Trp Leu Leu Asn  
 370 375 380

Glu Ile Arg Arg Leu Glu Arg Leu Asp His Leu Ala Glu Lys Phe Arg  
 385 390 395 400

Gln Lys Ala Ser Ile His Glu Ala Trp Thr Asp Gly Lys Glu Ala Met  
 405 410 415

Leu Arg Gln Lys Asp Tyr Glu Thr Ala Thr Leu Ser Glu Ile Lys Ala  
 420 425 430

Leu Leu Lys Lys His Glu Ala Phe Glu Ser Asp Leu Ala Ala His Gln  
 435 440 445

Asp Arg Val Glu Gln Ile Ala Ala Ile Ala Gln Glu Leu Asn Glu Leu  
 450 455 460

Asp Tyr Tyr Asp Ser Pro Ser Val Asn Ala Arg Cys Gln Lys Ile Cys  
 465 470 475 480

Asp Gln Trp Asp Asn Leu Gly Ala Leu Thr Gln Lys Arg Arg Glu Ala  
 485 490 495

Leu Glu Arg Thr Glu Lys Leu Leu Glu Thr Ile Asp Gln Leu Tyr Leu  
 500 505 510

Glu Tyr Ala Lys Arg Ala Ala Pro Phe Asn Asn Trp Met Glu Gly Ala  
 515 520 525

Met Glu Asp Leu Gln Asp Thr Phe Ile Val His Thr Ile Glu Glu Ile  
 530 535 540

Gln Gly Leu Thr Thr Ala His Glu Gln Phe Lys Ala Thr Leu Pro Asp  
 545 550 555 560

Ala Asp Lys Glu Arg Leu Ala Ile Leu Gly Ile His Asn Glu Val Ser  
 565 570 575

Lys Ile Val Gln Thr Tyr His Val Asn Met Ala Gly Thr Asn Pro Tyr  
 580 585 590

Thr Thr Ile Thr Pro Gln Glu Ile Asn Gly Lys Trp Asp His Val Arg  
 595 600 605

Gln Leu Val Pro Arg Arg Asp Gln Ala Leu Thr Glu Glu His Ala Arg  
 610 615 620

Gln Gln His Asn Glu Arg Leu Arg Lys Gln Phe Gly Ala Gln Ala Asn  
 625 630 635 640

Val Ile Gly Pro Trp Ile Gln Thr Lys Met Glu Glu Ile Gly Arg Ile  
 645 650 655

Ser Ile Glu Met His Gly Thr Leu Glu Asp Gln Leu Ser His Leu Arg  
 660 665 670

Gln Tyr Glu Lys Ser Ile Val Asn Tyr Lys Pro Lys Ile Asp Gln Leu  
 675 680 685

-continued

---

Glu Gly Asp His Gln Leu Ile Gln Glu Ala Leu Ile Phe Asp Asn Lys  
 690 695 700  
 His Thr Asn Tyr Thr Met Glu His Ile Arg Val Gly Trp Glu Gln Leu  
 705 710 715 720  
 Leu Thr Thr Ile Ala Arg Thr Ile Asn Glu Val Glu Asn Gln Ile Leu  
 725 730 735  
 Thr Arg Asp Ala Lys Gly Ile Ser Gln Glu Gln Met Asn Glu Phe Arg  
 740 745 750  
 Ala Ser Phe Asn His Phe Asp Arg Asp His Ser Gly Thr Leu Gly Pro  
 755 760 765  
 Glu Glu Phe Lys Ala Cys Leu Ile Ser Leu Gly Tyr Asp Ile Gly Asn  
 770 775 780  
 Asp Pro Gln Gly Glu Ala Glu Phe Ala Arg Ile Met Ser Ile Val Asp  
 785 790 795 800  
 Pro Asn Arg Leu Gly Val Val Thr Phe Gln Ala Phe Ile Asp Phe Met  
 805 810 815  
 Ser Arg Glu Thr Ala Asp Thr Asp Thr Ala Asp Gln Val Met Ala Ser  
 820 825 830  
 Phe Lys Ile Leu Ala Gly Asp Lys Asn Tyr Ile Thr Met Asp Glu Leu  
 835 840 845  
 Arg Arg Glu Leu Pro Pro Asp Gln Ala Glu Tyr Cys Ile Ala Arg Met  
 850 855 860  
 Ala Pro Tyr Thr Gly Pro Asp Ser Val Pro Gly Ala Leu Asp Tyr Met  
 865 870 875 880  
 Ser Phe Ser Thr Ala Leu Tyr Gly Glu Ser Asp Leu  
 885 890

&lt;210&gt; SEQ ID NO 34

&lt;211&gt; LENGTH: 286

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 34

Met Ala Asp Phe Asp Asp Arg Val Ser Asp Glu Glu Lys Val Arg Ile  
 1 5 10 15  
 Ala Ala Lys Phe Ile Thr His Ala Pro Pro Gly Glu Phe Asn Glu Val  
 20 25 30  
 Phe Asn Asp Val Arg Leu Leu Leu Asn Asn Asp Asn Leu Leu Arg Glu  
 35 40 45  
 Gly Ala Ala His Ala Phe Ala Gln Tyr Asn Met Asp Gln Phe Thr Pro  
 50 55 60  
 Val Lys Ile Glu Gly Tyr Glu Asp Gln Val Leu Ile Thr Glu His Gly  
 65 70 75 80  
 Asp Leu Gly Asn Ser Arg Phe Leu Asp Pro Arg Asn Lys Ile Ser Phe  
 85 90 95  
 Lys Phe Asp His Leu Arg Lys Glu Ala Ser Asp Pro Gln Pro Glu Glu  
 100 105 110  
 Ala Asp Gly Gly Leu Lys Ser Trp Arg Glu Ser Cys Asp Ser Ala Leu  
 115 120 125  
 Arg Ala Tyr Val Lys Asp His Tyr Ser Asn Gly Phe Cys Thr Val Tyr  
 130 135 140  
 Ala Lys Thr Ile Asp Gly Gln Gln Thr Ile Ile Ala Cys Ile Glu Ser  
 145 150 155 160





-continued

Lys Ile Gln Thr Gln Leu Gln Arg Asp His Ser Ala Ile Pro Val Ile  
 645 650 655  
 Asn Arg Ala Gln Ile Ile Asn Asp Ala Phe Asn Leu Ala Ser Ala His  
 660 665 670  
 Lys Val Pro Val Thr Leu Ala Leu Asn Asn Thr Leu Phe Leu Ile Glu  
 675 680 685  
 Glu Arg Gln Tyr Met Pro Trp Glu Ala Ala Leu Ser Ser Leu Ser Tyr  
 690 695 700  
 Phe Lys Leu Met Phe Asp Arg Ser Glu Val Tyr Gly Pro Met Lys Asn  
 705 710 715 720  
 Tyr Leu Lys Lys Gln Val Thr Pro Leu Phe Ile His Phe Arg Asn Asn  
 725 730 735  
 Thr Asn Asn Trp Arg Glu Ile Pro Glu Asn Leu Met Asp Gln Tyr Ser  
 740 745 750  
 Glu Val Asn Ala Ile Ser Thr Ala Cys Ser Asn Gly Val Pro Glu Cys  
 755 760 765  
 Glu Glu Met Val Ser Gly Leu Phe Lys Gln Trp Met Glu Asn Pro Asn  
 770 775 780  
 Asn Asn Pro Ile His Pro Asn Leu Arg Ser Thr Val Tyr Cys Asn Ala  
 785 790 795 800  
 Ile Ala Gln Gly Gly Glu Glu Glu Trp Asp Phe Ala Trp Glu Gln Phe  
 805 810 815  
 Arg Asn Ala Thr Leu Val Asn Glu Ala Asp Lys Leu Arg Ala Ala Leu  
 820 825 830  
 Ala Cys Ser Lys Glu Leu Trp Ile Leu Asn Arg Tyr Leu Ser Tyr Thr  
 835 840 845  
 Leu Asn Pro Asp Leu Ile Arg Lys Gln Asp Ala Thr Ser Thr Ile Ile  
 850 855 860  
 Ser Ile Thr Asn Asn Val Ile Gly Gln Gly Leu Val Trp Asp Phe Val  
 865 870 875 880  
 Gln Ser Asn Trp Lys Lys Leu Phe Asn Asp Tyr Gly Gly Gly Ser Phe  
 885 890 895  
 Ser Phe Ser Asn Leu Ile Gln Ala Val Thr Arg Arg Phe Ser Thr Glu  
 900 905 910  
 Tyr Glu Leu Gln Gln Leu Glu Gln Phe Lys Lys Asp Asn Glu Glu Thr  
 915 920 925  
 Gly Phe Gly Ser Gly Thr Arg Ala Leu Glu Gln Ala Leu Glu Lys Thr  
 930 935 940  
 Lys Ala Asn Ile Lys Trp Val Lys Glu Asn Lys Glu Val Val Leu Gln  
 945 950 955 960  
 Trp Phe Thr Glu Asn Ser Lys  
 965

<210> SEQ ID NO 36  
 <211> LENGTH: 259  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 36

Met Ser Glu Val Pro Val Ala Arg Val Trp Leu Val Leu Leu Leu Leu  
 1 5 10 15  
 Thr Val Gln Val Gly Val Thr Ala Gly Ala Pro Trp Gln Cys Ala Pro





-continued

---

```

Tyr Val Asn Lys Arg Asn Thr Thr Trp Gln Ala Gly His Asn Phe Tyr
    35                                40                                45
Asn Val Asp Met Ser Tyr Leu Lys Arg Leu Cys Gly Thr Phe Leu Gly
    50                                55                                60
Gly Pro Lys Pro Pro Gln Arg Val Met Phe Thr Glu Asp Leu Lys Leu
    65                                70                                75                                80
Pro Ala Ser Phe Asp Ala Arg Glu Gln Trp Pro Gln Cys Pro Thr Ile
    85                                90                                95
Lys Glu Ile Arg Asp Gln Gly Ser Cys Gly Ser Cys Trp Ala Phe Gly
    100                               105                               110
Ala Val Glu Ala Ile Ser Asp Arg Ile Cys Ile His Thr Asn Ala His
    115                               120                               125
Val Ser Val Glu Val Ser Ala Glu Asp Leu Leu Thr Cys Cys Gly Ser
    130                               135                               140
Met Cys Gly Asp Gly Cys Asn Gly Gly Tyr Pro Ala Glu Ala Trp Asn
    145                               150                               155                               160
Phe Trp Thr Arg Lys Gly Leu Val Ser Gly Gly Leu Tyr Glu Ser His
    165                               170                               175
Val Gly Cys Arg Pro Tyr Ser Ile Pro Pro Cys Glu His His Val Asn
    180                               185                               190
Gly Ser Arg Pro Pro Cys Thr Gly Glu Gly Asp Thr Pro Lys Cys Ser
    195                               200                               205
Lys Ile Cys Glu Pro Gly Tyr Ser Pro Thr Tyr Lys Gln Asp Lys His
    210                               215                               220
Tyr Gly Tyr Asn Ser Tyr Ser Val Ser Asn Ser Glu Lys Asp Ile Met
    225                               230                               235                               240
Ala Glu Ile Tyr Lys Asn Gly Pro Val Glu Gly Ala Phe Ser Val Tyr
    245                               250                               255
Ser Asp Phe Leu Leu Tyr Lys Ser Gly Val Tyr Gln His Val Thr Gly
    260                               265                               270
Glu Met Met Gly Gly His Ala Ile Arg Ile Leu Gly Trp Gly Val Glu
    275                               280                               285
Asn Gly Thr Pro Tyr Trp Leu Val Ala Asn Ser Trp Asn Thr Asp Trp
    290                               295                               300
Gly Asp Asn Gly Phe Phe Lys Ile Leu Arg Gly Gln Asp His Cys Gly
    305                               310                               315                               320
Ile Glu Ser Glu Val Val Ala Gly Ile Pro Arg Thr Asp Gln Tyr Trp
    325                               330                               335

Glu Lys Ile

```

&lt;210&gt; SEQ ID NO 39

&lt;211&gt; LENGTH: 718

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 39

```

Met Cys Ala Ser Val Lys Tyr Asn Ile Arg Gly Pro Ala Leu Ile Pro
 1      5      10      15
Arg Met Lys Thr Lys His Arg Ile Tyr Tyr Ile Thr Leu Phe Ser Ile
 20     25     30
Val Leu Leu Gly Leu Ile Ala Thr Gly Met Phe Gln Phe Trp Pro His
 35     40     45

```

-continued

---

Ser Ile Glu Ser Ser Asn Asp Trp Asn Val Glu Lys Arg Ser Ile Arg  
 50 55 60  
 Asp Val Pro Val Val Arg Leu Pro Ala Asp Ser Pro Ile Pro Glu Arg  
 65 70 80  
 Gly Asp Leu Ser Cys Arg Met His Thr Cys Phe Asp Val Tyr Arg Cys  
 85 90 95  
 Gly Phe Asn Pro Lys Asn Lys Ile Lys Val Tyr Ile Tyr Ala Leu Lys  
 100 105 110  
 Lys Tyr Val Asp Asp Phe Gly Val Ser Val Ser Asn Thr Ile Ser Arg  
 115 120 125  
 Glu Tyr Asn Glu Leu Leu Met Ala Ile Ser Asp Ser Asp Tyr Tyr Thr  
 130 135 140  
 Asp Asp Ile Asn Arg Ala Cys Leu Phe Val Pro Ser Ile Asp Val Leu  
 145 150 155 160  
 Asn Gln Asn Thr Leu Arg Ile Lys Glu Thr Ala Gln Ala Met Ala Gln  
 165 170 175  
 Leu Ser Arg Trp Asp Arg Gly Thr Asn His Leu Leu Phe Asn Met Leu  
 180 185 190  
 Pro Gly Gly Pro Pro Asp Tyr Asn Thr Ala Leu Asp Val Pro Arg Asp  
 195 200 205  
 Arg Ala Leu Leu Ala Gly Gly Gly Phe Ser Thr Trp Thr Tyr Arg Gln  
 210 215 220  
 Gly Tyr Asp Val Ser Ile Pro Val Tyr Ser Pro Leu Ser Ala Glu Val  
 225 230 235 240  
 Asp Leu Pro Glu Lys Gly Pro Gly Pro Arg Gln Tyr Phe Leu Leu Ser  
 245 250 255  
 Ser Gln Val Gly Leu His Pro Glu Tyr Arg Glu Asp Leu Glu Ala Leu  
 260 265 270  
 Gln Val Lys His Gly Glu Ser Val Leu Val Leu Asp Lys Cys Thr Asn  
 275 280 285  
 Leu Ser Glu Gly Val Leu Ser Val Arg Lys Arg Cys His Lys His Gln  
 290 295 300  
 Val Phe Asp Tyr Pro Gln Val Leu Gln Glu Ala Thr Phe Cys Val Val  
 305 310 315 320  
 Leu Arg Gly Ala Arg Leu Gly Gln Ala Val Leu Ser Asp Val Leu Gln  
 325 330 335  
 Ala Gly Cys Val Pro Val Val Ile Ala Asp Ser Tyr Ile Leu Pro Phe  
 340 345 350  
 Ser Glu Val Leu Asp Trp Lys Arg Ala Ser Val Val Val Pro Glu Glu  
 355 360 365  
 Lys Met Ser Asp Val Tyr Ser Ile Leu Gln Ser Ile Pro Gln Arg Gln  
 370 375 380  
 Ile Glu Glu Met Gln Arg Gln Ala Arg Trp Phe Trp Glu Ala Tyr Phe  
 385 390 395 400  
 Gln Ser Ile Lys Ala Ile Ala Leu Ala Thr Leu Gln Ile Ile Asn Asp  
 405 410 415  
 Arg Ile Tyr Pro Tyr Ala Ala Ile Ser Tyr Glu Glu Trp Asn Asp Pro  
 420 425 430  
 Pro Ala Val Lys Trp Gly Ser Val Ser Asn Pro Leu Phe Leu Pro Leu  
 435 440 445  
 Ile Pro Pro Gln Ser Gln Gly Phe Thr Ala Ile Val Leu Thr Tyr Asp



-continued

---

```

Asp Thr Gly Ser Ser Asn Leu Trp Val Pro Ser Ile His Cys Lys Leu
      100                               105           110
Leu Asp Ile Ala Cys Trp Ile His His Lys Tyr Asn Ser Asp Lys Ser
      115                               120           125
Ser Thr Tyr Val Lys Asn Gly Thr Ser Phe Asp Ile His Tyr Gly Ser
      130                               135           140
Gly Ser Leu Ser Gly Tyr Leu Ser Gln Asp Thr Val Ser Val Pro Cys
      145                               150           155           160
Gln Ser Ala Ser Ser Ala Ser Ala Leu Gly Gly Val Lys Val Glu Arg
      165                               170           175
Gln Val Phe Gly Glu Ala Thr Lys Gln Pro Gly Ile Thr Phe Ile Ala
      180                               185           190
Ala Lys Phe Asp Gly Ile Leu Gly Met Ala Tyr Pro Arg Ile Ser Val
      195                               200           205
Asn Asn Val Leu Pro Val Phe Asp Asn Leu Met Gln Gln Lys Leu Val
      210                               215           220
Asp Gln Asn Ile Phe Ser Phe Tyr Leu Ser Arg Asp Pro Asp Ala Gln
      225                               230           235           240
Pro Gly Gly Glu Leu Met Leu Gly Gly Thr Asp Ser Lys Tyr Tyr Lys
      245                               250           255
Gly Ser Leu Ser Tyr Leu Asn Val Thr Arg Lys Ala Tyr Trp Gln Val
      260                               265           270
His Leu Asp Gln Val Glu Val Ala Ser Gly Leu Thr Leu Cys Lys Glu
      275                               280           285
Gly Cys Glu Ala Ile Val Asp Thr Gly Thr Ser Leu Met Val Gly Pro
      290                               295           300
Val Asp Glu Val Arg Glu Leu Gln Lys Ala Ile Gly Ala Val Pro Leu
      305                               310           315           320
Ile Gln Gly Glu Tyr Met Ile Pro Cys Glu Lys Val Ser Thr Leu Pro
      325                               330           335
Ala Ile Thr Leu Lys Leu Gly Gly Lys Gly Tyr Lys Leu Ser Pro Glu
      340                               345           350
Asp Tyr Thr Leu Lys Val Ser Gln Ala Gly Lys Thr Leu Cys Leu Ser
      355                               360           365
Gly Phe Met Gly Met Asp Ile Pro Pro Pro Ser Gly Pro Leu Trp Ile
      370                               375           380
Leu Gly Asp Val Phe Ile Gly Arg Tyr Tyr Thr Val Phe Asp Arg Asp
      385                               390           395           400
Asn Asn Arg Val Gly Phe Ala Glu Ala Ala Arg Leu
      405                               410

```

```

<210> SEQ ID NO 41
<211> LENGTH: 2321
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

<400> SEQUENCE: 41

```

Met Gly Pro Gly Ala Arg Gly Arg Arg Arg Arg Arg Pro Met Ser
 1                               5           10           15
Pro Pro Pro Pro Pro Pro Pro Val Arg Ala Leu Pro Leu Leu Leu Leu
 20                               25           30
Leu Ala Gly Pro Gly Ala Ala Ala Pro Pro Cys Leu Asp Gly Ser Pro
 35                               40           45

```

-continued

---

Cys Ala Asn Gly Gly Arg Cys Thr Gln Leu Pro Ser Arg Glu Ala Ala  
 50 55 60

Cys Leu Cys Pro Pro Gly Trp Val Gly Glu Arg Cys Gln Leu Glu Asp  
 65 70 75 80

Pro Cys His Ser Gly Pro Cys Ala Gly Arg Gly Val Cys Gln Ser Ser  
 85 90 95

Val Val Ala Gly Thr Ala Arg Phe Ser Cys Arg Cys Pro Arg Gly Phe  
 100 105 110

Arg Gly Pro Asp Cys Ser Leu Pro Asp Pro Cys Leu Ser Ser Pro Cys  
 115 120 125

Ala His Gly Ala Arg Cys Ser Val Gly Pro Asp Gly Arg Phe Leu Cys  
 130 135 140

Ser Cys Pro Pro Gly Tyr Gln Gly Arg Ser Cys Arg Ser Asp Val Asp  
 145 150 155 160

Glu Cys Arg Val Gly Glu Pro Cys Arg His Gly Gly Thr Cys Leu Asn  
 165 170 175

Thr Pro Gly Ser Phe Arg Cys Gln Cys Pro Ala Gly Tyr Thr Gly Pro  
 180 185 190

Leu Cys Glu Asn Pro Ala Val Pro Cys Ala Pro Ser Pro Cys Arg Asn  
 195 200 205

Gly Gly Thr Cys Arg Gln Ser Gly Asp Leu Thr Tyr Asp Cys Ala Cys  
 210 215 220

Leu Pro Gly Phe Glu Gly Gln Asn Cys Glu Val Asn Val Asp Asp Cys  
 225 230 235 240

Pro Gly His Arg Cys Leu Asn Gly Gly Thr Cys Val Asp Gly Val Asn  
 245 250 255

Thr Tyr Asn Cys Gln Cys Pro Pro Glu Trp Thr Gly Gln Phe Cys Thr  
 260 265 270

Glu Asp Val Asp Glu Cys Gln Leu Gln Pro Asn Ala Cys His Asn Gly  
 275 280 285

Gly Thr Cys Phe Asn Thr Leu Gly Gly His Ser Cys Val Cys Val Asn  
 290 295 300

Gly Trp Thr Gly Glu Ser Cys Ser Gln Asn Ile Asp Asp Cys Ala Thr  
 305 310 315 320

Ala Val Cys Phe His Gly Ala Thr Cys His Asp Arg Val Ala Ser Phe  
 325 330 335

Tyr Cys Ala Cys Pro Met Gly Lys Thr Gly Leu Leu Cys His Leu Asp  
 340 345 350

Asp Ala Cys Val Ser Asn Pro Cys His Glu Asp Ala Ile Cys Asp Thr  
 355 360 365

Asn Pro Val Asn Gly Arg Ala Ile Cys Thr Cys Pro Pro Gly Phe Thr  
 370 375 380

Gly Gly Ala Cys Asp Gln Asp Val Asp Glu Cys Ser Ile Gly Ala Asn  
 385 390 395 400

Pro Cys Glu His Leu Gly Arg Cys Val Asn Thr Gln Gly Ser Phe Leu  
 405 410 415

Cys Gln Cys Gly Arg Gly Tyr Thr Gly Pro Arg Cys Glu Thr Asp Val  
 420 425 430

Asn Glu Cys Leu Ser Gly Pro Cys Arg Asn Gln Ala Thr Cys Leu Asp  
 435 440 445

-continued

---

Arg	Ile	Gly	Gln	Phe	Thr	Cys	Ile	Cys	Met	Ala	Gly	Phe	Thr	Gly	Thr
450						455					460				
Tyr	Cys	Glu	Val	Asp	Ile	Asp	Glu	Cys	Gln	Ser	Ser	Pro	Cys	Val	Asn
465					470					475					480
Gly	Gly	Val	Cys	Lys	Asp	Arg	Val	Asn	Gly	Phe	Ser	Cys	Thr	Cys	Pro
				485					490					495	
Ser	Gly	Phe	Ser	Gly	Ser	Thr	Cys	Gln	Leu	Asp	Val	Asp	Glu	Cys	Ala
			500					505					510		
Ser	Thr	Pro	Cys	Arg	Asn	Gly	Ala	Lys	Cys	Val	Asp	Gln	Pro	Asp	Gly
		515					520					525			
Tyr	Glu	Cys	Arg	Cys	Ala	Glu	Gly	Phe	Glu	Gly	Thr	Leu	Cys	Asp	Arg
	530					535						540			
Asn	Val	Asp	Asp	Cys	Ser	Pro	Asp	Pro	Cys	His	His	Gly	Arg	Cys	Val
545					550					555					560
Asp	Gly	Ile	Ala	Ser	Phe	Ser	Cys	Ala	Cys	Ala	Pro	Gly	Tyr	Thr	Gly
				565					570					575	
Thr	Arg	Cys	Glu	Ser	Gln	Val	Asp	Glu	Cys	Arg	Ser	Gln	Pro	Cys	Arg
			580					585					590		
His	Gly	Gly	Lys	Cys	Leu	Asp	Leu	Val	Asp	Lys	Tyr	Leu	Cys	Arg	Cys
		595					600					605			
Pro	Ser	Gly	Thr	Thr	Gly	Val	Asn	Cys	Glu	Val	Asn	Ile	Asp	Asp	Cys
	610					615					620				
Ala	Ser	Asn	Pro	Cys	Thr	Phe	Gly	Val	Cys	Arg	Asp	Gly	Ile	Asn	Arg
625					630					635					640
Tyr	Asp	Cys	Val	Cys	Gln	Pro	Gly	Phe	Thr	Gly	Pro	Leu	Cys	Asn	Val
				645					650					655	
Glu	Ile	Asn	Glu	Cys	Ala	Ser	Ser	Pro	Cys	Gly	Glu	Gly	Gly	Ser	Cys
			660					665						670	
Val	Asp	Gly	Glu	Asn	Gly	Phe	Arg	Cys	Leu	Cys	Pro	Pro	Gly	Ser	Leu
		675					680					685			
Pro	Pro	Leu	Cys	Leu	Pro	Pro	Ser	His	Pro	Cys	Ala	His	Glu	Pro	Cys
	690					695					700				
Ser	His	Gly	Ile	Cys	Tyr	Asp	Ala	Pro	Gly	Gly	Phe	Arg	Cys	Val	Cys
705					710					715					720
Glu	Pro	Gly	Trp	Ser	Gly	Pro	Arg	Cys	Ser	Gln	Ser	Leu	Ala	Arg	Asp
				725					730					735	
Ala	Cys	Glu	Ser	Gln	Pro	Cys	Arg	Ala	Gly	Gly	Thr	Cys	Ser	Ser	Asp
			740					745						750	
Gly	Met	Gly	Phe	His	Cys	Thr	Cys	Pro	Pro	Gly	Val	Gln	Gly	Arg	Gln
		755					760					765			
Cys	Glu	Leu	Leu	Ser	Pro	Cys	Thr	Pro	Asn	Pro	Cys	Glu	His	Gly	Gly
	770					775					780				
Arg	Cys	Glu	Ser	Ala	Pro	Gly	Gln	Leu	Pro	Val	Cys	Ser	Cys	Pro	Gln
785					790					795					800
Gly	Trp	Gln	Gly	Pro	Arg	Cys	Gln	Gln	Asp	Val	Asp	Glu	Cys	Ala	Gly
				805					810					815	
Pro	Ala	Pro	Cys	Gly	Pro	His	Gly	Ile	Cys	Thr	Asn	Leu	Ala	Gly	Ser
			820					825					830		
Phe	Ser	Cys	Thr	Cys	His	Gly	Gly	Tyr	Thr	Gly	Pro	Ser	Cys	Asp	Gln
		835					840					845			
Asp	Ile	Asn	Asp	Cys	Asp	Pro	Asn	Pro	Cys	Leu	Asn	Gly	Gly	Ser	Cys

-continued

850			855			860									
Gln	Asp	Gly	Val	Gly	Ser	Phe	Ser	Cys	Ser	Cys	Leu	Pro	Gly	Phe	Ala
865					870					875					880
Gly	Pro	Arg	Cys	Ala	Arg	Asp	Val	Asp	Glu	Cys	Leu	Ser	Asn	Pro	Cys
			885					890					895		
Gly	Pro	Gly	Thr	Cys	Thr	Asp	His	Val	Ala	Ser	Phe	Thr	Cys	Thr	Cys
			900				905					910			
Pro	Pro	Gly	Tyr	Gly	Gly	Phe	His	Cys	Glu	Gln	Asp	Leu	Pro	Asp	Cys
		915					920					925			
Ser	Pro	Ser	Ser	Cys	Phe	Asn	Gly	Gly	Thr	Cys	Val	Asp	Gly	Val	Asn
	930				935						940				
Ser	Phe	Ser	Cys	Leu	Cys	Arg	Pro	Gly	Tyr	Thr	Gly	Ala	His	Cys	Gln
945				950					955						960
His	Glu	Ala	Asp	Pro	Cys	Leu	Ser	Arg	Pro	Cys	Leu	His	Gly	Gly	Val
			965					970					975		
Cys	Ser	Ala	Ala	His	Pro	Gly	Phe	Arg	Cys	Thr	Cys	Leu	Glu	Ser	Phe
		980						985				990			
Thr	Gly	Pro	Gln	Cys	Gln	Thr	Leu	Val	Asp	Trp	Cys	Ser	Arg	Gln	Pro
		995					1000					1005			
Cys	Gln	Asn	Gly	Gly	Arg	Cys	Val	Gln	Thr	Gly	Ala	Tyr	Cys	Leu	
	1010					1015					1020				
Cys	Pro	Pro	Gly	Trp	Ser	Gly	Arg	Leu	Cys	Asp	Ile	Arg	Ser	Leu	
	1025					1030					1035				
Pro	Cys	Arg	Glu	Ala	Ala	Ala	Gln	Ile	Gly	Val	Arg	Leu	Glu	Gln	
	1040				1045						1050				
Leu	Cys	Gln	Ala	Gly	Gly	Gln	Cys	Val	Asp	Glu	Asp	Ser	Ser	His	
	1055					1060					1065				
Tyr	Cys	Val	Cys	Pro	Glu	Gly	Arg	Thr	Gly	Ser	His	Cys	Glu	Gln	
	1070					1075					1080				
Glu	Val	Asp	Pro	Cys	Leu	Ala	Gln	Pro	Cys	Gln	His	Gly	Gly	Thr	
	1085					1090					1095				
Cys	Arg	Gly	Tyr	Met	Gly	Gly	Tyr	Met	Cys	Glu	Cys	Leu	Pro	Gly	
	1100					1105					1110				
Tyr	Asn	Gly	Asp	Asn	Cys	Glu	Asp	Asp	Val	Asp	Glu	Cys	Ala	Ser	
	1115					1120					1125				
Gln	Pro	Cys	Gln	His	Gly	Gly	Ser	Cys	Ile	Asp	Leu	Val	Ala	Arg	
	1130					1135					1140				
Tyr	Leu	Cys	Ser	Cys	Pro	Pro	Gly	Thr	Leu	Gly	Val	Leu	Cys	Glu	
	1145					1150					1155				
Ile	Asn	Glu	Asp	Asp	Cys	Gly	Pro	Gly	Pro	Pro	Leu	Asp	Ser	Gly	
	1160					1165					1170				
Pro	Arg	Cys	Leu	His	Asn	Gly	Thr	Cys	Val	Asp	Leu	Val	Gly	Gly	
	1175					1180					1185				
Phe	Arg	Cys	Thr	Cys	Pro	Pro	Gly	Tyr	Thr	Gly	Leu	Arg	Cys	Glu	
	1190					1195					1200				
Ala	Asp	Ile	Asn	Glu	Cys	Arg	Ser	Gly	Ala	Cys	His	Ala	Ala	His	
	1205					1210					1215				
Thr	Arg	Asp	Cys	Leu	Gln	Asp	Pro	Gly	Gly	Gly	Phe	Arg	Cys	Leu	
	1220					1225					1230				
Cys	His	Ala	Gly	Phe	Ser	Gly	Pro	Arg	Cys	Gln	Thr	Val	Leu	Ser	
	1235					1240					1245				

-continued

---

Pro Cys	Glu Ser Gln Pro	Cys	Gln His Gly Gly Gln	Cys Arg Pro	
1250		1255		1260	
Ser Pro	Gly Pro Gly Gly	Gly	Leu Thr Phe Thr Cys	His Cys Ala	
1265		1270		1275	
Gln Pro	Phe Trp Gly Pro	Arg	Cys Glu Arg Val Ala	Arg Ser Cys	
1280		1285		1290	
Arg Glu	Leu Gln Cys Pro	Val	Gly Val Pro Cys Gln	Gln Thr Pro	
1295		1300		1305	
Arg Gly	Pro Arg Cys Ala	Cys	Pro Pro Gly Leu Ser	Gly Pro Ser	
1310		1315		1320	
Cys Arg	Ser Phe Pro Gly	Ser	Pro Pro Gly Ala Ser	Asn Ala Ser	
1325		1330		1335	
Cys Ala	Ala Ala Pro Cys	Leu	His Gly Gly Ser Cys	Arg Pro Ala	
1340		1345		1350	
Pro Leu	Ala Pro Phe Phe	Arg	Cys Ala Cys Ala Gln	Gly Trp Thr	
1355		1360		1365	
Gly Pro	Arg Cys Glu Ala	Pro	Ala Ala Ala Pro Glu	Val Ser Glu	
1370		1375		1380	
Glu Pro	Arg Cys Pro Arg	Ala	Ala Cys Gln Ala Lys	Arg Gly Asp	
1385		1390		1395	
Gln Arg	Cys Asp Arg Glu	Cys	Asn Ser Pro Gly Cys	Gly Trp Asp	
1400		1405		1410	
Gly Gly	Asp Cys Ser Leu	Ser	Val Gly Asp Pro Trp	Arg Gln Cys	
1415		1420		1425	
Glu Ala	Leu Gln Cys Trp	Arg	Leu Phe Asn Asn Ser	Arg Cys Asp	
1430		1435		1440	
Pro Ala	Cys Ser Ser Pro	Ala	Cys Leu Tyr Asp Asn	Phe Asp Cys	
1445		1450		1455	
His Ala	Gly Gly Arg Glu	Arg	Thr Cys Asn Pro Val	Tyr Glu Lys	
1460		1465		1470	
Tyr Cys	Ala Asp His Phe	Ala	Asp Gly Arg Cys Asp	Gln Gly Cys	
1475		1480		1485	
Asn Thr	Glu Glu Cys Gly	Trp	Asp Gly Leu Asp Cys	Ala Ser Glu	
1490		1495		1500	
Val Pro	Ala Leu Leu Ala	Arg	Gly Val Leu Val Leu	Thr Val Leu	
1505		1510		1515	
Leu Pro	Pro Glu Glu Leu	Leu	Arg Ser Ser Ala Asp	Phe Leu Gln	
1520		1525		1530	
Arg Leu	Ser Ala Ile Leu	Arg	Thr Ser Leu Arg Phe	Arg Leu Asp	
1535		1540		1545	
Ala His	Gly Gln Ala Met	Val	Phe Pro Tyr His Arg	Pro Ser Pro	
1550		1555		1560	
Gly Ser	Glu Pro Arg Ala	Arg	Arg Glu Leu Ala Pro	Glu Val Ile	
1565		1570		1575	
Gly Ser	Val Val Met Leu	Glu	Ile Asp Asn Arg Leu	Cys Leu Gln	
1580		1585		1590	
Ser Pro	Glu Asn Asp His	Cys	Phe Pro Asp Ala Gln	Ser Ala Ala	
1595		1600		1605	
Asp Tyr	Leu Gly Ala Leu	Ser	Ala Val Glu Arg Leu	Asp Phe Pro	
1610		1615		1620	

-continued

Tyr	Pro	Leu	Arg	Asp	Val	Arg	Gly	Glu	Pro	Leu	Glu	Pro	Pro	Glu
1625						1630					1635			
Pro	Ser	Val	Pro	Leu	Leu	Pro	Leu	Leu	Val	Ala	Gly	Ala	Val	Leu
1640						1645					1650			
Leu	Leu	Val	Ile	Leu	Val	Leu	Gly	Val	Met	Val	Ala	Arg	Arg	Lys
1655						1660					1665			
Arg	Glu	His	Ser	Thr	Leu	Trp	Phe	Pro	Glu	Gly	Phe	Ser	Leu	His
1670						1675					1680			
Lys	Asp	Val	Ala	Ser	Gly	His	Lys	Gly	Arg	Arg	Glu	Pro	Val	Gly
1685						1690					1695			
Gln	Asp	Ala	Leu	Gly	Met	Lys	Asn	Met	Ala	Lys	Gly	Glu	Ser	Leu
1700						1705					1710			
Met	Gly	Glu	Val	Ala	Thr	Asp	Trp	Met	Asp	Thr	Glu	Cys	Pro	Glu
1715						1720					1725			
Ala	Lys	Arg	Leu	Lys	Val	Glu	Glu	Pro	Gly	Met	Gly	Ala	Glu	Glu
1730						1735					1740			
Ala	Val	Asp	Cys	Arg	Gln	Trp	Thr	Gln	His	His	Leu	Val	Ala	Ala
1745						1750					1755			
Asp	Ile	Arg	Val	Ala	Pro	Ala	Met	Ala	Leu	Thr	Pro	Pro	Gln	Gly
1760						1765					1770			
Asp	Ala	Asp	Ala	Asp	Gly	Met	Asp	Val	Asn	Val	Arg	Gly	Pro	Asp
1775						1780					1785			
Gly	Phe	Thr	Pro	Leu	Met	Leu	Ala	Ser	Phe	Cys	Gly	Gly	Ala	Leu
1790						1795					1800			
Glu	Pro	Met	Pro	Thr	Glu	Glu	Asp	Glu	Ala	Asp	Asp	Thr	Ser	Ala
1805						1810					1815			
Ser	Ile	Ile	Ser	Asp	Leu	Ile	Cys	Gln	Gly	Ala	Gln	Leu	Gly	Ala
1820						1825					1830			
Arg	Thr	Asp	Arg	Thr	Gly	Glu	Thr	Ala	Leu	His	Leu	Ala	Ala	Arg
1835						1840					1845			
Tyr	Ala	Arg	Ala	Asp	Ala	Ala	Lys	Arg	Leu	Leu	Asp	Ala	Gly	Ala
1850						1855					1860			
Asp	Thr	Asn	Ala	Gln	Asp	His	Ser	Gly	Arg	Thr	Pro	Leu	His	Thr
1865						1870					1875			
Ala	Val	Thr	Ala	Asp	Ala	Gln	Gly	Val	Phe	Gln	Ile	Leu	Ile	Arg
1880						1885					1890			
Asn	Arg	Ser	Thr	Asp	Leu	Asp	Ala	Arg	Met	Ala	Asp	Gly	Ser	Thr
1895						1900					1905			
Ala	Leu	Ile	Leu	Ala	Ala	Arg	Leu	Ala	Val	Glu	Gly	Met	Val	Glu
1910						1915					1920			
Glu	Leu	Ile	Ala	Ser	His	Ala	Asp	Val	Asn	Ala	Val	Asp	Glu	Leu
1925						1930					1935			
Gly	Lys	Ser	Ala	Leu	His	Trp	Ala	Ala	Ala	Val	Asn	Asn	Val	Glu
1940						1945					1950			
Ala	Thr	Leu	Ala	Leu	Leu	Lys	Asn	Gly	Ala	Asn	Lys	Asp	Met	Gln
1955						1960					1965			
Asp	Ser	Lys	Glu	Glu	Thr	Pro	Leu	Phe	Leu	Ala	Ala	Arg	Glu	Gly
1970						1975					1980			
Ser	Tyr	Glu	Ala	Ala	Lys	Leu	Leu	Leu	Asp	His	Phe	Ala	Asn	Arg
1985						1990					1995			
Glu	Ile	Thr	Asp	His	Leu	Asp	Arg	Leu	Pro	Arg	Asp	Val	Ala	Gln

-continued

2000			2005			2010								
Glu	Arg	Leu	His	Gln	Asp	Ile	Val	Arg	Leu	Leu	Asp	Gln	Pro	Ser
2015						2020						2025		
Gly	Pro	Arg	Ser	Pro	Pro	Gly	Pro	His	Gly	Leu	Gly	Pro	Leu	Leu
2030						2035						2040		
Cys	Pro	Pro	Gly	Ala	Phe	Leu	Pro	Gly	Leu	Lys	Ala	Ala	Gln	Ser
2045						2050						2055		
Gly	Ser	Lys	Lys	Ser	Arg	Arg	Pro	Pro	Gly	Lys	Ala	Gly	Leu	Gly
2060						2065						2070		
Pro	Gln	Gly	Pro	Arg	Gly	Arg	Gly	Lys	Lys	Leu	Thr	Leu	Ala	Cys
2075						2080						2085		
Pro	Gly	Pro	Leu	Ala	Asp	Ser	Ser	Val	Thr	Leu	Ser	Pro	Val	Asp
2090						2095						2100		
Ser	Leu	Asp	Ser	Pro	Arg	Pro	Phe	Gly	Gly	Pro	Pro	Ala	Ser	Pro
2105						2110						2115		
Gly	Gly	Phe	Pro	Leu	Glu	Gly	Pro	Tyr	Ala	Ala	Ala	Thr	Ala	Thr
2120						2125						2130		
Ala	Val	Ser	Leu	Ala	Gln	Leu	Gly	Gly	Pro	Gly	Arg	Ala	Gly	Leu
2135						2140						2145		
Gly	Arg	Gln	Pro	Pro	Gly	Gly	Cys	Val	Leu	Ser	Leu	Gly	Leu	Leu
2150						2155						2160		
Asn	Pro	Val	Ala	Val	Pro	Leu	Asp	Trp	Ala	Arg	Leu	Pro	Pro	Pro
2165						2170						2175		
Ala	Pro	Pro	Gly	Pro	Ser	Phe	Leu	Leu	Pro	Leu	Ala	Pro	Gly	Pro
2180						2185						2190		
Gln	Leu	Leu	Asn	Pro	Gly	Thr	Pro	Val	Ser	Pro	Gln	Glu	Arg	Pro
2195						2200						2205		
Pro	Pro	Tyr	Leu	Ala	Val	Pro	Gly	His	Gly	Glu	Glu	Tyr	Pro	Val
2210						2215						2220		
Ala	Gly	Ala	His	Ser	Ser	Pro	Pro	Lys	Ala	Arg	Phe	Leu	Arg	Val
2225						2230						2235		
Pro	Ser	Glu	His	Pro	Tyr	Leu	Thr	Pro	Ser	Pro	Glu	Ser	Pro	Glu
2240						2245						2250		
His	Trp	Ala	Ser	Pro	Ser	Pro	Pro	Ser	Leu	Ser	Asp	Trp	Ser	Glu
2255						2260						2265		
Ser	Thr	Pro	Ser	Pro	Ala	Thr	Ala	Thr	Gly	Ala	Met	Ala	Thr	Thr
2270						2275						2280		
Thr	Gly	Ala	Leu	Pro	Ala	Gln	Pro	Leu	Pro	Leu	Ser	Val	Pro	Ser
2285						2290						2295		
Ser	Leu	Ala	Gln	Ala	Gln	Thr	Gln	Leu	Gly	Pro	Gln	Pro	Glu	Val
2300						2305						2310		
Thr	Pro	Lys	Arg	Gln	Val	Leu	Ala							
2315						2320								

<210> SEQ ID NO 42  
 <211> LENGTH: 149  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
 <400> SEQUENCE: 42  
 Met Ala Arg Ser Asn Leu Pro Leu Ala Leu Gly Leu Ala Leu Val Ala  
 1 5 10 15

-continued

---

Phe Cys Leu Leu Ala Leu Pro Arg Asp Ala Arg Ala Arg Pro Gln Glu  
                   20                                  25                                  30  
 Arg Met Val Gly Glu Leu Arg Asp Leu Ser Pro Asp Asp Pro Gln Val  
                   35                                  40                                  45  
 Gln Lys Ala Ala Gln Ala Ala Val Ala Ser Tyr Asn Met Gly Ser Asn  
                   50                                  55                                  60  
 Ser Ile Tyr Tyr Phe Arg Asp Thr His Ile Ile Lys Ala Gln Ser Gln  
                   65                  70                                  75                                  80  
 Leu Val Ala Gly Ile Lys Tyr Phe Leu Thr Met Glu Met Gly Ser Thr  
                   85                                  90                                  95  
 Asp Cys Arg Lys Thr Arg Val Thr Gly Asp His Val Asp Leu Thr Thr  
                   100                                  105                                  110  
 Cys Pro Leu Ala Ala Gly Ala Gln Gln Glu Lys Leu Arg Cys Asp Phe  
                   115                                  120                                  125  
 Glu Val Leu Val Val Pro Trp Gln Asn Ser Ser Gln Leu Leu Lys His  
                   130                                  135                                  140  
 Asn Cys Val Gln Met  
 145  
  
 <210> SEQ ID NO 43  
 <211> LENGTH: 485  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
  
 <400> SEQUENCE: 43  
 Met Ser Val Pro Leu Leu Lys Ile Gly Val Val Leu Ser Thr Met Ala  
 1                  5                                  10                                  15  
 Met Ile Thr Asn Trp Met Ser Gln Thr Leu Pro Ser Leu Val Gly Leu  
                   20                                  25                                  30  
 Asn Thr Thr Lys Leu Ser Ala Ala Gly Gly Gly Thr Leu Asp Arg Ser  
                   35                                  40                                  45  
 Thr Gly Val Leu Pro Thr Asn Pro Glu Glu Ser Trp Gln Val Tyr Ser  
                   50                                  55                                  60  
 Ser Ala Gln Asp Ser Glu Gly Arg Cys Ile Cys Thr Val Val Ala Pro  
                   65                  70                                  75                                  80  
 Gln Gln Thr Met Cys Ser Arg Asp Ala Arg Thr Lys Gln Leu Arg Gln  
                   85                                  90                                  95  
 Leu Leu Glu Lys Val Gln Asn Met Ser Gln Ser Ile Glu Val Leu Asp  
                   100                                  105                                  110  
 Arg Arg Thr Gln Arg Asp Leu Gln Tyr Val Glu Lys Met Glu Asn Gln  
                   115                                  120                                  125  
 Met Lys Gly Leu Glu Ser Lys Phe Lys Gln Val Glu Glu Ser His Lys  
                   130                                  135                                  140  
 Gln His Leu Ala Arg Gln Phe Lys Ala Ile Lys Ala Lys Met Asp Glu  
                   145                  150                                  155                                  160  
 Leu Arg Pro Leu Ile Pro Val Leu Glu Glu Tyr Lys Ala Asp Ala Lys  
                   165                                  170                                  175  
 Leu Val Leu Gln Phe Lys Glu Glu Val Gln Asn Leu Thr Ser Val Leu  
                   180                                  185                                  190  
 Asn Glu Leu Gln Glu Glu Ile Gly Ala Tyr Asp Tyr Asp Glu Leu Gln  
                   195                                  200                                  205  
 Ser Arg Val Ser Asn Leu Glu Glu Arg Leu Arg Ala Cys Met Gln Lys  
                   210                                  215                                  220

-continued

Leu Ala Cys Gly Lys Leu Thr Gly Ile Ser Asp Pro Val Thr Val Lys  
 225 230 235 240  
 Thr Ser Gly Ser Arg Phe Gly Ser Trp Met Thr Asp Pro Leu Ala Pro  
 245 250 255  
 Glu Gly Asp Asn Arg Val Trp Tyr Met Asp Gly Tyr His Asn Asn Arg  
 260 265 270  
 Phe Val Arg Glu Tyr Lys Ser Met Val Asp Phe Met Asn Thr Asp Asn  
 275 280 285  
 Phe Thr Ser His Arg Leu Pro His Pro Trp Ser Gly Thr Gly Gln Val  
 290 295 300  
 Val Tyr Asn Gly Ser Ile Tyr Phe Asn Lys Phe Gln Ser His Ile Ile  
 305 310 315 320  
 Ile Arg Phe Asp Leu Lys Thr Glu Thr Ile Leu Lys Thr Arg Ser Leu  
 325 330 335  
 Asp Tyr Ala Gly Tyr Asn Asn Met Tyr His Tyr Ala Trp Gly Gly His  
 340 345 350  
 Ser Asp Ile Asp Leu Met Val Asp Glu Ser Gly Leu Trp Ala Val Tyr  
 355 360 365  
 Ala Thr Asn Gln Asn Ala Gly Asn Ile Val Val Ser Arg Leu Asp Pro  
 370 375 380  
 Val Ser Leu Gln Thr Leu Gln Thr Trp Asn Thr Ser Tyr Pro Lys Arg  
 385 390 395 400  
 Ser Ala Gly Glu Ala Phe Ile Ile Cys Gly Thr Leu Tyr Val Thr Asn  
 405 410 415  
 Gly Tyr Ser Gly Gly Thr Lys Val His Tyr Ala Tyr Gln Thr Asn Ala  
 420 425 430  
 Ser Thr Tyr Glu Tyr Ile Asp Ile Pro Phe Gln Asn Lys Tyr Ser His  
 435 440 445  
 Ile Ser Met Leu Asp Tyr Asn Pro Lys Asp Arg Ala Leu Tyr Ala Trp  
 450 455 460  
 Asn Asn Gly His Gln Ile Leu Tyr Asn Val Thr Leu Phe His Val Ile  
 465 470 475 480  
 Arg Ser Asp Glu Leu  
 485

<210> SEQ ID NO 44  
 <211> LENGTH: 328  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 44

Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro  
 1 5 10 15  
 Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu Gly Ala Ser Gly  
 20 25 30  
 Gly Gly Gly Gly Ala Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys  
 35 40 45  
 Thr Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro Val Ala Pro Pro  
 50 55 60  
 Ala Ala Val Ala Ala Val Ala Gly Gly Ala Arg Met Pro Cys Ala Glu  
 65 70 75 80  
 Leu Val Arg Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg Leu



-continued

---

Asp Lys Ile Arg Leu Ile Ser Leu Thr Asp Glu Asn Ala Leu Ser Gly  
 115 120 125  
 Asn Glu Glu Leu Thr Val Lys Ile Lys Cys Asp Lys Glu Lys Asn Leu  
 130 135 140  
 Leu His Val Thr Asp Thr Gly Val Gly Met Thr Arg Glu Glu Leu Val  
 145 150 155 160  
 Lys Asn Leu Gly Thr Ile Ala Lys Ser Gly Thr Ser Glu Phe Leu Asn  
 165 170 175  
 Lys Met Thr Glu Ala Gln Glu Asp Gly Gln Ser Thr Ser Glu Leu Ile  
 180 185 190  
 Gly Gln Phe Gly Val Gly Phe Tyr Ser Ala Phe Leu Val Ala Asp Lys  
 195 200 205  
 Val Ile Val Thr Ser Lys His Asn Asn Asp Thr Gln His Ile Trp Glu  
 210 215 220  
 Ser Asp Ser Asn Glu Phe Ser Val Ile Ala Asp Pro Arg Gly Asn Thr  
 225 230 235 240  
 Leu Gly Arg Gly Thr Thr Ile Thr Leu Val Leu Lys Glu Glu Ala Ser  
 245 250 255  
 Asp Tyr Leu Glu Leu Asp Thr Ile Lys Asn Leu Val Lys Lys Tyr Ser  
 260 265 270  
 Gln Phe Ile Asn Phe Pro Ile Tyr Val Trp Ser Ser Lys Thr Glu Thr  
 275 280 285  
 Val Glu Glu Pro Met Glu Glu Glu Glu Ala Ala Lys Glu Glu Lys Glu  
 290 295 300  
 Glu Ser Asp Asp Glu Ala Ala Val Glu Glu Glu Glu Glu Lys Lys  
 305 310 315 320  
 Pro Lys Thr Lys Lys Val Glu Lys Thr Val Trp Asp Trp Glu Leu Met  
 325 330 335  
 Asn Asp Ile Lys Pro Ile Trp Gln Arg Pro Ser Lys Glu Val Glu Glu  
 340 345 350  
 Asp Glu Tyr Lys Ala Phe Tyr Lys Ser Phe Ser Lys Glu Ser Asp Asp  
 355 360 365  
 Pro Met Ala Tyr Ile His Phe Thr Ala Glu Gly Glu Val Thr Phe Lys  
 370 375 380  
 Ser Ile Leu Phe Val Pro Thr Ser Ala Pro Arg Gly Leu Phe Asp Glu  
 385 390 395 400  
 Tyr Gly Ser Lys Lys Ser Asp Tyr Ile Lys Leu Tyr Val Arg Arg Val  
 405 410 415  
 Phe Ile Thr Asp Asp Phe His Asp Met Met Pro Lys Tyr Leu Asn Phe  
 420 425 430  
 Val Lys Gly Val Val Asp Ser Asp Asp Leu Pro Leu Asn Val Ser Arg  
 435 440 445  
 Glu Thr Leu Gln Gln His Lys Leu Leu Lys Val Ile Arg Lys Lys Leu  
 450 455 460  
 Val Arg Lys Thr Leu Asp Met Ile Lys Lys Ile Ala Asp Asp Lys Tyr  
 465 470 475 480  
 Asn Asp Thr Phe Trp Lys Glu Phe Gly Thr Asn Ile Lys Leu Gly Val  
 485 490 495  
 Ile Glu Asp His Ser Asn Arg Thr Arg Leu Ala Lys Leu Leu Arg Phe  
 500 505 510  
 Gln Ser Ser His His Pro Thr Asp Ile Thr Ser Leu Asp Gln Tyr Val



-continued

65	70	75	80
Val Leu Lys Glu Glu Thr His Leu Ser Gln Ser Glu Arg Thr Ala Arg	85	90	95
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu	100	105	110
His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly	115	120	125
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu	130	135	140
Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg	145	150	155
Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly	165	170	175
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp	180	185	190
His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Asn Val	195	200	205
Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp	210	215	220
Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly	225	230	235
Val Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn Cys Gln	245	250	255
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg	260	265	270
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro	275	280	285
Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln Arg Leu	290	295	300
Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp	305	310	315
Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val	325	330	335
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly	340	345	350
Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile	355	360	365
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln Ser Gly	370	375	380
Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met Met Leu	385	390	395
Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile	405	410	415
His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro Glu Asp	420	425	430
Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr	435	440	445
His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala His	450	455	460
Ser Gly Pro Thr Arg Met Ala Thr Ala Ile Ala Arg Cys Ala Pro Asp	465	470	475
			480

-continued

Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg  
                   485                  490                  495  
 Gly Glu Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg Ala His  
                   500                  505                  510  
 Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu  
                   515                  520                  525  
 Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala Glu Ala  
                   530                  535                  540  
 Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr  
                   545                  550                  555                  560  
 Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro  
                   565                  570                  575  
 Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg  
                   580                  585                  590  
 Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys  
                   595                  600                  605  
 Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val Thr Val  
                   610                  615                  620  
 Ala Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu Pro Gly  
                   625                  630                  635  
 Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val  
                   645                  650                  655  
 Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu Ala Val  
                   660                  665                  670  
 Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln Ala Ser  
                   675                  680                  685  
 Gln Glu Leu Gln  
                   690

<210> SEQ ID NO 47  
 <211> LENGTH: 605  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 47

Met Ala Leu Arg Lys Gly Gly Leu Ala Leu Ala Leu Leu Leu Ser  
 1                  5                  10                  15  
 Trp Val Ala Leu Gly Pro Arg Ser Leu Glu Gly Ala Asp Pro Gly Thr  
                   20                  25                  30  
 Pro Gly Glu Ala Glu Gly Pro Ala Cys Pro Ala Ala Cys Val Cys Ser  
                   35                  40                  45  
 Tyr Asp Asp Asp Ala Asp Glu Leu Ser Val Phe Cys Ser Ser Arg Asn  
                   50                  55                  60  
 Leu Thr Arg Leu Pro Asp Gly Val Pro Gly Gly Thr Gln Ala Leu Trp  
                   65                  70                  75                  80  
 Leu Asp Gly Asn Asn Leu Ser Ser Val Pro Pro Ala Ala Phe Gln Asn  
                   85                  90                  95  
 Leu Ser Ser Leu Gly Phe Leu Asn Leu Gln Gly Gly Gln Leu Gly Ser  
                   100                  105                  110  
 Leu Glu Pro Gln Ala Leu Leu Gly Leu Glu Asn Leu Cys His Leu His  
                   115                  120                  125  
 Leu Glu Arg Asn Gln Leu Arg Ser Leu Ala Leu Gly Thr Phe Ala His

-continued

130			135			140			
Thr 145	Pro Ala Leu	Ala Leu Ala	Ser 150	Leu Gly Leu	Gly Leu Ser	Leu Ser Asn	Asn 155	Arg Leu Ser	Leu Ser Arg 160
Leu	Glu Asp Gly	Leu Phe Glu	165	Gly Gly Leu	170	Ser Leu Trp	175	Asp Leu Asn 175	
Leu	Gly Trp	Asn Ser Leu	180	Ala Val Leu	185	Pro Asp Ala	190	Ala Phe Arg Gly 190	
Leu	Gly Ser	Leu Arg Glu	195	Leu Val Leu	200	Ala Gly Asn	205	Arg Leu Ala Tyr 205	
Leu	Gln Pro	Ala Leu Phe	210	Ser Gly Leu	215	Ala Glu Leu	220	Arg Glu Leu Asp 220	
Leu	Ser Arg	Asn Ala Leu	225	Arg Ala Ile	230	Lys Ala Asn	235	Val Phe Val Gln 240	
Leu	Pro Arg	Leu Gln Lys	245	Leu Tyr Leu	250	Asp Arg Asn	255	Leu Ile Ala Ala 255	
Val	Ala Pro	Gly Ala Phe	260	Leu Gly Leu	265	Lys Ala Leu	270	Arg Trp Leu Asp 270	
Leu	Ser His	Asn Arg Val	275	Ala Gly Leu	280	Leu Glu Asp	285	Thr Phe Pro Gly 285	
Leu	Leu Gly	Leu Arg Val	290	Leu Arg Leu	295	Ser His Asn	300	Ala Ile Ala Ser 300	
Leu	Arg Pro	Arg Thr Phe	305	Lys Asp Leu	310	His Phe Leu	315	Glu Glu Leu Gln 320	
Leu	Gly His	Asn Arg Ile	325	Arg Gln Leu	330	Ala Glu Arg	335	Ser Phe Glu Gly 335	
Leu	Gly Gln	Leu Glu Val	340	Leu Thr Leu	345	Asp His Asn	350	Gln Leu Gln Glu 350	
Val	Lys Ala	Gly Ala Phe	355	Leu Gly Leu	360	Thr Asn Val	365	Ala Val Met Asn 365	
Leu	Ser Gly	Asn Cys Leu	370	Arg Asn Leu	375	Pro Glu Gln	380	Val Phe Arg Gly 380	
Leu	Gly Lys	Leu His Ser	385	Leu His Leu	390	Glu Gly Ser	395	Cys Leu Gly Arg 400	
Ile	Arg Pro	His Thr Phe	405	Thr Gly Leu	410	Ser Gly Leu	415	Arg Arg Leu Phe 415	
Leu	Lys Asp	Asn Gly Leu	420	Val Gly Ile	425	Glu Glu Gln	430	Ser Leu Trp Gly 430	
Leu	Ala Glu	Leu Leu Glu	435	Leu Asp Leu	440	Thr Ser Asn	445	Gln Leu Thr His 445	
Leu	Pro His	Arg Leu Phe	450	Gln Gly Leu	455	Gly Lys Leu	460	Glu Tyr Leu Leu 460	
Leu	Ser Arg	Asn Arg Leu	465	Ala Glu Leu	470	Pro Ala Asp	475	Ala Leu Gly Pro 480	
Leu	Gln Arg	Ala Phe Trp	485	Leu Asp Val	490	Ser His Asn	495	Arg Leu Glu Ala 495	
Leu	Pro Asn	Ser Leu Leu	500	Ala Pro Leu	505	Gly Arg Leu	510	Arg Tyr Leu Ser 510	
Leu	Arg Asn	Asn Ser Leu	515	Arg Thr Phe	520	Thr Pro Gln	525	Pro Pro Gly Leu 525	
Glu	Arg Leu	Trp Leu Glu	530	Gly Asn Pro	535	Trp Asp Cys	540	Gly Cys Pro Leu 540	

-continued

Lys Ala Leu Arg Asp Phe Ala Leu Gln Asn Pro Ser Ala Val Pro Arg  
 545 550 555 560  
 Phe Val Gln Ala Ile Cys Glu Gly Asp Asp Cys Gln Pro Pro Ala Tyr  
 565 570 575  
 Thr Tyr Asn Asn Ile Thr Cys Ala Ser Pro Pro Glu Val Val Gly Leu  
 580 585 590  
 Asp Leu Arg Asp Leu Ser Glu Ala His Phe Ala Pro Cys  
 595 600 605

<210> SEQ ID NO 48  
 <211> LENGTH: 586  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens  
 <400> SEQUENCE: 48

Met Pro Lys Pro Ile Asn Val Arg Val Thr Thr Met Asp Ala Glu Leu  
 1 5 10 15  
 Glu Phe Ala Ile Gln Pro Asn Thr Thr Gly Lys Gln Leu Phe Asp Gln  
 20 25 30  
 Val Val Lys Thr Ile Gly Leu Arg Glu Val Trp Tyr Phe Gly Leu His  
 35 40 45  
 Tyr Val Asp Asn Lys Gly Phe Pro Thr Trp Leu Lys Leu Asp Lys Lys  
 50 55 60  
 Val Ser Ala Gln Glu Val Arg Lys Glu Asn Pro Leu Gln Phe Lys Phe  
 65 70 75 80  
 Arg Ala Lys Phe Tyr Pro Glu Asp Val Ala Glu Glu Leu Ile Gln Asp  
 85 90 95  
 Ile Thr Gln Lys Leu Phe Phe Leu Gln Val Lys Glu Gly Ile Leu Ser  
 100 105  
 Asp Glu Ile Tyr Cys Pro Pro Glu Thr Ala Val Leu Leu Gly Ser Tyr  
 115 120 125  
 Ala Val Gln Ala Lys Phe Gly Asp Tyr Asn Lys Glu Val His Lys Ser  
 130 135 140  
 Gly Tyr Leu Ser Ser Glu Arg Leu Ile Pro Gln Arg Val Met Asp Gln  
 145 150 155 160  
 His Lys Leu Thr Arg Asp Gln Trp Glu Asp Arg Ile Gln Val Trp His  
 165 170 175  
 Ala Glu His Arg Gly Met Leu Lys Asp Asn Ala Met Leu Glu Tyr Leu  
 180 185 190  
 Lys Ile Ala Gln Asp Leu Glu Met Tyr Gly Ile Asn Tyr Phe Glu Ile  
 195 200 205  
 Lys Asn Lys Lys Gly Thr Asp Leu Trp Leu Gly Val Asp Ala Leu Gly  
 210 215 220  
 Leu Asn Ile Tyr Glu Lys Asp Asp Lys Leu Thr Pro Lys Ile Gly Phe  
 225 230 235 240  
 Pro Trp Ser Glu Ile Arg Asn Ile Ser Phe Asn Asp Lys Lys Phe Val  
 245 250 255  
 Ile Lys Pro Ile Asp Lys Lys Ala Pro Asp Phe Val Phe Tyr Ala Pro  
 260 265 270  
 Arg Leu Arg Ile Asn Lys Arg Ile Leu Gln Leu Cys Met Gly Asn His  
 275 280 285  
 Glu Leu Tyr Met Arg Arg Arg Lys Pro Asp Thr Ile Glu Val Gln Gln

-continued

290			295			300									
Met	Lys	Ala	Gln	Ala	Arg	Glu	Glu	Lys	His	Gln	Lys	Gln	Leu	Glu	Arg
305					310					315					320
Gln	Gln	Leu	Glu	Thr	Glu	Lys	Lys	Arg	Arg	Glu	Thr	Val	Glu	Arg	Glu
				325					330						335
Lys	Glu	Gln	Met	Met	Arg	Glu	Lys	Glu	Glu	Leu	Met	Leu	Arg	Leu	Gln
			340					345						350	
Asp	Tyr	Glu	Glu	Lys	Thr	Lys	Lys	Ala	Glu	Arg	Glu	Leu	Ser	Glu	Gln
		355					360						365		
Ile	Gln	Arg	Ala	Leu	Gln	Leu	Glu	Glu	Glu	Arg	Lys	Arg	Ala	Gln	Glu
	370					375					380				
Glu	Ala	Glu	Arg	Leu	Glu	Ala	Asp	Arg	Met	Ala	Ala	Leu	Arg	Ala	Lys
385					390					395					400
Glu	Glu	Leu	Glu	Arg	Gln	Ala	Val	Asp	Gln	Ile	Lys	Ser	Gln	Glu	Gln
				405					410						415
Leu	Ala	Ala	Glu	Leu	Ala	Glu	Tyr	Thr	Ala	Lys	Ile	Ala	Leu	Leu	Glu
			420					425						430	
Glu	Ala	Arg	Arg	Arg	Lys	Glu	Asp	Glu	Val	Glu	Glu	Trp	Gln	His	Arg
		435					440					445			
Ala	Lys	Glu	Ala	Gln	Asp	Asp	Leu	Val	Lys	Thr	Lys	Glu	Glu	Leu	His
	450					455					460				
Leu	Val	Met	Thr	Ala	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Val	Tyr	Glu	Pro
465					470					475					480
Val	Ser	Tyr	His	Val	Gln	Glu	Ser	Leu	Gln	Asp	Glu	Gly	Ala	Glu	Pro
				485					490						495
Thr	Gly	Tyr	Ser	Ala	Glu	Leu	Ser	Ser	Glu	Gly	Ile	Arg	Asp	Asp	Arg
			500					505						510	
Asn	Glu	Glu	Lys	Arg	Ile	Thr	Glu	Ala	Glu	Lys	Asn	Glu	Arg	Val	Gln
		515					520					525			
Arg	Gln	Leu	Leu	Thr	Leu	Ser	Ser	Glu	Leu	Ser	Gln	Ala	Arg	Asp	Glu
	530					535					540				
Asn	Lys	Arg	Thr	His	Asn	Asp	Ile	Ile	His	Asn	Glu	Asn	Met	Arg	Gln
545					550					555					560
Gly	Arg	Asp	Lys	Tyr	Lys	Thr	Leu	Arg	Gln	Ile	Arg	Gln	Gly	Asn	Thr
			565						570						575
Lys	Gln	Arg	Ile	Asp	Glu	Phe	Glu	Ala	Leu						
			580						585						

&lt;210&gt; SEQ ID NO 49

&lt;211&gt; LENGTH: 127

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 49

Met	Ser	Phe	Ser	Gly	Lys	Tyr	Gln	Leu	Gln	Ser	Gln	Glu	Asn	Phe	Glu
1				5					10						15
Ala	Phe	Met	Lys	Ala	Ile	Gly	Leu	Pro	Glu	Glu	Leu	Ile	Gln	Lys	Gly
			20					25						30	
Lys	Asp	Ile	Lys	Gly	Val	Ser	Glu	Ile	Val	Gln	Asn	Gly	Lys	His	Phe
		35					40					45			
Lys	Phe	Thr	Ile	Thr	Ala	Gly	Ser	Lys	Val	Ile	Gln	Asn	Glu	Phe	Thr
						55						60			

-continued

---

```

Val Gly Glu Glu Cys Glu Leu Glu Thr Met Thr Gly Glu Lys Val Lys
65          70          75          80

Thr Val Val Gln Leu Glu Gly Asp Asn Lys Leu Val Thr Thr Phe Lys
      85          90          95

Asn Ile Lys Ser Val Thr Glu Leu Asn Gly Asp Ile Ile Thr Asn Thr
      100          105          110

Met Thr Leu Gly Asp Ile Val Phe Lys Arg Ile Ser Lys Arg Ile
      115          120          125

```

```

<210> SEQ ID NO 50
<211> LENGTH: 1346
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 50

```

```

Met Lys Ser Pro Arg Arg Thr Thr Leu Cys Leu Met Phe Ile Val Ile
1          5          10          15

Tyr Ser Ser Lys Ala Ala Leu Asn Trp Asn Tyr Glu Ser Thr Ile His
      20          25          30

Pro Leu Ser Leu His Glu His Glu Pro Ala Gly Glu Glu Ala Leu Arg
      35          40          45

Gln Lys Arg Ala Val Ala Thr Lys Ser Pro Thr Ala Glu Glu Tyr Thr
      50          55          60

Val Asn Ile Glu Ile Ser Phe Glu Asn Ala Ser Phe Leu Asp Pro Ile
65          70          75          80

Lys Ala Tyr Leu Asn Ser Leu Ser Phe Pro Ile His Gly Asn Asn Thr
      85          90          95

Asp Gln Ile Thr Asp Ile Leu Ser Ile Asn Val Thr Thr Val Cys Arg
      100          105          110

Pro Ala Gly Asn Glu Ile Trp Cys Ser Cys Glu Thr Gly Tyr Gly Trp
      115          120          125

Pro Arg Glu Arg Cys Leu His Asn Leu Ile Cys Gln Glu Arg Asp Val
      130          135          140

Phe Leu Pro Gly His His Cys Ser Cys Leu Lys Glu Leu Pro Pro Asn
145          150          155          160

Gly Pro Phe Cys Leu Leu Gln Glu Asp Val Thr Leu Asn Met Arg Val
      165          170          175

Arg Leu Asn Val Gly Phe Gln Glu Asp Leu Met Asn Thr Ser Ser Ala
      180          185          190

Leu Tyr Arg Ser Tyr Lys Thr Asp Leu Glu Thr Ala Phe Arg Lys Gly
      195          200          205

Tyr Gly Ile Leu Pro Gly Phe Lys Gly Val Thr Val Thr Gly Phe Lys
      210          215          220

Ser Gly Ser Val Val Val Thr Tyr Glu Val Lys Thr Thr Pro Pro Ser
225          230          235          240

Leu Glu Leu Ile His Lys Ala Asn Glu Gln Val Val Gln Ser Leu Asn
      245          250          255

Gln Thr Tyr Lys Met Asp Tyr Asn Ser Phe Gln Ala Val Thr Ile Asn
      260          265          270

Glu Ser Asn Phe Phe Val Thr Pro Glu Ile Ile Phe Glu Gly Asp Thr
      275          280          285

Val Ser Leu Val Cys Glu Lys Glu Val Leu Ser Ser Asn Val Ser Trp
      290          295          300

```

-continued

---

Arg Tyr Glu Glu Gln Gln Leu Glu Ile Gln Asn Ser Ser Arg Phe Ser  
 305 310 315 320  
 Ile Tyr Thr Ala Leu Phe Asn Asn Met Thr Ser Val Ser Lys Leu Thr  
 325 330 335  
 Ile His Asn Ile Thr Pro Gly Asp Ala Gly Glu Tyr Val Cys Lys Leu  
 340 345 350  
 Ile Leu Asp Ile Phe Glu Tyr Glu Cys Lys Lys Lys Ile Asp Val Met  
 355 360 365  
 Pro Ile Gln Ile Leu Ala Asn Glu Glu Met Lys Val Met Cys Asp Asn  
 370 375 380  
 Asn Pro Val Ser Leu Asn Cys Cys Ser Gln Gly Asn Val Asn Trp Ser  
 385 390 395 400  
 Lys Val Glu Trp Lys Gln Glu Gly Lys Ile Asn Ile Pro Gly Thr Pro  
 405 410 415  
 Glu Thr Asp Ile Asp Ser Ser Cys Ser Arg Tyr Thr Leu Lys Ala Asp  
 420 425 430  
 Gly Thr Gln Cys Pro Ser Gly Ser Ser Gly Thr Thr Val Ile Tyr Thr  
 435 440 445  
 Cys Glu Phe Ile Ser Ala Tyr Gly Ala Arg Gly Ser Ala Asn Ile Lys  
 450 455 460  
 Val Thr Phe Ile Ser Val Ala Asn Leu Thr Ile Thr Pro Asp Pro Ile  
 465 470 475 480  
 Ser Val Ser Glu Gly Gln Asn Phe Ser Ile Lys Cys Ile Ser Asp Val  
 485 490 495  
 Ser Asn Tyr Asp Glu Val Tyr Trp Asn Thr Ser Ala Gly Ile Lys Ile  
 500 505 510  
 Tyr Gln Arg Phe Tyr Thr Thr Arg Arg Tyr Leu Asp Gly Ala Glu Ser  
 515 520 525  
 Val Leu Thr Val Lys Thr Ser Thr Arg Glu Trp Asn Gly Thr Tyr His  
 530 535 540  
 Cys Ile Phe Arg Tyr Lys Asn Ser Tyr Ser Ile Ala Thr Lys Asp Val  
 545 550 555 560  
 Ile Val His Pro Leu Pro Leu Lys Leu Asn Ile Met Val Asp Pro Leu  
 565 570 575  
 Glu Ala Thr Val Ser Cys Ser Gly Ser His His Ile Lys Cys Cys Ile  
 580 585 590  
 Glu Glu Asp Gly Asp Tyr Lys Val Thr Phe His Met Gly Ser Ser Ser  
 595 600 605  
 Leu Pro Ala Ala Lys Glu Val Asn Lys Lys Gln Val Cys Tyr Lys His  
 610 615 620  
 Asn Phe Asn Ala Ser Ser Val Ser Trp Cys Ser Lys Thr Val Asp Val  
 625 630 635 640  
 Cys Cys His Phe Thr Asn Ala Ala Asn Asn Ser Val Trp Ser Pro Ser  
 645 650 655  
 Met Lys Leu Asn Leu Val Pro Gly Glu Asn Ile Thr Cys Gln Asp Pro  
 660 665 670  
 Val Ile Gly Val Gly Glu Pro Gly Lys Val Ile Gln Lys Leu Cys Arg  
 675 680 685  
 Phe Ser Asn Val Pro Ser Ser Pro Glu Ser Pro Ile Gly Gly Thr Ile  
 690 695 700

-continued

---

Thr Tyr Lys Cys Val Gly Ser Gln Trp Glu Glu Lys Arg Asn Asp Cys  
 705 710 715 720  
 Ile Ser Ala Pro Ile Asn Ser Leu Leu Gln Met Ala Lys Ala Leu Ile  
 725 730 735  
 Lys Ser Pro Ser Gln Asp Glu Met Leu Pro Thr Tyr Leu Lys Asp Leu  
 740 745 750  
 Ser Ile Ser Ile Asp Lys Ala Glu His Glu Ile Ser Ser Ser Pro Gly  
 755 760 765  
 Ser Leu Gly Ala Ile Ile Asn Ile Leu Asp Leu Leu Ser Thr Val Pro  
 770 775 780  
 Thr Gln Val Asn Ser Glu Met Met Thr His Val Leu Ser Thr Val Asn  
 785 790 795 800  
 Val Ile Leu Gly Lys Pro Val Leu Asn Thr Trp Lys Val Leu Gln Gln  
 805 810 815  
 Gln Trp Thr Asn Gln Ser Ser Gln Leu Leu His Ser Val Glu Arg Phe  
 820 825 830  
 Ser Gln Ala Leu Gln Ser Gly Asp Ser Pro Pro Leu Ser Phe Ser Gln  
 835 840 845  
 Thr Asn Val Gln Met Ser Ser Thr Val Ile Lys Ser Ser His Pro Glu  
 850 855 860  
 Thr Tyr Gln Gln Arg Phe Val Phe Pro Tyr Phe Asp Leu Trp Gly Asn  
 865 870 875 880  
 Val Val Ile Asp Lys Ser Tyr Leu Glu Asn Leu Gln Ser Asp Ser Ser  
 885 890 895  
 Ile Val Thr Met Ala Phe Pro Thr Leu Gln Ala Ile Leu Ala Gln Asp  
 900 905 910  
 Ile Gln Glu Asn Asn Phe Ala Glu Ser Leu Val Met Thr Thr Thr Val  
 915 920 925  
 Ser His Asn Thr Thr Met Pro Phe Arg Ile Ser Met Thr Phe Lys Asn  
 930 935 940  
 Asn Ser Pro Ser Gly Gly Glu Thr Lys Cys Val Phe Trp Asn Phe Arg  
 945 950 955 960  
 Leu Ala Asn Asn Thr Gly Gly Trp Asp Ser Ser Gly Cys Tyr Val Glu  
 965 970 975  
 Glu Gly Asp Gly Asp Asn Val Thr Cys Ile Cys Asp His Leu Thr Ser  
 980 985 990  
 Phe Ser Ile Leu Met Ser Pro Asp Ser Pro Asp Pro Ser Ser Leu Leu  
 995 1000 1005  
 Gly Ile Leu Leu Asp Ile Ile Ser Tyr Val Gly Val Gly Phe Ser  
 1010 1015 1020  
 Ile Leu Ser Leu Ala Ala Cys Leu Val Val Glu Ala Val Val Trp  
 1025 1030 1035  
 Lys Ser Val Thr Lys Asn Arg Thr Ser Tyr Met Arg His Thr Cys  
 1040 1045 1050  
 Ile Val Asn Ile Ala Ala Ser Leu Leu Val Ala Asn Thr Trp Phe  
 1055 1060 1065  
 Ile Val Val Ala Ala Ile Gln Asp Asn Arg Tyr Ile Leu Cys Lys  
 1070 1075 1080  
 Thr Ala Cys Val Ala Ala Thr Phe Phe Ile His Phe Phe Tyr Leu  
 1085 1090 1095  
 Ser Val Phe Phe Trp Met Leu Thr Leu Gly Leu Met Leu Phe Tyr

-continued

1100	1105	1110
Arg Leu Val Phe Ile Leu His Glu Thr Ser Arg Ser Thr Gln Lys		
1115	1120	1125
Ala Ile Ala Phe Cys Leu Gly Tyr Gly Cys Pro Leu Ala Ile Ser		
1130	1135	1140
Val Ile Thr Leu Gly Ala Thr Gln Pro Arg Glu Val Tyr Thr Arg		
1145	1150	1155
Lys Asn Val Cys Trp Leu Asn Trp Glu Asp Thr Lys Ala Leu Leu		
1160	1165	1170
Ala Phe Ala Ile Pro Ala Leu Ile Ile Val Val Val Asn Ile Thr		
1175	1180	1185
Ile Thr Ile Val Val Ile Thr Lys Ile Leu Arg Pro Ser Ile Gly		
1190	1195	1200
Asp Lys Pro Cys Lys Gln Glu Lys Ser Ser Leu Phe Gln Ile Ser		
1205	1210	1215
Lys Ser Ile Gly Val Leu Thr Pro Leu Leu Gly Leu Thr Trp Gly		
1220	1225	1230
Phe Gly Leu Thr Thr Val Phe Pro Gly Thr Asn Leu Val Phe His		
1235	1240	1245
Ile Ile Phe Ala Ile Leu Asn Val Phe Gln Gly Leu Phe Ile Leu		
1250	1255	1260
Leu Phe Gly Cys Leu Trp Asp Leu Lys Val Gln Glu Ala Leu Leu		
1265	1270	1275
Asn Lys Phe Ser Leu Ser Arg Trp Ser Ser Gln His Ser Lys Ser		
1280	1285	1290
Thr Ser Leu Gly Ser Ser Thr Pro Val Phe Ser Met Ser Ser Pro		
1295	1300	1305
Ile Ser Arg Arg Phe Asn Asn Leu Phe Gly Lys Thr Gly Thr Tyr		
1310	1315	1320
Asn Val Ser Thr Pro Glu Ala Thr Ser Ser Ser Leu Glu Asn Ser		
1325	1330	1335
Ser Ser Ala Ser Ser Leu Leu Asn		
1340	1345	

<210> SEQ ID NO 51  
 <211> LENGTH: 760  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 51

Met Lys Thr Trp Val Lys Ile Val Phe Gly Val Ala Thr Ser Ala Val											
1	5		10				15				
Leu Ala Leu Leu Val Met Cys Ile Val Leu Arg Pro Ser Arg Val His											
20			25				30				
Asn Ser Glu Glu Asn Thr Met Arg Ala Leu Thr Leu Lys Asp Ile Leu											
35			40				45				
Asn Gly Thr Phe Ser Tyr Lys Thr Phe Phe Pro Asn Trp Ile Ser Gly											
50			55				60				
Gln Glu Tyr Leu His Gln Ser Ala Asp Asn Asn Ile Val Leu Tyr Asn											
65			70				75				80
Ile Glu Thr Gly Gln Ser Tyr Thr Ile Leu Ser Asn Arg Thr Met Lys											
85			90				95				

-continued

---

Ser	Val	Asn	Ala	Ser	Asn	Tyr	Gly	Leu	Ser	Pro	Asp	Arg	Gln	Phe	Val
		100						105					110		
Tyr	Leu	Glu	Ser	Asp	Tyr	Ser	Lys	Leu	Trp	Arg	Tyr	Ser	Tyr	Thr	Ala
		115					120					125			
Thr	Tyr	Tyr	Ile	Tyr	Asp	Leu	Ser	Asn	Gly	Glu	Phe	Val	Arg	Gly	Asn
	130					135					140				
Glu	Leu	Pro	Arg	Pro	Ile	Gln	Tyr	Leu	Cys	Trp	Ser	Pro	Val	Gly	Ser
145					150					155					160
Lys	Leu	Ala	Tyr	Val	Tyr	Gln	Asn	Asn	Ile	Tyr	Leu	Lys	Gln	Arg	Pro
				165					170					175	
Gly	Asp	Pro	Pro	Phe	Gln	Ile	Thr	Phe	Asn	Gly	Arg	Glu	Asn	Lys	Ile
			180					185					190		
Phe	Asn	Gly	Ile	Pro	Asp	Trp	Val	Tyr	Glu	Glu	Glu	Met	Leu	Pro	Thr
		195					200					205			
Lys	Tyr	Ala	Leu	Trp	Trp	Ser	Pro	Asn	Gly	Lys	Phe	Leu	Ala	Tyr	Ala
	210					215					220				
Glu	Phe	Asn	Asp	Thr	Asp	Ile	Pro	Val	Ile	Ala	Tyr	Ser	Tyr	Tyr	Gly
225					230					235					240
Asp	Glu	Gln	Tyr	Pro	Arg	Thr	Ile	Asn	Ile	Pro	Tyr	Pro	Lys	Ala	Gly
				245				250						255	
Ala	Lys	Asn	Pro	Val	Val	Arg	Ile	Phe	Ile	Ile	Asp	Thr	Thr	Tyr	Pro
			260					265					270		
Ala	Tyr	Val	Gly	Pro	Gln	Glu	Val	Pro	Val	Pro	Ala	Met	Ile	Ala	Ser
		275					280					285			
Ser	Asp	Tyr	Tyr	Phe	Ser	Trp	Leu	Thr	Trp	Val	Thr	Asp	Glu	Arg	Val
	290					295					300				
Cys	Leu	Gln	Trp	Leu	Lys	Arg	Val	Gln	Asn	Val	Ser	Val	Leu	Ser	Ile
305					310					315					320
Cys	Asp	Phe	Arg	Glu	Asp	Trp	Gln	Thr	Trp	Asp	Cys	Pro	Lys	Thr	Gln
				325					330					335	
Glu	His	Ile	Glu	Glu	Ser	Arg	Thr	Gly	Trp	Ala	Gly	Gly	Phe	Phe	Val
			340					345					350		
Ser	Thr	Pro	Val	Phe	Ser	Tyr	Asp	Ala	Ile	Ser	Tyr	Tyr	Lys	Ile	Phe
		355					360					365			
Ser	Asp	Lys	Asp	Gly	Tyr	Lys	His	Ile	His	Tyr	Ile	Lys	Asp	Thr	Val
	370					375					380				
Glu	Asn	Ala	Ile	Gln	Ile	Thr	Ser	Gly	Lys	Trp	Glu	Ala	Ile	Asn	Ile
385					390					395					400
Phe	Arg	Val	Thr	Gln	Asp	Ser	Leu	Phe	Tyr	Ser	Ser	Asn	Glu	Phe	Glu
				405					410					415	
Glu	Tyr	Pro	Gly	Arg	Arg	Asn	Ile	Tyr	Arg	Ile	Ser	Ile	Gly	Ser	Tyr
			420					425					430		
Pro	Pro	Ser	Lys	Lys	Cys	Val	Thr	Cys	His	Leu	Arg	Lys	Glu	Arg	Cys
		435					440					445			
Gln	Tyr	Tyr	Thr	Ala	Ser	Phe	Ser	Asp	Tyr	Ala	Lys	Tyr	Tyr	Ala	Leu
	450					455					460				
Val	Cys	Tyr	Gly	Pro	Gly	Ile	Pro	Ile	Ser	Thr	Leu	His	Asp	Gly	Arg
465					470				475					480	
Thr	Asp	Gln	Glu	Ile	Lys	Ile	Leu	Glu	Glu	Asn	Lys	Glu	Leu	Glu	Asn
			485					490						495	
Ala	Leu	Lys	Asn	Ile	Gln	Leu	Pro	Lys	Glu	Glu	Ile	Lys	Lys	Leu	Glu



-continued

---

Asp Gly Ile Val Gln Arg Gln Ala Cys Ala Ser Phe Asn Gly Asn Cys  
 100 105 110

Cys Leu Trp Asn Thr Thr Val Glu Val Lys Ala Cys Pro Gly Gly Tyr  
 115 120 125

Tyr Val Tyr Arg Leu Thr Lys Pro Ser Val Cys Phe His Val Tyr Cys  
 130 135 140

Gly His Phe Tyr Asp Ile Cys Asp Glu Asp Cys His Gly Ser Cys Ser  
 145 150 155 160

Asp Thr Ser Glu Cys Thr Cys Ala Pro Gly Thr Val Leu Gly Pro Asp  
 165 170 175

Arg Gln Thr Cys Phe Asp Glu Asn Glu Cys Glu Gln Asn Asn Gly Gly  
 180 185 190

Cys Ser Glu Ile Cys Val Asn Leu Lys Asn Ser Tyr Arg Cys Glu Cys  
 195 200 205

Gly Val Gly Arg Val Leu Arg Ser Asp Gly Lys Thr Cys Glu Asp Val  
 210 215 220

Glu Gly Cys His Asn Asn Asn Gly Gly Cys Ser His Ser Cys Leu Gly  
 225 230 235 240

Ser Glu Lys Gly Tyr Gln Cys Glu Cys Pro Arg Gly Leu Val Leu Ser  
 245 250 255

Glu Asp Asn His Thr Cys Gln Val Pro Val Leu Cys Lys Ser Asn Ala  
 260 265 270

Ile Glu Val Asn Ile Pro Arg Glu Leu Val Gly Gly Leu Glu Leu Phe  
 275 280 285

Leu Thr Asn Thr Ser Cys Arg Gly Val Ser Asn Gly Thr His Val Asn  
 290 295 300

Ile Leu Phe Ser Leu Lys Thr Cys Gly Thr Val Val Asp Val Val Asn  
 305 310 315 320

Asp Lys Ile Val Ala Ser Asn Leu Val Thr Gly Leu Pro Lys Gln Thr  
 325 330 335

Pro Gly Ser Ser Gly Asp Phe Ile Ile Arg Thr Ser Lys Leu Leu Ile  
 340 345 350

Pro Val Thr Cys Glu Phe Pro Arg Leu Tyr Thr Ile Ser Glu Gly Tyr  
 355 360 365

Val Pro Asn Leu Arg Asn Ser Pro Leu Glu Ile Met Ser Arg Asn His  
 370 375 380

Gly Ile Phe Pro Phe Thr Leu Glu Ile Phe Lys Asp Asn Glu Phe Glu  
 385 390 395 400

Glu Pro Tyr Arg Glu Ala Leu Pro Thr Leu Lys Leu Arg Asp Ser Leu  
 405 410 415

Tyr Phe Gly Ile Glu Pro Val Val His Val Ser Gly Leu Glu Ser Leu  
 420 425 430

Val Glu Ser Cys Phe Ala Thr Pro Thr Ser Lys Ile Asp Glu Val Leu  
 435 440 445

Lys Tyr Tyr Leu Ile Arg Asp Gly Cys Val Ser Asp Asp Ser Val Lys  
 450 455 460

Gln Tyr Thr Ser Arg Asp His Leu Ala Lys His Phe Gln Val Pro Val  
 465 470 475 480

Phe Lys Phe Val Gly Lys Asp His Lys Glu Val Phe Leu His Cys Arg  
 485 490 495

Val Leu Val Cys Gly Val Leu Asp Glu Arg Ser Arg Cys Ala Gln Gly

-continued

---

```

          500          505          510
Cys His Arg Arg Met Arg Arg Gly Ala Gly Gly Glu Asp Ser Ala Gly
   515          520          525

Leu Gln Gly Gln Thr Leu Thr Gly Gly Pro Ile Arg Ile Asp Trp Glu
   530          535          540

Asp
545

<210> SEQ ID NO 53
<211> LENGTH: 999
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 53

Met Ala Asp Lys Val Arg Arg Gln Arg Pro Arg Arg Arg Val Cys Trp
 1          5          10          15

Ala Leu Val Ala Val Leu Leu Ala Asp Leu Leu Ala Leu Ser Asp Thr
 20          25          30

Leu Ala Val Met Ser Val Asp Leu Gly Ser Glu Ser Met Lys Val Ala
 35          40          45

Ile Val Lys Pro Gly Val Pro Met Glu Ile Val Leu Asn Lys Glu Ser
 50          55          60

Arg Arg Lys Thr Pro Val Ile Val Thr Leu Lys Glu Asn Glu Arg Phe
 65          70          75          80

Phe Gly Asp Ser Ala Ala Ser Met Ala Ile Lys Asn Pro Lys Ala Thr
 85          90          95

Leu Arg Tyr Phe Gln His Leu Leu Gly Lys Gln Ala Asp Asn Pro His
 100         105         110

Val Ala Leu Tyr Gln Ala Arg Phe Pro Glu His Glu Leu Thr Phe Asp
 115         120         125

Pro Gln Arg Gln Thr Val His Phe Gln Ile Ser Ser Gln Leu Gln Phe
 130         135         140

Ser Pro Glu Glu Val Leu Gly Met Val Leu Asn Tyr Ser Arg Ser Leu
 145         150         155         160

Ala Glu Asp Phe Ala Glu Gln Pro Ile Lys Asp Ala Val Ile Thr Val
 165         170         175

Pro Val Phe Phe Asn Gln Ala Glu Arg Arg Ala Val Leu Gln Ala Ala
 180         185         190

Arg Met Ala Gly Leu Lys Val Leu Gln Leu Ile Asn Asp Asn Thr Ala
 195         200         205

Thr Ala Leu Ser Tyr Gly Val Phe Arg Arg Lys Asp Ile Asn Thr Thr
 210         215         220

Ala Gln Asn Ile Met Phe Tyr Asp Met Gly Ser Gly Ser Thr Val Cys
 225         230         235         240

Thr Ile Val Thr Tyr Gln Met Val Lys Thr Lys Glu Ala Gly Met Gln
 245         250         255

Pro Gln Leu Gln Ile Arg Gly Val Gly Phe Asp Arg Thr Leu Gly Gly
 260         265         270

Leu Glu Met Glu Leu Arg Leu Arg Glu Arg Leu Ala Gly Leu Phe Asn
 275         280         285

Glu Gln Arg Lys Gly Gln Arg Ala Lys Asp Val Arg Glu Asn Pro Arg
 290         295         300

```

-continued

---

Ala Met Ala Lys Leu Leu Arg Glu Ala Asn Arg Leu Lys Thr Val Leu  
305 310 315 320

Ser Ala Asn Ala Asp His Met Ala Gln Ile Glu Gly Leu Met Asp Asp  
325 330 335

Val Asp Phe Lys Ala Lys Val Thr Arg Val Glu Phe Glu Glu Leu Cys  
340 345 350

Ala Asp Leu Phe Glu Arg Val Pro Gly Pro Val Gln Gln Ala Leu Gln  
355 360 365

Ser Ala Glu Met Ser Leu Asp Glu Ile Glu Gln Val Ile Leu Val Gly  
370 375 380

Gly Ala Thr Arg Val Pro Arg Val Gln Glu Val Leu Leu Lys Ala Val  
385 390 395 400

Gly Lys Glu Glu Leu Gly Lys Asn Ile Asn Ala Asp Glu Ala Ala Ala  
405 410 415

Met Gly Ala Val Tyr Gln Ala Ala Ala Leu Ser Lys Ala Phe Lys Val  
420 425 430

Lys Pro Phe Val Val Arg Asp Ala Val Val Tyr Pro Ile Leu Val Glu  
435 440 445

Phe Thr Arg Glu Val Glu Glu Glu Pro Gly Ile His Ser Leu Lys His  
450 455 460

Asn Lys Arg Val Leu Phe Ser Arg Met Gly Pro Tyr Pro Gln Arg Lys  
465 470 475 480

Val Ile Thr Phe Asn Arg Tyr Ser His Asp Phe Asn Phe His Ile Asn  
485 490 495

Tyr Gly Asp Leu Gly Phe Leu Gly Pro Glu Asp Leu Arg Val Phe Gly  
500 505 510

Ser Gln Asn Leu Thr Thr Val Lys Leu Lys Gly Val Gly Asp Ser Phe  
515 520 525

Lys Lys Tyr Pro Asp Tyr Glu Ser Lys Gly Ile Lys Ala His Phe Asn  
530 535 540

Leu Asp Glu Ser Gly Val Leu Ser Leu Asp Arg Val Glu Ser Val Phe  
545 550 555 560

Glu Thr Leu Val Glu Asp Ser Ala Glu Glu Glu Ser Thr Leu Thr Lys  
565 570 575

Leu Gly Asn Thr Ile Ser Ser Leu Phe Gly Gly Gly Thr Thr Pro Asp  
580 585 590

Ala Lys Glu Asn Gly Thr Asp Thr Val Gln Glu Glu Glu Glu Ser Pro  
595 600 605

Ala Glu Gly Ser Lys Asp Glu Pro Gly Glu Gln Val Glu Leu Lys Glu  
610 615 620

Glu Ala Glu Ala Pro Val Glu Asp Gly Ser Gln Pro Pro Pro Pro Glu  
625 630 635 640

Pro Lys Gly Asp Ala Thr Pro Glu Gly Glu Lys Ala Thr Glu Lys Glu  
645 650 655

Asn Gly Asp Lys Ser Glu Ala Gln Lys Pro Ser Glu Lys Ala Glu Ala  
660 665 670

Gly Pro Glu Gly Val Ala Pro Ala Pro Glu Gly Glu Lys Lys Gln Lys  
675 680 685

Pro Ala Arg Lys Arg Arg Met Val Glu Glu Ile Gly Val Glu Leu Val  
690 695 700

Val Leu Asp Leu Pro Asp Leu Pro Glu Asp Lys Leu Ala Gln Ser Val

-continued

705		710				715				720					
Gln	Lys	Leu	Gln	Asp	Leu	Thr	Leu	Arg	Asp	Leu	Glu	Lys	Gln	Glu	Arg
				725					730					735	
Glu	Lys	Ala	Ala	Asn	Ser	Leu	Glu	Ala	Phe	Ile	Phe	Glu	Thr	Gln	Asp
			740					745					750		
Lys	Leu	Tyr	Gln	Pro	Glu	Tyr	Gln	Glu	Val	Ser	Thr	Glu	Glu	Gln	Arg
		755					760					765			
Glu	Glu	Ile	Ser	Gly	Lys	Leu	Ser	Ala	Ala	Ser	Thr	Trp	Leu	Glu	Asp
	770					775						780			
Glu	Gly	Val	Gly	Ala	Thr	Thr	Val	Met	Leu	Lys	Glu	Lys	Leu	Ala	Glu
	785					790					795				800
Leu	Arg	Lys	Leu	Cys	Gln	Gly	Leu	Phe	Phe	Arg	Val	Glu	Glu	Arg	Lys
				805					810					815	
Lys	Trp	Pro	Glu	Arg	Leu	Ser	Ala	Leu	Asp	Asn	Leu	Leu	Asn	His	Ser
			820						825				830		
Ser	Met	Phe	Leu	Lys	Gly	Ala	Arg	Leu	Ile	Pro	Glu	Met	Asp	Gln	Ile
		835					840					845			
Phe	Thr	Glu	Val	Glu	Met	Thr	Thr	Leu	Glu	Lys	Val	Ile	Asn	Glu	Thr
	850					855					860				
Trp	Ala	Trp	Lys	Asn	Ala	Thr	Leu	Ala	Glu	Gln	Ala	Lys	Leu	Pro	Ala
	865				870					875					880
Thr	Glu	Lys	Pro	Val	Leu	Leu	Ser	Lys	Asp	Ile	Glu	Ala	Lys	Met	Met
				885					890					895	
Ala	Leu	Asp	Arg	Glu	Val	Gln	Tyr	Leu	Leu	Asn	Lys	Ala	Lys	Phe	Thr
			900					905					910		
Lys	Pro	Arg	Pro	Arg	Pro	Lys	Asp	Lys	Asn	Gly	Thr	Arg	Ala	Glu	Pro
		915					920					925			
Pro	Leu	Asn	Ala	Ser	Ala	Ser	Asp	Gln	Gly	Glu	Lys	Val	Ile	Pro	Pro
	930					935					940				
Ala	Gly	Gln	Thr	Glu	Asp	Ala	Glu	Pro	Ile	Ser	Glu	Pro	Glu	Lys	Val
	945				950					955					960
Glu	Thr	Gly	Ser	Glu	Pro	Gly	Asp	Thr	Glu	Pro	Leu	Glu	Leu	Gly	Gly
				965					970					975	
Pro	Gly	Ala	Glu	Pro	Glu	Gln	Lys	Glu	Gln	Ser	Thr	Gly	Gln	Lys	Arg
			980					985					990		
Pro	Leu	Lys	Asn	Asp	Glu	Leu									
	995														

&lt;210&gt; SEQ ID NO 54

&lt;211&gt; LENGTH: 480

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 54

Met	Arg	Phe	Val	Val	Ala	Leu	Val	Leu	Leu	Asn	Val	Ala	Ala	Ala	Gly
1				5					10					15	
Ala	Val	Pro	Leu	Leu	Ala	Thr	Glu	Ser	Val	Lys	Gln	Glu	Glu	Ala	Gly
			20					25					30		
Val	Arg	Pro	Ser	Ala	Gly	Asn	Val	Ser	Thr	His	Pro	Ser	Leu	Ser	Gln
			35				40					45			
Arg	Pro	Gly	Gly	Ser	Thr	Lys	Ser	His	Pro	Glu	Pro	Gln	Thr	Pro	Lys
			50			55						60			

-continued

Asp	Ser	Pro	Ser	Lys	Ser	Ser	Ala	Glu	Ala	Gln	Thr	Pro	Glu	Asp	Thr	65	70	75	80
Pro	Asn	Lys	Ser	Gly	Ala	Glu	Ala	Lys	Thr	Gln	Lys	Asp	Ser	Ser	Asn	85	90	95	
Lys	Ser	Gly	Ala	Glu	Ala	Lys	Thr	Gln	Lys	Gly	Ser	Thr	Ser	Lys	Ser	100	105	110	
Gly	Ser	Glu	Ala	Gln	Thr	Thr	Lys	Asp	Ser	Thr	Ser	Lys	Ser	His	Pro	115	120	125	
Glu	Leu	Gln	Thr	Pro	Lys	Asp	Ser	Thr	Gly	Lys	Ser	Gly	Ala	Glu	Ala	130	135	140	
Gln	Thr	Pro	Glu	Asp	Ser	Pro	Asn	Arg	Ser	Gly	Ala	Glu	Ala	Lys	Thr	145	150	155	160
Gln	Lys	Asp	Ser	Pro	Ser	Lys	Ser	Gly	Ser	Glu	Ala	Gln	Thr	Thr	Lys	165	170	175	
Asp	Val	Pro	Asn	Lys	Ser	Gly	Ala	Asp	Gly	Gln	Thr	Pro	Lys	Asp	Gly	180	185	190	
Ser	Ser	Lys	Ser	Gly	Ala	Glu	Asp	Gln	Thr	Pro	Lys	Asp	Val	Pro	Asn	195	200	205	
Lys	Ser	Gly	Ala	Glu	Lys	Gln	Thr	Pro	Lys	Asp	Gly	Ser	Asn	Lys	Ser	210	215	220	
Gly	Ala	Glu	Glu	Gln	Gly	Pro	Ile	Asp	Gly	Pro	Ser	Lys	Ser	Gly	Ala	225	230	235	240
Glu	Glu	Gln	Thr	Ser	Lys	Asp	Ser	Pro	Asn	Lys	Val	Val	Pro	Glu	Gln	245	250	255	
Pro	Ser	Arg	Lys	Asp	His	Ser	Lys	Pro	Ile	Ser	Asn	Pro	Ser	Asp	Asn	260	265	270	
Lys	Glu	Leu	Pro	Lys	Ala	Asp	Thr	Asn	Gln	Leu	Ala	Asp	Lys	Gly	Lys	275	280	285	
Leu	Ser	Pro	His	Ala	Phe	Lys	Thr	Glu	Ser	Gly	Glu	Glu	Thr	Asp	Leu	290	295	300	
Ile	Ser	Pro	Pro	Gln	Glu	Glu	Val	Lys	Ser	Ser	Glu	Pro	Thr	Glu	Asp	305	310	315	320
Val	Glu	Pro	Lys	Glu	Ala	Glu	Asp	Asp	Asp	Thr	Gly	Pro	Glu	Glu	Gly	325	330	335	
Ser	Pro	Pro	Lys	Glu	Glu	Lys	Glu	Lys	Met	Ser	Gly	Ser	Ala	Ser	Ser	340	345	350	
Glu	Asn	Arg	Glu	Gly	Thr	Leu	Ser	Asp	Ser	Thr	Gly	Ser	Glu	Lys	Asp	355	360	365	
Asp	Leu	Tyr	Pro	Asn	Gly	Ser	Gly	Asn	Gly	Ser	Ala	Glu	Ser	Ser	His	370	375	380	
Phe	Phe	Ala	Tyr	Leu	Val	Thr	Ala	Ala	Ile	Leu	Val	Ala	Val	Leu	Tyr	385	390	395	400
Ile	Ala	His	His	Asn	Lys	Arg	Lys	Ile	Ile	Ala	Phe	Val	Leu	Glu	Gly	405	410	415	
Lys	Arg	Ser	Lys	Val	Thr	Arg	Arg	Pro	Lys	Ala	Ser	Asp	Tyr	Gln	Arg	420	425	430	
Leu	Asp	Gln	Lys	Tyr	Val	Leu	Ile	Leu	Asn	Val	Phe	Pro	Ala	Pro	Pro	435	440	445	
Lys	Arg	Ser	Phe	Leu	Pro	Gln	Val	Leu	Thr	Glu	Trp	Tyr	Ile	Pro	Leu	450	455	460	
Glu	Lys	Asp	Glu	Arg	His	Gln	Trp	Ile	Val	Leu	Leu	Ser	Phe	Gln	Leu				



-continued

---

```

Lys Glu His Pro Asp Arg Phe Ile Glu Cys Tyr Ile Ala Glu Gln Asn
  355                               360                365

Met Val Ser Ile Ala Val Gly Cys Ala Thr Arg Asn Arg Thr Val Pro
  370                               375                380

Phe Cys Ser Thr Phe Ala Ala Phe Phe Thr Arg Ala Phe Asp Gln Ile
  385                               390                395                400

Arg Met Ala Ala Ile Ser Glu Ser Asn Ile Asn Leu Cys Gly Ser His
  405                               410                415

Cys Gly Val Ser Ile Gly Glu Asp Gly Pro Ser Gln Met Ala Leu Glu
  420                               425                430

Asp Leu Ala Met Phe Arg Ser Val Pro Thr Ser Thr Val Phe Tyr Pro
  435                               440                445

Ser Asp Gly Val Ala Thr Glu Lys Ala Val Glu Leu Ala Ala Asn Thr
  450                               455                460

Lys Gly Ile Cys Phe Ile Arg Thr Ser Arg Pro Glu Asn Ala Ile Ile
  465                               470                475                480

Tyr Asn Asn Asn Glu Asp Phe Gln Val Gly Gln Ala Lys Val Val Leu
  485                               490                495

Lys Ser Lys Asp Asp Gln Val Thr Val Ile Gly Ala Gly Val Thr Leu
  500                               505                510

His Glu Ala Leu Ala Ala Ala Glu Leu Leu Lys Lys Glu Lys Ile Asn
  515                               520                525

Ile Arg Val Leu Asp Pro Phe Thr Ile Lys Pro Leu Asp Arg Lys Leu
  530                               535                540

Ile Leu Asp Ser Ala Arg Ala Thr Lys Gly Arg Ile Leu Thr Val Glu
  545                               550                555                560

Asp His Tyr Tyr Glu Gly Gly Ile Gly Glu Ala Val Ser Ser Ala Val
  565                               570                575

Val Gly Glu Pro Gly Ile Thr Val Thr His Leu Ala Val Asn Arg Val
  580                               585                590

Pro Arg Ser Gly Lys Pro Ala Glu Leu Leu Lys Met Phe Gly Ile Asp
  595                               600                605

Arg Asp Ala Ile Ala Gln Ala Val Arg Gly Leu Ile Thr Lys Ala
  610                               615                620

```

```

<210> SEQ ID NO 56
<211> LENGTH: 1897
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 56

```

```

Met Val Pro Leu Val Pro Ala Leu Val Met Leu Gly Leu Val Ala Gly
  1                               5                10                15

Ala His Gly Asp Ser Lys Pro Val Phe Ile Lys Val Pro Glu Asp Gln
  20                               25                30

Thr Gly Leu Ser Gly Gly Val Ala Ser Phe Val Cys Gln Ala Thr Gly
  35                               40                45

Glu Pro Lys Pro Arg Ile Thr Trp Met Lys Lys Gly Lys Lys Val Ser
  50                               55                60

Ser Gln Arg Phe Glu Val Ile Glu Phe Asp Asp Gly Ala Gly Ser Val
  65                               70                75                80

Leu Arg Ile Gln Pro Leu Arg Val Gln Arg Asp Glu Ala Ile Tyr Glu
  85                               90                95

```

-continued

---

Cys Thr Ala Thr Asn Ser Leu Gly Glu Ile Asn Thr Ser Ala Lys Leu  
 100 105 110  
 Ser Val Leu Glu Glu Gln Leu Pro Pro Gly Phe Pro Ser Ile Asp  
 115 120 125  
 Met Gly Pro Gln Leu Lys Val Val Glu Lys Ala Arg Thr Ala Thr Met  
 130 135 140  
 Leu Cys Ala Ala Gly Gly Asn Pro Asp Pro Glu Ile Ser Trp Phe Lys  
 145 150 155 160  
 Asp Phe Leu Pro Val Asp Pro Ala Thr Ser Asn Gly Arg Ile Lys Gln  
 165 170 175  
 Leu Arg Ser Gly Ala Leu Gln Ile Glu Ser Ser Glu Glu Ser Asp Gln  
 180 185 190  
 Gly Lys Tyr Glu Cys Val Ala Thr Asn Ser Ala Gly Thr Arg Tyr Ser  
 195 200 205  
 Ala Pro Ala Asn Leu Tyr Val Arg Val Arg Arg Val Ala Pro Arg Phe  
 210 215 220  
 Ser Ile Pro Pro Ser Ser Gln Glu Val Met Pro Gly Gly Ser Val Asn  
 225 230 235 240  
 Leu Thr Cys Val Ala Val Gly Ala Pro Met Pro Tyr Val Lys Trp Met  
 245 250 255  
 Met Gly Ala Glu Glu Leu Thr Lys Glu Asp Glu Met Pro Val Gly Arg  
 260 265 270  
 Asn Val Leu Glu Leu Ser Asn Val Val Arg Ser Ala Asn Tyr Thr Cys  
 275 280 285  
 Val Ala Ile Ser Ser Leu Gly Met Ile Glu Ala Thr Ala Gln Val Thr  
 290 295 300  
 Val Lys Ala Leu Pro Lys Pro Pro Ile Asp Leu Val Val Thr Glu Thr  
 305 310 315 320  
 Thr Ala Thr Ser Val Thr Leu Thr Trp Asp Ser Gly Asn Ser Glu Pro  
 325 330 335  
 Val Thr Tyr Tyr Gly Ile Gln Tyr Arg Ala Ala Gly Thr Glu Gly Pro  
 340 345 350  
 Phe Gln Glu Val Asp Gly Val Ala Thr Thr Arg Tyr Ser Ile Gly Gly  
 355 360 365  
 Leu Ser Pro Phe Ser Glu Tyr Ala Phe Arg Val Leu Ala Val Asn Ser  
 370 375 380  
 Ile Gly Arg Gly Pro Pro Ser Glu Ala Val Arg Ala Arg Thr Gly Glu  
 385 390 395 400  
 Gln Ala Pro Ser Ser Pro Pro Arg Arg Val Gln Ala Arg Met Leu Ser  
 405 410 415  
 Ala Ser Thr Met Leu Val Gln Trp Glu Pro Pro Glu Glu Pro Asn Gly  
 420 425 430  
 Leu Val Arg Gly Tyr Arg Val Tyr Tyr Thr Pro Asp Ser Arg Arg Pro  
 435 440 445  
 Pro Asn Ala Trp His Lys His Asn Thr Asp Ala Gly Leu Leu Thr Thr  
 450 455 460  
 Val Gly Ser Leu Leu Pro Gly Ile Thr Tyr Ser Leu Arg Val Leu Ala  
 465 470 475 480  
 Phe Thr Ala Val Gly Asp Gly Pro Pro Ser Pro Thr Ile Gln Val Lys  
 485 490 495

-continued

---

Thr Gln Gln Gly Val Pro Ala Gln Pro Ala Asp Phe Gln Ala Glu Val  
 500 505 510

Glu Ser Asp Thr Arg Ile Gln Leu Ser Trp Leu Leu Pro Pro Gln Glu  
 515 520 525

Arg Ile Ile Met Tyr Glu Leu Val Tyr Trp Ala Ala Glu Asp Glu Asp  
 530 535 540

Gln Gln His Lys Val Thr Phe Asp Pro Thr Ser Ser Tyr Thr Leu Glu  
 545 550 555 560

Asp Leu Lys Pro Asp Thr Leu Tyr Arg Phe Gln Leu Ala Ala Arg Ser  
 565 570 575

Asp Met Gly Val Gly Val Phe Thr Pro Thr Ile Glu Ala Arg Thr Ala  
 580 585 590

Gln Ser Thr Pro Ser Ala Pro Pro Gln Lys Val Met Cys Val Ser Met  
 595 600 605

Gly Ser Thr Thr Val Arg Val Ser Trp Val Pro Pro Pro Ala Asp Ser  
 610 615 620

Arg Asn Gly Val Ile Thr Gln Tyr Ser Val Ala His Glu Ala Val Asp  
 625 630 635 640

Gly Glu Asp Arg Gly Arg His Val Val Asp Gly Ile Ser Arg Glu His  
 645 650 655

Ser Ser Trp Asp Leu Val Gly Leu Glu Lys Trp Thr Glu Tyr Arg Val  
 660 665 670

Trp Val Arg Ala His Thr Asp Val Gly Pro Gly Pro Glu Ser Ser Pro  
 675 680 685

Val Leu Val Arg Thr Asp Glu Asp Val Pro Ser Gly Pro Pro Arg Lys  
 690 695 700

Val Glu Val Glu Pro Leu Asn Ser Thr Ala Val His Val Tyr Trp Lys  
 705 710 715 720

Leu Pro Val Pro Ser Lys Gln His Gly Gln Ile Arg Gly Tyr Gln Val  
 725 730 735

Thr Tyr Val Arg Leu Glu Asn Gly Glu Pro Arg Gly Leu Pro Ile Ile  
 740 745 750

Gln Asp Val Met Leu Ala Glu Ala Gln Trp Arg Pro Glu Glu Ser Glu  
 755 760 765

Asp Tyr Glu Thr Thr Ile Ser Gly Leu Thr Pro Glu Thr Thr Tyr Ser  
 770 775 780

Val Thr Val Ala Ala Tyr Thr Thr Lys Gly Asp Gly Ala Arg Ser Lys  
 785 790 795 800

Pro Lys Ile Val Thr Thr Thr Gly Ala Val Pro Gly Arg Pro Thr Met  
 805 810 815

Met Ile Ser Thr Thr Ala Met Asn Thr Ala Leu Leu Gln Trp His Pro  
 820 825 830

Pro Lys Glu Leu Pro Gly Glu Leu Leu Gly Tyr Arg Leu Gln Tyr Cys  
 835 840 845

Arg Ala Asp Glu Ala Arg Pro Asn Thr Ile Asp Phe Gly Lys Asp Asp  
 850 855 860

Gln His Phe Thr Val Thr Gly Leu His Lys Gly Thr Thr Tyr Ile Phe  
 865 870 875 880

Arg Leu Ala Ala Lys Asn Arg Ala Gly Leu Gly Glu Glu Phe Glu Lys  
 885 890 895

Glu Ile Arg Thr Pro Glu Asp Leu Pro Ser Gly Phe Pro Gln Asn Leu

-continued

900					905					910					
His	Val	Thr	Gly	Leu	Thr	Thr	Ser	Thr	Thr	Glu	Leu	Ala	Trp	Asp	Pro
	915						920					925			
Pro	Val	Leu	Ala	Glu	Arg	Asn	Gly	Arg	Ile	Ile	Ser	Tyr	Thr	Val	Val
	930					935					940				
Phe	Arg	Asp	Ile	Asn	Ser	Gln	Gln	Glu	Leu	Gln	Asn	Ile	Thr	Thr	Asp
	945					950					955				960
Thr	Arg	Phe	Thr	Leu	Thr	Gly	Leu	Lys	Pro	Asp	Thr	Thr	Tyr	Asp	Ile
				965							970				975
Lys	Val	Arg	Ala	Trp	Thr	Ser	Lys	Gly	Ser	Gly	Pro	Leu	Ser	Pro	Ser
			980					985					990		
Ile	Gln	Ser	Arg	Thr	Met	Pro	Val	Glu	Gln	Val	Phe	Ala	Lys	Asn	Phe
			995				1000					1005			
Arg	Val	Ala	Ala	Ala	Met	Lys	Thr	Ser	Val	Leu	Leu	Ser	Trp	Glu	
	1010					1015					1020				
Val	Pro	Asp	Ser	Tyr	Lys	Ser	Ala	Val	Pro	Phe	Lys	Ile	Leu	Tyr	
	1025					1030					1035				
Asn	Gly	Gln	Ser	Val	Glu	Val	Asp	Gly	His	Ser	Met	Arg	Lys	Leu	
	1040					1045					1050				
Ile	Ala	Asp	Leu	Gln	Pro	Asn	Thr	Glu	Tyr	Ser	Phe	Val	Leu	Met	
	1055					1060					1065				
Asn	Arg	Gly	Ser	Ser	Ala	Gly	Gly	Leu	Gln	His	Leu	Val	Ser	Ile	
	1070					1075					1080				
Arg	Thr	Ala	Pro	Asp	Leu	Leu	Pro	His	Lys	Pro	Leu	Pro	Ala	Ser	
	1085					1090					1095				
Ala	Tyr	Ile	Glu	Asp	Gly	Arg	Phe	Asp	Leu	Ser	Met	Pro	His	Val	
	1100					1105					1110				
Gln	Asp	Pro	Ser	Leu	Val	Arg	Trp	Phe	Tyr	Ile	Val	Val	Val	Pro	
	1115					1120					1125				
Ile	Asp	Arg	Val	Gly	Gly	Ser	Met	Leu	Thr	Pro	Arg	Trp	Ser	Thr	
	1130					1135					1140				
Pro	Glu	Glu	Leu	Glu	Leu	Asp	Glu	Leu	Leu	Glu	Ala	Ile	Glu	Gln	
	1145					1150					1155				
Gly	Gly	Glu	Glu	Gln	Arg	Arg	Arg	Arg	Arg	Gln	Ala	Glu	Arg	Leu	
	1160					1165					1170				
Lys	Pro	Tyr	Val	Ala	Ala	Gln	Leu	Asp	Val	Leu	Pro	Glu	Thr	Phe	
	1175					1180					1185				
Thr	Leu	Gly	Asp	Lys	Lys	Asn	Tyr	Arg	Gly	Phe	Tyr	Asn	Arg	Pro	
	1190					1195					1200				
Leu	Ser	Pro	Asp	Leu	Ser	Tyr	Gln	Cys	Phe	Val	Leu	Ala	Ser	Leu	
	1205					1210					1215				
Lys	Glu	Pro	Met	Asp	Gln	Lys	Arg	Tyr	Ala	Ser	Ser	Pro	Tyr	Ser	
	1220					1225					1230				
Asp	Glu	Ile	Val	Val	Gln	Val	Thr	Pro	Ala	Gln	Gln	Gln	Glu	Glu	
	1235					1240					1245				
Pro	Glu	Met	Leu	Trp	Val	Thr	Gly	Pro	Val	Leu	Ala	Val	Ile	Leu	
	1250					1255					1260				
Ile	Ile	Leu	Ile	Val	Ile	Ala	Ile	Leu	Leu	Phe	Lys	Arg	Lys	Arg	
	1265					1270					1275				
Thr	His	Ser	Pro	Ser	Ser	Lys	Asp	Glu	Gln	Ser	Ile	Gly	Leu	Lys	
	1280					1285					1290				

-continued

---

Asp Ser	Leu Leu Ala His	Ser	Ser Asp Pro Val Glu	Met Arg Arg
1295		1300		1305
Leu Asn	Tyr Gln Thr Pro	Gly	Met Arg Asp His Pro	Pro Ile Pro
1310		1315		1320
Ile Thr	Asp Leu Ala Asp	Asn	Ile Glu Arg Leu Lys	Ala Asn Asp
1325		1330		1335
Gly Leu	Lys Phe Ser Gln	Glu	Tyr Glu Ser Ile Asp	Pro Gly Gln
1340		1345		1350
Gln Phe	Thr Trp Glu Asn	Ser	Asn Leu Glu Val Asn	Lys Pro Lys
1355		1360		1365
Asn Arg	Tyr Ala Asn Val	Ile	Ala Tyr Asp His Ser	Arg Val Ile
1370		1375		1380
Leu Thr	Ser Ile Asp Gly	Val	Pro Gly Ser Asp Tyr	Ile Asn Ala
1385		1390		1395
Asn Tyr	Ile Asp Gly Tyr	Arg	Lys Gln Asn Ala Tyr	Ile Ala Thr
1400		1405		1410
Gln Gly	Pro Leu Pro Glu	Thr	Met Gly Asp Phe Trp	Arg Met Val
1415		1420		1425
Trp Glu	Gln Arg Thr Ala	Thr	Val Val Met Met Thr	Arg Leu Glu
1430		1435		1440
Glu Lys	Ser Arg Val Lys	Cys	Asp Gln Tyr Trp Pro	Ala Arg Gly
1445		1450		1455
Thr Glu	Thr Cys Gly Leu	Ile	Gln Val Thr Leu Leu	Asp Thr Val
1460		1465		1470
Glu Leu	Ala Thr Tyr Thr	Val	Arg Thr Phe Ala Leu	His Lys Ser
1475		1480		1485
Gly Ser	Ser Glu Lys Arg	Glu	Leu Arg Gln Phe Gln	Phe Met Ala
1490		1495		1500
Trp Pro	Asp His Gly Val	Pro	Glu Tyr Pro Thr Pro	Ile Leu Ala
1505		1510		1515
Phe Leu	Arg Arg Val Lys	Ala	Cys Asn Pro Leu Asp	Ala Gly Pro
1520		1525		1530
Met Val	Val His Cys Ser	Ala	Gly Val Gly Arg Thr	Gly Cys Phe
1535		1540		1545
Ile Val	Ile Asp Ala Met	Leu	Glu Arg Met Lys His	Glu Lys Thr
1550		1555		1560
Val Asp	Ile Tyr Gly His	Val	Thr Cys Met Arg Ser	Gln Arg Asn
1565		1570		1575
Tyr Met	Val Gln Thr Glu	Asp	Gln Tyr Val Phe Ile	His Glu Ala
1580		1585		1590
Leu Leu	Glu Ala Ala Thr	Cys	Gly His Thr Glu Val	Pro Ala Arg
1595		1600		1605
Asn Leu	Tyr Ala His Ile	Gln	Lys Leu Gly Gln Val	Pro Pro Gly
1610		1615		1620
Glu Ser	Val Thr Ala Met	Glu	Leu Glu Phe Lys Leu	Leu Ala Ser
1625		1630		1635
Ser Lys	Ala His Thr Ser	Arg	Phe Ile Ser Ala Asn	Leu Pro Cys
1640		1645		1650
Asn Lys	Phe Lys Asn Arg	Leu	Val Asn Ile Met Pro	Tyr Glu Leu
1655		1660		1665

-continued

Thr Arg Val Cys Leu Gln Pro Ile Arg Gly Val Glu Gly Ser Asp  
 1670 1675 1680  
 Tyr Ile Asn Ala Ser Phe Leu Asp Gly Tyr Arg Gln Gln Lys Ala  
 1685 1690 1695  
 Tyr Ile Ala Thr Gln Gly Pro Leu Ala Glu Ser Thr Glu Asp Phe  
 1700 1705 1710  
 Trp Arg Met Leu Trp Glu His Asn Ser Thr Ile Ile Val Met Leu  
 1715 1720 1725  
 Thr Lys Leu Arg Glu Met Gly Arg Glu Lys Cys His Gln Tyr Trp  
 1730 1735 1740  
 Pro Ala Glu Arg Ser Ala Arg Tyr Gln Tyr Phe Val Val Asp Pro  
 1745 1750 1755  
 Met Ala Glu Tyr Asn Met Pro Gln Tyr Ile Leu Arg Glu Phe Lys  
 1760 1765 1770  
 Val Thr Asp Ala Arg Asp Gly Gln Ser Arg Thr Ile Arg Gln Phe  
 1775 1780 1785  
 Gln Phe Thr Asp Trp Pro Glu Gln Gly Val Pro Lys Thr Gly Glu  
 1790 1795 1800  
 Gly Phe Ile Asp Phe Ile Gly Gln Val His Lys Thr Lys Glu Gln  
 1805 1810 1815  
 Phe Gly Gln Asp Gly Pro Ile Thr Val His Cys Ser Ala Gly Val  
 1820 1825 1830  
 Gly Arg Thr Gly Val Phe Ile Thr Leu Ser Ile Val Leu Glu Arg  
 1835 1840 1845  
 Met Arg Tyr Glu Gly Val Val Asp Met Phe Gln Thr Val Lys Thr  
 1850 1855 1860  
 Leu Arg Thr Gln Arg Pro Ala Met Val Gln Thr Glu Asp Gln Tyr  
 1865 1870 1875  
 Gln Leu Cys Tyr Arg Ala Ala Leu Glu Tyr Leu Gly Ser Phe Asp  
 1880 1885 1890  
 His Tyr Ala Thr  
 1895

&lt;210&gt; SEQ ID NO 57

&lt;211&gt; LENGTH: 532

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 57

Met Ala Pro Ser Ser Pro Arg Pro Ala Leu Pro Ala Leu Leu Val Leu  
 1 5 10 15  
 Leu Gly Ala Leu Phe Pro Gly Pro Gly Asn Ala Gln Thr Ser Val Ser  
 20 25 30  
 Pro Ser Lys Val Ile Leu Pro Arg Gly Gly Ser Val Leu Val Thr Cys  
 35 40 45  
 Ser Thr Ser Cys Asp Gln Pro Lys Leu Leu Gly Ile Glu Thr Pro Leu  
 50 55 60  
 Pro Lys Lys Glu Leu Leu Leu Pro Gly Asn Asn Arg Lys Val Tyr Glu  
 65 70 75 80  
 Leu Ser Asn Val Gln Glu Asp Ser Gln Pro Met Cys Tyr Ser Asn Cys  
 85 90 95  
 Pro Asp Gly Gln Ser Thr Ala Lys Thr Phe Leu Thr Val Tyr Trp Thr  
 100 105 110

-continued

---

Pro Glu Arg Val Glu Leu Ala Pro Leu Pro Ser Trp Gln Pro Val Gly  
 115 120 125  
 Lys Asn Leu Thr Leu Arg Cys Gln Val Glu Gly Gly Ala Pro Arg Ala  
 130 135 140  
 Asn Leu Thr Val Val Leu Leu Arg Gly Glu Lys Glu Leu Lys Arg Glu  
 145 150 155 160  
 Pro Ala Val Gly Glu Pro Ala Glu Val Thr Thr Thr Val Leu Val Arg  
 165 170 175  
 Arg Asp His His Gly Ala Asn Phe Ser Cys Arg Thr Glu Leu Asp Leu  
 180 185 190  
 Arg Pro Gln Gly Leu Glu Leu Phe Glu Asn Thr Ser Ala Pro Tyr Gln  
 195 200 205  
 Leu Gln Thr Phe Val Leu Pro Ala Thr Pro Pro Gln Leu Val Ser Pro  
 210 215 220  
 Arg Val Leu Glu Val Asp Thr Gln Gly Thr Val Val Cys Ser Leu Asp  
 225 230 235 240  
 Gly Leu Phe Pro Val Ser Glu Ala Gln Val His Leu Ala Leu Gly Asp  
 245 250 255  
 Gln Arg Leu Asn Pro Thr Val Thr Tyr Gly Asn Asp Ser Phe Ser Ala  
 260 265 270  
 Lys Ala Ser Val Ser Val Thr Ala Glu Asp Glu Gly Thr Gln Arg Leu  
 275 280 285  
 Thr Cys Ala Val Ile Leu Gly Asn Gln Ser Gln Glu Thr Leu Gln Thr  
 290 295 300  
 Val Thr Ile Tyr Ser Phe Pro Ala Pro Asn Val Ile Leu Thr Lys Pro  
 305 310 315 320  
 Glu Val Ser Glu Gly Thr Glu Val Thr Val Lys Cys Glu Ala His Pro  
 325 330 335  
 Arg Ala Lys Val Thr Leu Asn Gly Val Pro Ala Gln Pro Leu Gly Pro  
 340 345 350  
 Arg Ala Gln Leu Leu Leu Lys Ala Thr Pro Glu Asp Asn Gly Arg Ser  
 355 360 365  
 Phe Ser Cys Ser Ala Thr Leu Glu Val Ala Gly Gln Leu Ile His Lys  
 370 375 380  
 Asn Gln Thr Arg Glu Leu Arg Val Leu Tyr Gly Pro Arg Leu Asp Glu  
 385 390 395 400  
 Arg Asp Cys Pro Gly Asn Trp Thr Trp Pro Glu Asn Ser Gln Gln Thr  
 405 410 415  
 Pro Met Cys Gln Ala Trp Gly Asn Pro Leu Pro Glu Leu Lys Cys Leu  
 420 425 430  
 Lys Asp Gly Thr Phe Pro Leu Pro Ile Gly Glu Ser Val Thr Val Thr  
 435 440 445  
 Arg Asp Leu Glu Gly Thr Tyr Leu Cys Arg Ala Arg Ser Thr Gln Gly  
 450 455 460  
 Glu Val Thr Arg Lys Val Thr Val Asn Val Leu Ser Pro Arg Tyr Glu  
 465 470 475 480  
 Ile Val Ile Ile Thr Val Val Ala Ala Ala Val Ile Met Gly Thr Ala  
 485 490 495  
 Gly Leu Ser Thr Tyr Leu Tyr Asn Arg Gln Arg Lys Ile Lys Lys Tyr  
 500 505 510

-continued

---

Arg Leu Gln Gln Ala Gln Lys Gly Thr Pro Met Lys Pro Asn Thr Gln  
515 520 525

Ala Thr Pro Pro  
530

<210> SEQ ID NO 58

<211> LENGTH: 860

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 58

Met Gly Pro Trp Gly Trp Lys Leu Arg Trp Thr Val Ala Leu Leu Leu  
1 5 10 15

Ala Ala Ala Gly Thr Ala Val Gly Asp Arg Cys Glu Arg Asn Glu Phe  
20 25 30

Gln Cys Gln Asp Gly Lys Cys Ile Ser Tyr Lys Trp Val Cys Asp Gly  
35 40 45

Ser Ala Glu Cys Gln Asp Gly Ser Asp Glu Ser Gln Glu Thr Cys Leu  
50 55 60

Ser Val Thr Cys Lys Ser Gly Asp Phe Ser Cys Gly Gly Arg Val Asn  
65 70 75 80

Arg Cys Ile Pro Gln Phe Trp Arg Cys Asp Gly Gln Val Asp Cys Asp  
85 90 95

Asn Gly Ser Asp Glu Gln Gly Cys Pro Pro Lys Thr Cys Ser Gln Asp  
100 105 110

Glu Phe Arg Cys His Asp Gly Lys Cys Ile Ser Arg Gln Phe Val Cys  
115 120 125

Asp Ser Asp Arg Asp Cys Leu Asp Gly Ser Asp Glu Ala Ser Cys Pro  
130 135 140

Val Leu Thr Cys Gly Pro Ala Ser Phe Gln Cys Asn Ser Ser Thr Cys  
145 150 155 160

Ile Pro Gln Leu Trp Ala Cys Asp Asn Asp Pro Asp Cys Glu Asp Gly  
165 170 175

Ser Asp Glu Trp Pro Gln Arg Cys Arg Gly Leu Tyr Val Phe Gln Gly  
180 185 190

Asp Ser Ser Pro Cys Ser Ala Phe Glu Phe His Cys Leu Ser Gly Glu  
195 200 205

Cys Ile His Ser Ser Trp Arg Cys Asp Gly Gly Pro Asp Cys Lys Asp  
210 215 220

Lys Ser Asp Glu Glu Asn Cys Ala Val Ala Thr Cys Arg Pro Asp Glu  
225 230 235 240

Phe Gln Cys Ser Asp Gly Asn Cys Ile His Gly Ser Arg Gln Cys Asp  
245 250 255

Arg Glu Tyr Asp Cys Lys Asp Met Ser Asp Glu Val Gly Cys Val Asn  
260 265 270

Val Thr Leu Cys Glu Gly Pro Asn Lys Phe Lys Cys His Ser Gly Glu  
275 280 285

Cys Ile Thr Leu Asp Lys Val Cys Asn Met Ala Arg Asp Cys Arg Asp  
290 295 300

Trp Ser Asp Glu Pro Ile Lys Glu Cys Gly Thr Asn Glu Cys Leu Asp  
305 310 315 320

Asn Asn Gly Gly Cys Ser His Val Cys Asn Asp Leu Lys Ile Gly Tyr  
325 330 335

-continued

---

Glu Cys Leu Cys Pro Asp Gly Phe Gln Leu Val Ala Gln Arg Arg Cys  
                   340                                  345                                  350

Glu Asp Ile Asp Glu Cys Gln Asp Pro Asp Thr Cys Ser Gln Leu Cys  
                   355                                  360                                  365

Val Asn Leu Glu Gly Gly Tyr Lys Cys Gln Cys Glu Glu Gly Phe Gln  
                   370                                  375                                  380

Leu Asp Pro His Thr Lys Ala Cys Lys Ala Val Gly Ser Ile Ala Tyr  
 385                                  390                                  395                                  400

Leu Phe Phe Thr Asn Arg His Glu Val Arg Lys Met Thr Leu Asp Arg  
                   405                                  410                                  415

Ser Glu Tyr Thr Ser Leu Ile Pro Asn Leu Arg Asn Val Val Ala Leu  
                   420                                  425                                  430

Asp Thr Glu Val Ala Ser Asn Arg Ile Tyr Trp Ser Asp Leu Ser Gln  
                   435                                  440                                  445

Arg Met Ile Cys Ser Thr Gln Leu Asp Arg Ala His Gly Val Ser Ser  
                   450                                  455                                  460

Tyr Asp Thr Val Ile Ser Arg Asp Ile Gln Ala Pro Asp Gly Leu Ala  
 465                                  470                                  475                                  480

Val Asp Trp Ile His Ser Asn Ile Tyr Trp Thr Asp Ser Val Leu Gly  
                   485                                  490                                  495

Thr Val Ser Val Ala Asp Thr Lys Gly Val Lys Arg Lys Thr Leu Phe  
                   500                                  505                                  510

Arg Glu Asn Gly Ser Lys Pro Arg Ala Ile Val Val Asp Pro Val His  
                   515                                  520                                  525

Gly Phe Met Tyr Trp Thr Asp Trp Gly Thr Pro Ala Lys Ile Lys Lys  
                   530                                  535                                  540

Gly Gly Leu Asn Gly Val Asp Ile Tyr Ser Leu Val Thr Glu Asn Ile  
 545                                  550                                  555                                  560

Gln Trp Pro Asn Gly Ile Thr Leu Asp Leu Leu Ser Gly Arg Leu Tyr  
                   565                                  570                                  575

Trp Val Asp Ser Lys Leu His Ser Ile Ser Ser Ile Asp Val Asn Gly  
                   580                                  585                                  590

Gly Asn Arg Lys Thr Ile Leu Glu Asp Glu Lys Arg Leu Ala His Pro  
                   595                                  600                                  605

Phe Ser Leu Ala Val Phe Glu Asp Lys Val Phe Trp Thr Asp Ile Ile  
                   610                                  615                                  620

Asn Glu Ala Ile Phe Ser Ala Asn Arg Leu Thr Gly Ser Asp Val Asn  
 625                                  630                                  635                                  640

Leu Leu Ala Glu Asn Leu Leu Ser Pro Glu Asp Met Val Leu Phe His  
                   645                                  650                                  655

Asn Leu Thr Gln Pro Arg Gly Val Asn Trp Cys Glu Arg Thr Thr Leu  
                   660                                  665                                  670

Ser Asn Gly Gly Cys Gln Tyr Leu Cys Leu Pro Ala Pro Gln Ile Asn  
                   675                                  680                                  685

Pro His Ser Pro Lys Phe Thr Cys Ala Cys Pro Asp Gly Met Leu Leu  
                   690                                  695                                  700

Ala Arg Asp Met Arg Ser Cys Leu Thr Glu Ala Glu Ala Ala Val Ala  
 705                                  710                                  715                                  720

Thr Gln Glu Thr Ser Thr Val Arg Leu Lys Val Ser Ser Thr Ala Val  
                   725                                  730                                  735





-continued

---

```

Pro Pro Thr Gly Glu Glu Asp Thr Ala Glu Lys Asp Glu Leu
      645                               650

<210> SEQ ID NO 60
<211> LENGTH: 1250
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 60

Met Ala Arg Gly Asp Ala Gly Arg Gly Arg Gly Leu Leu Ala Leu Thr
 1      5      10      15

Phe Cys Leu Leu Ala Ala Arg Gly Glu Leu Leu Leu Pro Gln Glu Thr
 20      25      30

Thr Val Glu Leu Ser Cys Gly Val Gly Pro Leu Gln Val Ile Leu Gly
 35      40      45

Pro Glu Gln Ala Ala Val Leu Asn Cys Ser Leu Gly Ala Ala Ala Ala
 50      55      60

Gly Pro Pro Thr Arg Val Thr Trp Ser Lys Asp Gly Asp Thr Leu Leu
 65      70      75      80

Glu His Asp His Leu His Leu Leu Pro Asn Gly Ser Leu Trp Leu Ser
 85      90      95

Gln Pro Leu Ala Pro Asn Gly Ser Asp Glu Ser Val Pro Glu Ala Val
 100     105     110

Gly Val Ile Glu Gly Asn Tyr Ser Cys Leu Ala His Gly Pro Leu Gly
 115     120     125

Val Leu Ala Ser Gln Thr Ala Val Val Lys Leu Ala Thr Leu Ala Asp
 130     135     140

Phe Ser Leu His Pro Glu Ser Gln Thr Val Glu Glu Asn Gly Thr Ala
 145     150     155     160

Arg Phe Glu Cys His Ile Glu Gly Leu Pro Ala Pro Ile Ile Thr Trp
 165     170     175

Glu Lys Asp Gln Val Thr Leu Pro Glu Glu Pro Arg Leu Ile Val Leu
 180     185     190

Pro Asn Gly Val Leu Gln Ile Leu Asp Val Gln Glu Ser Asp Ala Gly
 195     200     205

Pro Tyr Arg Cys Val Ala Thr Asn Ser Ala Arg Gln His Phe Ser Gln
 210     215     220

Glu Ala Leu Leu Ser Val Ala His Arg Gly Ser Leu Ala Ser Thr Arg
 225     230     235     240

Gly Gln Asp Val Val Ile Val Ala Ala Pro Glu Asn Thr Thr Val Val
 245     250     255

Ser Gly Gln Ser Val Val Met Glu Cys Val Ala Ser Ala Asp Pro Thr
 260     265     270

Pro Phe Val Ser Trp Val Arg Gln Asp Gly Lys Pro Ile Ser Thr Asp
 275     280     285

Val Ile Val Leu Gly Arg Thr Asn Leu Leu Ile Ala Asn Ala Gln Pro
 290     295     300

Trp His Ser Gly Val Tyr Val Cys Arg Ala Asn Lys Pro Arg Thr Arg
 305     310     315     320

Asp Phe Ala Thr Ala Ala Ala Glu Leu Arg Val Leu Ala Ala Pro Ala
 325     330     335

Ile Thr Gln Ala Pro Glu Ala Leu Ser Arg Thr Arg Ala Ser Thr Ala
 340     345     350

```



-continued

---

Pro Ala His Val His Ala Glu Ser Asn Ser Ser Thr Ser Ile Trp Leu  
 755 760 765

Arg Trp Lys Lys Pro Asp Phe Thr Thr Val Lys Ile Val Asn Tyr Thr  
 770 775 780

Val Arg Phe Ser Pro Trp Gly Leu Arg Asn Ala Ser Leu Val Thr Tyr  
 785 790 795 800

Tyr Thr Ser Ser Gly Glu Asp Ile Leu Ile Gly Gly Leu Lys Pro Phe  
 805 810 815

Thr Lys Tyr Glu Phe Ala Val Gln Ser His Gly Val Asp Met Asp Gly  
 820 825 830

Pro Phe Gly Ser Val Val Glu Arg Ser Thr Leu Pro Asp Arg Pro Ser  
 835 840 845

Thr Pro Pro Ser Asp Leu Arg Leu Ser Pro Leu Thr Pro Ser Thr Val  
 850 855 860

Arg Leu His Trp Cys Pro Pro Thr Glu Pro Asn Gly Glu Ile Val Glu  
 865 870 875 880

Tyr Leu Ile Leu Tyr Ser Ser Asn His Thr Gln Pro Glu His Gln Trp  
 885 890 895

Thr Leu Leu Thr Thr Gln Gly Asn Ile Phe Ser Ala Glu Val His Gly  
 900 905 910

Leu Glu Ser Asp Thr Arg Tyr Phe Phe Lys Met Gly Ala Arg Thr Glu  
 915 920 925

Val Gly Pro Gly Pro Phe Ser Arg Leu Gln Asp Val Ile Thr Leu Gln  
 930 935 940

Glu Lys Leu Ser Asp Ser Leu Asp Met His Ser Val Thr Gly Ile Ile  
 945 950 955 960

Val Gly Val Cys Leu Gly Leu Leu Cys Leu Leu Ala Cys Met Cys Ala  
 965 970 975

Gly Leu Arg Arg Ser Pro His Arg Glu Ser Leu Pro Gly Leu Ser Ser  
 980 985 990

Thr Ala Thr Pro Gly Asn Pro Ala Leu Tyr Ser Arg Ala Arg Leu Gly  
 995 1000 1005

Pro Pro Ser Pro Pro Ala Ala His Glu Leu Glu Ser Leu Val His  
 1010 1015 1020

Pro His Pro Gln Asp Trp Ser Pro Pro Pro Ser Asp Val Glu Asp  
 1025 1030 1035

Arg Ala Glu Val His Ser Leu Met Gly Gly Gly Val Ser Glu Gly  
 1040 1045 1050

Arg Ser His Ser Lys Arg Lys Ile Ser Trp Ala Gln Pro Ser Gly  
 1055 1060 1065

Leu Ser Trp Ala Gly Ser Trp Ala Gly Cys Glu Leu Pro Gln Ala  
 1070 1075 1080

Gly Pro Arg Pro Ala Leu Thr Arg Ala Leu Leu Pro Pro Ala Gly  
 1085 1090 1095

Thr Gly Gln Thr Leu Leu Leu Gln Ala Leu Val Tyr Asp Ala Ile  
 1100 1105 1110

Lys Gly Asn Gly Arg Lys Lys Ser Pro Pro Ala Cys Arg Asn Gln  
 1115 1120 1125

Val Glu Ala Glu Val Ile Val His Ser Asp Phe Ser Ala Ser Asn  
 1130 1135 1140

Gly Asn Pro Asp Leu His Leu Gln Asp Leu Glu Pro Glu Asp Pro

-continued

---

```

1145          1150          1155
Leu Pro  Pro Glu Ala Pro Asp  Leu Ile Ser Gly Val  Gly Asp Pro
1160          1165          1170

Gly Gln  Gly Ala Ala Trp Leu  Asp Arg Glu Leu Gly  Gly Cys Glu
1175          1180          1185

Leu Ala  Ala Pro Gly Pro Asp  Arg Leu Thr Cys Leu  Pro Glu Ala
1190          1195          1200

Ala Ser  Ala Ser Cys Ser Tyr  Pro Asp Leu Gln Pro  Gly Glu Val
1205          1210          1215

Leu Glu  Glu Thr Pro Gly Asp  Ser Cys Gln Leu Lys  Ser Pro Cys
1220          1225          1230

Pro Leu  Gly Ala Ser Pro Gly  Leu Pro Arg Ser Pro  Val Ser Ser
1235          1240          1245

Ser Ala
1250

<210> SEQ ID NO 61
<211> LENGTH: 653
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 61

Met Pro Val Gly Gly Leu Leu Pro Leu Phe Ser Ser Pro Ala Gly Gly
1          5          10          15

Val Leu Gly Gly Gly Leu Gly Gly Gly Gly Arg Lys Gly Ser Gly
20          25          30

Pro Ala Ala Leu Arg Leu Thr Glu Lys Phe Val Leu Leu Leu Val Phe
35          40          45

Ser Ala Phe Ile Thr Leu Cys Phe Gly Ala Ile Phe Phe Leu Pro Asp
50          55          60

Ser Ser Lys Leu Leu Ser Gly Val Leu Phe His Ser Ser Pro Ala Leu
65          70          75          80

Gln Pro Ala Ala Asp His Lys Pro Gly Pro Gly Ala Arg Ala Glu Asp
85          90          95

Ala Ala Glu Gly Arg Ala Arg Arg Arg Glu Glu Gly Ala Pro Gly Asp
100         105         110

Pro Glu Ala Ala Leu Glu Asp Asn Leu Ala Arg Ile Arg Glu Asn His
115         120         125

Glu Arg Ala Leu Arg Glu Ala Lys Glu Thr Leu Gln Lys Leu Pro Glu
130         135         140

Glu Ile Gln Arg Asp Ile Leu Leu Glu Lys Lys Lys Val Ala Gln Asp
145         150         155         160

Gln Leu Arg Asp Lys Ala Pro Phe Arg Gly Leu Pro Pro Val Asp Phe
165         170         175

Val Pro Pro Ile Gly Val Glu Ser Arg Glu Pro Ala Asp Ala Ala Ile
180         185         190

Arg Glu Lys Arg Ala Lys Ile Lys Glu Met Met Lys His Ala Trp Asn
195         200         205

Asn Tyr Lys Gly Tyr Ala Trp Gly Leu Asn Glu Leu Lys Pro Ile Ser
210         215         220

Lys Gly Gly His Ser Ser Ser Leu Phe Gly Asn Ile Lys Gly Ala Thr
225         230         235         240

```

-continued

---

Ile Val Asp Ala Leu Asp Thr Leu Phe Ile Met Glu Met Lys His Glu  
 245 250 255  
 Phe Glu Glu Ala Lys Ser Trp Val Glu Glu Asn Leu Asp Phe Asn Val  
 260 265 270  
 Asn Ala Glu Ile Ser Val Phe Glu Val Asn Ile Arg Phe Val Gly Gly  
 275 280 285  
 Leu Leu Ser Ala Tyr Tyr Leu Ser Gly Glu Glu Ile Phe Arg Lys Lys  
 290 295 300  
 Ala Val Glu Leu Gly Val Lys Leu Leu Pro Ala Phe His Thr Pro Ser  
 305 310 315  
 Gly Ile Pro Trp Ala Leu Leu Asn Met Lys Ser Gly Ile Gly Arg Asn  
 325 330 335  
 Trp Pro Trp Ala Ser Gly Gly Ser Ser Ile Leu Ala Glu Phe Gly Thr  
 340 345 350  
 Leu His Leu Glu Phe Met His Leu Ser His Leu Ser Gly Asn Pro Ile  
 355 360 365  
 Phe Ala Glu Lys Val Met Asn Ile Arg Thr Val Leu Asn Lys Leu Glu  
 370 375 380  
 Lys Pro Gln Gly Leu Tyr Pro Asn Tyr Leu Asn Pro Ser Ser Gly Gln  
 385 390 395 400  
 Trp Gly Gln His His Val Ser Val Gly Gly Leu Gly Asp Ser Phe Tyr  
 405 410 415  
 Glu Tyr Leu Leu Lys Ala Trp Leu Met Ser Asp Lys Thr Asp Leu Glu  
 420 425 430  
 Ala Lys Lys Met Tyr Phe Asp Ala Val Gln Ala Ile Glu Thr His Leu  
 435 440 445  
 Ile Arg Lys Ser Ser Ser Gly Leu Thr Tyr Ile Ala Glu Trp Lys Gly  
 450 455 460  
 Gly Leu Leu Glu His Lys Met Gly His Leu Thr Cys Phe Ala Gly Gly  
 465 470 475 480  
 Met Phe Ala Leu Gly Ala Asp Ala Ala Pro Glu Gly Met Ala Gln His  
 485 490 495  
 Tyr Leu Glu Leu Gly Ala Glu Ile Ala Arg Thr Cys His Glu Ser Tyr  
 500 505 510  
 Asn Arg Thr Phe Met Lys Leu Gly Pro Glu Ala Phe Arg Phe Asp Gly  
 515 520 525  
 Gly Val Glu Ala Ile Ala Thr Arg Gln Asn Glu Lys Tyr Tyr Ile Leu  
 530 535 540  
 Arg Pro Glu Val Met Glu Thr Tyr Met Tyr Met Trp Arg Leu Thr His  
 545 550 555 560  
 Asp Pro Lys Tyr Arg Lys Trp Ala Trp Glu Ala Val Glu Ala Leu Glu  
 565 570 575  
 Asn His Cys Arg Val Asn Gly Gly Tyr Ser Gly Leu Arg Asp Val Tyr  
 580 585 590  
 Leu Leu His Glu Ser Tyr Asp Asp Val Gln Gln Ser Phe Phe Leu Ala  
 595 600 605  
 Glu Thr Leu Lys Tyr Leu Tyr Leu Ile Phe Ser Asp Asp Asp Leu Leu  
 610 615 620  
 Pro Leu Glu His Trp Ile Phe Asn Ser Glu Ala His Leu Leu Pro Ile  
 625 630 635 640  
 Leu Pro Lys Asp Lys Lys Glu Val Glu Ile Arg Glu Glu



-continued

---

Leu Asp Gly Ala Asp Cys Ile Met Leu Ser Gly Glu Thr Ala Lys Gly  
 355 360 365  
 Asp Tyr Pro Leu Glu Ala Val Arg Met Gln His Leu Ile Ala Arg Glu  
 370 375 380  
 Ala Glu Ala Ala Ile Tyr His Leu Gln Leu Phe Glu Glu Leu Arg Arg  
 385 390 395 400  
 Leu Ala Pro Ile Thr Ser Asp Pro Thr Glu Ala Thr Ala Val Gly Ala  
 405 410 415  
 Val Glu Ala Ser Phe Lys Cys Cys Ser Gly Ala Ile Ile Val Leu Thr  
 420 425 430  
 Lys Ser Gly Arg Ser Ala His Gln Val Ala Arg Tyr Arg Pro Arg Ala  
 435 440 445  
 Pro Ile Ile Ala Val Thr Arg Asn Pro Gln Thr Ala Arg Gln Ala His  
 450 455 460  
 Leu Tyr Arg Gly Ile Phe Pro Val Leu Cys Lys Asp Pro Val Gln Glu  
 465 470 475 480  
 Ala Trp Ala Glu Asp Val Asp Leu Arg Val Asn Phe Ala Met Asn Val  
 485 490 495  
 Gly Lys Ala Arg Gly Phe Phe Lys Lys Gly Asp Val Val Ile Val Leu  
 500 505 510  
 Thr Gly Trp Arg Pro Gly Ser Gly Phe Thr Asn Thr Met Arg Val Val  
 515 520 525  
 Pro Val Pro  
 530

&lt;210&gt; SEQ ID NO 63

&lt;211&gt; LENGTH: 543

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 63

Met Glu Gln Val Asn Glu Leu Lys Glu Lys Gly Asn Lys Ala Leu Ser  
 1 5 10 15  
 Val Gly Asn Ile Asp Asp Ala Leu Gln Cys Tyr Ser Glu Ala Ile Lys  
 20 25 30  
 Leu Asp Pro His Asn His Val Leu Tyr Ser Asn Arg Ser Ala Ala Tyr  
 35 40 45  
 Ala Lys Lys Gly Asp Tyr Gln Lys Ala Tyr Glu Asp Gly Cys Lys Thr  
 50 55 60  
 Val Asp Leu Lys Pro Asp Trp Gly Lys Gly Tyr Ser Arg Lys Ala Ala  
 65 70 75 80  
 Ala Leu Glu Phe Leu Asn Arg Phe Glu Glu Ala Lys Arg Thr Tyr Glu  
 85 90 95  
 Glu Gly Leu Lys His Glu Ala Asn Asn Pro Gln Leu Lys Glu Gly Leu  
 100 105 110  
 Gln Asn Met Glu Ala Arg Leu Ala Glu Arg Lys Phe Met Asn Pro Phe  
 115 120 125  
 Asn Met Pro Asn Leu Tyr Gln Lys Leu Glu Ser Asp Pro Arg Thr Arg  
 130 135 140  
 Thr Leu Leu Ser Asp Pro Thr Tyr Arg Glu Leu Ile Glu Gln Leu Arg  
 145 150 155 160  
 Asn Lys Pro Ser Asp Leu Gly Thr Lys Leu Gln Asp Pro Arg Ile Met  
 165 170 175

-continued

---

```

Thr Thr Leu Ser Val Leu Leu Gly Val Asp Leu Gly Ser Met Asp Glu
      180                               185                               190

Glu Glu Glu Ile Ala Thr Pro Pro Pro Pro Pro Pro Lys Lys Glu
      195                               200                               205

Thr Lys Pro Glu Pro Met Glu Glu Asp Leu Pro Glu Asn Lys Lys Gln
      210                               215                               220

Ala Leu Lys Glu Lys Glu Leu Gly Asn Asp Ala Tyr Lys Lys Lys Asp
      225                               230                               235                               240

Phe Asp Thr Ala Leu Lys His Tyr Asp Lys Ala Lys Glu Leu Asp Pro
      245                               250                               255

Thr Asn Met Thr Tyr Ile Thr Asn Gln Ala Ala Val Tyr Phe Glu Lys
      260                               265                               270

Gly Asp Tyr Asn Lys Cys Arg Glu Leu Cys Glu Lys Ala Ile Glu Val
      275                               280                               285

Gly Arg Glu Asn Arg Glu Asp Tyr Arg Gln Ile Ala Lys Ala Tyr Ala
      290                               295                               300

Arg Ile Gly Asn Ser Tyr Phe Lys Glu Glu Lys Tyr Lys Asp Ala Ile
      305                               310                               315                               320

His Phe Tyr Asn Lys Ser Leu Ala Glu His Arg Thr Pro Asp Val Leu
      325                               330                               335

Lys Lys Cys Gln Gln Ala Glu Lys Ile Leu Lys Glu Gln Glu Arg Leu
      340                               345                               350

Ala Tyr Ile Asn Pro Asp Leu Ala Leu Glu Glu Lys Asn Lys Gly Asn
      355                               360                               365

Glu Cys Phe Gln Lys Gly Asp Tyr Pro Gln Ala Met Lys His Tyr Thr
      370                               375                               380

Glu Ala Ile Lys Arg Asn Pro Lys Asp Ala Lys Leu Tyr Ser Asn Arg
      385                               390                               395                               400

Ala Ala Cys Tyr Thr Lys Leu Leu Glu Phe Gln Leu Ala Leu Lys Asp
      405                               410                               415

Cys Glu Glu Cys Ile Gln Leu Glu Pro Thr Phe Ile Lys Gly Tyr Thr
      420                               425                               430

Arg Lys Ala Ala Ala Leu Glu Ala Met Lys Asp Tyr Thr Lys Ala Met
      435                               440                               445

Asp Val Tyr Gln Lys Ala Leu Asp Leu Asp Ser Ser Cys Lys Glu Ala
      450                               455                               460

Ala Asp Gly Tyr Gln Arg Cys Met Met Ala Gln Tyr Asn Arg His Asp
      465                               470                               475                               480

Ser Pro Glu Asp Val Lys Arg Arg Ala Met Ala Asp Pro Glu Val Gln
      485                               490                               495

Gln Ile Met Ser Asp Pro Ala Met Arg Leu Ile Leu Glu Gln Met Gln
      500                               505                               510

Lys Asp Pro Gln Ala Leu Ser Glu His Leu Lys Asn Pro Val Ile Ala
      515                               520                               525

Gln Lys Ile Gln Lys Leu Met Asp Val Gly Leu Ile Ala Ile Arg
      530                               535                               540

```

&lt;210&gt; SEQ ID NO 64

&lt;211&gt; LENGTH: 707

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Homo sapiens

-continued

&lt;400&gt; SEQUENCE: 64

---

```

Met Ser Leu Trp Gln Pro Leu Val Leu Val Leu Leu Val Leu Gly Cys
1      5      10      15
Cys Phe Ala Ala Pro Arg Gln Arg Gln Ser Thr Leu Val Leu Phe Pro
20      25      30
Gly Asp Leu Arg Thr Asn Leu Thr Asp Arg Gln Leu Ala Glu Glu Tyr
35      40      45
Leu Tyr Arg Tyr Gly Tyr Thr Arg Val Ala Glu Met Arg Gly Glu Ser
50      55      60
Lys Ser Leu Gly Pro Ala Leu Leu Leu Leu Gln Lys Gln Leu Ser Leu
65      70      75      80
Pro Glu Thr Gly Glu Leu Asp Ser Ala Thr Leu Lys Ala Met Arg Thr
85      90      95
Pro Arg Cys Gly Val Pro Asp Leu Gly Arg Phe Gln Thr Phe Glu Gly
100     105     110
Asp Leu Lys Trp His His His Asn Ile Thr Tyr Trp Ile Gln Asn Tyr
115     120     125
Ser Glu Asp Leu Pro Arg Ala Val Ile Asp Asp Ala Phe Ala Arg Ala
130     135     140
Phe Ala Leu Trp Ser Ala Val Thr Pro Leu Thr Phe Thr Arg Val Tyr
145     150     155     160
Ser Arg Asp Ala Asp Ile Val Ile Gln Phe Gly Val Ala Glu His Gly
165     170     175
Asp Gly Tyr Pro Phe Asp Gly Lys Asp Gly Leu Leu Ala His Ala Phe
180     185     190
Pro Pro Gly Pro Gly Ile Gln Gly Asp Ala His Phe Asp Asp Asp Glu
195     200     205
Leu Trp Ser Leu Gly Lys Gly Val Val Val Pro Thr Arg Phe Gly Asn
210     215     220
Ala Asp Gly Ala Ala Cys His Phe Pro Phe Ile Phe Glu Gly Arg Ser
225     230     235     240
Tyr Ser Ala Cys Thr Thr Asp Gly Arg Ser Asp Gly Leu Pro Trp Cys
245     250     255
Ser Thr Thr Ala Asn Tyr Asp Thr Asp Asp Arg Phe Gly Phe Cys Pro
260     265     270
Ser Glu Arg Leu Tyr Thr Arg Asp Gly Asn Ala Asp Gly Lys Pro Cys
275     280     285
Gln Phe Pro Phe Ile Phe Gln Gly Gln Ser Tyr Ser Ala Cys Thr Thr
290     295     300
Asp Gly Arg Ser Asp Gly Tyr Arg Trp Cys Ala Thr Thr Ala Asn Tyr
305     310     315     320
Asp Arg Asp Lys Leu Phe Gly Phe Cys Pro Thr Arg Ala Asp Ser Thr
325     330     335
Val Met Gly Gly Asn Ser Ala Gly Glu Leu Cys Val Phe Pro Phe Thr
340     345     350
Phe Leu Gly Lys Glu Tyr Ser Thr Cys Thr Ser Glu Gly Arg Gly Asp
355     360     365
Gly Arg Leu Trp Cys Ala Thr Thr Ser Asn Phe Asp Ser Asp Lys Lys
370     375     380
Trp Gly Phe Cys Pro Asp Gln Gly Tyr Ser Leu Phe Leu Val Ala Ala
385     390     395     400

```

-continued

---

His Glu Phe Gly His Ala Leu Gly Leu Asp His Ser Ser Val Pro Glu  
 405 410 415  
 Ala Leu Met Tyr Pro Met Tyr Arg Phe Thr Glu Gly Pro Pro Leu His  
 420 425 430  
 Lys Asp Asp Val Asn Gly Ile Arg His Leu Tyr Gly Pro Arg Pro Glu  
 435 440 445  
 Pro Glu Pro Arg Pro Pro Thr Thr Thr Thr Pro Gln Pro Thr Ala Pro  
 450 455 460  
 Pro Thr Val Cys Pro Thr Gly Pro Pro Thr Val His Pro Ser Glu Arg  
 465 470 475 480  
 Pro Thr Ala Gly Pro Thr Gly Pro Pro Ser Ala Gly Pro Thr Gly Pro  
 485 490 495  
 Pro Thr Ala Gly Pro Ser Thr Ala Thr Thr Val Pro Leu Ser Pro Val  
 500 505 510  
 Asp Asp Ala Cys Asn Val Asn Ile Phe Asp Ala Ile Ala Glu Ile Gly  
 515 520 525  
 Asn Gln Leu Tyr Leu Phe Lys Asp Gly Lys Tyr Trp Arg Phe Ser Glu  
 530 535 540  
 Gly Arg Gly Ser Arg Pro Gln Gly Pro Phe Leu Ile Ala Asp Lys Trp  
 545 550 555 560  
 Pro Ala Leu Pro Arg Lys Leu Asp Ser Val Phe Glu Glu Pro Leu Ser  
 565 570 575  
 Lys Lys Leu Phe Phe Phe Ser Gly Arg Gln Val Trp Val Tyr Thr Gly  
 580 585 590  
 Ala Ser Val Leu Gly Pro Arg Arg Leu Asp Lys Leu Gly Leu Gly Ala  
 595 600 605  
 Asp Val Ala Gln Val Thr Gly Ala Leu Arg Ser Gly Arg Gly Lys Met  
 610 615 620  
 Leu Leu Phe Ser Gly Arg Arg Leu Trp Arg Phe Asp Val Lys Ala Gln  
 625 630 635 640  
 Met Val Asp Pro Arg Ser Ala Ser Glu Val Asp Arg Met Phe Pro Gly  
 645 650 655  
 Val Pro Leu Asp Thr His Asp Val Phe Gln Tyr Arg Glu Lys Ala Tyr  
 660 665 670  
 Phe Cys Gln Asp Arg Phe Tyr Trp Arg Val Ser Ser Arg Ser Glu Leu  
 675 680 685  
 Asn Gln Val Asp Gln Val Gly Tyr Val Thr Tyr Asp Ile Leu Gln Cys  
 690 695 700  
 Pro Glu Asp  
 705  
  
 <210> SEQ ID NO 65  
 <211> LENGTH: 1231  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo Sapiens  
  
 <400> SEQUENCE: 65  
 Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys  
 1 5 10 15  
 Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile  
 20 25 30  
 Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Gly Thr Gln

-continued

35				40				45							
Ala	Ile	Tyr	Lys	Cys	Arg	Pro	Gly	Tyr	Arg	Ser	Leu	Gly	Asn	Val	Ile
50						55					60				
Met	Val	Cys	Arg	Lys	Gly	Glu	Trp	Val	Ala	Leu	Asn	Pro	Leu	Arg	Lys
65				70						75					80
Cys	Gln	Lys	Arg	Pro	Cys	Gly	His	Pro	Gly	Asp	Thr	Pro	Phe	Gly	Thr
				85					90					95	
Phe	Thr	Leu	Thr	Gly	Gly	Asn	Val	Phe	Glu	Tyr	Gly	Val	Lys	Ala	Val
			100					105					110		
Tyr	Thr	Cys	Asn	Glu	Gly	Tyr	Gln	Leu	Leu	Gly	Glu	Ile	Asn	Tyr	Arg
		115					120					125			
Glu	Cys	Asp	Thr	Asp	Gly	Trp	Thr	Asn	Asp	Ile	Pro	Ile	Cys	Glu	Val
	130					135					140				
Val	Lys	Cys	Leu	Pro	Val	Thr	Ala	Pro	Glu	Asn	Gly	Lys	Ile	Val	Ser
145					150					155					160
Ser	Ala	Met	Glu	Pro	Asp	Arg	Glu	Tyr	His	Phe	Gly	Gln	Ala	Val	Arg
				165					170					175	
Phe	Val	Cys	Asn	Ser	Gly	Tyr	Lys	Ile	Glu	Gly	Asp	Glu	Glu	Met	His
			180					185					190		
Cys	Ser	Asp	Asp	Gly	Phe	Trp	Ser	Lys	Glu	Lys	Pro	Lys	Cys	Val	Glu
		195					200					205			
Ile	Ser	Cys	Lys	Ser	Pro	Asp	Val	Ile	Asn	Gly	Ser	Pro	Ile	Ser	Gln
	210					215					220				
Lys	Ile	Ile	Tyr	Lys	Glu	Asn	Glu	Arg	Phe	Gln	Tyr	Lys	Cys	Asn	Met
225					230					235					240
Gly	Tyr	Glu	Tyr	Ser	Glu	Arg	Gly	Asp	Ala	Val	Cys	Thr	Glu	Ser	Gly
				245					250					255	
Trp	Arg	Pro	Leu	Pro	Ser	Cys	Glu	Glu	Lys	Ser	Cys	Asp	Asn	Pro	Tyr
			260					265					270		
Ile	Pro	Asn	Gly	Asp	Tyr	Ser	Pro	Leu	Arg	Leu	Lys	His	Arg	Thr	Gly
		275				280						285			
Asp	Glu	Leu	Thr	Tyr	Gln	Cys	Arg	Asn	Gly	Phe	Tyr	Pro	Ala	Thr	Arg
	290					295					300				
Gly	Asn	Thr	Ala	Lys	Cys	Thr	Ser	Thr	Gly	Trp	Ile	Pro	Ala	Pro	Arg
305					310					315				320	
Cys	Thr	Leu	Lys	Pro	Cys	Asp	Tyr	Pro	Asp	Ile	Lys	His	Gly	Gly	Leu
				325					330					335	
Tyr	His	Glu	Asn	Met	Arg	Arg	Pro	Tyr	Phe	Pro	Val	Ala	Val	Gly	Lys
		340						345					350		
Tyr	Tyr	Ser	Tyr	Tyr	Cys	Asp	Glu	His	Phe	Glu	Thr	Pro	Ser	Gly	Ser
		355					360					365			
Tyr	Trp	Asp	His	Ile	His	Cys	Thr	Gln	Asp	Gly	Trp	Ser	Pro	Ala	Val
	370					375					380				
Pro	Cys	Leu	Arg	Lys	Cys	Tyr	Phe	Pro	Tyr	Leu	Glu	Asn	Gly	Tyr	Asn
385					390					395					400
Gln	Asn	His	Gly	Arg	Lys	Phe	Val	Gln	Gly	Lys	Ser	Ile	Asp	Val	Ala
				405					410					415	
Cys	His	Pro	Gly	Tyr	Ala	Leu	Pro	Lys	Ala	Gln	Thr	Thr	Val	Thr	Cys
			420					425					430		
Met	Glu	Asn	Gly	Trp	Ser	Pro	Thr	Pro	Arg	Cys	Ile	Arg	Val	Lys	Thr
	435						440					445			

-continued

---

Cys Ser Lys Ser Ser Ile Asp Ile Glu Asn Gly Phe Ile Ser Glu Ser  
 450 455 460  
 Gln Tyr Thr Tyr Ala Leu Lys Glu Lys Ala Lys Tyr Gln Cys Lys Leu  
 465 470 475 480  
 Gly Tyr Val Thr Ala Asp Gly Glu Thr Ser Gly Ser Ile Arg Cys Gly  
 485 490 495  
 Lys Asp Gly Trp Ser Ala Gln Pro Thr Cys Ile Lys Ser Cys Asp Ile  
 500 505 510  
 Pro Val Phe Met Asn Ala Arg Thr Lys Asn Asp Phe Thr Trp Phe Lys  
 515 520 525  
 Leu Asn Asp Thr Leu Asp Tyr Glu Cys His Asp Gly Tyr Glu Ser Asn  
 530 535 540  
 Thr Gly Ser Thr Thr Gly Ser Ile Val Cys Gly Tyr Asn Gly Trp Ser  
 545 550 555 560  
 Asp Leu Pro Ile Cys Tyr Glu Arg Glu Cys Glu Leu Pro Lys Ile Asp  
 565 570 575  
 Val His Leu Val Pro Asp Arg Lys Lys Asp Gln Tyr Lys Val Gly Glu  
 580 585 590  
 Val Leu Lys Phe Ser Lys Pro Gly Phe Thr Ile Val Gly Pro Asn Ser  
 595 600 605  
 Val Gln Cys Tyr His Phe Gly Leu Ser Pro Asp Leu Pro Ile Cys Lys  
 610 615 620  
 Glu Gln Val Gln Ser Cys Gly Pro Pro Pro Glu Leu Leu Asn Gly Asn  
 625 630 635 640  
 Val Lys Glu Lys Thr Lys Glu Glu Tyr Gly His Ser Glu Val Val Glu  
 645 650 655  
 Tyr Tyr Cys Asn Pro Arg Phe Leu Met Lys Gly Pro Asn Lys Ile Gln  
 660 665 670  
 Cys Val Asp Gly Glu Trp Thr Thr Leu Pro Val Cys Ile Val Glu Glu  
 675 680 685  
 Ser Thr Cys Gly Asp Ile Pro Glu Leu Glu His Gly Trp Ala Gln Leu  
 690 695 700  
 Ser Ser Pro Pro Tyr Tyr Tyr Gly Asp Ser Val Glu Phe Asn Cys Ser  
 705 710 715 720  
 Glu Ser Phe Thr Met Ile Gly His Arg Ser Ile Thr Cys Ile His Gly  
 725 730 735  
 Val Trp Thr Gln Leu Pro Gln Cys Val Ala Ile Asp Lys Leu Lys Lys  
 740 745 750  
 Cys Lys Ser Ser Asn Leu Ile Ile Leu Glu Glu His Leu Lys Asn Lys  
 755 760 765  
 Lys Glu Phe Asp His Asn Ser Asn Ile Arg Tyr Arg Cys Arg Gly Lys  
 770 775 780  
 Glu Gly Trp Ile His Thr Val Cys Ile Asn Gly Arg Trp Asp Pro Glu  
 785 790 795 800  
 Val Asn Cys Ser Met Ala Gln Ile Gln Leu Cys Pro Pro Pro Gln  
 805 810 815  
 Ile Pro Asn Ser His Asn Met Thr Thr Thr Leu Asn Tyr Arg Asp Gly  
 820 825 830  
 Glu Lys Val Ser Val Leu Cys Gln Glu Asn Tyr Leu Ile Gln Glu Gly  
 835 840 845



1. A method for diagnosis of neonatal sepsis in a mammalian subject comprising:

- (a) testing in a sample of biological fluid obtained from said subject the level of one or more proteins selected from the group consisting of C-reactive protein precursor (SEQ ID NO:1), Interleukin-1 receptor accessory protein precursor (SEQ ID NO:2), Interleukin-6 precursor (SEQ ID NO:3), Interleukin-1 receptor-like 1 precursor (SEQ ID NO:4), Serum amyloid A protein precursor (SEQ ID NO:5), CD5 antigen-like precursor (SEQ ID NO:6), Beta-2-microglobulin precursor (SEQ ID NO:7), Bone-marrow proteoglycan precursor (SEQ ID NO:8), Selenium-binding protein 1 (SEQ ID NO:9), Lipopolysaccharide-binding protein precursor (SEQ ID NO:10), Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO:11), Osteopontin precursor (SEQ ID NO:12), Rho GDP-dissociation inhibitor 2 (SEQ ID NO:13), Carbonic anhydrase 2 (SEQ ID NO:14), Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO:15), Collagen alpha-5(IV) chain precursor (SEQ ID NO:16), Connective tissue growth factor precursor (SEQ ID NO:17), Macrophage colony-stimulating factor 1 precursor (SEQ ID NO:18), Protein kinase C-binding protein NELL2 precursor (SEQ ID NO:19), Neudesin precursor (SEQ ID NO:20), Protein disulfide-isomerase precursor (SEQ ID NO:21), Ribonuclease pancreatic precursor (SEQ ID NO:22), Delta-like protein precursor (SEQ ID NO:23), Chromogranin-A precursor (SEQ ID NO:24), Osteomodulin precursor (SEQ ID NO:25), Collagen alpha-2(I) chain precursor (SEQ ID NO:26), Prolo-density lipoprotein receptor-related protein 1 precursor (SEQ ID NO:27), Laminin subunit gamma-1 precursor (SEQ ID NO:28), Laminin subunit beta-1 precursor (SEQ ID NO:29), Collagen alpha-1(II) chain precursor (SEQ ID NO:30), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), Protein FAM3C precursor (SEQ ID NO:32), Alpha-actinin-1 (SEQ ID NO:33), F-actin-capping protein subunit alpha-1 (SEQ ID NO:34), Aminopeptidase N (SEQ ID NO:35), Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Cell adhesion molecule 1 precursor (SEQ ID NO:37), Cathepsin B precursor (SEQ ID NO:38), Exostosin-2 (SEQ ID NO:39), Cathepsin D precursor (SEQ ID NO:40), Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO:41), Cystatin-M precursor (SEQ ID NO:42), Noelin precursor (SEQ ID NO:43), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Endoplasmin precursor (SEQ ID NO:45), Pro-protein convertase subtilisin/kexin type 9 precursor (SEQ ID NO:46), Insulin-like growth factor-binding protein complex acid labile chain precursor (SEQ ID NO:47), Ezrin (SEQ ID NO:48), Fatty acid-binding protein, liver (SEQ ID NO:49), Probable G-protein coupled receptor 116 precursor (SEQ ID NO:50), Seprase (SEQ ID NO:51), Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO:52), Hypoxia up-regulated protein 1 precursor (SEQ ID NO:53), Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO:54), Transketolase (SEQ ID NO:55), Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO:56), Intercellular adhesion molecule 1 precursor (SEQ ID NO:57), Low-density lipoprotein receptor precursor (SEQ ID NO:58), 78 kDa glucose-regulated pro-

tein precursor (SEQ ID NO:59), Neighbor of punc e11 precursor (SEQ ID NO:60), Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ ID NO:61), Pyruvate kinase isozymes M1/M2 (SEQ ID NO:62), Matrix metalloproteinase-9 (SEQ ID NO:64), Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and Stress-induced-phosphoprotein 1 (SEQ ID NO:63), relative to the level in normal biological fluid or biological fluid known to be indicative of neonatal sepsis; and

- (b) diagnosing said subject with neonatal sepsis if said level shows a statistically significant difference relative to the level in said normal biological fluid, or does not show a statistically significant difference relative to the level in said biological fluid known to be indicative of neonatal sepsis.

2. The method of claim 1, wherein the subject is a human patient.

3. The method of claim 2, wherein said testing is implemented using an apparatus adapted to determine the level of said proteins.

4. The method of claim 2, wherein said testing is performed by using a software program executed by a suitable processor.

5. The method of claim 4, wherein the program is embodied in software stored on a tangible medium.

6. The method of claim 5, wherein the tangible medium is selected from the group consisting of a CD-ROM, a floppy disk, a hard drive, a DVD, and a memory associated with the processor.

7. The method of any one of claims 2 to 6, further comprising the step of preparing a report recording the results of said testing or the diagnosis.

8. The method of claim 7, wherein said report is recorded or stored on a tangible medium.

9. The method of claim 8, wherein the tangible medium is paper.

10. The method of claim 8, wherein the tangible medium is selected from the group consisting of a CD-ROM, a floppy disk, a hard drive, a DVD, and a memory associated with the processor.

11. The method of any one of claims 2 to 6, further comprising the step of communicating the results of said diagnosis to an interested party.

12. The method of claim 11, wherein the interested party is the patient or the attending physician.

13. The method of claim 11, wherein the communication is in writing, by email, or by telephone.

14. The method of claim 1, wherein said biological fluid is selected from the group consisting of cord blood, cerebrospinal fluid, and neonatal serum.

15. The method of claim 14, wherein said biological fluid is cord blood.

16. The method of claim 2, wherein said diagnosis is determined within 24 hours of birth.

17. The method of claim 2 comprising testing the level of at least two of said proteins.

18. The method of claim 2 comprising testing the level of at least three of said proteins.

19. The method of claim 2 comprising testing the level of at least four of said proteins.

20. The method of claim 2 comprising testing the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Interleukin-6 precursor (SEQ ID NO:3), C-reactive protein precursor (SEQ ID NO:1), Beta-2-microglobulin precursor (SEQ ID NO:7), Cathepsin B pre-

cursor (SEQ ID NO:38), Cystatin-M precursor (SEQ ID NO:42), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Matrix metalloproteinase-9 (SEQ ID NO:64), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), and Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and diagnosing said subject with neonatal sepsis, if one or more of said tested proteins shows a significant difference in the cord blood sample relative to normal cord blood.

**21.** The method of claim **20** comprising diagnosing said subject with neonatal sepsis, if all of said tested proteins show a significant difference in the cord blood sample relative to normal cord blood.

**22.** The method of claim **2** wherein said level is determined by an immunoassay.

**23.** The method of claim **2** wherein level is determined by mass spectrometry.

**24.** The method of claim **2** wherein level is determined using a protein array.

**25.** Use of any one or more proteins selected from the group consisting of C-reactive protein precursor (SEQ ID NO:1), Interleukin-1 receptor accessory protein precursor (SEQ ID NO:2), Interleukin-6 precursor (SEQ ID NO:3), Interleukin-1 receptor-like 1 precursor (SEQ ID NO:4), Serum amyloid A protein precursor (SEQ ID NO:5), CD5 antigen-like precursor (SEQ ID NO:6), Beta-2-microglobulin precursor (SEQ ID NO:7), Bone-marrow proteoglycan precursor (SEQ ID NO:8), Selenium-binding protein 1 (SEQ ID NO:9), Lipopolysaccharide-binding protein precursor (SEQ ID NO:10), Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO:11), Osteopontin precursor (SEQ ID NO:12), Rho GDP-dissociation inhibitor 2 (SEQ ID NO:13), Carbonic anhydrase 2 (SEQ ID NO:14), Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO:15), Collagen alpha-5 (IV) chain precursor (SEQ ID NO:16), Connective tissue growth factor precursor (SEQ ID NO:17), Macrophage colony-stimulating factor 1 precursor (SEQ ID NO:18), Protein kinase C-binding protein NELL2 precursor (SEQ ID NO:19), Neudesin precursor (SEQ ID NO:20), Protein disulfide-isomerase precursor (SEQ ID NO:21), Ribonuclease pancreatic precursor (SEQ ID NO:22), Delta-like protein precursor (SEQ ID NO:23), Chromogranin-A precursor (SEQ ID NO:24), Osteomodulin precursor (SEQ ID NO:25), Collagen alpha-2(I) chain precursor (SEQ ID NO:26), Prolow-density lipoprotein receptor-related protein 1 precursor (SEQ ID NO:27), Laminin subunit gamma-1 precursor (SEQ ID NO:28), Laminin subunit beta-1 precursor (SEQ ID NO:29), Collagen alpha-1(II) chain precursor (SEQ ID NO:30), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), Protein FAM3C precursor (SEQ ID NO:32), Alpha-actinin-1 (SEQ ID NO:33), F-actin-capping protein subunit alpha-1 (SEQ ID NO:34), Aminopeptidase N (SEQ ID NO:35), Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Cell adhesion molecule 1 precursor (SEQ ID NO:37), Cathepsin B precursor (SEQ ID NO:38), Exostosin-2 (SEQ ID NO:39), Cathepsin D precursor (SEQ ID NO:40), Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO:41), Cystatin-M precursor (SEQ ID NO:42), Noelin precursor (SEQ ID NO:43), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Endoplasmic precursor (SEQ ID NO:45), Propionin convertase subtilisin/kexin type 9 precursor (SEQ ID NO:46), Insulin-like growth factor-binding protein complex acid labile chain precursor (SEQ ID NO:47), Ezrin (SEQ ID NO:48), Fatty acid-binding protein, liver (SEQ ID NO:49), Probable G-protein coupled receptor

116 precursor (SEQ ID NO:50), Seprase (SEQ ID NO:51), Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO:52), Hypoxia up-regulated protein 1 precursor (SEQ ID NO:53), Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO:54), Transketolase (SEQ ID NO:55), Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO:56), Intercellular adhesion molecule 1 precursor (SEQ ID NO:57), Low-density lipoprotein receptor precursor (SEQ ID NO:58), 78 kDa glucose-regulated protein precursor (SEQ ID NO:59), Neighbor of punc e11 precursor (SEQ ID NO:60), Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ ID NO:61), Pyruvate kinase isozymes M1/M2 (SEQ ID NO:62), Matrix metalloproteinase-9 (SEQ ID NO:64), Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and Stress-induced-phosphoprotein 1 (SEQ ID NO:63), in the manufacture of a proteomic profile of a biological fluid for the early diagnosis of neonatal sepsis in a subject.

**26.** The use of claim **25** wherein the subject is a human patient.

**27.** The use of claim **25** wherein the biological fluid is selected from the group consisting of cord blood, neonatal serum and cerebrospinal fluid.

**28.** The use of claim **26** wherein the proteomic profile comprises information of the level of said proteins and wherein the diagnosis of said subject with neonatal sepsis is made if one or more of said tested proteins shows a significant difference in the biological fluid sample relative to normal biological fluid.

**29.** The use of claim **26**, wherein said diagnosis is determined within 24 hours of birth.

**30.** The use of claim **26** wherein the proteomic profile comprises information of the level of at least two of said proteins.

**31.** The use of claim **26** wherein the proteomic profile comprises information of the level of at least three of said proteins.

**32.** The use of claim **26** wherein the proteomic profile comprises information of the level of at least four of said proteins.

**33.** The use of claim **2** wherein the proteomic profile comprises information of the level of proteins Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Interleukin-6 precursor (SEQ ID NO:3), C-reactive protein precursor (SEQ ID NO:1), Beta-2-microglobulin precursor (SEQ ID NO:7), Cathepsin B precursor (SEQ ID NO:38), Cystatin-M precursor (SEQ ID NO:42), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Matrix metalloproteinase-9 (SEQ ID NO:64), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), and Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and wherein the diagnosis of said subject with neonatal sepsis is made if one or more of said tested proteins shows a significant difference in the biological fluid sample relative to normal biological fluid.

**34.** The use of claim **33** wherein the diagnosis of said subject with neonatal sepsis is made if all of said tested proteins show a significant difference in the biological fluid sample relative to normal biological fluid.

**35.** The use of claim **26** wherein said level is determined by an immunoassay.

**36.** The use of claim **26** wherein said level is determined by mass spectrometry.

**37.** The use of claim **26** wherein said level is determined using a protein array.

**38.** An immunoassay kit comprising antibodies and reagents for the detection of one or more proteins selected from the group consisting of C-reactive protein precursor (SEQ ID NO:1), Interleukin-1 receptor accessory protein precursor (SEQ ID NO:2), Interleukin-6 precursor (SEQ ID NO:3), Interleukin-1 receptor-like 1 precursor (SEQ ID NO:4), Serum amyloid A protein precursor (SEQ ID NO:5), CD5 antigen-like precursor (SEQ ID NO:6), Beta-2-microglobulin precursor (SEQ ID NO:7), Bone-marrow proteoglycan precursor (SEQ ID NO:8), Selenium-binding protein 1 (SEQ ID NO:9), Lipopolysaccharide-binding protein precursor (SEQ ID NO:10), Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO:11), Osteopontin precursor (SEQ ID NO:12), Rho GDP-dissociation inhibitor 2 (SEQ ID NO:13), Carbonic anhydrase 2 (SEQ ID NO:14), Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO:15), Collagen alpha-5(IV) chain precursor (SEQ ID NO:16), Connective tissue growth factor precursor (SEQ ID NO:17), Macrophage colony-stimulating factor 1 precursor (SEQ ID NO:18), Protein kinase C-binding protein NELL2 precursor (SEQ ID NO:19), Neudesin precursor (SEQ ID NO:20), Protein disulfide-isomerase precursor (SEQ ID NO:21), Ribonuclease pancreatic precursor (SEQ ID NO:22), Delta-like protein precursor (SEQ ID NO:23), Chromogranin-A precursor (SEQ ID NO:24), Osteomodulin precursor (SEQ ID NO:25), Collagen alpha-2(I) chain precursor (SEQ ID NO:26), Pro-low-density lipoprotein receptor-related protein 1 precursor (SEQ ID NO:27), Laminin subunit gamma-1 precursor (SEQ ID NO:28), Laminin subunit beta-1 precursor (SEQ ID NO:29), Collagen alpha-1(II) chain precursor (SEQ ID NO:30), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), Protein FAM3C precursor (SEQ ID NO:32), Alpha-actinin-1 (SEQ ID NO:33), F-actin-capping protein subunit alpha-1 (SEQ ID NO:34), Aminopeptidase N (SEQ ID NO:35), Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Cell adhesion molecule 1 precursor (SEQ ID NO:37), Cathepsin B precursor (SEQ ID NO:38), Exostosin-2 (SEQ ID NO:39), Cathepsin D precursor (SEQ ID NO:40), Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO:41), Cystatin-M precursor (SEQ ID NO:42), Noelin precursor (SEQ ID NO:43), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Endoplasmin precursor (SEQ ID NO:45), Proprotein convertase subtilisin/kexin type 9 precursor (SEQ ID NO:46), Insulin-like growth factor-binding protein complex acid labile chain precursor (SEQ ID NO:47), Ezrin (SEQ ID NO:48), Fatty acid-binding protein, liver (SEQ ID NO:49), Probable G-protein coupled receptor 116 precursor (SEQ ID NO:50), Seprase (SEQ ID NO:51), Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO:52), Hypoxia up-regulated protein 1 precursor (SEQ ID NO:53), Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO:54), Transketolase (SEQ ID NO:55), Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO:56), Intercellular adhesion molecule 1 precursor (SEQ ID NO:57), Low-density lipoprotein receptor precursor (SEQ ID NO:58), 78 kDa glucose-regulated protein precursor (SEQ ID NO:59), Neighbor of p115 precursor (SEQ ID NO:60), Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ ID NO:61), Pyruvate kinase isozymes M1/M2 (SEQ ID NO:62), Matrix metalloproteinase-9 (SEQ ID NO:64), Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and Stress-induced-phosphoprotein 1 (SEQ ID NO:63).

**39.** An immunoassay kit comprising antibodies and reagents for the detection of one or more proteins selected from the group consisting of Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Interleukin-6 precursor (SEQ ID NO:3), C-reactive protein precursor (SEQ ID NO:1), Beta-2-microglobulin precursor (SEQ ID NO:7), Cathepsin B precursor (SEQ ID NO:38), Cystatin-M precursor (SEQ ID NO:42), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Matrix metalloproteinase-9 (SEQ ID NO:64), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), and Alpha-1-acid glycoprotein 1 (SEQ ID NO:65).

**40.** The immunoassay kit of claim **38** comprising antibodies and reagents for the detection of all of said proteins.

**41.** A report comprising the results of and/or diagnosis based on a test comprising

- (a) testing in a sample of biological fluid obtained from said subject the level of one or more proteins selected from the group consisting of C-reactive protein precursor (SEQ ID NO:1), Interleukin-1 receptor accessory protein precursor (SEQ ID NO:2), Interleukin-6 precursor (SEQ ID NO:3), Interleukin-1 receptor-like 1 precursor (SEQ ID NO:4), Serum amyloid A protein precursor (SEQ ID NO:5), CD5 antigen-like precursor (SEQ ID NO:6), Beta-2-microglobulin precursor (SEQ ID NO:7), Bone-marrow proteoglycan precursor (SEQ ID NO:8), Selenium-binding protein 1 (SEQ ID NO:9), Lipopolysaccharide-binding protein precursor (SEQ ID NO:10), Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO:11), Osteopontin precursor (SEQ ID NO:12), Rho GDP-dissociation inhibitor 2 (SEQ ID NO:13), Carbonic anhydrase 2 (SEQ ID NO:14), Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO:15), Collagen alpha-5(IV) chain precursor (SEQ ID NO:16), Connective tissue growth factor precursor (SEQ ID NO:17), Macrophage colony-stimulating factor 1 precursor (SEQ ID NO:18), Protein kinase C-binding protein NELL2 precursor (SEQ ID NO:19), Neudesin precursor (SEQ ID NO:20), Protein disulfide-isomerase precursor (SEQ ID NO:21), Ribonuclease pancreatic precursor (SEQ ID NO:22), Delta-like protein precursor (SEQ ID NO:23), Chromogranin-A precursor (SEQ ID NO:24), Osteomodulin precursor (SEQ ID NO:25), Collagen alpha-2(I) chain precursor (SEQ ID NO:26), Pro-low-density lipoprotein receptor-related protein 1 precursor (SEQ ID NO:27), Laminin subunit gamma-1 precursor (SEQ ID NO:28), Laminin subunit beta-1 precursor (SEQ ID NO:29), Collagen alpha-1(II) chain precursor (SEQ ID NO:30), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), Protein FAM3C precursor (SEQ ID NO:32), Alpha-actinin-1 (SEQ ID NO:33), F-actin-capping protein subunit alpha-1 (SEQ ID NO:34), Aminopeptidase N (SEQ ID NO:35), Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Cell adhesion molecule 1 precursor (SEQ ID NO:37), Cathepsin B precursor (SEQ ID NO:38), Exostosin-2 (SEQ ID NO:39), Cathepsin D precursor (SEQ ID NO:40), Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO:41), Cystatin-M precursor (SEQ ID NO:42), Noelin precursor (SEQ ID NO:43), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Endoplasmin precursor (SEQ ID NO:45), Proprotein convertase subtilisin/kexin type 9 precursor (SEQ ID NO:46), Insulin-like growth factor-binding

protein complex acid labile chain precursor (SEQ ID NO:47), Ezrin (SEQ ID NO:48), Fatty acid-binding protein, liver (SEQ ID NO:49), Probable G-protein coupled receptor 116 precursor (SEQ ID NO:50), Seprase (SEQ ID NO:51), Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO:52), Hypoxia up-regulated protein 1 precursor (SEQ ID NO:53), Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO:54), Transketolase (SEQ ID NO:55), Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO:56), Intercellular adhesion molecule 1 precursor (SEQ ID NO:57), Low-density lipoprotein receptor precursor (SEQ ID NO:58), 78 kDa glucose-regulated protein precursor (SEQ ID NO:59), Neighbor of punc e11 precursor (SEQ ID NO:60), Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ ID NO:61), Pyruvate kinase isozymes M1/M2 (SEQ ID NO:62), Matrix metalloproteinase-9 (SEQ ID NO:64), Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and Stress-induced-phosphoprotein 1 (SEQ ID NO:63), relative to the level in normal biological fluid or biological fluid known to be indicative of neonatal sepsis; and

- (b) diagnosing said subject with neonatal sepsis if said level shows a statistically significant difference relative to the level in said normal biological fluid, or does not show a statistically significant difference relative to the level in said biological fluid known to be indicative of neonatal sepsis.

**42.** A tangible medium storing the results of and/or diagnosis based on a test comprising

- (a) testing in a sample of biological fluid obtained from said subject the level of one or more proteins selected from the group consisting of C-reactive protein precursor (SEQ ID NO:1), Interleukin-1 receptor accessory protein precursor (SEQ ID NO:2), Interleukin-6 precursor (SEQ ID NO:3), Interleukin-1 receptor-like 1 precursor (SEQ ID NO:4), Serum amyloid A protein precursor (SEQ ID NO:5), CD5 antigen-like precursor (SEQ ID NO:6), Beta-2-microglobulin precursor (SEQ ID NO:7), Bone-marrow proteoglycan precursor (SEQ ID NO:8), Selenium-binding protein 1 (SEQ ID NO:9), Lipopolysaccharide-binding protein precursor (SEQ ID NO:10), Chondroitin sulfate proteoglycan 4 precursor (SEQ ID NO:11), Osteopontin precursor (SEQ ID NO:12), Rho GDP-dissociation inhibitor 2 (SEQ ID NO:13), Carbonic anhydrase 2 (SEQ ID NO:14), Neutrophil gelatinase-associated lipocalin precursor (SEQ ID NO:15), Collagen alpha-5(IV) chain precursor (SEQ ID NO:16), Connective tissue growth factor precursor (SEQ ID NO:17), Macrophage colony-stimulating factor 1 precursor (SEQ ID NO:18), Protein kinase C-binding protein NELL2 precursor (SEQ ID NO:19), Neudesin precursor (SEQ ID NO:20), Protein disulfide-isomerase precursor (SEQ ID NO:21), Ribonuclease

pancreatic precursor (SEQ ID NO:22), Delta-like protein precursor (SEQ ID NO:23), Chromogranin-A precursor (SEQ ID NO:24), Osteomodulin precursor (SEQ ID NO:25), Collagen alpha-2(I) chain precursor (SEQ ID NO:26), Pro-low-density lipoprotein receptor-related protein 1 precursor (SEQ ID NO:27), Laminin subunit gamma-1 precursor (SEQ ID NO:28), Laminin subunit beta-1 precursor (SEQ ID NO:29), Collagen alpha-1(II) chain precursor (SEQ ID NO:30), Metalloproteinase inhibitor 1 precursor (SEQ ID NO:31), Protein FAM3C precursor (SEQ ID NO:32), Alpha-actinin-1 (SEQ ID NO:33), F-actin-capping protein subunit alpha-1 (SEQ ID NO:34), Aminopeptidase N (SEQ ID NO:35), Insulin-like growth factor-binding protein 1 precursor (SEQ ID NO:36), Cell adhesion molecule 1 precursor (SEQ ID NO:37), Cathepsin B precursor (SEQ ID NO:38), Exostosin-2 (SEQ ID NO:39), Cathepsin D precursor (SEQ ID NO:40), Neurogenic locus notch homolog protein 3 precursor (SEQ ID NO:41), Cystatin-M precursor (SEQ ID NO:42), Noelin precursor (SEQ ID NO:43), Insulin-like growth factor-binding protein 2 precursor (SEQ ID NO:44), Endoplasmic precursor (SEQ ID NO:45), Pro-protein convertase subtilisin/kexin type 9 precursor (SEQ ID NO:46), Insulin-like growth factor-binding protein complex acid labile chain precursor (SEQ ID NO:47), Ezrin (SEQ ID NO:48), Fatty acid-binding protein, liver (SEQ ID NO:49), Probable G-protein coupled receptor 116 precursor (SEQ ID NO:50), Seprase (SEQ ID NO:51), Oncoprotein-induced transcript 3 protein precursor (SEQ ID NO:52), Hypoxia up-regulated protein 1 precursor (SEQ ID NO:53), Trans-Golgi network integral membrane protein 2 precursor (SEQ ID NO:54), Transketolase (SEQ ID NO:55), Receptor-type tyrosine-protein phosphatase F precursor (SEQ ID NO:56), Intercellular adhesion molecule 1 precursor (SEQ ID NO:57), Low-density lipoprotein receptor precursor (SEQ ID NO:58), 78 kDa glucose-regulated protein precursor (SEQ ID NO:59), Neighbor of punc e11 precursor (SEQ ID NO:60), Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (SEQ ID NO:61), Pyruvate kinase isozymes M1/M2 (SEQ ID NO:62), Matrix metalloproteinase-9 (SEQ ID NO:64), Alpha-1-acid glycoprotein 1 (SEQ ID NO:65), and Stress-induced-phosphoprotein 1 (SEQ ID NO:63), relative to the level in normal biological fluid or biological fluid known to be indicative of neonatal sepsis; and

- (b) diagnosing said subject with neonatal sepsis if said level shows a statistically significant difference relative to the level in said normal biological fluid, or does not show a statistically significant difference relative to the level in said biological fluid known to be indicative of neonatal sepsis.

\* \* \* \* \*

专利名称(译)	用于检测生物液中新生儿败血症的生物标志物		
公开(公告)号	<a href="#">US20100190652A1</a>	公开(公告)日	2010-07-29
申请号	US12/693387	申请日	2010-01-25
[标]申请(专利权)人(译)	NAGALLA斯里尼瓦沙 格拉维特米迦勒		
申请(专利权)人(译)	NAGALLA斯里尼瓦沙 格拉维特米迦勒		
当前申请(专利权)人(译)	NAGALLA斯里尼瓦沙 格拉维特米迦勒		
[标]发明人	NAGALLA SRINIVASA GRAVETT MICHAEL		
发明人	NAGALLA, SRINIVASA GRAVETT, MICHAEL		
IPC分类号	C40B30/00 G01N33/53 G01N33/573		
CPC分类号	G01N33/6893 G01N2800/60 G01N2800/26 G01N2550/00		
优先权	61/147635 2009-01-27 US		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

摘要(译)

本发明涉及使用全局蛋白质组学方法鉴定和检测新生儿败血症的生物流体生物标志物。

